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A b s t r a c t  
This thesis describes a prospective observational longitudinal study that examines the 
relationship between the systemic inflammatory response, vitamin concentrations and 
outcome in patients with critical illness.  Venous blood samples were collected from 
patients admitted in the Intensive Care Unit of Glasgow Royal Infirmary on admission 
(n=126) and on follow-up (n=77).  The concentrations of vitamins B2, B6, C, A, E, lutein, 
lycopene, α-carotene and β-carotene in plasma, red cells and white cells and plasma total 
and free malondialdehyde, that was used as a marker of lipid peroxidation, were assessed 
by high performance liquid chromatography (HPLC). 
In Chapter 3, vitamin B2 was examined.  The results of this study showed that the ratio of 
plasma FAD to riboflavin in critically ill patients on admission and on follow-up was much 
lower than that of the plasma ratio in the controls.  There were also similar findings with 
respect to the red cell FAD to riboflavin ratios in controls and critically ill patients.  
However, on admission the reduction of the FAD to riboflavin ratio was greater in the 
plasma (83%) compared with the red cells (49%).  These results showed perturbation of 
the relationship between plasma FAD and riboflavin in patients with critical illness.  
Moreover, this appeared to be primarily due to a relative reduction in plasma and 
intracellular FAD concentrations although red cell FAD concentrations were all within the 
reference interval. 
In Chapter 4, vitamin B6 was examined.  The results of this study showed that, in plasma, 
red cells and white cells, PLP is strongly and directly associated with the concentrations of 
PL in patients with critical illness.  The ratio of plasma PLP to PL in critically ill patients 
on admission and on follow-up was much lower than that of the plasma controls.  There 
were also similar findings with respect to the red cell PLP to PL ratios in controls and 
critically ill patients.  However, on admission the reduction of the PLP to PL ratio was 
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greater in the plasma (55%) compared with the red cells (18%).  These results report that 
the relationship between plasma PLP and PL in controls is similar to that found in red and 
white cells, in patients with critical illness.  Given that, compared to plasma PLP, 
concentrations of plasma PL were more strongly correlated with those in the red or white 
cells and that red cell and white cell PL concentrations were strongly and similarly 
correlated with their respective PLP concentrations, demonstrates the importance of PL in 
the intracellular metabolism of PLP in normal subjects and critically ill patients.  One 
interpretation of these results could suggest that plasma PL may be a good surrogate 
measure of intracellular PLP concentrations.  However, PL is not the physiologically active 
form of vitamin B6 and therefore, the clinical relevance of measuring plasma PL 
concentrations is not clear.  Therefore, the present intracellular measurements of PLP, 
compared with plasma, may be a more accurate reflection of vitamin B6 status. 
In Chapter 5, vitamin C was examined.  The results of this study showed that plasma 
ascorbic acid concentrations in critically ill patients were below reference intervals 
whereas white cell ascorbic acid concentrations were within the reference intervals.  
Moreover, plasma and intracellular concentrations of both vitamin C and α-tocopherol 
were poorly correlated and did not increase with supplementation in the ICU.  Taken 
together these results would suggest that plasma ascorbic acid concentrations may poorly 
reflect intracellular concentrations in patients with critical illness. 
In Chapter 6, vitamin E was examined.  The results of this study showed that, compared 
with control subjects, the critically-ill patient group had lower plasma α-tocopherol 
concentrations and also when expressed per mmol of triglycerides.  In contrast, α-
tocopherol concentrations were higher when expressed per mmol of cholesterol despite 
these patients receiving no vitamin E supplementation in ICU.  Moreover, neither plasma 
α-tocopherol nor plasma α-tocopherol expressed per mmol of lipids was strongly 
correlated with red cell α-tocopherol concentrations in the critically-ill patients.  Finally, 
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median red cell α-tocopherol concentrations were the same in the healthy subjects and 
patients with critical illness and systemic inflammatory response syndrome.  Taken 
together the results indicate that plasma α-tocopherol alone or expressed per mmol of lipids 
(using either cholesterol or triglycerides) may be a less reliable marker of vitamin E status 
than red cell α-tocopherol in patients with a systemic inflammatory response. 
In Chapter 7, lipid soluble antioxidants A, E and carotenoids and lipid peroxidation, as 
measured by malondialdehyde (MDA, total and free), were examined.  The results of this 
study showed that, on admission to ICU, the free MDA fraction was increased and 
carotenoid concentrations were low in patients with critical illness.  The majority of 
patients had plasma retinol concentrations below the reference interval on admission to 
ICU and these were directly and significantly related to α-tocopherol and the carotenoids.  
Moreover, this relationship was maintained on follow-up.  Both albumin and C-reactive 
protein were consistently correlated with these lipid soluble antioxidant concentrations.  
Therefore, the reduction of lipid soluble antioxidant concentrations, in particular 
carotenoids, is likely to be multifactorial and not solely dependent on consumption during 
lipid peroxidation. 
In Chapter 8, the behaviour of plasma and intracellular B2, B6 and C vitamin 
concentrations during supplementation in patients with critical illness was studied.  The 
results of the present study show a discrepancy in the behaviour of plasma and intracellular 
B2, B6 and C vitamin concentrations during supplementation in patients with critical 
illness.  Indeed, on admission to ICU, almost 1/3 of the patients had plasma vitamin B2, B6 
and C concentrations below the reference interval.  In contrast, on admission to ICU, red 
cell FAD, red cell PLP and white cell ascorbic acid concentrations were significantly 
higher in the patients with records of prior supplementation compared with the patients 
without.  The longitudinal findings were in agreement with this observation and taken 
together, this study may suggest that cellular concentrations of vitamins B2, B6 and C may 
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be more accurate markers of their respective vitamin status and may be expected to be a 
more true reflection of the presence of supplementation than their respective plasma 
concentrations. 
In Chapter 9, the relationship between lipid peroxidation, water and lipid soluble vitamins 
and severity of illness or hospital outcome in critically ill patients was examined.  The 
results of this study showed that lipid peroxidation, as evidenced by an elevated free MDA 
fraction, was most significantly associated with death in hospital.  The concentrations of 
retinol and the carotenoids in the plasma were well below the reference intervals and 
although correlated with the free MDA fraction, had no independent prognostic value.  
Albumin was directly associated with the lipid soluble vitamins in the plasma, in particular 
retinol, α-tocopherol, lutein and lycopene.  Albumin was shown to have prognostic value 
independent of APACHE II and when albumin was removed from the multivariate model, 
lycopene became an independent predictor of hospital death.  None of the intracellular 
vitamin concentrations were related to severity of illness in critically ill patients.  Taken 
together these results would suggest that low plasma levels of lipid soluble vitamins may 
be due to redistribution in the same way that albumin concentrations fall as part of the 
systemic inflammatory response syndrome. 
In summary, the current thesis showed that, during the systemic inflammatory response, 
intracellular vitamin concentrations may be more accurate than plasma concentrations as 
indicators of vitamin status in patients with critical illness. 
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A b b r e v i a t i o n s  
ALP    Alkaline phosphatase 
APACHE   Acute Physiology and Chronic Health Evaluation 
ARDS    Acute respiratory distress syndrome 
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KCAL    Kilocalories 
KG    Kilogram 
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LDL    Low Density Lipoprotein 
MDA    Malondialdehyde 
MODS    Multiple Organ Dysfunction Syndrome 
NF-κB    Nuclear transcription factor-kappa B 
PBS    Phosphate buffered saline 
PL    Pyridoxal 
PLP    5’-Pyridoxal phosphate 
ROS    Reactive oxygen species 
SIRS    Systemic inflammatory response syndrome 
SOFA    Sequential Organ Failure Assessment 
TBARS   Thiobarbituric acid-reactive substances 
TCA    Trichloroacetic acid 
TNF    Tumour necrosis factor 
TRAP    Total radical-trapping antioxidant parameter 
UV    Ultraviolet 
VLDL    Very Low Density Lipoprotein 
WC    White cells (counts) 
 1 Introduction 
The importance of antioxidant concentrations in the tissues and their relationship to the 
prevention of multiple organ dysfunction syndrome (MODS) and the increased mortality 
that accompanies it has been of considerable interest in the last two decades.  During the 
course of critical illness a number of metabolic changes affecting micronutrient utilization 
and distribution have been documented.  Micronutrient deficiencies have been associated 
with morbidity and mortality in this compromised group and thus it is of little surprise that 
researchers have focused on provision of optimal nutrition and micronutrient supplements, 
either enterally or parenterally, in order to mitigate organ dysfunction and mortality in 
patients with critical illness. 
The assessment of micronutrient status and their provision to such patients has been 
monitored either by using functional tests (enzymatic activity) or by measuring 
micronutrient concentrations in plasma.  However, since most micronutrients behave as 
acute phase reactants, the value of such plasma measurements has been questioned 
(Galloway et al. 2000). 
Recent advances in methods of micronutrient assessment allow the direct measurement of 
their concentrations within the blood plasma and red cells (Talwar et al. 2003a).  For 
example, based on these direct methods it has been shown that redistribution of B-vitamins 
between plasma and blood cells takes place during elective surgery (Gray et al. 2004) and 
critical illness (Talwar et al. 2003b; Quasim et al. 2005).  This evidence questions the 
existence of micronutrient deficiency in these patients as well as the accuracy of 
micronutrient biochemical assessment methods used previously to assess these 
deficiencies. 
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1.1 Critical illness in Scotland 
1.1.1 Demographics 
The critically ill are the patients with the most deranged physiology of the health care 
setting.  Due to their need for intensive nursing and their high mortality rates (31% hospital 
mortality for the critically ill patients admitted in ICUs in 2007) (Scottish Intensive Care 
Society Audit Group 2008), these patients are treated in a special designed area, the 
intensive care unit (ICU).  There were 348 admissions in the Glasgow Royal Infirmary 
ICU in 2007.  Having different pathologies (Ridley et al. 1997), the critically-ill patients 
are a heterogeneous group admitted in the ICU either from the hospital wards (25%) or as 
high-risk post-surgery patients (42%) with established or potential organ failure (Scottish 
Intensive Care Society Audit Group 2008). 
Patients admitted to ICU suffer from organ dysfunction (or organ failure) of one or more 
organs with the most common failure being that of the respiratory system.  Organ failure is 
one of the variables independently associated with an increased risk of mortality (Vincent 
et al. 1995).  A single organ system failure lasting more than one day results in a mortality 
rate approaching 40%, where for three or more organ system failures for more than three 
days the death rates increase to 98% (Knaus et al. 1985a).  It seems that at the final stage of 
multiple organ dysfunction syndrome (MODS) an immunologic dissonance occurs, 
characterized by an imbalance between the pro- and anti-inflammatory mediators (Bone 
1996).  It has been shown that organ failure, prolonged ICU stay, and high infection and 
mortality rates are associated with the presence of the systemic inflammatory response 
syndrome (Lobo et al. 2003).  
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1.1.2 Illness severity scoring systems 
1.1.2.1 APACHE II score 
Using the Acute Physiology And Chronic Health Evaluation II (APACHE II) diagnostic 
classification (Knaus et al. 1985b, Figure 1-1), patients can be grouped into nine categories 
according to the primary organ system failure leading to ICU admission.  Previous research 
(Beck et al. 1997; Pappachan et al. 1999; Woods et al. 2000) has shown that the APACHE 
II score is the most reliable scoring system for assessing severity of disease in the ICU for 
the U.K.  In Glasgow, the overall five–year mortality rate for patients being admitted in the 
ICU was 47%, 3.4 times higher than that of the general population (Wright, Plenderleith & 
Ridley 2003). 
1.1.2.2 SOFA score 
The need for producing the Sequential Organ Failure Assessment (SOFA) score resulted 
because of the fact that outcome prediction scores, such as APACHE II, rely on ICU 
admission values and could ignore many factors that can influence patient outcome during 
their ICU stay (Vincent et al. 1996, Figure 1-2).  The total maximum SOFA score (adding 
the highest value for each variable in the duration of stay) and the difference between total 
maximum and admission SOFA scores reflect the degree of organ failure during ICU stay 
(Moreno et al. 1999).  The initial and highest SOFA score of more than 11 and mean 
SOFA score of more than 5, independent of length of stay, have been found to correlate 
well with mortality in ICU (Ferreira et al. 2001).  Regardless of the initial value, when the 
score increased in the first four days the mortality rate was greater than 50%, 27-35% if it 
remained unchanged and less than 27% when it decreased (Ferreira et al. 2001).
  
Figure 1-1 The Acute Physiology And Chronic Health Evaluation (APACHE) II score system. 
(Knaus et al. 1985b)
  
 
 
Figure 1-2 Sequential Organ Failure Assessment (SOFA) score system. 
(Vincent et al. 1996)
  
1.2 Nutritional management in critical illness 
1.2.1 Nutritional support 
‘The aims of nutrition support in critical ill patients are to minimise nutritional losses and 
provide basic nutrient requirements to sustain life’ (Webster-Gandy, Madden & 
Holdsworth 2006). 
In the presence of infectious disease, inadequate nutrition not only reduces the availability 
of endogenous stores of nutrients but it may also lead to increased susceptibility to 
secondary infection through reduced synthesis of pro-inflammatory cytokines and impaired 
cell-mediated immunity (Wan, Haw & Blackburn 1989).  The European Prevalence of 
Infection in Intensive Care (EPIC) study showed that in a sample of 10,038 critically ill 
patients suffering trauma, sepsis, or major surgery, there is a high risk of developing 
nosocomial infection (21%) resulting in increased mortality (r2 =0.68) (Vincent et al. 
1995).  Indeed, one out of four severely ill patients have been assessed as malnourished 
(Edington et al. 2000) and in addition, mechanically ventilated critically ill patients are 
more likely to receive <67% of energy and protein than non–ventilated patients (Kyle et al. 
2006).  Thus, feeding this group of patients seems to be of great importance.  
Feeding and supplementing the compromised patient has been common practice over the 
last two decades.  Nutritional requirements of the critically ill patient focus on their energy, 
protein, carbohydrate, lipid, fluid balance, electrolyte and micronutrient needs.  
Nevertheless, evidence on the actual amounts of nutrients that these patients require for 
optimal recovery can be limited in most cases.  Thus, the clinicians and dietitians focus 
mainly in providing nutrition that aims to prevent further nutritional deterioration and on 
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the other hand avoid metabolic and non-metabolic complications of overfeeding, such as 
diarrhoea, metabolic acidosis, hyperglycaemia, increased respiratory quotient, etc.   
Generally in critically ill patients enteral nutrition may result in fewer infectious 
complications compared with parenteral nutrition (Simpson & Doig 2005; Gramlich et al. 
2004).  However a statistically significant mortality benefit in favour of parenteral nutrition 
was evident in a recent meta–analysis of 11 trials (OR=0.56, p=0.03) and this benefit was 
greatest in trials in which enteral nutrition was delayed for more than 24 hours (Simpson & 
Doig 2005). 
Enteral nutrition is initially considered for the newly admitted patients to the intensive care 
units.  In 2006, the European Society of Parenteral and Enteral Nutrition (ESPEN) 
summarised the existing evidence on enteral nutrition in the intensive care unit and 
published guidelines for its use by dietitians working in the intensive care setting 
(Kreymann et al. 2006).  Table 1-1 summarises these results. 
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Table 1-1 ESPEN guidelines for patients with critical illness. 
(Kreymann et al. 2006) 
Indications All patients who are not expected to be on a full oral diet within 3 days should 
receive enteral nutrition (EN). 
Application There are no data showing improvement in relevant outcome parameters using 
early EN in critically ill patients. Nevertheless, the expert committee 
recommends that haemodynamically stable critically ill patients who have a 
functioning gastrointestinal tract should be fed early (< 24 h) using an 
appropriate amount of feed. 
No general amount can be recommended as EN therapy has to be adjusted to the 
progression/ course of the disease and to gut tolerance. 
Exogenous 
energy 
supply 
During the acute and initial phase of critical illness: in excess of 20–25 kcal/kg 
BW/day may be associated with a less favourable outcome. 
During the anabolic recovery phase and in patients with severe undernutrition, 
the aim should be to provide 25–30 kcal/kg BW/day. 
If these target values are not reached supplementary parenteral nutrition should 
be given. 
Route Use EN in patients who can be fed via the enteral route. Avoid additional 
parenteral nutrition in patients who tolerate EN and can be fed approximately to 
the target values. 
Use supplemental parenteral nutrition in patients who cannot be fed sufficiently 
via the enteral route. Consider careful parenteral nutrition in patients intolerant to 
EN at a level equal to but not exceeding the nutritional needs of the patient. 
Type of 
formula 
 
Whole protein formulae are appropriate in most patients because no clinical 
advantage of peptidebased formulae could be shown. Immune-modulating 
formulae (formulae enriched with arginine, nucleotides and n-3 fatty acids) are 
superior to standard enteral formulae: in elective upper GI surgical patients (see 
guidelines surgery), in patients with a mild sepsis (APACHE II <15), in patients 
with severe sepsis, however, immune-modulating formulae may be harmful and 
are therefore not recommended, in patients with ARDS (formulae containing n-3 
fatty acids and antioxidants). 
ICU patients with very severe illness who do not tolerate more than 700 ml/day 
of enteral formulae should not receive an immune-modulating formula enriched 
with arginine, nucleotides and ω-3 fatty acids. There are not sufficient data to 
support glutamine supplementation in surgical or heterogenous critically ill 
patients. 
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1.2.2 Immunonutrition 
More recently, the concept of immunonutrition, i.e. nutrition that boosts the immune 
response to illness, has been introduced to critical care, and this appears to show beneficial 
effects such as improved immune function and reduced frequency of infectious 
complications (Beale, Bryg & Bihari 1999; Heys et al. 1999).  The most common 
immune–enhancing substrates contained in these type of diets are arginine, nucleotides, 
branched–chain amino acids, glutamine or/and ω–3 fatty acids.  
A randomised trial (Kudsk et al. 1996) compared a small group of critically ill trauma 
patients (n=16) who received an immune-enhancing diet (containing glutamine, arginine, 
ω-3 fatty acids and nucleotides) with critically ill patients on an isonitrogenous standard 
diet.  This study showed that the immuno-enhancing diet significantly reduced major 
infectious complications (by 35%, p<0.05), hospital stay (by 16 days, p<0.05) and 
therapeutic antibiotics requirements (by 4 days, p<0.05).  For burn patients immuno-
enhancing diet administration (without glutamine) did not appear to show similar benefits 
(Saffle et al. 1997). 
The effects of the immune–enhancing diets can be different depending on the subset of 
patients analyzed or on the methological quality of the studies included in the meta–
analysis (Heyland et al. 2001).  When it comes to subgroups of patients it seems that 
enteral immunonutrition benefits the surgical patients more (Beale, Bryg & Bihari 1999; 
Heyland et al. 2001; Montejo et al. 2003). 
Certainly, it appears that the routine administration of immuno-enhancing nutrition in 
critically ill patients should be judged after the development of understanding the patient’s 
patho-physiological situation and development of methods for monitoring immune 
responses and status to avoid adverse effects in recovery (Suchner, Kuhn & Fürst 2000).  
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Indeed, in critically ill patients with severe sepsis, enteral immunonutrition containing L-
arginine, ω-3 fatty acids, vitamin E, β-carotene, zinc and selenium appears to show higher 
ICU mortality rates (44% vs 14%, p<0.05) compared with the patients that received 
parenteral nutrition (Bertolini et al. 2003).  Furthermore, immune-enhanced enteral 
nutrition has been shown to be superior to parenteral nutrition in terms of episodes of 
sepsis or septic shock (5% vs 13%) and ICU length of stay (4d shorter) in critically ill 
patients without septic shock or severe sepsis (Radrizzani et al. 2006).  Other studies have 
shown either benefit from the administration of similar immuno-enhancing formulas, e.g. 
in hospital length of stay (Bower et al. 1995), or no benefits (Mendez et al. 1997) 
compared with standard formulas. 
A recent meta-analysis (24 studies) has reported an improved outcome, i.e reduced 
mortality, secondary infections and length of stay, in medical ICU patients receiving 
immuno-enhancing diets with fish oil while supplementation with arginine with or without 
additional glutamine or fish oil did not appear to provide any advantages compared with 
standard enteral formulas in trauma and burn patients admitted in ICU (Marik & Zaloga 
2008). 
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1.3 The systemic inflammatory response 
The systemic inflammatory response syndrome (SIRS) is a complex coordinated response 
to acute injury and has been associated with a number of clinical conditions, such as 
infection, pancreatitis, ischemia, burns, multiple trauma and tissue injury, hemorrhagic 
shock, and immunologically mediated organ injury (Bone et al. 1992; Levy et al. 2003) in 
areas located far from the initial invasion.  Inflammation may generally be beneficial to the 
host until its clinical manifestations become unmanageable by the body (Bone 1996).  
Previous work has shown that almost all critically–ill patients satisfy the criteria for 
systemic inflammatory response syndrome (Pittet et al. 1995).  This generalized tissue 
injury may lead to progressive organ failure, which has a high mortality rate (Lobo et al. 
2003). 
The SIRS is manifested by two or more of the following clinical conditions (Bone et al. 
1992; Levy et al. 2003): (1) temperature > 38º C or < 36º C; (2) heart rate > 90 beats per 
minute; (3) respiratory rate > 20 breaths per minute or PaCO2 <32 mm Hg; and (4) white 
blood cell count >12,000/ cu mm, <4,000/ cu mm, or >10% immature (band) forms. 
1.3.1 Inflammatory response and SIRS in health and critical illness 
1.3.1.1 SIR and acute phase proteins 
It is recognised that, in healthy conditions, the protein concentrations in plasma are 
determined by their synthesis and degradation rate.  However, during the systemic 
inflammatory response, a number of changes in these liver-derived proteins occurs 
resulting in altered protein concentrations in blood (Gabay & Kushner 1999, Figure 1-3).  
Interleukin-1 (IL-1) or tumour necrosis factor (TNF) or both appear to participate in the 
initiation of the systemic inflammatory response (Dinarello 1984a; 1984b, 1988).  More 
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particularly, IL-1 has been shown to be involved in triggering the transcription and 
synthesis of the acute-phase proteins by the liver (Ramadori et al. 1985).   
The increase in the inter–cellular endothelial gaps (McDonald, Thurston & Baluk 1999) 
allows the translocation of proteins with small molecular weight, such as albumin 
(molecular weight=66,000), from the circulation to the extravascular space (Raines et al. 
1984; Fleck et al. 1985).  Indeed, in acute infectious disease, albumin concentrations in 
plasma significantly correlate with the albumin transcapillary escape rate (r=0.83, p<0.05) 
(Ballmer, Ochsenbein & Schutz-Hofmann 1994).  As albumin is the main carrier protein 
for the majority of vitamins and trace elements, its decrease in plasma might be expected to 
affect the micronutrient concentrations in this blood compartment. 
This mechanism is reflected in the first 2–4 hours of inflammation with a decrease in the 
negative inflammatory proteins’ concentrations (albumin, transferrin, retinol–binding 
protein and pre–albumin), and an increase in the concentrations of the positive 
inflammatory proteins (fibrinogen, α1–antitrypsin, caeruloplasmin, and C-reactive protein) 
(Colley et al. 1983; Myers et al. 1984). 
One of the most sensitive positive acute phase proteins is C-reactive protein (CRP), which 
was originally identified due to its peculiar property of precipitating with the C 
polysaccharide derived from the cell wall of pneumococcus (Tillet & Francis 1930).  It 
contains 187 amino acids in a single polypeptide chain with a minimal molecular weight of 
20,949 daltons (Oliveira, Gotschlich & Liu 1979).  In serum, CRP has a variable molecular 
weight ranging from 110,000 to 144,000 (Gotschlich & Edelman 1965).  Early 
observations (MacLeod & Avery 1941) showed that CRP was present in many acute 
illnesses but could not be detected in the plasma or serum of normal individuals. During 
SIRS a 1000-fold increase in CRP concentrations has been reported (Figure 3; Gabay & 
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Kushner 1999), primarily due to increased hepatic synthesis, a peak that is observed 48 
hours after the initial insult (Colley et al. 1983). 
CRP has many pathophysiologic roles in the inflammatory process. It induces the 
production of inflammatory cytokines and tissue necrosis factor from monocytes (Cermak 
et al. 1993) thus acting as a pro-inflammatory molecule.  It has recently been reported that 
98% of the mechanically ventilated ICU patients have CRP concentrations greater than 30 
mg/L and 36% of this group have albumin concentrations lower than 30 g/L (Kyle et al. 
2006) indicating the inverse relationship between the two proteins during the systemic 
inflammatory response syndrome. A CRP decrease ≥50 mg/L between admission and day 
4 has been found to be an independent predictor of recovery in critically ill patients and in 
combination with SIRS it provides the best model to diagnose infection at admission (Reny 
et al. 2002).
  
 
Figure 1-3 Acute phase proteins and the systemic inflammatory response. 
(From Gitlin & Cotlen 1987 as modified in Gabay & Kushner 1999)
  
1.4 The role of systemic inflammatory response in the 
development of multiple organ dysfunction syndrome 
(MODS) 
1.4.1 Oxidative stress and MODS 
1.4.1.1 Cytokine effect on reactive oxygen species production 
There is mounting evidence that tissue injury is mediated at least in part by oxidative 
metabolites, or reactive oxygen species (ROS), derived from inflammatory cells and/or 
hypoxia (Hill & Hill 1998).  ROS induce direct oxidative tissue injury by means of 
peroxidation of cellular membranes, oxidation of critical enzymatic and structural proteins 
and induction apoptosis. In addition, the activation of nuclear factor–kappa B (NF-κB) by 
ROS leads to the induction of genes critical to the initiation and establishment of the 
systemic inflammatory response (Ziegler-Heitbrock et al. 1993). As radicals may be 
produced via normal intracellular processes, but during inflammation in an exaggerated 
manner by inflammatory cells, a vicious cycle occurs.  Any insult, if severe enough, may 
induce the release of proinflammatory mediators and may result in the formation of 
reactive oxygen species, possibly as following the activation of polymorphonuclear 
leukocyte and other reticulo-endothelial cells. 
1.4.1.2 Increased oxidative stress, NF-κB cycle and development of MODS  
The activity of ROS is normally limited by the antioxidant defence system of the body. In 
critically ill patients, the antioxidant capacity is likely to be compromised due to increased 
utilization in the face of increased ROS production (Goode & Webster 1993) and perhaps 
redistribution due to the acute–phase response (Louw et al.1992; Shenkin 1997). 
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Many critically ill surgical patients survive their initial physiologic insult only to die of 
infection or organ dysfunction over the ensuing days to weeks.  The profound oxidative 
stress that occurs during critical illness is likely to lead to early depletion of many 
endogenous antioxidants.  In general, plasma antioxidant vitamin concentrations seem to 
decrease and measures of oxidative stress seem to increase in critically ill populations 
(Oldham & Bowen 1998).  It has been proposed that the critically ill patient has an 
increased need for antioxidants, due to hypermetabolism and increased losses.  The relative 
decrease in antioxidant capacity appears to correlate with the severity of illness and 
suggests a causal relationship between antioxidant depletion and organ dysfunction (Goode 
et al. 1995; Borrelli et al. 1996).  Micronutrient deficiency is often associated with defects 
in a number of organ systems, including the gastrointestinal, cardiovascular, 
haematological and musculoskeletal systems. 
Antioxidant capacity may also be compromised in critically ill patients through 
redistribution of plasma–binding proteins, i.e. albumin, as part of the acute inflammatory 
response (Galloway, McMillan & Sattar 2000), poor nutritional state, and inadequate 
provision of optimal nutrition (O'Leary-Kelley et al. 2005).  Given the apparent role 
oxidative stress and anti-oxidant mediated injury play in the development of acute 
respiratory distress syndrome and multiple organ failure, supplementation with 
antioxidants may augment endogenous antioxidant defences and serve to modulate the 
development of organ dysfunction.   
There is some evidence that patients admitted to the ICU have reduced antioxidant 
capacity (Cowley et al. 1996; Alonso de Vega et al. 2002; Doise et al. 2008).  It has been 
demonstrated that plasma redox status, as measured by the ratio of plasma total antioxidant 
capacity to lipoperoxides, significantly correlates to severity of disease, as measured by 
APACHE III (r2=0.56, p<0.001), and survival in critically ill patients (Alonso de Vega et 
al. 2002).  Moreover, survivors tend to have greater plasma antioxidant potential, by 
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approximately 8%, compared with nonsurvivors and, despite having an initial plasma 
antioxidant potential value lower than normal, survivors seem to be able to attain normal or 
supranormal values rapidly comparing to non-survivors that do not seem able to reach the 
normal values (Cowley et al. 1996). 
Indeed, the critically ill patients appear to have decreased concentrations of plasma total 
radical–trapping antioxidant parameter (TRAP) and its components, such as vitamin C, 
vitamin E, and plasma unidentified antioxidants (Tsai et al. 2000; Alonso de Vega et al. 
2002) and increased lipid peroxidation as shown by elevated concentrations of 
thiobarbituric acid–reactive substances (TBARS; Motoyama et al. 2003).  In addition, the 
magnitude of oxidative stress appears to be proportional to the severity of multiple organ 
dysfunction syndrome (Motoyama et al. 2003).  Modulating the oxidative stress seems to 
be one important intervention to control the systemic inflammatory response associated 
with acute respiratory distress syndrome and sepsis (Zhang, Slutsky & Vincent 2000; Lang 
et al. 2002).  
As oxidative stress, measured by markers like malondialdehyde (MDA) and F2 
isoprostanes, has been found to be increased (1.2 and 1.3 times, respectively) in non-
survivor critically ill patients compared to survivors (Mishra et al. 2005), antioxidant 
deficiency may be related to less optimal recovery of the critically ill patient.  Indeed in 
critically ill patients, MDA and F2 isoprostanes have both been shown to be positively 
correlated with multiple organ dysfunction syndrome on admission to ICU (Mishra et al. 
2005).  In patients with severe burns, increased oxidative stress (TBARS, 2.5 times higher 
comparing to healthy controls) is consistent with decreased plasma concentrations of the 
antioxidant vitamin C by approximately 60% (Bertin-Maghit et al. 2000). 
The role of malondialdehyde concentrations in critical illness is not well understood.  
However, increased free MDA (unbound to plasma proteins) has been previously been 
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described to be an important marker during lipid peroxidation (Lee & Csallany 1987; 
Carbonneau et al. 1991; Draper et al. 1993; Cighetti et al. 2005; Hong et al. 2000; Grotto et 
al. 2007) and therefore increased free MDA concentrations may reflect increased free 
radical damage.  Furthermore, increased free MDA concentrations may also have the 
potential to directly damage cellular proteins and DNA (Fleming et al. 1982; Cross et al. 
1987; Hruszkewycz 1988).  Measurement of MDA concentrations in combination with 
micronutrient concentrations have been proposed to be one of the most reliable markers of 
oxidative stress in patients with critical illness (Grune & Berger 2007). 
A proposed mechanism of how the production and circulation of free radicals can 
exacerbate the inflammatory response has recently been described.  Free radicals may 
cause a cascade of intracellular events which appear to be involved in the liberation of 
nuclear transcription factor-kappa B (NF-kB) from its inhibitory protein IkB in the 
cytoplasm (Flohe et al. 1997; Bulger, Garcia & Maier 2002).  This would allow its 
translocation into the nucleus and its binding with the DNA, enabling the initiation of the 
transcription process.  NF-κB has been demonstrated to be a central transcription factor 
that controls the production of the acute phase mediators including cytokines and 
macrophage stimulating factors (Flohe et al. 1997; Bulger, Garcia & Maier 2002).  These 
factors may in turn activate NF-kB in macrophages, amplifying the inflammatory cascade 
involved in the regulation of several inflammatory genes (Flohe et al. 1997; Bulger, Garcia 
& Maier 2002).  Thus, activation of NF-κB may lead to the induction of genes integral to 
the systemic inflammatory response (Ziegler-Heitbrock et al. 1993; Blackwell & 
Christman 1997) leading to a viscous cycle of products that activate each other resulting in 
a difficult to control inflammatory status.  It is therefore of interest that the activation of 
the NF-κB is blocked by several antioxidants including α-tocopherol (Suzuki & Packer 
1993; Packer & Suzuki 1993; Schreck & Baeuerle 1994). 
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Taken together these results suggest that supplementing these patients with antioxidants 
might reverse the effect of oxidative stress, reduce the incidence of multiple organ failure 
and perhaps reduce mortality.  Indeed, patients receiving antioxidants (α-tocopherol and 
ascorbate) were less likely to develop multiple organ failure and had a 1.2 day reduction in 
their ICU length of stay (Nathens et al. 2002). 
However, micronutrient concentrations are recognized to decrease acutely as part of the 
systemic inflammatory response in apparently healthy subjects and patients undergoing 
elective surgery (Galloway et al. 2000; Gray et al. 2004; Gray et al. 2005) and therefore 
differentiation of the effect of reduced dietary intake, redistribution or increased 
consumption on antioxidant concentrations is problematical and raises a number of 
important issues: 
How important is vitamin supplementation for patients with critical illness? 
More specifically: 
How do we assess and monitor vitamin status accurately and reliably so that we know 
when the critically ill patient is deficient and requires supplementation? 
Are intracellular (red cell or white cell) concentrations of vitamins, compared with 
functional tests or plasma concentrations, firstly independent of the magnitude of injury, 
secondly more reliable indicators of vitamin status and thirdly closely associated with poor 
outcome in patients with critical illness? 
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1.5 The inflammatory response and outcome in critical illness 
1.5.1 The prognostic role of C-reactive protein in critical illness 
C-reactive protein concentrations have been found to be predictive of outcome in various 
chronic inflammatory diseases, such as advanced cancer (O'Gorman, McMillan & 
McArdle 2000; Mahmoud & Rivera 2002; Scott et al. 2002; Bromwich et al. 2004). 
In critical illness, high C-reactive protein concentrations have been associated with organ 
dysfunction, longer ICU length of stay, and high mortality rates.  Indeed, in patients with 
C-reactive protein concentrations >10 mg/dl, a decrease in C-reactive protein 
concentrations 48 hours after admission has been associated with a mortality rate of 15% 
while an increase has been associated with a mortality rate of 61% (Lobo et al. 2003).  In 
addition, an increment in C-reactive protein concentrations by 10 mg/l has been associated 
with an increased odds ratio of post–ICU death (OR=1.09, 95% CI=1.03-1.16) 
independently of predictive scores such as APACHE II and SOFA scores (Ho et al. 2008).  
In contrast, a previous study failed to show such discrimination between hospital survivors 
and non-survivors, with suspected sepsis, after discharged from ICU (Pettila et al. 2002). 
1.5.2 The prognostic role of albumin in critical illness 
It is common knowledge that plasma albumin concentrations, in acute and chronic illness, 
are inversely related to risk of death.  In a meta-analysis of 10 studies (Goldwasser & 
Feldman 1997) estimated that there is an increase in the odds of death ranges from 24-56% 
for each 2.5 g/l decrement in albumin concentrations.  The association was persistent even 
when it was adjusted for other known risk factors, pre-existing illness, and exclusion of 
early mortality (Goldwasser & Feldman 1997).  Another more recent meta-analysis 
showed similar results in 90 cohort studies, with each 10 g/l albumin decline to 
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significantly raise the mortality odds by 137% independent of both nutritional status and 
inflammation (Vincent et al. 2003).   
In order to correct hypoalbuminaemia, replace volume and support colloid oncotic pressure 
(Soni 1995) the use of albumin has been advocated in the past.  However, no beneficial 
effect on the administration of albumin has been found on mortality and there is a strong 
suggestion that it may increase the risk of death by 6% in patients with hypovolaemia, 
burns, or hypoproteinaemia compared with controls (Roberts 1998).  In the SOAP study, 
albumin administration was associated with decreased survival in ICU with approximately 
7% greater ICU and hospital mortality rates compared with controls (Vincent et al. 2005).  
In contrast, the SAFE study, which included more than six thousand ICU patients, showed 
that the outcome of resuscitation of whether albumin or saline is independent of the 
baseline albumin concentrations (Finfer et al. 2006).  Finally, the meta-analysis by Vincent 
and coworkers (2003) suggested that in order for albumin replacement to become effective, 
albumin concentrations should exceed 30 g/l.   
Possible reasons for this adverse effect of albumin replacement therapy may be the 
increased anticoagulant activity and the increased oedema that albumin administration may 
cause (Fleck et al. 1985; Soni 1995), which could both be detrimental for the compromised 
critically ill patient. 
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1.6 Assessment of vitamin status in hospitalised patients 
Vitamin status can be defined as the extent to which an individual’s physiologic need for 
vitamins is being met.  It is in other words the state of vitamin sufficiency or deficiency of 
any person.  Optimal vitamin status is a balance between vitamin intake and vitamin 
requirements and a balance in these two factors is crucial in determining an individual’s 
state of health.  Vitamin intake depends on actual food consumption which can be 
influenced by various factors such as economic status, eating behaviour, emotional status, 
cultural influences, disease, and the ability to absorb the vitamins consumed.  Vitamin 
requirements are also influenced by many factors, including infection, disease, fever or 
trauma, growth, pregnancy, etc.  
1.6.1 Malnutrition 
Malnutrition is a major clinical problem in the UK and is often unrecognized and untreated 
in hospitals. Indeed, around 70% of the malnourished patients go unrecognised following 
their hospital admission (Kelly et al., 2000).  Malnutrition predisposes to disease, delays 
recovery from illness, and adversely affects body function, well-being and clinical 
outcome.  Approximately 40% of the patients admitted to Scottish hospitals are already 
undernourished while the percentage of patients at risk of being malnourished is even 
greater (McWhirter & Pennington, 1994).  In 2000, one out of four patients admitted to 
four hospitals in England were malnourished and this adversely affected their length of 
stay, the numbers of new prescriptions needed, prevalence of infections and disease 
severity (Edington et al., 2000).  It is even more worrying that nutritional status is known 
to deteriorate over the course of the hospital stay, with 75% of the malnourished patients 
on admission having lost even more weight upon discharge, reclassifying 37% of those 
initially assessed as moderately undernourished to severely undernourished (McWhirter & 
Pennington, 1994).  It has been estimated that the length of hospital stay for patients at risk 
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of malnutrition is 50% longer and costs are 36% higher than for those of well nourished 
patients (Chima et al., 1997) and thus it is noteworthy that malnutrition costs the UK more 
than ₤ 7.3 billion of actual expenditure each year while obesity costs less than half of this 
amount (BAPEN 2005).  
One of the reasons why malnutrition is still such a major clinical problem in hospitals is 
the lack of consistent and universally accepted criteria which can clearly distinguish 
between malnourished and well – nourished patients.  Generally the diagnosis of 
malnutrition is based on objective and subjective measurements of nutritional status, 
including assessments of oral energy intake, weight loss, anthropometric measurements, 
determination of cell - mediated immunity, biochemical indices and body composition 
analysis (Pablo et al., 2003).  As the criteria used to define undernutrition vary, studies that 
try to address the problem use different methods to assess nutritional status and thus 
comparison between the studies is almost impossible.  Revision of guidelines to give 
specific directions on the anthropometric, clinical and biochemical components that should 
be included in the nutritional assessment (Corish & Kennedy, 2000) and also a practical 
definition of malnutrition (Edington et al., 2000) seem to be an on-going challenge.  This is 
a necessity if we are to address properly the problem of malnutrition through scientific 
research (Corish & Kennedy, 2000) and/or education of the health care professionals in 
hospitals and in the community (Edington et al., 2000).  
Weight may be not an accurate measurement of nutritional status in critical illness, as it 
can change due to oedema and fluid retention.  Lately, it has become evident that during 
acute illness the amount of weight loss generally is not as important for outcome as the fat-
free mass that has been lost.  A low fat free mass was noted in 37% of patients hospitalized 
1-2 days and this increased to 56% of patients hospitalized > 12 days (Pichard et al., 2004).  
Patients with lower fat – free mass index (fat free mass corrected for height) had twice 
longer lengths of hospital stay comparing to patients with normal or high fat –free mass 
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index (Pichard et al., 2004).  Also, 1 in 4 of acutely ill and 1 in 3 of chronically ill patients 
admitted to the hospital have been shown to have fat free mass below the 10th percentile as 
assessed by BIA measurements and these did not correlate with their BMI measurements 
(approximately 16% of acutely ill and 19% of chronically ill with BMI ≤ 20 kg/m2) (Kyle 
et al., 2002).   
1.6.2 Clinical assessment of vitamin deficiency 
Clinical evidence of vitamin deficiency is rare in modern Western medical practice. In 
addition, clinical symptoms occur at the final stages of vitamin deficiency thus their value 
as markers of vitamin deficiency and predictors of outcome in patients with critical illness 
comes possibly too late for both the clinician and the patient. 
In critical illness where requirements for anti-oxidant and other vitamins may be increased, 
subclinical deficiency of many vitamins could have a negative impact on survival.  
Identifying patients likely to have relative deficiencies of important vitamins may be 
helpful in guiding the need for replacement and in anticipating the response to 
supplementation. The first step in identifying such patients is awareness of possible 
underlying conditions, co-morbidities or pre-existing illness that may predispose to 
clinically relevant vitamin deficiency. 
1.6.3 Assessment of comorbidity which might lead to vitamin deficiency  
In Scotland there were 42,430 alcohol related discharges from general hospitals in 
2007/2008 with 13, 495 discharges in Greater Glasgow and Clyde specifically (Alcohol 
Statistics Scotland 2009).  Subclinical thiamine deficiency develops in alcoholics who tend 
to have low thiamine intake and impaired absorption of the vitamin (Gallacher 2004).  In 
addition, thiamine is important for the metabolism of ethanol so it may be consumed more 
rapidly in alcoholics (Jolliffe, Colbert & Joffe 1936; Gallacher 2004).  Wernicke-
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Korsakoff syndrome is a type of encephalopathy, which usually occurs when deficiency 
persists, and its signs range from mild confusion to coma.   
Other diseases or comorbidities that might lead to vitamin deficiency are: 
1. Diseases/ Comorbidities that have a negative impact to appetite and food intake 
such as prolonged illness and hospitalisation with inadequate nutritional support, 
old age, some cancers that can obstruct the GI tract such as head and neck cancers, 
cancer treatment such as radiotherapy. 
2. Diseases/ Comorbidities that have a negative impact to vitamin absorption, such as 
Crohn’s disease, short gut syndrome, liver disease and pancreatic disease, or an 
increased impact in vitamin excretion such as renal disease.  
3. Diseases that have an increased demand of specific vitamins and antioxidants such 
as burns, trauma, inflammatory and septic states.   
4. A combination of the above may occur such as the common scenario in Glasgow 
Royal Infirmary of alcoholics with acute pancreatitis admitted to ICU 2-3 weeks 
into the illness having developed infected pancreatic necrosis. 
1.6.4 Assessment of vitamin intake 
Nutritional and more specifically vitamin requirements increase due to different reasons in 
specific illnesses, reasons which may vary between dysphagia to malabsorption.  This 
would also indicate that consideration of the route of supplementation, i.e. via oral, enteral 
or parenteral routes, is an essential step in prevention or, at a further stage, correction of 
any vitamin deficiencies.  The response of supplementation should then be assessed taking 
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into consideration the extent of pre-existing deficiency, the amount and frequency of the 
supplementation and the requirements of the underlying illness. 
When there is inadequate intake, impaired absorption and/ or increased nutrient losses, this 
can lead to body stores (tissue) depletion which has as a consequence a series of states such 
as biologic dysfunction, physiologic dysfunction, cellular dysfunction, clinical signs and 
symptoms of deficiency, morbidity and finally mortality as the deficiency progresses.  As a 
first approach of nutritional assessment a weight and dietary history could be obtained to 
assess adequacy of intake.  The second level of vitamin assessment is biochemical 
measurements in order to identify store depletion when inadequate intake, compromised 
absorption and/or increased vitamin losses progress.  At a further stage assessment of 
clinica signs and symptoms could identify cellular dysfunction and morbidity.  
Nevertheless, most of the above methods of assessing nutritional status are often of limited 
value in the critically ill patient, bringing challenge to the assessment of vitamin status 
(Manning & Shenkin 1995; Winkler & Malone 2004).  The critically ill patients are a 
heterogenous group with different medical backgrounds, and are usually unable to provide 
a dietary history due to sedation/confusion, weight measurements may be erroneous after 
fluid resuscitation and/ or oedema, and anthropometric measurements are not easily 
attainable, may be erroneous due to oedema, have been shown to be less sensitive to acute 
changes of status (Harvey et al. 1981; Winkler & Malone 2004). 
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1.7 Vitamin concentrations and biochemical assessment during 
the systemic inflammatory response and critical illness 
For most watersoluble vitamins, biochemical measurements were performed using 
functional tests. This is routinely assessed by measuring activity in red cell enzymes that 
require the vitamins as cofactors (Tomkins 2003).  However, such functional tests are 
indirect, prone to error and maybe affected by factors other than vitamin status (Talwar et 
al. 2000).  It is now generally accepted that direct measurements of vitamins, usually in 
plasma, are more reliable for assessing status (Talwar et al. 2000).  In the patient with 
critical illness, this presents a problem since plasma or serum concentrations of many 
vitamins are substantially changed as part of the systemic inflammatory response.  Indeed, 
it has been proposed that vitamin concentrations are only of value in these patients when 
used sequentially, and when interpretation is linked to changes in the magnitude of the 
acute–phase response, e.g. by measuring C-reactive protein concentrations (Shenkin 2000). 
1.7.1 Vitamins B1, B2, B6 
In the critically-ill patient, vitamin B deficiencies have been associated with the serious 
complications of Wernicke – Korsakoff syndrome (Denny–Brown 1958), compromised 
immune and antioxidant status (Grimble 1997) and poor survival (Cruickshank, Telfer & 
Shenkin 1988; Shenkin, Cruickshank & Shenkin 1989).  For example, the role of B2 and 
B6 vitamins on immune function, by maintenance of glutathione status, has been well–
described (Grimble 1997).  Vitamin B2 has shown a suppressive effect on the production 
of tissue inflammatory mediators and also decreases plasma elevated nitric oxide levels 
(Kodama et al. 2005).  Vitamin B6 status appears to positively relate to lymphocyte 
proliferation (Kwak et al. 2002; Cheng et al. 2006).  Therefore, the accurate assessment of 
B-vitamin status in patients with critical illness is of considerable importance.  
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1.7.1.1 Functional tests 
Functional tests have been used extensively in the past and continue to be used for the 
assessment of B-vitamin status for both healthy and critically ill patients.  In healthy 
patients undergoing elective surgery, for example, erythrocyte riboflavin coefficient 
concentrations were not reported to change significantly (Louw et al. 1992).  Also, in 
patients on long–term parenteral nutrition and evidence of inflammatory response 
functional tests for both vitamins B1 and B2 were normal (Labadarios et al. 1988).  In 
contrast, low levels of vitamins B1 (Cruickshank, Telfer & Shenkin 1988) and B2 status 
(Shenkin, Chruickshank & Shenkin 1989), as assessed by erythrocyte trasketolase activity 
and erythrocyte glutathione reductase activation respectively, have both been shown to be 
associated with worse outcome in patients with critical illness.  Indeed, of the patients who 
died, 29% had low vitamin B1 status compared with 11% in those who survived (p<0.01; 
Cruickshank, Telfer & Shenkin 1988).  
The effect of supplementation appears to be reflected in enzymatic activity measurements. 
Bradley and coworkers (1978) reported that, in critically ill patients, red cell B1, B2 and 
B6 status, as measured by methods based on red cell enzyme saturation, was increased by 
the daily administration of a parenteral multivitamin supplement containing 50 mg vitamin 
B1–chloride hydrochloride, 10 mg vitamin B2–5–phosphate sodium salt and 15 mg 
vitamin B6 hydrochloride. Moreover, this increased and normalised vitamin status was 
associated with improved clinical outcome (Bradley et al. 1978). 
1.7.1.2 Plasma measurements 
In plasma, B–vitamin concentrations are lowered in the presence of a systemic 
inflammatory response in both healthy subjects and critically ill patients.  For vitamin B6, 
for example, a significant decrease, approximately 50%, has been reported in subjects 
undergoing elective surgery (Louw et al. 1992; Gray et al. 2004), critically ill patients 
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(Huang et al. 2005) and in elderly healthy subjects (Friso et al. 2001).  The inverse effect 
of inflammation on plasma vitamin concentrations agrees with the observations of 
Labadarios and co-workers (1988) who observed low plasma B6 concentrations in the 
great majority of their patients who had evidence of inflammation.  In the same manner, in 
46 critically ill patients, Huang and co-workers (2002) showed that vitamin B6 
supplementation (15 mg) was unable to increase their plasma pyridoxal 5’-phosphate and 
pyridoxal concentrations.  Indeed, plasma concentrations for both markers decreased by 
approximately 20%. 
1.7.1.3 Red cell measurements 
Hustad and coworkers (2002) have reported that plasma flavine adenine dinucleotide 
(FAD) is possibly an inappropriate indicator of vitamin B2 status and that the measurement 
of plasma riboflavin and erythrocyte flavine mononucleotide (FMN) could be more 
appropriate for population studies.  There might be a problem with hydrolysis of FAD to 
FMN within the first minutes of sampling (Akimoto et al. 2006). 
Also, Talwar and colleagues (2003b) reported that during the presence of a systemic 
inflammatory response, plasma pyridoxal 5’-phosphate (PLP) but not red cell PLP 
concentrations were decreased by approximately 50% in critically ill patients compared 
with healthy subjects. This would suggest that vitamin B6 status, as measured by PLP, may 
not reflect supplementation of vitamin B6 in critically ill patients.  In agreement it has been 
reported that, on supplementation, PLP concentrations were increased in red cells but not 
in plasma in critically ill patients (Talwar et al. 2003b; Quasim et al. 2005). It is not clear 
whether red cell and functional tests of B vitamins correlate in critically ill patients as they 
do in healthy subjects (Talwar et al. 2000; Hustad et al. 2002). 
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1.7.1.4 White cell measurements 
White cell B6 vitamin concentrations correlate well with either plasma or functional tests 
in healthy subjects (Kwak et al. 2002).  However, from the literature the relationship 
between plasma, red cell and white cell B–vitamin concentrations and outcome in patients 
with critical illness has not been examined.  
1.7.2 Vitamin C 
The role of vitamin C in alleviating the oxidant stress in vitro is well documented (Cross et 
al. 1990; Dhariwal, Washko & Levine 1990; Downing et al. 1993).  However, there is 
conflicting evidence on whether supplementation with vitamin C is of any benefit for 
patients with critical illness.  Supplementation of ascorbic acid (500mg/d) and α–
tocopherol (400 IU/d) was reported to reduce oxidative stress, as measured by plasma 
TBARS and plasma PGF2α isoprostanes, and to reduce 28-day mortality in critically ill 
patients approximately by 20% (45.7% in the antioxidant group and 67.5% in the control 
group, p<0.05; Crimi et al. 2004).   
However, vitamin C supplementation (12.5 mg/kg body weight) immediately after injury 
was found to act as a pro-oxidant by increasing oxidative stress and tissue damage 
probably because of its role in mobilization of metals, such as iron, from their stores 
(Childs et al. 2001).   
Therefore, it is important to accurately and reliably assess vitamin C status and the effect 
of supplementation especially in patients with critical illness, as oxidative stress may 
contribute to multiple organ dysfunction syndrome.  Assessment of vitamin C status is 
usually carried out in plasma or white cells since red cell vitamin C is analytically difficult 
to measure in presence of oxygen and the potential of oxidation of vitamin C by the 
haemoglobin iron (Jacob, Scala & Omaye 1987; Fell & Talwar 1998). 
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1.7.2.1 Plasma measurements 
Plasma vitamin C concentrations have been found to be negatively correlated with plasma 
C-reactive protein concentrations in patients with gastrointestinal adenocarcinoma, and in 
addition, weight-losing patients had lower concentrations of the vitamin compared with the 
weight-stable patients (Georgiannos, Weston & Goode 1993).  In patients on prolonged 
parenteral nutrition, 25 out of 30 had lower than normal plasma vitamin C concentrations 
(Labadarios et al. 1988).  In critically ill patients, the severity of acute phase response has 
also been reported to be in part responsible for the lowering of plasma vitamin C 
concentrations.  For example, plasma vitamin C concentrations were 25% lower in 
critically ill patients compared with control subjects, and were related to increased length 
of ICU stay and the severity of acute phase response, as measured by C–reactive protein 
(Schorah et al. 1996). 
In healthy patients with normal pre–operative plasma concentrations of ascorbic acid, a 
single oral supplementation with 1,000 mg of ascorbic acid was unable to prevent the fall 
in postoperative plasma concentrations (Rumelin et al. 2002).  In the same manner, 
supplementation of intravenous 1,000 mg vitamin C for 3 days was unable to prevent the 
fall of plasma concentrations to undetectable levels by day 12 in alcoholic critically ill 
patients (Mishra et al. 2005). 
In healthy subjects, parenteral supplementation with large amounts of ascorbic acid 
(500mg four times in 12 hours and then 500mg twice a day) post–operatively, is suggested 
to be able to sustain the preoperative plasma concentrations (Rumelin et al. 2005).  In 
critically ill surgical patients, a combined parenteral supplement of a-tocopherol (1000 
IU/d) and ascorbic acid (1000 mg/d) eight times per day was able to increase plasma 
concentrations of these vitamins and reduce the incidence of organ failure, shorten the 
duration of mechanical ventilation and ICU length of stay (Nathens et al. 2002).  
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1.7.2.2 White cell measurements 
In white cells, vitamin C measurements are considered to be the best marker of status 
however it is analytically too difficult to be suitable for use routinely.  White cell vitamin 
C has been found to decrease during the systemic inflammatory response by approximately 
40% in patients undergoing orthopaedic surgery (Louw et al. 1992).  To date the 
relationship between plasma and white cell vitamin C concentrations and outcome in 
patients with critical illness has not been examined. 
1.7.3 Vitamin E 
Patients admitted to the ICU may have reduced total antioxidant capacity, with low plasma 
concentrations of vitamin E (α-tocopherol) (Goode et al. 1995; Borrelli et al. 1996; Metnitz 
et al. 1999).  Low plasma concentrations of α-tocopherol have been shown in patients with 
sepsis and secondary organ dysfunction (Goode et al. 1995).  This depletion appears to 
correlate with the severity of illness and has a causal relationship between antioxidant 
depletion and increasing levels of organ dysfunction (Goode et al. 1995; Borrelli et al. 
1996; Cowley et al. 1996; Mishra et al. 2005).  In addition, these patients appear to have a 
substantial increase of nitrite excretion (Goode et al. 1995) as well as of products of lipid 
peroxidation all markers of increased free radical activity.  For example, patients with 
trauma or sepsis appear to have increased lipid peroxidation and decreased circulating 
endogenous antioxidants including vitamin E (Goode et al. 1995; Metnitz et al. 1999). 
Vitamin E (α-tocopherol) is one of the most important lipid soluble antioxidants with its 
biological function in biomembranes.  It has been described as the major chain- breaking 
antioxidant, interrupting the chain of membrane lipid peroxidation.  Vitamin E is also 
present in lipoproteins, protecting polyunsaturated fatty acids from peroxidation.  In case 
of inflammation, vitamin E is thought to be necessary for the maintenance of an 
appropriate immune response to infection.  Vitamin E supplementation has been shown to 
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reduce organ failure and infectious complications in patients with critical illness (Nathens 
et al. 2002). 
The depletion of circulating antioxidants, such as vitamin E is likely to have a considerable 
impact on the antioxidant reserve in critical illness.  However, the presence of antioxidant 
vitamins deficiency in plasma may not reflect cellular deficiency.  Systemic inflammatory 
response syndrome is associated with a redistribution of vitamins and trace elements from 
the circulating compartment to tissues and organs, which are involved in protein synthesis 
and immune cell production (Galloway, McMillan & Sattar 2000). 
1.7.3.1 Plasma measurements 
Being one of the most important antioxidants, the role of vitamin E in critical illness has 
long been of interest.  Goode and coworkers (1995) showed that plasma α-tocopherol 
(vitamin E) was well below the reference ranges for all critically ill patients.  Borrelli and 
coworkers (1996) however, did not find a difference in plasma α-tocopherol concentrations 
between critically ill patients who developed or not multiple organ failure. However, both 
of these studies investigated only a small number of patients (n=16) and did not express 
their plasma vitamin E concentrations per mmol of cholesterol, that act as a carrier in the 
plasma and fall in the presence of the inflammatory response (Quasim et al. 2003; Gray et 
al. 2005).  Therefore, the role of plasma concentrations of vitamin E in outcome in patients 
with critical illness is not clear.  
1.7.3.2 Red cell measurements 
Red cell α-tocopherol is thought to be a reliable marker of vitamin E status in 
biomembranes (Kitagawa, Nakagawa & Mino 1983).  Although there is a positive 
correlation between plasma and red cell α-tocopherol concentrations in non-inflamed 
subjects (Kitagawa, Nakagawa & Mino 1983), this relation is not as high as would be 
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expected in vitro studies, which show α-tocopherol freely exchanged between plasma and 
blood cells (Silber, Winter & Kayden 1969).  Moreover, there are strong correlations 
between red cell and liver α-tocopherol, whilst this correlation did not occur for plasma 
vitamin E concentrations (Mino, Kasugai & Shimizu 1985).  In addition, studies by Simon 
and coworkers (1997; 1998) in hypercholesterolemic men showed that red blood cell 
vitamin E content was decreased although their α-tocopherol plasma concentrations, 
expressed per mmol of lipids, were unchanged compared to normocholesterolemic men.  
Lehmann and coworkers (1988) in a study of healthy subjects reported that plasma α- 
tocopherol was weakly correlated with red cell concentrations.  Moreover, red cell α-
tocopherol concentration was more sensitive to supplementation. 
There are studies that have used red cell α-tocopherol concentrations as a marker of 
vitamin E status instead of plasma; these measurements have been used to assess the 
potential changes within and between groups in cystic fibrosis (Winklhoferroob et al. 
1992), in smoker and non smoker groups (Brown, Morrice & Duthie 1997), in type I 
diabetic children (Jain, McVie & Smith 2000) and in early stages of atherosclerosis 
(Bonithon-Kopp et al. 1997).  Results from these studies showed significant correlations 
between red cell vitamin E status and markers of oxidative stress, or a dose response 
relationship in cases of supplementation.   
A study by Simon and coworkers (2001) in subjects at cardiovascular risk found a negative 
correlation between of carotid intima-media thickness indicator, an indicator of early 
atherosclerosis, and red cell α-tocopherol concentrations while no such correlation was 
found in plasma, expressed or not per HDL concentrations, α-tocopherol concentrations. 
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1.7.4 Carotenoids 
1.7.4.1 Plasma measurements 
Recently, there is some evidence that carotenoids may be implicated in the oxidative stress 
observed during the acute phase response in critically ill patients (Quasim et al. 2003).  
Lycopene seems to be the carotenoid affected in a greater scale comparing to the others 
during this increased breakdown (McMillan et al. 2002) and it has also been shown that β-
carotene, the most active of the carotenoids, is also inversely related to systemic markers of 
inflammation (Erlinger et al. 2001).  On the other hand, when expressed per mmol of 
cholesterol (i.e. the concentrations of the carotenoids were expressed per mmol of 
cholesterol to correct for the effect of the systemic inflammatory response on lipids; 
Thurnham et al. 1986; Thurnham et al. 2008; Doise et al. 2008) , neither α–tocopherol, 
lutein, lycopene, α–carotene nor β–carotene plasma concentrations decrease following 
elective surgery, showing that the redistribution that occurs during the systemic 
inflammatory response may falsely be interpreted as overconsumption of these 
antioxidants (Gray et al. 2005).  Therefore, the role of plasma concentrations of 
carotenoids in outcome in patients with critical illness is not clear. 
  
Table 1-2 The effect of SIRS on vitamin B, C, A, E and carotenoids’ concentrations in critically patients with or without vitamin supplementation. 
 
Study Type of study 
and number of 
subjects 
Vitamins 
assessed 
Method of 
measurement 
Markers affected Effect Nutrition 
Bradley et al. 
1978 
Surgical critically 
ill patients (N=26) 
 
Non–randomised 
controlled trial 
Vitamin B1 
Vitamin B2 
Vitamin B6 
Vitamin C 
Red cell 
enzymatic 
saturation 
White cell 
vitamin C 
Vitamin B1, vitamin B6 and 
vitamin low on baseline, 
normalized by the end of the 
treatment period. 
12% decrease in enzymatic saturation 
for vitamin B1 
17% decrease in enzymatic saturation 
for vitamin B6 
29% increase in white cell vitamin C 
concentrations 
IV supplementation 
of 50 mg vitamin 
B1, 10 mg vitamin 
B2, 15 mg of 
vitamin B6 and 500 
mg of vitamin C 
Cruickshank, 
Telfer & 
Shenkin 1988  
Critically ill 
patients (N=158) 
 
Retrospective study 
Vitamin B1 Erythrocyte 
transketolase 
activity 
Lower levels in non – 
survivors compared with 
survivors  
 
Supplementation unable to 
correct abnormal levels 
Non – survivors: median enzyme 
activation = 15% 
 
Survivors : median enzyme activation = 
10% 
(Normal activity: <25%) 
Full continuous IV 
with 1.2 mg 
thiamine per day 
Shenkin, 
Cruickshank 
& Shenkin 
1989 
Critically ill 
patients (N=152) 
 
Retrospective study 
Vitamin B1 
 
 
 
Vitamin B2 
Erythrocyte 
transketolase 
activation 
 
Erythrocyte 
glutathione 
reductase  
 
Lower levels in non – 
survivors compared with 
survivors for both of the 
vitamins 
 
Levels for B2 were normal 
for both groups although 
significantly lower for non – 
survivors 
Non – survivors: median enzyme 
activation B1 = 15%, B2 = 29% 
 
Survivors : median enzyme activation 
B1=10%, B2=12% 
 
IV supplementation 
with 1.8 mg 
riboflavin per day 
Huang et al. 
2002 
Critically ill 
patients (N=46) 
 
Prospective, 
observational study 
Vitamin B6 Plasma PLP and 
PL 
EALT–AC 
EAST–AC  
Low concentrations even 
with supplementation 
No change in functional 
tests 
Plasma PLP and PL decreased by 19% 
 
EN, TPN or IV 
supplementation of 
15 mg vitamin B6 
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Table 1-2 The effect of SIRS on vitamin B, C, A, E and carotenoids’ concentrations in critically patients with or without vitamin supplementation 
(continued). 
Study Type of study 
and number of 
subjects 
Vitamins 
assessed 
Method of 
measurement 
Markers affected Effect Nutrition 
Talwar et al. 
2003b 
 
Critically ill 
patients (N=18) 
 
Prospective, 
observational study 
Vitamin B6 Plasma PLP 
 
Red cell PLP 
Decrease in plasma but not 
in red cells 
49% lower plasma PLP concentrations compared 
with controls 
 
Huang et al. 
2005 
Critically ill 
patients (N=40) 
 
Cross–sectional 
observational study 
Vitamin B6 Plasma PLP and 
PL 
EALT–AC 
EAST–AC 
Marginal PLP deficiency 
compared with controls 
No change in functional 
tests 
Decreased immune response markers  
Quasim et al. 
2005 
Surgical critically 
ill patients (N=41) 
 
Cross–sectional 
observational study 
Vitamin B2 
 
 
Vitamin B6 
Plasma and red 
cell FAD 
 
Plasma and red 
cell PLP 
Plasma concentrations not 
increased with 
supplementation 
Red cell concentrations 
increased with 
supplementation 
Non – supplemented patients: 60% lower plasma 
FAD and 70% lower plasma PLP concentrations 
compared with healthy controls. 
Red cell PLP concentrations were almost two –
fold higher compared with the non–supplemented 
group. 
4 mg riboflavin and 
150 mg pyridoxine 
Cheng et al. 
2006  
Critically ill 
patients (N=51) 
 
Single–blind 
intervention study 
Vitamin B6 Plasma PLP and 
PL 
 
EALT–AC 
EAST–AC  
Increase of plasma PLP and 
PL concentrations with 
supplementation 
50 mg pyridoxine supplementation: 
Plasma PLP increased by 250% and PL by 5000% 
 
100 mg supplementation:  
Plasma PLP increased by 170% and PL by 2500% 
 
IV 50 mg or 100 
mg vitamin B6 for 
14 days 
Schorah et al. 
1996 
Critically ill 
patients (N=62) 
 
Prospective, 
observational study 
Vitamin C Plasma ascorbic 
acid 
Plasma concentrations 
significantly lower 
compared with healthy 
controls. 
More than 25% of the critically ill patients had 
plasma ascorbic acid concentrations 82% lower 
compared with healthy controls. 
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Table 1-2 The effect of SIRS on vitamin B, C, A, E and carotenoids’ concentrations in critically patients with or without vitamin supplementation 
(continued). 
Study Type of study 
and number of 
subjects 
Vitamins 
assessed 
Method of 
measurement 
Markers affected Effect Nutrition 
Tsai et al. 
2000 
Patients with 
evidence of SIRS 
(N=135) 
 
Prospective, 
observational study 
Vitamin E 
 
Vitamin C 
 
Oxidative stress 
Plasma α–
tocopherol 
Plasma ascorbate 
 
TRAP 
Plasma vitamin C and 
TRAP concentrations 
significantly lower by day 
14 in non – survivors 
compared with survivors. 
TRAP showed to be related 
to MODS and CRP.  
Plasma vitamin C was 64% less in 
non–survivors compared to survivors. 
Plasma vitamin E was 18% more in 
non–survivors compared with 
survivors. 
TRAP concentrations were 
significantly correlated to MODS 
(r=0.431, p<0.001) and CRP (r=0.288, 
p=0.03). 
IV supplementation with 
10 mg α–tocopherol and 
100 mg of vitamin C. 
Nathens et al. 
2002 
Trauma/surgical 
critically ill patients 
(N=595) 
 
Randomised, 
prospective trial 
Vitamin E 
 
 
Vitamin C 
Plasma α–
tocopherol 
 
Plasma ascorbate 
There was no change in 
controls while decreased 
plasma concentrations 
normalized in the 
supplemented group. 
Reduced incidence of organ 
failure, duration of 
mechanical ventilation and 
ICU LOS for the 
supplemented group. 
Organ failure incidence decreased by 
57% 
Duration of mechanical ventilation 
decreased by 0.7 days 
ICU LOS decreased by 1 day 
Pulmonary mortality decreased by 19% 
Oral and IV supplement 
of 1000 IU α–tocopherol 
and 1000 mg ascorbic 
acid respectively per day, 
on admission and for 28 
days 
Alonso de 
Vega et al. 
2002 
Critically ill 
patients (N=73) 
 
Prospective, cohort 
study 
Plasma redox 
status 
Plasma antioxidant 
capacity/ 
lipoperoxides 
Plasma redox status on 
admission significantly 
correlated with severity of 
illness and a relationship 
with survival was shown. 
Negative correlation of plasma 
antioxidant capacity (r2=0.53) and 
positive correlation of lipoperoxides 
(r2=0.71) with APACHE III. 
In comparison with survivors (100%), 
non–survivors had increased plasma 
lipoperoxides (147%) and decreased 
total antioxidant capacity (84%).  
Measurements on 
admission before feeding 
administration 
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Table 1-2 The effect of SIRS on vitamin B, C, A, E and carotenoids’ concentrations in critically patients with or without vitamin supplementation 
(continued). 
Study Type of study and 
number of subjects 
Vitamins 
assessed 
Method of 
measurement 
Markers affected Effect Nutrition 
Crimi et al. 
2004 
Critically ill patients 
(N=216) 
 
Randomised, double–
blind, placebo–controlled 
supplementation trial 
Vitamin E 
 
Vitamin C 
 
Oxidative stress 
Plasma and LDL α–
tocopherol 
Plasma ascorbate 
 
TBARS 
Isoprostanes 
Reduced oxidative stress, days 
on ventilator and 28–day 
mortality 
Plasma and LDL α–tocopherol 
increased by 40% 
TBARS reduced by 55% 
Isoprostanes reduced by 37% 
Duration of mechanical 
ventilation decreased by 4.5 days 
28-day mortality decreased by 
22% 
Enteral supplement of 
400 IU α–tocopherol 
and 500 mg ascorbic 
acid per day for 10 days 
Mishra et 
al. 2005 
Critically ill patients 
(N=60)  
 
Prospective, observational 
study 
Vitamin C Plasma ascorbic acid Plasma concentrations decreased 
despite supplementation 
Plasma ascorbic acid 
concentrations fell to 
undetectable levels by 12. 
IV supplementation of 
1000 mg vitamin C per 
day for 3 days 
Doise et al. 
2008 
Critically ill patients 
(N=56) 
 
Prospective, observational 
study 
Total antioxidant 
capacity (TAC) 
 
Vitamin A 
Vitamin E 
 
Vitamin C 
Plasma TAC 
 
 
Plasma retinol 
Plasma α-tocopherol 
Plasma ascorbic acid 
Vitamins A, E and C were 
decreased on baseline in the 
critically ill patients compared to 
controls. 
TAC values statistically declined 
over 10d of ICU stay. Vitamins 
A and E increased over time and 
vitamin C concentrations 
decreased over time. 
 
Vitamins A, E and C were 
decreased on baseline in the 
critically ill patients compared to 
controls by 67%, 46% and 71% 
respectively. 
 
 
Goode et al. 
1995 
Critically ill patients with 
septic shock (N=16) 
 
Prospective, observational 
study 
Vitamin E 
 
 
Carotenoids 
Plasma α-tocopherol 
 
Lycopene 
β-carotene 
Plasma antioxidant 
concentration low compared 
with healthy subjects 
Plasma antioxidant 
concentrations below the 
reference range. 
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Table 1-2 The effect of SIRS on vitamin B, C, A, E and carotenoids’ concentrations in critically patients with or without vitamin supplementation 
(continued). 
Study Type of study 
and number of 
subjects 
Vitamins 
assessed 
Method of 
measurement 
Markers affected Effect Nutrition 
Borrelli et al. 
1996 
Surgical critically 
ill patients (N=16) 
 
Prospective, 
observational study 
Vitamin C 
 
 
Vitamin E 
Plasma ascorbic 
acid 
 
Plasma α-
tocopherol 
Low vitamin C 
concentrations in patients 
going into multiple organ 
failure compared with those 
that were not. 
Approximately 2-3 times lower plasma 
vitamin C concentrations in patients 
with multiple organ failure compared 
with those of the non multiple organ 
failure group. 
No difference was observed for plasma 
vitamin E concentrations. 
 
Quasim et al. 
2003 
Surgical critically 
ill patients (N=43) 
 
Prospective, cross-
sectional study 
Vitamin E 
 
 
Carotenoids 
 
 
 
 
Oxidative stress 
Plasma α-
tocopherol 
 
Lutein 
Lycopene 
α-carotene 
β-carotene 
 
Malonyldialdehyde 
(MDA) 
Compared with healthy 
subjects, plasma antioxidant 
concentrations were 
significantly lower in 
critically ill patients. 
 
Compared with healthy 
subjects, plasma MDA 
concentrations were 
significantly higher in 
critically ill patients. 
 
Lutein and lycopene concentrations 
decreased by 65% and 80% 
respectively in critically ill patients 
when compared with controls. α-
carotene and 
β-carotene were also significantly 
decreased. 
  
After expressing per mmol of 
cholesterol, only α – tocopherol 
concentrations were higher in critically 
ill patients when compared with 
controls or longitudinally. Only 
lycopene concentrations remained in 
low levels when expressed per mmol of 
cholesterol. 
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1.8 Aims of the thesis 
From the introduction there is evidence of the transient changes of plasma vitamin 
concentrations during the systemic inflammatory response.  Therefore the aims of the 
thesis were; 
A) To examine whether, compared with plasma, intracellular vitamin concentrations 
are a more reliable measure of status in patients with critical illness.  And, 
B)  To examine the relationship between plasma and intracellular vitamin 
concentrations and hospital mortality in patients with critical illness. 
In order to address these aims a prospective longitudinal study of the systemic 
inflammatory response, plasma and intracellular vitamin concentrations and outcome in 
patients with critical illness was undertaken. 
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2 Materials and Methods 
2.1.1 Controls, patients and study design 
Blood samples for population references values were obtained from laboratory staff, from 
local health centres and from people attending a cardiovascular risk clinic.  None of the 
subjects were taking any vitamin supplements or had any significant medical history or 
evidence of a systemic inflammatory response (serum C-reactive protein <10 mg/ l).  No 
formal diet histories were taken (Talwar et al. 2003a; Quasim et al. 2005). 
Patients in the Intensive Care Unit (ICU) of the Royal Infirmary, Glasgow, who had 
respiratory failure requiring ventilatory support, were ≥ 18 years old, and who had evidence of 
the systemic inflammatory response syndrome as per Bone’s criteria (1992), were studied.  
Venous blood samples (EDTA) were withdrawn on admission (day 1) and on follow–up (days 
2-7) for the analysis of plasma, red and white cell vitamin analysis.  APACHE II score (Knaus 
et al. 1985b) and associated predicted mortality, SOFA score individual value components 
(Vincent et al. 1996) and vitamin supplementation were recorded from the database system of 
the ICU (CareVue and WardWatcher softwares).  Hospital mortality data were recorded from 
the ICU database system (WardWatcher software) or, when data were not available on 
Carevue, from the discharges of the main hospital database system.    
Enteral feeding was usually instituted on the second day in ICU and provided RDA levels of 
vitamin B1, B2, B6, A, E, C and carotenoids in 1500kcal. More specifically, the dietary 
(energy, macronutrient and fluid) requierements for each patient were calculated by the 
specialist dietitian and continuous feed of 1 kcal per mL was initiated slowly (30 mL/hr) for 
the first 4 hours to increase to maximum of 50-60 mL/hr by the first 24 hours when there are 
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aspirates <150mL. Target is the patient to receive approximately 50-75 mL/hr by day 3, 
always taking into consideration patient tolerance to the feed.  In the Intensive Care Unit of 
Glasgow Royal Infirmary, the following enteral formulas were used: Osmolite® (standard feed 
without fibre, post gastric surgery patients and patients with gut issues; Abbott Laboratories), 
Jevity® (standard feed with fibre, burns and medical patients; Abbott Laboratories) and 
Peptisorb® (elemental feed, patients with pancreatitis; Nutricia) via usually a nasogastric tube 
unless there were aspirates of more than 150 mLs after 48 hours of feed initiation.  In such a 
case the tube would be replaced with a nasojejunal tube to avoid feed aspiration and associated 
pneumonia. 
Patients received vitamin supplementation in ICU if they were considered clinically to be 
malnourished, had a history of excessive alcohol intake or were considered to have a general 
requirement for additional vitamin intake.  Vitamin supplementation was recorded from the 
drug cardex and given parenterally as Pabrinex® (Link Pharmaceuticals Ltd, West Sussex, 
UK) one dose of which contains 500mg ascorbic acid, 160mg nicotinamide, 50mg pyridoxine 
hydrochloride, 4mg riboflavin, 250mg thiamine hydrochloride.  In those patients who received 
vitamin B supplementation a single dose of Pabrinex was given on the morning of day 2 and 
daily during their ICU stay.  Some patients received additional doses such that the median 
number of doses received was 3 per day in those who had follow-up measurements. 
With respect to the critically ill patients, the study was approved by the ethics committees of 
the North Glasgow NHS Trust and Multicentre Research Ethics Committee (MREC) Scotland.  
When patients were unable to give signed informed consent, consent was obtained from the 
patients’ next of kin or welfare guardian in accordance with the requirements of the Adults 
with Incapacity Scotland (2000) Act. 
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2.1.2 Analytical methods 
2.1.2.1 White cell preparation 
One mL of EDTA whole blood was transferred into a 15ml (16 x 100mm) conical tube and the 
red blood cells were lysed, within 4-6 hours of blood sampling, with 9mL of cold ammonium 
chloride (83g/L) containing EDTA solution (372 mg/L).  EDTA has been shown to prevent 
platelet binding to leukocytes (Milne, Ralston & Wallwork 1985).  In order to minimise 
damage to white cells, resulting in low leucocytes yields, the pH of the lysing solution was 
adjusted to 7.4 (Hinks, Colmsee & Delves 1982).  The samples were gently mixed for 2 
minutes and kept at -15 oC for 10 minutes, to avoid the creation of clumps and simplify the 
elimination of haemoglobin (Hinks, Colmsee, Delves 1982).  
The samples were then centrifuged (200g, 4 oC, 10mins) and the red supernatant containing 
haemoglobin were discarded.  The remaining pellet containing enriched white cells was 
washed with 10mL of cold Dulbecco’s Phosphate Buffered Saline (PBS, Sigma Chemical).  
This process was performed twice.  The samples were centrifuged again but at 100g in order 
to keep the lighter platelets in the supernatant so they could be removed.  The supernatant was 
removed and the resulting pellet was dispersed in 1mL of PBS and the number of cells/L 
counted using a hemocytometer (KX–21N, Sysmex, UK Ltd).  In addition, white blood cells 
and lymphocyte numbers were measured in whole blood by the same counter. The method 
provided a white cell extraction yield of 63% (n=76, 50-93%) containing mainly neutrophils 
(>90%; Appendix 5). 
Following a final brief centrifugation (5000g, 3mins), the supernatant was removed and the 
resulting pellet was dispersed in 250µL of deionised water.  The cell suspension was stored at -
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80°C for vitamin analysis.  Before analysis, the cell suspension was sonicated for 10 min to 
ensure complete lysis of the cells. 
2.1.2.2 Laboratory measurement of whole blood and plasma proteins 
Total protein, albumin, C-reactive protein, alkaline phosphatase, cholesterol and triglycerides 
were measured, in accordance with the manufacturers’ instructions, by routine laboratory 
procedures using an automated analyser (Architect, Abbott Diagnostics, USA).  The inter-
assay coefficient of variation was less than 5% over the sample concentration range for total 
protein, alkaline phosphatase, cholesterol and triglycerides.  Globulin concentrations were 
calculated from the difference between total protein and albumin concentrations. 
Albumin was measured by a BCP dye-binding method and C-reactive protein was measured 
using an automated analyser (Architect, Abbott Diagnostics, USA).  For C-reactive protein the 
limit of detection was 5 mg/l.  The inter-assay coefficient of variation was less than 3% and 
5% over the sample concentration range for albumin and C-reactive protein respectively.  The 
limit of detection for albumin was 10 g/L.   
Haemoglobin estimation was performed using Drabkins Reagent (Sigma Diagnostics, UK).  
Haemoglobin is oxidised and converted to stable cyanmethaemoglobin and the absorbance 
measured at the main wavelength of 546nm using automatic analyser (Sapphire 350, Audit 
Diagnostics, Ireland).  The within batch imprecision (CV%) was 0.95% at 6.9g/dL.  The 
between imprecision (CV%) was 4.7% at 7.1 g/dL. 
2.1.2.3 Laboratory measurement of TDP 
Since thiamine diphosphate (TDP) is present almost entirely within red cells, vitamin B1 
status was assessed by measuring TDP in whole blood by HPLC using post-column 
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ferricyanide derivatisation and fluorimetric detection as previously described (Talwar et al. 
2000).  The within batch imprecision for red cell TDP was 5.1% at 380ng/gHb.  Plasma TDP 
concentrations are extremely low accounting for less than 5% of the plasma TDP 
concentration and were below the detection limits of the assay.   
TDP concentrations in red cells were expressed per gram of haemoglobin (Hb) rather than per 
volume of packed red cells because of the difficulty in accurately pipetting packed red cells, 
due to high viscosity.  The reference intervals for the above assays as established in our 
laboratory were as follows: whole blood TDP 275–675 ng/ g Hb. 
2.1.2.4 Laboratory measurement of FAD, FMN and riboflavin 
FAD, FMN and riboflavin were measured in plasma, red and white cells by HPLC with 
reverse phase C18 column and detected by fluorescence based on the method of Speek and 
coworkers (Speek et al. 1982).  Plasma or diluted red cell haemolysates are precipitated with 
methanol, centrifuged and the supernatant injected for HPLC analysis. FAD, FMN and 
riboflavin were separated on an isocratic HPLC system. The within batch imprecision for 
plasma FAD was 5.9% at 33 nmol/l and 4.4% at 79 nmol/l, for red cell FAD was 4.8% at 2.8 
nmol/gHb and for white cell FAD was 3.4% at 55 pmol/ 106 cells.  The within batch 
imprecision for plasma FMN and riboflavin was 7.1% and 5.6% respectively.  The 
corresponding values for red cell FMN and riboflavin were 5.3% and 8.9% respectively.  
Within batch imprecision for white cell riboflavin was 4.2% at 2.95 pmol/ 106 cells. 
FAD concentrations in red cells were expressed per gram of haemoglobin (Hb) rather than per 
volume of packed red cells because accurate pipetting of packed red cells is difficult, due to 
high viscosity.  This was the haemoglobin measured in the blood sample which reflects the 
haemoglobin of the patient also.  The critically ill patient haemoglobin cannot be used as a 
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nutritional marker as it changes constantly, e.g. due to resuscitation, reflecting fluid balance 
rather than nutritional status.  White blood cell vitamin B2 concentrations were not measured 
in the controls as this was not part of the original protocol for establishing reference intervals 
in a healthy population and therefore could not be compared with values in the critically ill 
group.   
2.1.2.5 Laboratory measurement of PLP and PL 
PLP and PL concentrations were measured in plasma, red cells and white cells by high 
performance liquid chromatography (HPLC) using pre-column semi-carbazide derivatisation 
and fluorescent detection (Talwar et al. 2003a; 2003b).  Plasma (500uL) diluted red cell 
haemolysates (300uL of red cell in 700uL of water) or white cell preparation (250uL) were 
derivatized with semicarbazide.  The mixtures were then deproteinized with perchloric acid, 
stabilized with sodium hydroxide and injected on the HPLC column via an autosampler 
(Waters, Watford, UK) (Talwar et al. 2003a). 
The within batch imprecision for plasma PLP was 4.9% at 59nmol/l and 6.3% at 16nmol/l.  
The within batch imprecision for red cell PLP 5.2% at 367pmol/ gHb (Talwar et al. 2003a) 
and for white cell PLP was 3.4% at 1.64 nmol/ 109cells (Vasilaki A, McMillan DC, Kinsella J, 
Duncan A, O’Reilly DS, Talwar D, unpublished data).  The within batch imprecision for 
plasma PL was 4.6% at 36 nmol/l and 3.0% at 144 nmol/l, for red cell PL 4.6% at 36 
pmol/gHb and for white cell PL 2.8% at 0.92 nmol/ 109cells.  White blood cell vitamin B6 
concentrations were not measured in the controls as this was not part of the original protocol 
for establishing reference intervals in a healthy population and therefore could not be 
compared with values in the critically ill group.   
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PLP concentrations in red cells were expressed per gram of haemoglobin (Hb) rather than per 
volume of packed red cells because accurate pipetting of packed red cells is difficult, due to 
high viscosity.  This was the haemoglobin measured in the blood sample which reflects the 
haemoglobin of the patient also.  The critically ill patient haemoglobin cannot be used as a 
nutritional marker as it changes constantly, e.g. due to resuscitation, reflecting fluid balance 
rather than nutritional status.  The 95% reference intervals for the above assays established in 
our laboratory were as follows: plasma PLP 17–135 nmol/ l, plasma PL 5-26 nmol/ l, red cell 
PLP 250–680 pmol/ gHb, and red cell PL 25-195 pmol/ gHb. 
2.1.2.6 Laboratory measurement of plasma vitamin C 
Samples were analyzed for vitamin C in the same assay to minimize the effect of interassay 
variation. 
Plasma and white cell samples were stabilised to prevent oxidation and deproteinised with 
metaphosphoric acid. Following centrifugation and separation, an aliquot of the supernatant 
was injected on to a C18 reverse phase chromatographic column and the ascorbic acid 
concentration assayed using an electrochemical detector. 
Ascorbic acid concentrations in white cells were expressed per number of white cells.  The 
reference interval as established in our laboratory for plasma ascorbic acid was15-90 umol/L.  
The reference interval for white cell ascorbic acid was taken as 1.5-2.5 umol/109 cells as 
reported by Lee and coworkers (1982).  The within batch imprecision for plasma ascorbic acid 
was 1.0% at 31.66 µmol/l and between batch was 3.7% at 38.16 µmol/l.  White blood cell 
vitamin C concentrations were not measured in the controls as this was not part of the original 
protocol for establishing reference intervals in a healthy population and therefore could not be 
compared with values in the critically ill group.   
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2.1.2.7 Measurement of plasma and red cell vitamin E 
Laboratory measurement of plasma and red cell α-tocopherol concentrations were determined 
by a high-performance liquid chromatography (HPLC) method (Talwar et al. 1998).  Plasma 
and red cell α-tocopherol measurements in samples from the same patient were carried out in 
the same batch to minimise intra-patient measurement error.  Plasma was deproteinised with 
alcohol containing tocopherol acetate as an internal standard and extraction was performed 
using hexane.  HPLC analysis was carried out using a reverse-phase analytical column (5 µm 
C18; 3.2 x 250mm, Nucleosil, Phenomenex, Macclesfield, UK) with UV monitoring at 
295nm.  The limit of sensitivity for plasma α-tocopherol was 3 umol/ l.  The intra-assay 
coefficient of variation was less than 9% over the sample concentration range.   
Analysis of red cell α-tocopherol was performed using a modified procedure of Talwar et al. 
(1998).  Eight hundred µl of the ascorbic acid stabilised red cell sample was thawed and after 
vortex mixing, 400µl was used for α-tocopherol measurement with the remainder retained for 
haemoglobin (Hb) estimation.  Since in red cells vitamin E is bound to cell membranes, it was 
important to ensure that the ascorbic acid red cell sample was vortex mixed thoroughly before 
taking it through the extraction procedure.  For extraction of α-tocopherol from red cell 
membranes, 400µl of the vortex mixed red cell sample was diluted with an equal volume of 
ascorbic acid (1%) and 100µl of internal standard (α-tocopherol nicotinate 50umol/l) added.  
This mixture was deproteinised with 1.5ml of ethanol and the α-tocopherol was extracted 
twice with 3ml of hexane.  The hexane layer was removed and evaporated to dryness under a 
stream of air at 40ºC.  The residue was reconstituted with 100µl ethanol and 50µl injected onto 
the column via an autosampler.  The chromatographic conditions were as described above for 
plasma α-tocopherol (Talwar et al. 1998).  Red cell concentration of α-tocopherol was based 
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on a standard curve prepared by extracting ethanolic α-tocopherol standards as described 
above for red cells. 
The concentration of α-tocopherol in red cells was also expressed as a ratio to haemoglobin 
concentrations (to improve the precision of the assay since the accurate pipetting of packed red 
cells is difficult, due to high viscosity, Talwar et al. 2000; 2003a).  This was the haemoglobin 
measured in the blood sample which reflects the haemoglobin of the patient also.  The 
critically ill patient haemoglobin cannot be used as a nutritional marker as it changes 
constantly, e.g. due to resuscitation, reflecting fluid balance rather than nutritional status.  The 
intra-assay coefficient of variation was <7% over the sample concentration range. 
2.1.2.8 Measurement of lipid soluble antioxidants 
Laboratory measurements of plasma retinol, lutein, lycopene, α-carotene and β-carotene 
concentrations were determined by a high-performance liquid chromatography (HPLC) 
method (Talwar et al. 1998).  Plasma was deproteinised with alcohol containing internal 
standards and extraction of the analytes of interest was performed using hexane.  Analysis was 
carried out using reversed-phase HPLC (5 mm microbore, Phenomenex, Macclesfield, UK) 
and dual wavelength monitoring (Waters, MA, USA).  The limit of sensitivity for retinol, 
lutein, lycopene, α-carotene and β-carotene was 5 umol/ l.  The intra-assay coefficient of 
variation was less than 9% for all analytes over the sample concentration range. 
2.1.2.9 Measurement of Malondialdehyde (MDA) 
The majority of MDA exists in plasma in bound form (approximately 85%, Pilz, Meineke & 
Gleiter 2000), to a number of different macromolecules, but primarily to plasma proteins 
(Esterbauer, Schaur & Zollner 1991).  Critically ill patients often have low circulating plasma 
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proteins so both total MDA and free (unbound) MDA and the free fraction in EDTA-treated 
plasma were studied. 
Total malondialdehyde was measured using reversed-phase HPLC with fluorometric detection 
as described by Young and Trimble (1991).  Fifty micro litres of EDTA plasma sample or 
standard (tetramethoxypropane) was hydrolysed with orthophosphoric acid (100°C).  The 
MDA released from plasma proteins and the unbound MDA reacted with thiobarbituric acid 
(TBA) to form the MDA-TBA adduct and this was measured using reverse-phase HPLC using 
fluorimetric detection to increase sensitivity and specificity (Young & Trimble 1991).  The 
intra-assay coefficient of variation was 9% over the sample concentration range. 
For the measurement of free MDA, 30µl of 50% trichloroacetic acid (TCA) was added to 
200ul of plasma sample to precipitate the proteins.  After centrifugation 50ul of supernatant 
was then hydrolysed as described above for total MDA.  The remaining steps in the procedure 
were carried out identically to those described in total MDA analysis, to achieve consistency 
and minimise possible sources of confusion and error. 
Total MDA was also expressed per gram of total protein as total protein concentrations fall 
during the systemic inflammatory response.  The free MDA fraction was defined as the ratio 
of free MDA to total MDA concentration. 
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3 The relationship between riboflavin, flavin 
mononucleotide and flavin adenine dinucleotide 
concentrations in plasma and red cells in patients with 
critical illness 
3.1 Introduction 
It has long been recognised that physiological active coenzyme form of vitamin B2, FAD, is 
required for normal immune function, by maintenance of glutathione status (Grimble 1997).  
Vitamin B2 has shown a suppressive effect on the production of tissue inflammatory 
mediators and also decreases plasma elevated nitric oxide levels (Kodama et al. 2005).  
Shenkin and coworkers (1989) reported that in patients with critical illness suboptimal 
concentrations of vitamin B2 were linked to adverse mortality outcomes.  Riboflavin is an 
essential constituent of the coenzymes flavin mononucleotide (FMN) and flavin adenine 
dinucleotide (FAD), which carry out redox reactions in a variety of metabolic pathways 
(McCormick et al. 1988).  Therefore, the accurate assessment of B-vitamin status in patients 
with critical illness is of considerable importance to identify critically-ill patients with ’true’ 
deficiency of vitamin B2 who may benefit from supplementation and also to avoid 
inappropriate supplementation of vitamins which brings the risk of tissue accumulation and 
toxicity. 
In contrast to functional tests, direct measurements of FAD concentrations in blood are 
thought to more reliably reflect nutritional status of vitamin B2 (Bates 1997; Tietz 2006).  
Recently, Hustad and coworkers (2002) proposed that direct measurements of plasma 
riboflavin followed by red cell FMN and FAD were the most sensitive markers of low dose 
riboflavin supplementation in apparently healthy subjects.  However, it is recognised that the 
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physiologically active form of vitamin B2 in plasma and tissue is FAD (Massey 2000; Tietz 
2006).  Furthermore, Stripp (1965) reported that following oral supplementation of 500 mg 
FMN, in apparently healthy subjects, there was a 1.7-fold increase in red cell FAD 
concentrations.  
Recent work has shown that, as part of the systemic inflammatory response, plasma FAD 
concentrations, in contrast to red cells, are reduced such that the relationship between plasma 
and red cell FAD concentrations is disturbed (Gray et al. 2004; Quasim et al. 2005).  Louw 
and coworkers (1992) reported in patients undergoing elective surgery that vitamin B2 
concentrations in the plasma were affected by albumin redistribution due to the systemic 
inflammatory response.  It is recognised that, in plasma, riboflavin is extensively bound to 
proteins mainly albumin and globulins, primarily immunoglobulins (Innis, McCormick & 
Merrill 1986).  More recently, in a small study of patients with critical illness, low dose 
supplementation with riboflavin was associated with an increase in concentrations of FAD in 
the red cell, but not in the plasma (Quasim et al. 2005).  However, the basis of this observation 
is as yet unclear.   
Therefore, the aim of the present study was to examine the cross sectional and longitudinal 
inter-relationships between riboflavin, FMN and FAD concentrations in plasma and red cells 
in patients with critical illness.  This information is required to assess reliability of these 
measurements as indicators of vitamin B2 status in the critically ill patient. 
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3.2 Materials and Methods 
3.2.1 Controls, patients and study design 
See paragraph 2.1.1 
3.2.2 Analytical methods 
3.2.2.1 Collection and preparation of blood samples 
The EDTA samples were centrifuged (500g, 4oC, 10mins) and plasma was removed into 
another plastic tube for measurements of plasma FAD, FMN and riboflavin.  After removing 
the buffy coat, the remaining packed red cells were kept for red blood cell vitamin B2 
determination.  All tubes were stored at -70o C until analysis.  All samples were protected 
from light and assayed in a single batch for each of the analytes to minimise interbatch 
analytical variation. 
3.2.2.2 Laboratory measurements of FAD, FMN and riboflavin 
See paragraph 2.1.2.4 
3.2.2.3 Laboratory measurements of whole blood and plasma proteins 
See paragraph 2.1.2.2 
3.2.3 Statistics 
Data from normal subjects and critically ill patients groups are presented as median and range.  
Comparison between the control and critically groups were carried out with the use of the 
Mann-Whitney U test. Correlations between variables in the control and critically-ill groups 
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were carried out using the Spearman rank correlation (rs).  Data from different time points in 
the patient groups were tested for statistical significance with the use of the Wilcoxon signed 
rank test.  Because of the number of statistical comparisons, a p-value of <0.01 was considered 
to be significant.  Analysis was performed with the use of SPSS software (version 15; SPSS 
Inc., Chicago, IL). 
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3.3 Results 
The baseline characteristics of controls (n=119) and critically ill patients (n=125) studied are 
shown in Table 3-1.  The majority of patients were men, >50 years, and similar to the control 
group.  The patients’ median APACHE II score was 21 and the associated median predicted 
mortality was 34%.  The majority of patients had low concentrations of albumin and high 
concentrations of C-reactive protein.   
The 95% reference intervals in the normal subjects for plasma and red cell FAD were 57-149 
nmol/ l and 0.75-3.35 pmol/gHb respectively.  Plasma FAD was significantly lower in the 
critically ill patients compared with the controls (p<0.001) with 63% of patients having 
concentrations below the reference interval (69 out of 125).  Median red cell FAD 
concentrations were significantly lower in the critically ill patients compared with the controls 
group (p<0.001) however, all patients had red cell FAD concentrations within the reference 
interval.  Compared with the control group, median plasma FMN concentrations were higher 
(p<0.001) and red cell FMN concentrations were similar in the critically ill group.  Compared 
with the control group, median plasma riboflavin concentrations were higher (p<0.001) and 
red cell riboflavin concentrations were similar in the critically ill group.  Compared with the 
control group, median plasma and red cell FAD to riboflavin ratio were significantly lower in 
the critically ill group (both p<0.001).  In the control and critically ill patients’ group plasma 
FAD and FMN were not significantly correlated with red cell FAD, red cell FMN or red cell 
riboflavin.  In contrast, plasma riboflavin was correlated with red cell FAD (rs=0.52, p<0.001), 
red cell FMN (rs=0.55, p<0.001) and red cell riboflavin (rs=0.60, p<0.001) in the critically ill 
patients’ group but not in the control group.   
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The interrelationships between the concentrations of FAD, FMN and riboflavin in the plasma 
and red cells in the control population are shown in Table 3-2.  Plasma FAD was directly 
associated with plasma FMN (rs=0.51, p<0.001) and plasma riboflavin (rs=0.49, p<0.001).  
Plasma FMN was directly associated with plasma riboflavin (rs=0.55, p<0.001).  Red cell 
FAD was directly associated with red cell FMN (rs=0.44, p<0.001) but not with red cell 
riboflavin.  Red cell FMN was directly associated with red cell riboflavin (rs=0.52, p<0.001). 
The interrelationships between the concentrations of FAD, FMN and riboflavin in the plasma 
and red cells in the critically ill patients on admission to ICU are shown in Table 3-3.  Plasma 
FAD was inversely associated with C-reactive protein (rs=-0.24, p<0.01) and directly 
associated with albumin (rs=0.31, p<0.001) and alkaline phosphatase (rs=0.35, p<0.001).  
Globulins were directly associated with albumin (rs=0.24, p<0.001) and alkaline phosphatase 
(rs=0.37, p<0.001).  Plasma FMN was directly associated with plasma riboflavin (rs=0.52, 
p<0.001).  Plasma riboflavin was correlated with red cell FAD (rs=0.52, p<0.001), red cell 
FMN (rs=0.55, p<0.001) and red cell riboflavin (rs=0.60, p<0.001).  Alkaline phosphatase was 
directly associated with red cell FAD (rs=0.31, p<0.001) and red cell riboflavin (rs=0.32, 
p<0.001).  Red cell FAD was directly associated with red cell FMN (rs=0.83, p<0.001) and red 
cell riboflavin (rs=0.72, p<0.001).  Red cell FMN was directly associated with red cell 
riboflavin (rs=0.79, p<0.001). 
Of the 123 patients who were admitted in the ICU, 60 had longitudinal measurements of both 
plasma and red cell FAD concentrations (Table 3-4).  In those 60 critically-ill patients with 
follow-up samples, 18 patients had recorded supplementation prior to admission to ICU and 
38 patients had supplementation in ICU and 16 patients had recorded supplementation before 
and after admission to ICU.  22 patients had no recorded supplementation in ICU.  The rest of 
the patients did not have a longitudinal measurement due to discharge (n=59) or death (n=4). 
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The time between admission and follow-up samples was median 4 (2-12) days.  There was a 
significant decrease in albumin concentrations (p<0.001) between the admission and follow-
up measurements.  There was a significant increase in red cell FAD (p<0.001) and red cell 
FMN (p<0.01) concentrations between admission and follow-up measurements. 
The interrelationships between the changes in FAD, FMN and riboflavin concentrations in the 
plasma and red cells in the critically ill patients are shown in Table 3-5.  The change in plasma 
FAD was directly associated with the change in plasma albumin (rs=0.40, p<0.01).  The 
change in plasma FAD was directly associated with the change in plasma riboflavin (rs=0.42, 
p<0.01), red cell FAD (rs=0.37, p<0.01), red cell FMN (rs=0.40, p<0.01) and red cell 
riboflavin (rs=0.45, p<0.01).  The change in plasma riboflavin was directly associated with the 
change in alkaline phosphatase (rs=0.43, p<0.01), the change in red cell FAD (rs=0.60, 
p<0.001), red cell FMN (rs=0.46, p<0.01) and red cell riboflavin (rs=0.70, p<0.001).  The 
change globulins was directly associated with the change in alkaline phosphatase (rs=0.39, 
p<0.001).  The change in red cell FAD was directly associated with the change in red cell 
FMN (rs=0.83, p<0.001) and the change in red cell riboflavin (rs=0.62, p<0.001).  The change 
in red cell FMN was directly associated with the change in red cell riboflavin (rs=0.59, 
p<0.001). 
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3.4 Discussion 
The results of the present study show that plasma riboflavin is directly associated with red cell 
concentrations of FAD, FMN and riboflavin in patients with critical illness.  Moreover, red 
cell riboflavin was strongly and directly associated with red cell FAD and FMN.  In contrast, 
although red cell FMN was associated with red cell FAD, plasma FMN was not associated 
with either plasma or red cell FAD.  These results indicate that riboflavin, either in the plasma 
or in the cell, is the main determinant of FAD status in patients with critical illness.  Given 
that, compared with plasma FAD and FMN, concentrations of plasma riboflavin are more 
strongly correlated with those in the red cells and that red cell riboflavin concentrations are 
strongly and similarly correlated with their respective FAD concentrations, this demonstrates 
the importance of riboflavin in the intracellular metabolism of FAD in critically ill patients.   
In the present study, it was also of interest that the ratio of plasma FAD to riboflavin in 
critically ill patients on admission and on follow-up was much lower than that of the plasma 
ratio in the controls.  There were also similar findings with respect to the red cell FAD to 
riboflavin ratios in controls and critically ill patients.  However, on admission the reduction of 
the FAD to riboflavin ratio was greater in the plasma (83%) compared with the red cells 
(49%).  To date, the present study shows, for the first time, perturbation of the relationship 
between plasma FAD and riboflavin in patients with critical illness.  Moreover, this appears to 
be primarily due to a relative reduction in plasma and intracellular FAD concentrations 
although red cell FAD concentrations were all within the reference interval.   
The basis of these results is not clear since few studies have examined the relationship 
between plasma and intracellular concentrations of FAD, FMN and riboflavin.  However, it is 
recognised that FAD, FMN and riboflavin are bound to plasma proteins and that these fall as 
  84
part of the systemic inflammatory response (Gabay & Kushner 1999).  Also, both FAD and 
FMN require to be hydrolysed in order to enter the cells (Aw, Jones & McCormick 1983; 
McCormick & Zhang 1993) and that this hydrolysis is carried out mainly by phosphatases.  
Indeed, in the present study, plasma alkaline phosphatase activity was greatly elevated in some 
patients with critical illness and there was a significant association with FAD in the red cell.  It 
has also been reported that the increase in red cell FAD during infection is associated with a 
reduction of hepatic flavokinase (which convert riboflavin to FMN), an increase in FAD 
synthetase and FAD pyrophosphatase (which convert FMN to FAD) such that there is a loss of 
FAD from the liver (Brijlal et al. 1996).  Furthermore, increased urinary loss of riboflavin 
during infection has been reported (Brijlal & Lakshmi 1999).  Therefore, it would appear that 
during the systemic inflammatory response there is mobilisation of riboflavin from the liver to 
the cells, including red cells.  Taken together, systemic inflammation might have accounted 
for the redistribution of FAD and FMN observed in the critically ill patient in the present 
study.   
Hustad and coworkers (2002) reported that, in 124 healthy subjects, red cell FAD and FMN 
correlated with each other and with plasma riboflavin.  Also in a subgroup of these subjects 
(n=46), they showed that supplementation (low dose riboflavin–1.6mg/d) increased 
concentrations of plasma FMN, plasma riboflavin, red cell FAD and red cell FMN, but not 
plasma FAD (they were unable to detect red cell riboflavin).  One interpretation of these and 
the present results is that plasma riboflavin would be a good surrogate measure of intracellular 
FAD concentrations.  However, it is recognised that the biological variation of plasma 
riboflavin is large (Hustad et al. 2002).  Moreover, plasma riboflavin does not correlate with 
functional tests in apparently healthy subjects (Hustad et al. 2002).  Also, given that riboflavin 
is not the physiologically active form of vitamin B2 (Massey 2000; Tietz 2006), the basis and 
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the clinical relevance of measuring plasma riboflavin concentrations is not certain.  In 
contrast, the biological variation of red cell FAD is small (Hustad et al. 2002; Talwar et al. 
2005), correlates with functional tests (Hustad et al. 2002) and is the physiologically active 
form of vitamin B2 (Massey 2000; Tietz 2006).  Furthermore, the longitudinal red cell FAD 
measurements appeared to be the most responsive to low dose supplementation.  Therefore, 
we believe that the red cell measurements of FAD are an accurate reflection of vitamin B2 
status in patients with critical illness.   
Patients admitted to intensive care are under severe metabolic stress and in a catabolic state 
and may have increased utilization and consumption of vitamin B2 and therefore some 
workers have advocated supplementation of vitamin B2 in these patients, which appears to 
have a beneficial effect on immune responses (Shenkin, Cruikshank & Shenkin 1989; Grimble 
1997; Kodama et al. 2005).  In the present study, the extreme high concentrations of plasma 
FAD and riboflavin were measured in those patients who had recorded supplementation.  In 
contrast, all concentrations of red cell FAD both on admission and follow-up were within the 
normal range.  Therefore, it is likely that the extreme values of plasma FAD, FMN and 
riboflavin reflect the effect of supplementation and recent intake and not analytical or 
methodological error and more importantly vitamin B2 status.  Indeed, it was of interest that, 
on admission, a few patients had extremely high concentrations of plasma FAD, FMN and 
riboflavin suggesting that some patients had received supplementation prior to admission and 
would confirm the utility of red cell measurements.  The question of whether red cell 
concentrations are more likely to detect deficiencies or toxicity in these patients cannot be 
definitively answered by the present study since intra-cellular concentrations were not 
measured in other tissues.  Nevertheless, in future studies it will be important to establish 
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whether deficiencies in red cell FAD concentrations are related to outcome in the critically-ill 
patients. 
In summary, the relationship between plasma FAD, FMN and riboflavin is disturbed in 
patients with critical illness.  This is less pronounced in red cells.  Therefore, red cell FAD 
concentrations are likely to be a more reliable measure of status in the critically ill patient.  
Also, from these data, critical illness does not seem to be related to vitamin B2 deficiency. 
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Table 3-1 Characteristics and B2 vitamin concentrations in healthy subjects and 
critically-ill patients on admission 
 Control subjects 
(n=119) 
Critically-ill patients 
(n=125) 
p-value 
Age (yr) 53 (35-73) 60 (18-100) 0.084 
Sex (M/F) 67/ 52 82/ 43 0.137 
APACHE II score  21 (3-38)  
Predicted mortality (%)  33.7 (0.2-92.6)  
SOFA score  7 (0-18)  
Medical/ Surgical  56/ 69  
ICU stay (days)  3.5 (0.2-76.4)  
ICU death (no/ yes)  101/ 24  
Hospital stay (days)  21.4 (0.40-508)  
Hospital death (no/ yes)  93/ 32  
    
C-reactive protein (mg/ l) <6* 108 (<6-565)  
Albumin (g/ l) 32-45* 17 (9-47)  
Globulins (g/ l) 23-38* 27 (8-56)  
Alkaline phosphatase (IU/ l) 40-150* 83 (16-2326)  
Plasma FAD (nmol/ l) 101 (57-170) 45 (10-1916) <0.001 
Plasma FMN (nmol/ l) 6.3 (3.3-14.1) 17.0 (2.8-75.6) <0.001 
Plasma Riboflavin (nmol/ l) 11 (4-34) 33 (3-748) <0.001 
Plasma FAD/ Riboflavin ratio  8.8 (3.2-29.5) 1.5 (0.0-9.7) <0.001 
Red cell FAD (pmol/gHb) 1.9 (0.7-3.8) 1.5 (1.0-2.6) <0.001 
Red cell FMN (pmol/ gHb) 0.11 (0.04-0.44) 0.09 (0.05-0.48) 0.299 
Red cell Riboflavin (pmol/ gHb) 0.02 (0.01-0.13) 0.03 (0.00-0.23) 0.037 
Red cell FAD/ Riboflavin ratio  96.6 (13.2-280.0) 49.6 (9.5-423.6) <0.001 
Median (range) 
*laboratory reference intervals 
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Table 3-2 Spearman correlations of characteristics and vitamin B2 concentrations in the control population 
(n=119) 
 Plasma 
FMN 
Plasma 
Riboflavin 
Red cell 
FAD 
Red cell 
FMN 
Red cell 
Riboflavin 
Plasma      
Plasma FAD 0.51*** 0.49*** 0.21* -0.10 0.12 
Plasma FMN  0.55*** 0.11 -0.02 0.13 
Plasma Riboflavin   0.20* 0.06 0.06 
Intracellular      
Red cell FAD    0.44*** 0.05 
Red cell FMN     0.52*** 
*p<0.05, **p<0.01, ***p<0.001 
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Table 3-3 Spearman correlations of characteristics and vitamin B2 concentrations in critically-ill patients on admission to ICU 
(n=125) 
 Plasma 
FMN 
Plasma 
Riboflavin 
CRP Albumin Globulins Alkaline 
phosphatase 
Red cell 
FAD 
Red cell 
FMN 
Red cell 
Riboflavin 
Plasma          
Plasma FAD 0.25 0.07 -0.24** 0.31*** 0.22* 0.35*** 0.14 0.08 0.20* 
Plasma FMN  0.52** -0.06 0.28 0.11 0.18 0.03 0.05 0.02 
Plasma 
Riboflavin 
  0.06 -0.02 0.12 0.24* 0.52*** 0.55*** 0.60*** 
CRP    -0.36*** 0.12 0.13 0.16 0.10 0.09 
Albumin     0.24** -0.03 -0.16 -0.15 -0.12 
Globulins      0.37*** 0.14 -0.02 0.08 
Alkaline 
phosphatase 
      0.31*** 0.17 0.32*** 
Intracellular          
Red cell FAD        0.83*** 0.72*** 
Red cell FMN         0.79*** 
*p<0.05, **p<0.01, ***p<0.001 
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Table 3-4 Characteristics and B2 vitamin concentrations in critically-ill patients on 
admission and follow-up 
 Critically-ill patients (n=60)  
 Admission Follow-up p-valueb 
Age (yr) 61 (18-86)   
Sex (M/F) 43/ 17   
APACHE II 23 (7-38)   
Predicted mortality (%) 41.1 (4.3-92.6)   
SOFA score 7 (1-14) 7 (0-16) 0.085 
Medical/ Surgical 26/ 34   
ICU stay (days) 9.3 (0.9-76.4)   
ICU death (no/ yes) 40/ 20   
Hospital stay (days) 21.4 (0.4-508)   
Hospital death (no/ yes) 36/ 24   
    
C-reactive protein (mg/ l) 97 (2-565) 131 (20-356) 0.340 
Albumin (g/ l) 16 (9-45) 15 (9-29) <0.001 
Globulins (g/ l) 26 (8-56) 25 (9-41) 0.684 
Alkaline phosphatase 91 (16-1089) 115 (17-659) 0.085 
Plasma FAD (nmol/ l) 51 (10-1916) 55 (12-5479) 0.123 
Plasma FMN (nmol/ l)a 11.5 (2.80-34.2) 6.9 (4.1-23.1) 0.075 
Plasma Riboflavin (nmol/ l) 41.3 (3-748.1) 58.1 (3-910.8) 0.034 
Plasma FAD/ Riboflavin ratio 1.2 (0.0-8.9) 0.6 (0.1-20.7) 0.016 
Red cell FAD (pmol/gHb) 1.6 (1.0-2.6) 1.8 (1.0-2.6) 0.001 
Red cell FMN (pmol/ gHb) 0.12 (0.05-0.33) 0.13 (0.05-0.25) 0.006 
Red cell Riboflavin (pmol/ gHb) 0.04 (0.01-0.22) 0.06 (0.00-0.62) 0.043 
Red cell FAD/ Riboflavin ratio 41.7 (9.5-226.4) 33.1 (4.1-242.7) 0.038 
Median (range) 
a
n=11, bWilcoxon signed rank test
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Table 3-5 Spearman correlations of the changes of the characteristics and vitamin B2 concentrations in critically-ill patients between 
admission and follow-up to ICU 
(n=60) 
 Plasma 
FMNa 
Plasma 
Riboflavin 
CRP Albumin Globulins Alkaline 
phosphatase 
Red cell 
FAD 
Red cell 
FMN 
Red cell 
Riboflavin 
Plasma          
Plasma FAD 0.50 0.42** -0.19 0.40** 0.11 0.25 0.37** 0.40** 0.45** 
Plasma FMNa  0.62* 0.16 0.13 0.20 -0.04 0.49 0.35 0.53 
Plasma Riboflavin   -0.06 0.31* 0.21 0.43** 0.60*** 0.46** 0.70*** 
CRP    -0.12 0.15 -0.22 0.14 0.14 0.12 
Albumin     0.19 0.31* 0.06 -0.03 0.24 
Globulins      0.39** 0.06 0.08 -0.07 
Alkaline phosphatase       0.13 0.20 0.08 
Intracellular          
Red cell FAD        0.83*** 0.62*** 
Red cell FMN         0.59*** 
       a
n=11, *p<0.05, **p<0.01, ***p<0.001 
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4 The relationship between pyridoxal and pyridoxal 
phosphate concentrations in plasma, red cells and white 
cells in patients with critical illness 
4.1 Introduction 
Vitamin B6 is an essential precursor of pyridoxal (PL) and pyridoxamine phosphate 
coenzymes of a wide variety of enzymes of intermediary metabolism (Leklem 1991).  It is 
recognised that the active form of vitamin B6 in plasma and tissue is pyridoxal phosphate 
(PLP).  In health, plasma PLP appears to be determined primarily by intake of vitamin B6, its’ 
binding to albumin and its’ hydrolysis to PL, by alkaline phosphatase (Merrill et al. 1984; 
Brussaard et al. 1997). 
In contrast to functional tests, direct measurement of PLP concentrations in plasma is thought 
to most accurately reflect nutritional status of vitamin B6 (Vuilleumier et al. 1991; Bates 
1997).  In health, PLP concentrations in plasma and tissues are determined mainly by the 
intake and conversion of pyridoxine to PLP and then to PL and therefore, there is a strong 
association in the plasma and in the tissues between PLP and PL (Johansson, Lindstedt & 
Tiselius 1974; Talwar et al. 2003a).  However, recent work has shown that, as part of the 
systemic inflammatory response, plasma PLP concentrations are reduced such that the 
relationship between plasma and red cell PLP concentrations is disturbed (Talwar et al. 2003b; 
Gray et al. 2004).  For example, in patients with critical illness, supplementation with 
pyridoxine is associated with an increase in concentrations of PLP in the red cell, but not in 
the plasma (Quasim et al. 2005).  The mechanisms underlying this observation are as yet 
unclear.  Cheng and coworkers (2006) reported that, during pyridoxine supplementation in 
critically-ill patients, plasma PL concentrations increased 15-20 fold whereas plasma PLP 
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concentrations only increased approximately 3 fold.  However, it is unclear whether the 
reduced plasma PLP concentrations in critically-ill patients are due to reduced binding of PLP 
to albumin, increased hydrolysis of PLP by alkaline phosphatase or both.  Moreover, to date, 
the relationship between the intracellular PL and PLP concentrations has not been previously 
examined in the critically ill patient.   
Therefore, the aim of the present study was to examine the cross sectional and longitudinal 
inter-relationships between PL and PLP concentrations in plasma, red cell and white cell in 
patients with critical illness.  This information is required to assess reliability of these 
measurements as indicators of vitamin B6 status in the critically ill patient. 
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4.2 Materials and Methods 
4.2.1 Controls, patients and study design 
See paragraph 2.1.1. 
4.2.2 Analytical methods  
4.2.2.1 Collection and preparation of blood samples 
The ethylenediaminetetraacetic acid (EDTA) samples were centrifuged (500g, 4oC, 10mins) 
and plasma was removed into another plastic tube for measurements of plasma PLP and PL.  
After removing the buffy coat, the remaining packed red cells were kept for red blood cell B6 
determination.  All tubes were stored at -70o C until analysis.  All samples were protected from 
light and assayed in a single batch for each of the analytes to minimise interbatch analytical 
variation (Talwar et al. 2003a). 
4.2.2.2 Laboratory measurements of PLP and PL 
See paragraph 2.1.2.5 
4.2.2.3 Laboratory measurement of whole blood and plasma proteins 
See paragraph 2.1.2.2 
4.2.3 Statistics 
Data from normal subjects and critically ill patients groups are presented as median and range.  
Comparison between the control and critically groups were carried out using the Mann-
Whitney U-test. Correlations between variables in the critically-ill group were carried out 
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using the Spearman rank correlation (rs).  Data from different time points in the patient groups 
were tested for statistical significance using the Wilcoxon signed rank test.  Due to the number 
of statistical comparisons a p-value of less than 0.01 was considered to be significant.  
Analysis was performed using SPSS software (version 15, SPSS Inc., Chicago, Illinois, 
U.S.A.). 
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4.3 Results 
The baseline characteristics of controls (n=126) and critically ill patients (n=96) studied are 
shown in Table 4-1.  The majority of patients were male, over the age of 50 years, and similar 
to the control group.  The patients’ median APACHE II score was 20 and the associated 
median predicted mortality was 32%.  The majority of patients had low haemoglobin and 
albumin concentrations, and high concentrations of C-reactive protein and alkaline 
phosphatase.  There were 96 patients admitted in the ICU who had plasma PLP and also PL 
concentrations measured.  Of these patients seventy four also had red cell and white cell PLP 
and PL concentrations measured.  There were 43 out of the 69 patients with plasma PLP 
below the reference interval and 46 out of the 69 patients with red cell PLP be low the 
reference interval.  Compared with the control group, median plasma PLP, PL and their ratio 
(PLP/ PL) were significantly lower in the critically ill group (p<0.001, p<0.01 and p<0.001 
respectively).  Compared with the control group, median red cell PLP and the ratio of red cell 
PLP to PL were significantly lower in the critically ill group (p<0.001 and p<0.01 
respectively).  White blood cell vitamin B6 concentrations were not measured in the controls 
as this was not part of the original protocol for establishing reference intervals in a healthy 
population and therefore could not be compared with values in the critically ill group.  The 
correlations between plasma PLP and red cell PLP were 0.90 (p<0.001) and 0.46 (p<0.001) in 
the control and the critically ill group respectively.  In the critically ill patients the plasma PLP 
to PL ratio was significantly lower compared with red cell PLP to PL ratio (p=0.001) and 
white cell PLP to PL ratio (p=0.008).  In contrast, the red cell and white cell PLP to PL ratios 
were not significantly different (p=0.515). 
The interrelationships between the concentrations of PLP and PL in the plasma and red cell in 
the control population are shown in Table 4-2.  Plasma PLP was directly associated with 
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plasma PL (rs=0.58, p<0.001).  Plasma PL was directly associated with both red cell PLP 
(rs=0.51, p<0.001) and red cell PL (rs=0.36, p<0.001).  Red cell PLP was directly associated 
with red cell PL (rs=0.66, p<0.001). 
The interrelationships between the concentrations of PLP, PL and proteins in the plasma, red 
cell and white cell in critically ill patients are shown in Table 4-3.  Plasma PLP was directly 
associated with plasma PL (rs=0.51, p<0.001).  Plasma PL was directly associated with both 
red cell PL (rs=0.73, p<0.001) and white cell PL (rs=0.68, p<0.001).  Red cell PL and white 
cell PL were directly associated with red cell PLP (rs=0.82, p<0.001) and white cell PLP 
(rs=0.68, p<0.001) respectively.  The red cell PLP to PL ratio was significantly correlated with 
the white cell PLP to PL ratio (rs=0.70, p<0.001). 
Of the 96 patients who were admitted in the ICU, 48 had longitudinal measurements of both 
PL and PLP concentrations (Table 4-4).  These patients had a higher APACHE II score 
(p<0.001) and predicted mortality score (p<0.01) and lower albumin concentrations (p<0.01) 
compared with those patients who did not have a follow-up sample.  There were no significant 
differences in PL and PLP concentrations between the subgroups.  In those 48 critically-ill 
patients with follow-up samples, 15 patients had recorded supplementation prior to admission 
to ICU and 31 patients had supplementation in ICU and 13 patients had recorded 
supplementation before and after admission to ICU.  Of these patients thirty five also had 
longitudinal measurements of red cell and white cell PL and PLP concentrations.  The rest of 
the patients did not have a longitudinal measurement due to discharge (n=45) or death (n=3). 
The time between admission and follow-up samples was median 4 (range 2-12) days. There 
was a significant decrease in albumin concentrations (p<0.01) between the admission and 
follow-up measurements.   
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The interrelationships between the changes in PLP and PL concentrations in the plasma, red 
cell and white cell are shown in Table 4-5.  The change in plasma PLP was directly associated 
with the change in plasma PL (rs=0.67, p<0.001).  The change in plasma PL was directly 
associated with the change in both red cell (rs=0.83, p<0.001) and white cell PL (rs=0.67, 
p<0.001).  The change in red cell PL and white cell PL were directly associated with the 
change in red cell PLP (rs=0.95, p<0.001) and white cell PLP (rs=0.72, p<0.001) respectively. 
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4.4 Discussion 
It has long been recognised that the physiological active coenzyme form of vitamin B6, PLP, 
is required for normal nucleic acid and protein synthesis and for cellular multiplication.  
Vitamin B6 deficiencies cause a more profound effect on humoral and cell mediated immune 
function than deficiencies of any other B-group vitamins (Leklem 1991).  Indeed, low vitamin 
B6 status appears to impair lymphocyte proliferation in normal subjects and patients with 
critical illness (Kwak et al. 2002; Cheng et al. 2006).  Therefore, it is of considerable 
importance to identify critically-ill patients with ’true’ deficiency of vitamin B6 and to avoid 
inappropriate supplementation of vitamins which brings the risk of tissue accumulation and 
toxicity. 
Few studies have examined the relationship between plasma and intracellular concentrations 
of pyridoxal and pyridoxal phosphate.  Two such studies have reported relationships in small 
numbers of healthy subjects (Hamfelt 1967; Shephard, van der Westhuizen & Labadarios 
1989).  Hamfelt (1967) reported that, in 10 healthy children and 37 adults, there were 
significant correlations between plasma, red cell and white cell pyridoxal phosphate 
concentrations.  However, they noted that the correlation between plasma and white cell 
pyridoxal phosphate concentrations appeared to be weaker than the corresponding plasma and 
red cell concentrations (Hamfelt 1967).  Also, Shephard and colleagues (1989) reviewed the 
concentrations of pyridoxal phosphate in plasma, red cells and white cells of healthy subjects.  
In the present study, we did not measure pyridoxal phosphate in the white cells of healthy 
subjects.  However, the concentration of PLP in white cells was approximately twofold higher 
in the critically ill patients compared with previous concentrations reported in the literature 
(Shephard, van der Westhuizen & Labadarios 1989). 
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With respect to comparison of the present red cell PLP concentrations in healthy subjects to 
previous reports (Hamfelt 1967; Shephard, van der Westhuizen & Labadarios 1989), this is 
problematical due to methodological differences.  For example, both these previous reports 
used postcolumn derivatisation whereas the present study used pre-column semicarbazide 
derivatisation.  It is recognised that the acid precipitation in the postcolumn derivatisation 
method may lead to suboptimal extraction of PLP from red cells (Srivastava & Beutler 1973; 
Talwar et al. 2003a). 
The results of the present study show that, in plasma, red cells and white cells, PLP is strongly 
and directly associated with the concentrations of PL in patients with critical illness.  It was of 
interest that the ratio of plasma PLP to PL in critically ill patients on admission and on follow-
up was much lower than that of the plasma controls.  There were also similar findings with 
respect to the red cell PLP to PL ratios in controls and critically ill patients.  However, on 
admission the reduction of the PLP to PL ratio was greater in the plasma (55%) compared with 
the red cells (18%).  To date, the present study shows, for the first time, that the relationship 
between plasma PLP and PL in controls is similar to that found in red and white cells, in 
patients with critical illness.  Given that, compared to plasma PLP, concentrations of plasma 
PL are more strongly correlated with those in the red or white cells and that red cell and white 
cell PL concentrations are strongly and similarly correlated with their respective PLP 
concentrations, this demonstrates the importance of PL in the intracellular metabolism of PLP 
in normal subjects and critically ill patients.  One interpretation of the results of the present 
study might be to suggest that plasma PL would be a good surrogate measure of intracellular 
PLP concentrations.  However, pyridoxal is not the physiologically active form of vitamin B6 
and therefore, the clinical relevance of measuring plasma PL concentrations is not certain.  
Therefore, we believe that the present intracellular measurements of PLP, compared with 
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plasma, are a more accurate reflection of vitamin B6 status and should be used in routine 
assessment of the patient with critical illness. 
The results of the present study are therefore, consistent with previous small cross-sectional 
studies, which questioned the use of plasma PLP as a marker of vitamin B6 status in subjects 
with evidence of a systemic inflammatory response (Talwar et al. 2003b; Gray et al. 2004).  
There are parallels between the present study of vitamin B6 and previous work on selenium 
and glutathione peroxidase activity (Fell & Talwar 1998).  Also, it has recently been reported 
that the prognostic value of plasma PLP concentrations, as a marker of myocardial infarction 
risk, can be accounted for, in large part, by the presence of a systemic inflammatory response 
as evidenced by an elevated C-reactive protein concentration (Dierkes et al. 2007).   
The basis of the relatively low plasma PLP concentrations in these patients is not clear.  
However, albumin, whose binding appears to protect PLP from hydrolysis, was low both on 
admission and on follow-up.  Furthermore, albumin was directly associated with plasma PLP 
both in the cross-sectional measurements and longitudinal changes.  Interestingly, Keniston 
and coworkers (1988; 1989) reported that the ratio of PLP concentration in deproteinised 
(bound and unbound PLP) and non-deproteinised (unbound PLP) plasma samples varies with 
clinical condition.  Since albumin is the main binding protein in PLP in plasma, they 
concluded that albumin concentration affects PLP concentration in plasma.  Indeed, since 
albumin is readily redistributed from plasma, as part of the systemic inflammatory response, 
this is consistent with the observation that plasma concentrations of vitamin B6 are transiently 
decreased in subjects undergoing elective surgery (Gray et al. 2004) and that vitamin-B6 
supplementation in critically-ill patients was unable to increase plasma PLP concentration 
(Quasim et al. 2005; Louw et al. 1992; Huang et al. 2002). 
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Alkaline phosphatase is another potentially important determinant of plasma PLP 
concentrations in patients with critical illness.  In contrast to albumin, alkaline phosphatase 
activity was not associated with plasma PLP either in the cross-sectional or longitudinal 
studies.  However, the laboratory measurement of alkaline phosphatase might not indicate the 
true functional activity since the analytical method requires dilution of the serum sample and 
serum phosphate concentration in the clinically observed range inhibits ALP activity under 
physiological conditions (Coburn et al. 1998).  Clearly, this may have contributed to the weak 
correlation observed in the present study between plasma PLP concentrations and measured 
ALP activity.  These results are consistent with the concept that plasma PLP concentrations 
are determined, at least in part, by its binding to albumin, and that any free PLP is subject to 
hydrolysis to PL by alkaline phosphatase (Brussaard et al. 1997). 
The results of the present study do not address the question of increased utilization and 
metabolic turnover of plasma PLP.  However, the results of studies of Huang and colleagues 
show that the metabolic end product of PLP, pyridoxic acid, is significantly increased both in 
the plasma and in the urine of critically ill patients (Huang et al. 2005; Cheng et al. 2006).  
Taken together with the results of the present study would suggest that the low concentrations 
of vitamin B6 in plasma are influenced both by increased redistribution and catabolism. 
Patients admitted to intensive care are under severe metabolic stress and may have increased 
utilization and consumption of vitamin B6 and therefore some workers have advocated 
supplementation of vitamin B6 in these patients, which appears to have a beneficial effect on 
immune responses (Huang et al. 2005; Cheng et al. 2006).  In the present study the extreme 
high concentrations of red cell PL and PLP were measured in those patients who had recorded 
supplementation.  Therefore, it is likely that the extreme values reflect the effect of 
supplementation and not analytical or methodological error.  Indeed, it was of interest that, on 
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admission, a few patients had extremely high concentrations of red cell PLP and PL 
suggesting that some patients had received supplementation prior to admission and would 
confirm the utility of red cell measurements.  Furthermore, it is not clear whether red or white 
cells should be used, in preference to plasma.  However, taking into consideration the higher 
sensitivity and that red cells are simpler to separate and analyse, we would recommend red cell 
analysis for assessment of vitamin B6 status and to guide supplementation in patients with 
critical illness. 
The question of whether red cell concentrations are more likely to detect deficiencies or 
toxicity in these patients cannot be definitively answered by the present study since intra-
cellular concentrations were not measured in other tissues.  With respect to red cell PLP, it has 
been proposed as a more relevant measure of vitamin B6 status because the site of PLP 
coenzyme function is intracellular (Leklem 1990; Vermaak et al. 1990).  In addition, in health 
red cell PLP concentrations have been shown to be associated with the dietary intake of 
vitamin B6, vitamin B6 supplementation and with the functional tests used to assess vitamin 
B6 status (Heiskanen et al. 1994; Heiskanen et al. 1996; Hansen et al. 2001).  This work 
showed that red cell values were less sensitive to acute changes compared with plasma values.  
Nevertheless, in future studies it will be important to establish whether deficiencies in red cell 
vitamin B6 concentrations are related to outcome in the critically-ill patients. 
Although there is little evidence from the literature that supplementation with vitamin B6 is 
toxic, the doses given in the present study (median 150mg/day) are above the 
recommendations which have, on the basis of development of sensory neuropathy, set the 
tolerable upper intake level of 100mg/day (Food and Nutrition Board IOM 1998).  Given that 
there is significant accumulation in the red cells (approximately 30 times the upper limit of 
normal values in some patients) and assuming that red cell PLP concentrations reflect the 
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concentrations in other tissues, there is evidence of significant accumulation in patients with 
critical illness.  It would therefore be reasonable to adopt a cautious approach to vitamin B6 
supplementation in these patients. 
Therefore, given the results of the present study it would be important to monitor red cell PLP 
concentrations to identify patients with evidence of excessive cellular accumulation of vitamin 
B6 and to regulate subsequent vitamin B6 supplementation accordingly.  In the Royal 
Infirmary, Glasgow, we routinely monitor for accumulation of vitamin B6 (PLP) in red blood 
cells in critically-ill patients.  On the basis of these results we advise that there is significant 
tissue accumulation of PLP in red cells, when concentrations in red cells are above 4000 
pmol/gHb (approximately 5 times the upper limit of normal), and the potential risk of toxicity. 
In summary, the relationship between plasma PLP and PL is disturbed in patients with critical 
illness.  This is less pronounced in both red cells and white cells.  Therefore, intracellular PLP 
concentrations are likely to be a more reliable measure of status than plasma measurements in 
the critically-ill patient.  Also, from these data, critical illness could be related to true vitamin 
B6 deficiency and supplementation with vitamin B6 could be important for some patients 
admitted in ICU. 
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Table 4-1 Characteristics and vitamin B6 concentrations in controls and critically-ill 
patients on admission to ICU 
 Normal subjects 
(n=126) 
Critically-ill patients 
Admission 
(n= 96) 
p-value** 
Age (yr) 53 (31-73) 60 (18-100) 0.113 
Sex (M/F) 67/ 59 61/35 0.122 
APACHE II  20 (3-38)  
Predicted mortality (%)  32.3 (0.9-92.6)  
    
Haemoglobin (g/dL) 11.5-17.7* 9.9 (6.7-16.2)  
C-reactive protein (mg/l) <6  110 (<6-565) <0.001 
Albumin (g/l) 43 (38-49) 18 (9-45) <0.001 
Alkaline phosphatase (U/l) 40-150* 84 (16-1221)  
    
Plasma PLP (nmol/l) 52 (19–194) 20 (<2-333) <0.001 
Plasma PL (nmol/l) 10 (3-40) 9 (<2-1346) 0.004 
Plasma PLP/PL 4.9 (2.5-44.7) 2.2 (0.0-61.8) <0.001 
    
Red cell PLP (pmol/gHb) 391 (234–815) 261 (104-25583) <0.001 
Red cell PL (pmol/gHb) a 72 (25-248) 44 (6-53480) 0.040 
Red cell PLP/ PL a 6.1 (2.8-14.5) 4.9 (0.2-24) 0.003 
    
White cell PLP (pmol/ 106 cells)a NM 2.2 (0.4-8.2)  
White cell PL (pmol/ 106 cells) a NM 0.5 (0.1-10.3)  
White cell PLP/ PL a NM 4.4 (0.3-10.7)  
Median (range), an=75, *laboratory reference intervals, **Mann-Witney U-test, NM=not measured 
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Table 4-2 The relationship between plasma and red cell vitamin B6 concentrations in the control population 
(n=126) 
 Plasma PL Red cell PLP Red cell PL 
Plasma    
Plasma PLP r=0.58*** r=0.90*** r=0.57***  
Plasma PL  r=0.51*** r=0.36*** 
Intracellular    
Red cell PLP   r=0.66*** 
***P<0.001,  Correlations between variables were carried out using the Spearman rank correlation (rs) 
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Table 4-3 The relationship between laboratory characteristics, plasma and red cell vitamin B6 concentrations in critically-ill patients on 
admission to ICU 
(n=96) 
 Plasma PL Albumin Alkaline 
phosphatase 
CRP Haemoglobin Red cell 
PLP 
Red cell 
PLa 
White cell 
PLPa 
White cell 
PLa 
Plasma          
Plasma PLP r=0.51*** r=0.38*** r=0.20 r=-0.37*** r=0.23 r=0.46*** r=0.54*** r=0.56*** r=0.55*** 
Plasma PL  r=0.20 r=0.24 r=-0.16 r=0.07 r=0.66*** r=0.73*** r=0.60*** r=0.68*** 
Albumin   r=0.02 r=-0.40*** r=0.50*** r=-0.06 r=0.00 r=0.31** r=0.08 
Alkaline 
phosphatase 
   r=0.12 r=0.00 r=0.29** r=0.38*** r=0.38** r=0.21 
CRP     r=-0.28** r=0.05 r=0.00 r=-0.40** r=-0.01 
Intracellular          
Haemoglobin      r=-0.21 r=-0.04 r=0.22 r=0.04 
Red cell PLP       r=0.82*** r=0.48*** r=0.73*** 
Red cell PLa         r=0.61*** r=0.88*** 
White cell 
PLPa 
        r=0.68*** 
a
n=74, **P<0.01, ***P<0.001,  Correlations between variables were carried out using the Spearman rank correlation (rs)
  108
 
Table 4-4 Characteristics and B6 vitamin concentrations in critically-ill patients on 
admission and follow-up 
 Critically-ill patients (n=48)  
 Admission Follow-up p-valueb 
Age (yr) 61 (20-81)   
Sex (M/F) 32/ 16   
APACHE II 23 (7-38)   
Predicted mortality (%) 43.5 (4.3-92.6)   
    
Haemoglobin (g/dl) 9.6 (6.7-16.2) 9.0 (6.8-13.5) 0.085 
C-reactive protein (mg/l) 105 (<6-565) 136 (20-356) 0.528 
Albumin (g/l) 15 (9-32) 14 (9-29) 0.001 
Alkaline phosphatase (U/l) 95 (16-1089) 118 (17-659) 0.067 
Plasma PLP (nmol/l) 21 (<2-296) 23 (<2-357) 0.695 
Plasma PL (nmol/l) 9 (<2-912) 16 (<2-1057) 0.042 
Plasma PLP/ PL 2.2 (0.1-62) 1.1 (0.02-17) <0.001 
    
Red cell PLP (pmol/gHb)  300 (111-25583) 548 (51-33797) 0.415 
Red cell PL (pmol/gHb)  65 (17-53480) 331 (12-28868) 0.694 
Red cell PLP/ PL 4.5 (0.2-15) 2.1 (0.6-9) 0.012 
    
White cell PLP (pmol/106 cells)a 2.2 (0.9-6.2) 2.2 (1.4-7.2) 0.574 
White cell PL (pmol/106 cells)a 0.7 (0.2-9.8) 1.3 (0.2-10.3) 0.091 
White cell PLP/ PLa 3.1 (0.3-10) 1.7 (0.3-8) 0.004 
Median (range), an=35, bWilcoxon signed rank test 
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Table 4-5 The relationship between the changes in laboratory characteristics and vitamin B6 concentrations in critically-ill patients 
between admission and follow-up in ICU 
(n=48) 
 Change 
Plasma 
PL 
Change 
Albumin 
Change 
Alkaline 
phosphatase 
Change 
CRP 
Change 
Haemoglobin 
Change 
Red cell 
PLP 
Change 
Red cell 
PL 
Change 
White cell 
PLPa 
Change 
White cell 
PLa 
Plasma          
Change Plasma 
PLP 
r=0.67**
* 
r=0.37** r=-0.04 r=0.03 r=0.21 r=0.55*** r=0.57*** r=0.23 r=0.41 
Change Plasma 
PL  
 r=0.28 r=-0.05 r=0.11 r=-0.03 r=0.83*** r=0.83*** r=0.43 r=0.67*** 
Change Albumin   r=0.27 r=-0.15 r=0.55*** r=0.12 r=0.27 r=-0.11 r=-0.09 
Change Alkaline 
phosphatase 
   r=-0.22 r=0.07 r=-0.22 r=-0.20 r=-0.36 r=-0.54** 
Change CRP     r=-0.37 r=0.34 r=0.29 r=-0.15 r=0.15 
Intracellular          
Change 
Haemoglobin 
     r=-0.16 r=-0.06 r=-0.23 r=-0.19 
Change Red cell 
PLP 
      r=0.95*** r=0.49** r=0.79*** 
Change Red cell 
PL  
       r=0.41 r=0.81*** 
Change White 
cell PLPa 
        r=0.72*** 
a
n=35, **P<0.01, ***P<0.001,  Correlations between the changes in variables were carried out using the Spearman rank correlation (rs) 
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5 Assessment of vitamin C status in patients with critical 
illness: Plasma or white cells? 
5.1 Introduction 
Vitamin C (ascorbic acid) has long been recognised to be one of the most effective water 
soluble antioxidants.  Vitamin C is proposed to act in synergy with the fat soluble antioxidants 
such as vitamin E and β-carotene to protect cell membranes (Cross et al. 1990; Dhariwal, 
Washko & Levine 1990; Downing et al. 1993).  Indeed, there has been continuing interest in 
its use in clinical conditions associated with increased generation of reactive oxygen species.  
For example, there is increasing evidence that the enhanced production of reactive oxygen 
species may be associated with adverse outcome in patients with critical illness (Cowley et al. 
1996; Alonso de Vega et al. 2000).  Therefore, there is considerable interest in the use of 
antioxidants, in particular ascorbic acid, in these patients. 
The role of vitamin C in alleviating the oxidant stress and recycling the oxidized α-tocopherol 
is well recognised.  Plasma α-tocopherol concentrations, in addition to being redistributed as 
part of the systemic inflammatory response, have been reported to be regenerated by vitamin 
C.  Early work on fat autoxidation performed by Golumbic and Mattill (1941) reported the 
antioxygenic action of ascorbate in association with tocopherols.  More recently, in vitro 
studies have was shown that ascorbic acid reduces the tocopheroxyl radical (Packer, Slater & 
Willson 1979) and thereby restores the radical-scavenging activity of tocopherol (Niki et al. 
1982; Niki 1987; Wayner et al. 1987; Doba, Burton & Ingold 1985; Lambelet, Saucy & 
Lölliger 1985).  It would appear that the tocopheroxyl radical, that forms in membranes, is 
thought to react with ascorbic acid to yield tocopherol and the ascorbyl radical, the result of 
which is to maintain radical scavenging potential within the membrane by regenerating 
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tocopherol and to transfer the oxidative challenge to the aqueous phase. However, although 
such a synergistic activity has been shown using model systems, direct and unambiguous 
evidence for its occurrence in biological systems has yet to be presented. 
There is consistent evidence that plasma ascorbic concentrations are extremely low in patients 
with critical illness (Schorah et al. 1996; Nathens et al. 2002; Mishra et al. 2005).  However, it 
has been recognised for some time that plasma ascorbic acid concentrations decrease as part of 
the systemic inflammatory response and its value as an assessment of status, during the 
systemic inflammatory response has been questioned (Galloway, McMillan & Sattar 2000).  
Following injury or critical illness, there is a profound and self-limiting systemic 
inflammatory response as evidenced by an increase in C-reactive protein up to 1000-fold and a 
decrease in albumin concentrations up to 2-fold (Gabay & Kushner 1999).  Indeed, Louw and 
coworkers (1992) reported that, following elective orthopaedic surgery, both plasma ascorbic 
acid concentrations and white cell ascorbic acid concentrations fell significantly although the 
white cell concentrations did not fall as much.  To date, no studies have examined the 
relationship between plasma and white cell ascorbic acid concentrations in patients with 
critical illness. 
Therefore, the aim of the present study was to examine the longitudinal inter-relationship 
between plasma and white cell ascorbic acid in patients with critical illness.  
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5.2 Materials and Methods 
5.2.1 Controls, patients and study design 
See paragraph 2.1.1 
5.2.2 Analytical Methods 
5.2.2.1 Collection and preparation of blood samples 
An EDTA tube containing approximately 6 mL of whole blood was taken for each patient on 
admission and follow-up.  The EDTA sample was centrifuged (500g, 4oC, 10mins) and 500 
uL of plasma was removed into another plastic tube containing, metaphosphoric acid 6%, for 
plasma vitamin C determination.  All tubes were stored at -70o C until analysis. All samples 
were assayed in a single batch for each of the analytes to minimise interbatch analytical 
variation. 
5.2.2.2 White cell preparation 
See paragraph 2.1.2.1 
5.2.2.3 Laboratory measurement of plasma vitamin C 
See paragraph 2.1.2.6 
5.2.2.4 Measurement of plasma and red cell vitamin E and plasma β-carotene 
See paragraphs 2.1.2.7 and 2.1.2.8 
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5.2.2.5 Measurement of free and total MDA concentrations 
See paragraph 2.1.2.9 
5.2.2.6 Measurement of whole blood and plasma proteins concentrations 
See paragraph 2.1.2.2 
5.2.3 Statistics 
Data from normal subject and critically ill patient groups are presented as median and range.  
Comparisons between the control and critically groups were performed with the use of the 
Mann-Whitney U test.  Correlations between variables in the critically ill group were 
performed with the use of the Spearman’s rank correlation (rs).  Data from different time 
points in the patient groups were tested for statistical significance with the use of the 
Wilcoxon’s signed-rank test. Because of the number of statistical comparisons, a P value 
of<0.01 was considered to be significant.  Analysis was performed with the use of SPSS 
software (version 15; SPSS Inc, Chicago, Illinois, U.S.A.). 
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5.3 Results 
In total, thirty eight healthy controls and eighty three critically ill patients (medical n=36, 
surgical n=47) were studied (Table 5-1).  The patients were not different in terms of age and 
sex compared with the controls.  The patients had median APACHE II score of 20, predicted 
hospital mortality of 32% and SOFA score of 7.   
Compared with controls, C-reactive protein concentrations were significantly higher in the 
critically ill patients group (p<0.001). Total protein and albumin concentrations were 
significantly lower in the critically ill patients group (both p<0.001).  Plasma ascorbic acid, 
plasma α-tocopherol and plasma β-carotene were significantly lower in the critically ill 
patients compared with controls (all p<0.001).  Sixty three out of 83 patients had plasma 
ascorbic acid concentrations below the reference interval and 10 out of 41 patients had white 
cell ascorbic acid concentrations below the reference interval.  Total MDA/g total protein was 
higher in the critically ill patients compared with controls (p<0.001). 
The interrelationships between plasma concentrations of ascorbic acid, plasma α-tocopherol, 
plasma β-carotene and MDA in the control subjects are shown in Table 5-2.  Total MDA /g 
total protein was directly associated with free MDA (rs=0.77, p<0.001).  
The interrelationships between plasma and white cell concentrations of ascorbic acid, plasma 
and red cell concentrations of α-tocopherol, plasma β-carotene and proteins in the critically-ill 
patients are shown in Table 5-3.  Plasma ascorbic acid was directly associated with white cell 
ascorbic acid (rs=0.48, p<0.01).  Plasma α-tocopherol was directly associated with total 
protein (rs=0.60, p<0.001), and albumin (rs=0.56, p<0.001) and inversely associated with C-
reactive protein (rs=-0.32, p<0.01).  Plasma β-carotene was directly associated with albumin 
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(rs =0.29, p<0.01), plasma α-tocopherol (rs=0.50, p<0.001) and red cell α-tocopherol (rs=0.36, 
p<0.01).  
Of the 83 patients who were admitted to the intensive care unit, 44 had longitudinal 
measurements (Table 5-4).  Those patients with a follow-up sample had a higher APACHE II 
score, predicted mortality, ICU length of stay, ICU death and total MDA/g of total protein 
than did those patients who did not (p<0.01).  The patients who did not have a longitudinal 
measurement were either discharged from ICU (n=38) or dead in ICU (n=1).  The time 
between admission and follow-up samples was a median of 3 days (range: 2–12 days).  There 
were no significant differences in plasma and white cell ascorbic acid, plasma and red cell α-
tocopherol, or plasma β-carotene concentrations between the admission values of those with 
and without a follow-up sample.  
Between the admission and follow-up measurements there was a decrease in albumin 
concentrations (p<0.001). 
There were no significant differences in age, sex, APACHE II, predicted mortality, patient 
type, and SOFA score between patients that received vitamin C supplementation (n=28) and 
those who did not (n=15).  Similarly there were no significant differences in total protein, C-
reactive, albumin, white cell counts, plasma and white cell ascorbic acid, plasma and red cell 
α-tocopherol, plasma β–carotene, total and free MDA between these two groups. 
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5.4 Discussion 
In the present prospective longitudinal study plasma ascorbic acid concentrations in critically 
ill patients were below reference intervals whereas, white cell ascorbic acid concentrations 
were within the reference intervals.  Moreover, plasma and intracellular concentrations of both 
vitamin C and α-tocopherol were poorly correlated and did not increase with supplementation 
in the ICU.  Taken together these results would suggest that plasma ascorbic acid 
concentrations poorly reflect intracellular concentrations in patients with critical illness. 
In contrast, there is a good correlation between plasma and white cell vitamin C 
concentrations in healthy subjects (Bates 1977; Jacob, Skala & Omaye 1987; Omaye et al. 
1987).  Moreover, it has been shown that both plasma and white cell vitamin C concentrations 
are increased on supplementation in healthy subjects (Jacob, Skala & Omaye 1987).  
Furthermore, previous studies in healthy subjects suggest that plasma vitamin C 
concentrations reflect recent dietary intake, whereas white cell concentrations reflect cellular 
stores and vitamin C status (Omaye et al. 1987).   
Schorah and colleagues (1996) reported that plasma vitamin C concentrations were 25% lower 
in critically ill patients compared with control subjects, and were directly related to the 
severity of the systemic inflammatory response (as evidenced by C-reactive protein) and to the 
length of ICU stay.  Interestingly, Mishra and coworkers (2005) using a similar dose of 
vitamin C to that in the present study (1,000 mg for 3 days) reported that they were unable to 
prevent the fall of plasma ascorbic acid concentrations to undetectable levels by day 12 in 
alcoholic critically ill patients.  In contrast, Nathens and workers (2002) reported that, in 
patients with critical illness, supplementation with large doses (approximately 10 times that 
used in the present study) was associated with a normalisation of plasma vitamin C 
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concentrations.  Therefore, these studies would confirm the concept that plasma vitamin C 
concentrations reflect intake poorly in patients with critical illness and are in agreement with 
the results of the present study.   
To date, there no studies which have reported white cell vitamin C concentrations or the effect 
of vitamin C supplementation in critically ill patients.  Therefore, the value of white cell 
vitamin C concentrations in critically ill patients remains unclear.  A limitation of the present 
study was that the number of patients with white cell results was limited to approximately half 
of the total number of patients.  This difference in numbers occurred because vitamin C has to 
be stabilised within 4-6 hours of sampling and some of the samples arrived during evening and 
night times, and secondly because a number of patients had very low white cell counts for the 
white cell extraction method to be of use.      
There is some indirect evidence of the utility of white cell vitamin C concentrations such as in 
the present study the median of white cell vitamin C concentrations was within the reference 
interval and remained within the reference interval on follow up.  In contrast, on admission, 
white cell vitamin C concentrations were poorly correlated with α-tocopherol concentrations 
and the lipid peroxidation product MDA, and they did not increase with supplementation in 
the ICU despite the recognised role of vitamin C in alleviating the oxidant stress and recycling 
the oxidized α-tocopherol.  These results question whether the interrelationship between 
vitamin C and vitamin E and lipid peroxidation is important in inflammatory states but could 
also be confounded by the smaller numbers of white cell ascorbic acid observations.  It may be 
that white cell vitamin C concentrations do not increase on supplementation in the critically ill 
patients due to increased consumption or urinary loss of vitamin C or both.  In the present 
study, urine samples were not available thus future studies comparing the effect of vitamin C 
supplementation on vitamin C urine exretion in patients with critical illness could assess this 
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possibility.  Another explanation could be that not all of these patients had recorded vitamin C 
supplementation in ICU and thus the results of the present study could be compromised by the 
data of the patients that did not have recorded supplementation.  Also, the possibility of a 
saturation effect could be considered as an additional explanation as some of the patients had 
records of supplementation prior to ICU admission.  The effect of supplementation on both the 
patients that had or did not have recorded ICU supplementation is discussed in Chapter 8. 
In summary, the results of the present study indicate that plasma vitamin C concentrations are 
of limited value and suggest that white cell vitamin C concentrations may be of value in 
assessing status in patients with critical illness.  Also, from these data, critical illness could be 
related to true vitamin C deficiency and supplementation could be important for some patients 
admitted in ICU. 
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Table 5-1 Characteristics and vitamin C in healthy subjects and critically-ill patients on 
admission to ICU 
 Healthy subjects 
(n=38) 
Critically–ill 
patients (n=83) 
p-value** 
Age (yr) 55 (43-73) 59 (20-86) 0.376 
Sex (M/F) 21/ 17 51/ 32 0.522 
APACHE II  20 (3-38)  
Predicted mortality (%)  32.2 (0.9-92.6)  
Medical/ Surgical   36/ 47  
SOFA score  7 (0-14)  
Alive/ Dead  68/ 15  
Total protein (g/ l) 73 (66-81) 46 (23-83) <0.001 
C-reactive protein (mg/ l) 6 (<6-8) 96 (1-565) <0.001 
Albumin (g/ l) 44 (38-50) 18 (9-45) <0.001 
White cell counts (x 109 cells)  12 (3.8-34.2)  
    
Plasma ascorbic acid (µmol/ l) 27 (2-82) <5 (<5-136) <0.001 
Neutrophil ascorbic acid (µmol/ 109 
cells) 
1.5-2.5* 1.9 (0.5-8.8)a  
    
Plasma α-tocopherol (µmol/ l) 30 (14-42) 15 (5-41) <0.001 
Red cell α-tocopherol (pmol/ g Hb) 19 (12-28)* 18 (3-39)b  
    
Plasma β-carotene (µg/ l) 162 (57-708) 25 (<5-518) <0.001 
    
Total MDA/ total protein (µmol/ g) 0.01 (0.00-0.02) 0.01 (0.01-0.53)c <0.001 
Free MDA (µmol/ l) 0.08 (0.04-0.10) 0.09 (0.02-5.96)c 0.043 
Median (range) 
a
n=41, bn=60, c n=70, *reference interval, **Mann-Whitney U test
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Table 5-2 Spearman correlations between plasma concentrations of ascorbic acid, plasma α-tocopherol, plasma β-carotene and MDA 
in the control subjects 
(n=38) 
 Plasma  
α-tocopherol 
Plasma  
β-carotene 
Total MDA/ total protein Free MDA 
Plasma ascorbic acid 0.28 0.14 -0.04 -0.20 
Plasma α-tocopherol  0.34* 0.15 0.11 
Plasma β-carotene   -0.17 -0.22 
Total MDA/ total protein    0.77*** 
*P<0.05, ** P<0.01, *** P<0.001 
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Table 5-3 Spearman correlations between plasma and white cell concentrations of ascorbic acid, plasma and red cell concentrations of 
α-tocopherol, plasma β-carotene and proteins in the critically-ill patients on admission to ICU 
(n=83) 
 CRP Albumin Plasma 
ascorbic acid 
White cell 
ascorbic acid 
Plasma  
α-tocopherol 
Red cell  
α-tocopherol 
Plasma  
β-carotene 
Total MDA/ 
total protein 
Free MDA 
Total protein -0.18 0.74*** 0.21 -0.02 0.60*** -0.01 0.28* -0.37** -0.07 
CRP  -0.36** 0.14 0.16 -0.32** -0.12 -0.25* -0.16 0.05 
Albumin   0.23* 0.04 0.56*** -0.02 0.29** -0.20 -0.22 
Plasma 
ascorbic acid 
   0.48** -0.00 -0.05 0.04 -0.23 0.18 
White cell 
ascorbic acid 
    0.13 0.12 0.07 -0.16 0.18 
Plasma  
α-tocopherol 
     0.23 0.50*** -0.06 -0.13 
Red cell 
α-tocopherol 
      0.36** -0.20 0.10 
Plasma  
β-carotene 
       -0.10 -0.11 
Total MDA/ 
total protein 
        0.30* 
*P<0.05, ** P<0.01, *** P<0.001 
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Table 5-4 Characteristics and vitamin C, E, β-carotene concentrations in critically ill 
patients on admission and at follow-up 
 Critically–ill patients (n=44)  
 Admission Follow-up p-value* 
Age (yr) 61 (20-86)   
Sex (M/F) 30/ 14   
APACHE II 23 (7-38)   
Predicted mortality (%) 41.1 (4.3-92.6)   
Medical/ Surgical  19/ 25   
SOFA score 7 (1-14) 6 (1-16) 0.035 
Alive/ Dead 30/ 14   
    
Total protein (g/ l) 43 (23-82) 42 (27-62) 0.020 
C-reactive protein (mg/ l) 103 (2-565) 149 (23-336) 0.316 
Albumin (g/ l) 17 (9-45) 15 (9-29) <0.001 
White cell counts (x 109 cells) 11.5 (3.8-31.2) 12.3 (3.9-29.5) 0.095 
    
Plasma ascorbic acid (µmol/ l) <10 (<10-136) <10 (<10-69) 0.242 
Neutrophil ascorbic acid (µmol/ 109)a 2.0 (0.5-8.8) 2.2 (0.7-5.8) 0.563 
    
Plasma α-tocopherol (umol/ l) 14 (5-41) 16 (8-34) 0.102 
Red cell α-tocopherol (pmol/ g Hb)b 19 (3-39) 22 (8-48) 0.141 
    
Plasma β-carotene (µg/ l) 23 (<5-402) 25 (<5-248) 0.052 
    
Total MDA/ total protein (µmol/ g)b 0.02 (0.01-0.53) 0.01 (0.01-0.57) 0.898 
Free MDA (µmol/ l)b 0.15 (0.04-5.96) 0.13 (0.03-9.41) 0.518 
Median (range) 
a 
n=23, b n=38, *Wilcoxon signed rank test 
  124
6 Assessment of vitamin E status in patients with systemic 
inflammatory response syndrome: Plasma, plasma 
expressed per mmol of lipids or red cell measurements? 
6.1 Introduction 
There is increasing evidence that plasma concentrations of a number of important 
micronutrient biomarkers are influenced by the presence of a systemic inflammatory response 
(Fell & Talwar 1998; Galloway, McMillan & Sattar 2000; Schweigert 2001).  Such an effect 
has been reported in apparently healthy individuals (Gray et al. 2004; Gray et al. 2005; Oakes 
et al. 2008), patients with chronic disease (Talwar et al. 1997; McMillan et al. 2000; 
Almushatat et al. 2006; Leung et al. 2008; El Muhtaseb et al. 2009) and acute illness (Quasim 
et al. 2003; Quasim et al. 2005).  In particular, plasma concentrations of vitamins are reduced 
as part of the systemic inflammatory response in apparently healthy individuals (Gray et al. 
2005), chronic disease (Talwar et al. 1997; McMillan et al. 2000; McMillan et al. 2002; 
Almushatat et al. 2006) and acute illness (Goode et al. 1995; Nathens et al. 2002; Quasim et 
al. 2003) independent of status.  Some workers have proposed either expressing plasma 
vitamin concentrations per lipid concentrations (Thurnham et al. 1986; 2008) or measurement 
of intracellular vitamin concentrations (Talwar et al. 2003b). 
Vitamin E is the major chain breaking lipophilic antioxidant in cell membranes and plasma, 
where it protects polyunsaturated fatty acids against free radical mediated peroxidation.  It is 
also essential, along with cholesterol, for the structural stability of membranes.  The most 
biological active form of vitamin E is α-tocopherol which accounts for more than 83% of the 
vitamin E in tissues (Chow 1975).  Vitamin E status is usually assessed by measurement of α-
tocopherol in plasma although its correlation in tissues is not clearly established.  Moreover, 
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plasma concentrations of vitamin E are strongly associated with their carrier lipids, principally 
cholesterol and triglycerides.  To overcome this limitation it has been proposed the plasma α-
tocopherol concentrations should be expressed in relation to plasma lipid concentrations, 
usually cholesterol (Thurnham et al. 1986; Thurnham et al. 2008; Doise et al. 2008). 
Indeed, in healthy subjects undergoing elective surgery, there is a significant transient 
decrease in both α-tocopherol and cholesterol concentrations during the evolution of the 
systemic inflammatory response (Gray et al. 2005).  However, when plasma α-
tocopherol/mmol of cholesterol, as proposed by Thurnham and coworkers (1986), was applied 
there was no significant alteration in plasma α-tocopherol concentrations (Gray et al. 2005).  
However, we have observed that, in patients with systemic inflammatory response syndrome, 
when expressed per mmol of cholesterol, α-tocopherol concentrations were significantly 
higher than controls (Quasim et al. 2003).  Therefore, it would appear that the simple 
expression of plasma α-tocopherol per mmol of cholesterol may overestimate vitamin E status 
in patients with systemic inflammatory response syndrome. 
Since vitamin E is mainly present in cell membranes with plasma concentrations only 
representing a small fraction of total body vitamin E, it may be that the measurement of red 
cell α-tocopherol concentrations will prove to be a more reliable indicator of vitamin E status 
(Kitagawa, Nakagawa & Mino 1983).  In animal studies, it has been reported that there is a 
good correlation between tissue and red cell α-tocopherol concentrations in the presence of 
variable plasma concentrations (Lehmann 1981).  Also, red cell α-tocopherol concentrations 
have been used to assess vitamin E status in cystic fibrosis (Winklhofer-Roob et al. 1992), in 
cigarette smoking (Brown, Morrice & Duthie 1997), in type I diabetes (Jain, McVie & Smith 
2000) and in atherosclerosis (Bonithon-Kopp et al. 1997).  Results from these studies showed 
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significant correlations between red cell vitamin E status and markers of oxidative stress, or a 
dose response relationship in cases of supplementation. 
Therefore, the aim of the present study was to examine the longitudinal inter-relationships 
between α-tocopherol in the plasma, in the plasma expressed per mmol of lipids and in the red 
cell of patients with systemic inflammatory response syndrome. 
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6.2 Materials and Methods 
6.2.1 Controls, patients and study design 
See paragraph 2.1.1 
6.2.2 Collection and preparation of blood samples 
The EDTA sample was centrifuged (500g, 4oC, 10mins) and plasma was removed into a 
plastic tube for vitamin determination, the buffy coat was discarded and packed red cells were 
washed with saline (NaCl 0.9%).  Red cells were centrifuged again and saline removed.  To 
stabilise the vitamin E in the red cells 400µl of washed red cells were mixed with an equal 
volume of ascorbic acid solution (2%).  For long term storage of samples at -70o C, it was 
found necessary to stabilise the α-tocopherol in the red cell sample with ascorbic acid.  Under 
these conditions the α-tocopherol was stable for at least 6 months. 
6.2.3 Analytical Methods 
6.2.3.1 Measurement of plasma and red cell vitamin E 
See paragraph 2.1.2.7 
6.2.3.2 Measurement of plasma and whole blood protein and lipid concentrations 
See paragraph 2.1.2.2 
6.2.4 Statistics 
Data from normal subject and critically ill patient groups are presented as median and range.  
Comparisons between the control and critically groups were performed with the use of the 
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Mann-Whitney U test.  Correlations between variables in the critically ill group were 
performed with the use of the Spearman’s rank correlation (rs).  Data from different time 
points in the patient groups were tested for statistical significance with the use of the 
Wilcoxon’s signed-rank test. Because of the number of statistical comparisons, a P value of 
<0.01 was considered to be significant.  Analysis was performed with the use of SPSS 
software (version 15; SPSS Inc, Chicago, Illinois, U.S.A.). 
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6.3 Results 
In total, sixty seven healthy controls and eighty two critically ill patients (medical n=38, 
surgical n=44) were studied (Table 6-1).  The patients were not different in terms of age and 
sex compared with the controls.  The patients had median APACHE II score of 21, predicted 
hospital mortality of 36% and SOFA score of 7.  Patients had a median length of ICU stay of 6 
days and median hospital stay of 23 days. 
The 95% reference intervals in the normal subjects for plasma α-tocopherol, plasma α-
tocopherol/mmol of cholesterol, plasma α-tocopherol/mmol of triglycerides and red cell α-
tocopherol/g of haemoglobin were 14-45 umol/ l, 2.36-48.00 umol/ mmol, 2.17-6.23 umol/ 
mmol and 7.8-30.8 nmol/gHb respectively.  Compared with controls, C-reactive protein 
concentrations were significantly higher and albumin concentrations were significantly lower 
in the critically ill patients group (both p<0.001).  Plasma cholesterol concentrations were 
significantly lower, but triglycerides were similar (p=0.218) in the critically ill patients 
compared with the controls (all p<0.001).  Plasma α-tocopherol was significantly lower in the 
critically ill patients compared with the controls (all p<0.001) with 41% of patients having 
concentrations below the reference interval.  In contrast, when expressed per mmol of 
cholesterol, α-tocopherol concentrations were significantly higher in the critically ill patients 
compared with the controls group (p<0.001, 27% above the reference interval) and when 
expressed per mmol of triglycerides, α-tocopherol concentrations were significantly lower in 
the critically ill patients compared with the controls group (p<0.001).  Red cell α-tocopherol/g 
of haemoglobin was similar (p=0.852) in the critically ill patients compared with control 
subjects. 
  130
The interrelationships between plasma and red cell concentrations of α-tocopherol, lipids and 
albumin in the control subjects are shown in Table 6-2.  Plasma α-tocopherol was directly 
associated with cholesterol (rs=0.35, p<0.01), triglycerides (rs=0.40, p<0.01) and inversely 
with albumin (rs=-0.46, p<0.01) but not red cell α-tocopherol/g of haemoglobin.  Plasma α-
tocopherol/mmol of cholesterol was directly associated with red cell α-tocopherol/g of 
haemoglobin (rs=0.51, p<0.01). 
The interrelationships between plasma and red cell concentrations of α-tocopherol, lipids and 
proteins in the critically-ill patients are shown in Table 6-3.  Plasma α-tocopherol was directly 
associated with cholesterol (rs=0.87, p<0.001), triglycerides (rs=0.66, p<0.001) and albumin 
(rs=0.60, p<0.001) but not red cell α-tocopherol/g of haemoglobin at the p<0.01 level.  Plasma 
α-tocopherol/mmol of cholesterol was inversely associated with albumin (rs=-0.41, p<0.01).  
Plasma α-tocopherol/mmol of triglycerides was directly associated with red cell α-
tocopherol/g of haemoglobin (rs=0.35, p<0.01).   
Of the 82 patients who were admitted to the intensive care unit, 53 had longitudinal 
measurements of both plasma and red cell α-tocopherol concentrations (Table 6-4).  Those 
patients with a follow-up sample had a higher APACHE II score than did those patients who 
did not (p<0.01).  The patients who did not have a longitudinal measurement were either 
discharged from ICU (n=28) or dead in ICU (n=1).  The time between admission and follow-
up samples was a median of 4 days (range: 2–12 days).  There were no significant differences 
in plasma or red cell α-tocopherol concentrations between the admission values of those with 
and without a follow-up sample.  
Between the admission and follow-up measurements there was a decrease in albumin 
concentrations (p<0.01).  There was also a significant increase in α-tocopherol/mmol of 
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cholesterol (p<0.01), but no difference in α-tocopherol/mmol of triglycerides (p=0.117) or red 
cell α-tocopherol concentrations/g of haemoglobin (p=0.066) at the p<0.01 level, between the 
admission and follow-up measurements. 
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6.4 Discussion 
Plasma vitamin E (α-tocopherol) is most frequently used for assessing status although the 
relationship between plasma and tissue vitamin E concentrations has not been clearly 
established.  In the plasma, α-tocopherol is recognised to circulate primarily bound to the 
lipoproteins in the lipid fraction, cholesterol and triglycerides (Rubinstein, Diez & Srinivasan 
1969).  It has been previously reported that where there are small changes in the plasma lipid 
fraction, plasma α-tocopherol concentrations are also altered (Bieri, Evarts & Thorp 1977).  
Therefore, plasma α-tocopherol concentration expressed per mmol of lipids (whether 
cholesterol or triglycerides) is considered to be a more reliable measurement.  However, the 
basis for such a calculation in the presence of systemic inflammation, where there are marked 
changes in plasma lipid concentration that occur as part of the acute phase response 
(Carpentier & Scruel 2002), has not been established.  
In the present study, compared with control subjects, the critically-ill patient group had lower 
plasma α-tocopherol concentrations and also when expressed per mmol of triglycerides.  In 
contrast, α-tocopherol concentrations were higher when expressed per mmol of cholesterol 
despite these patients receiving no vitamin E supplementation prior or during their ICU stay.  
Moreover, neither plasma α-tocopherol nor plasma α-tocopherol/mmol of cholesterol were 
strongly correlated with red cell α-tocopherol concentrations in the critically-ill patients.  
Finally, median red cell α-tocopherol concentrations were the same in the healthy subjects and 
patients with critical illness and systemic inflammatory response syndrome.  Taken together 
the results of the present study indicate that red cell α-tocopherol concentrations may be a 
more accurate marker of vitamin E status than plasma α-tocopherol in patients with a systemic 
inflammatory response however this would need further examination, e.g. examining the 
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effect of vitamin E supplementation on the plasma or red cell concentrations of depleted 
patients. 
The low plasma α-tocopherol concentrations in critically ill patients with systemic 
inflammation are in agreement with previous reports (Goode et al. 1995; Borrelli et al. 1996; 
Kharb, Ghalaut & Ghalaut 1999; Nathens et al. 2002; Quasim et al. 2003).  However, the basis 
of the elevated plasma α-tocopherol when expressed per mmol of lipids is not clear.  From the 
present results, the basis appears to be due to the variable and disproportionately lower α-
tocopherol (48%), cholesterol (61%) and triglyceride (15%) concentrations in the critically ill 
patients compared with controls.  These variable changes in α-tocopherol, cholesterol and 
triglycerides are such that when α-tocopherol was expressed per mmol of cholesterol and 
mmol of triglycerides there were inconsistent values (31% higher and 43% lower, 
respectively).  Given that, in the plasma, α-tocopherol is present in the greatest amount in the 
low density (LDL) and high density (HDL) lipoprotein fractions (McCormick, Cornwell & 
Brown 1960) and cholesterol concentrations are markedly reduced whilst very low density 
lipoprotein (VLDL) and triglycerides not significantly so, this may have contributed to the 
inconsistency of the results when expressed by mmol of these plasma lipids and thus to the 
unreliable estimation of α-tocopherol when expressed per mmol of these lipid fractions. 
In vitro studies have shown that whilst α-tocopherol is transferred from all lipoprotein 
fractions to red cell membranes (and also presumably membranes of other cells), the relative 
ability to affect this transfer is 3 times greater with HDL and LDL compared with VLDL 
(Kayden & Bjornson 1972).  It is recognised that, as part of the systemic inflammatory 
response, the concentration and composition of plasma lipid and lipoproteins is markely 
altered.  In particular, plasma cholesterol concentrations are substantially reduced whereas 
plasma triglyceride concentrations are minimally reduced (Carpentier & Scruel 2002).  In the 
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present study, critically-ill patients had a much reduced cholesterol/ triglyceride ratio 
compared with the controls largely due to the fall in plasma cholesterol concentration.  LDL, 
in man, is derived from VLDL and the two lipoprotein classes differ in that VLDL is larger 
and contains more triglyceride.  Therefore, in the presence of a systemic inflammatory 
response, it is likely that the transport of α-tocopherol is predominantly associated with 
triglycerides, i.e. VLDL rather the LDL, the concentration of which is relatively more reduced.  
This may have resulted in a reduced transfer of α-tocopherol from plasma to cell membranes 
and/or reduced turnover of plasma α-tocopherol relative to plasma cholesterol.  As a result, in 
the presence of a systemic inflammatory response, plasma α-tocopherol concentration may fall 
less than cholesterol leading to an increase in lipid expressed α-tocopherol values in plasma.  
Clearly, the analysis of α-tocopherol in the above lipid fractions in the presence of a systemic 
inflammatory response is required to test this hypothesis. 
In contrast, red cell α-tocopherol concentrations primarily reflect that in the red cell membrane 
(Chow 1975) and therefore, less influenced by the acute changes in plasma lipid fractions as 
part of the systemic inflammatory response.  Indeed, Lehmann and coworkers (1988), in 
normal subjects, reported that red cell α-tocopherol was more sensitive to dietary intake than 
the corresponding plasma measurement.  In addition, the susceptibility of red blood cells to 
haemolysis in the presence of hydrogen peroxide is more directly related to α-tocopherol 
concentration in red blood cells than in plasma.  Also the results of the present study are 
similar to those of previous studies (Bieri, Tolliver & Catignani 1979; Bonithon-Kopp et al. 
1997; Campoy et al. 2003).  Taken together these observations indicate that red cell α-
tocopherol is a more reliable measure of vitamin E status.  
In summary, the results of the present study indicate that there is a discrepancy between 
vitamin E measurements in plasma, in plasma expressed per mmol of lipids and in red cells.  
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Although the value of expressing vitamin E concentrations per mmol of lipids is well 
established in population studies, the present study indicates that such calculation is unreliable 
in the presence of systemic inflammatory response syndrome and that vitamin E status should 
be assessed using red cell α-tocopherol measurements. 
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Table 6-1 Characteristics and vitamin E in critically-ill patients on admission to ICU 
 
 Healthy subjects 
(n=67) 
Critically–ill patients 
(n=82) 
p-valueb 
Age (yr) 55 (29-79) 60 (18-81) 0.123 
Sex (M/F) 36/ 31 52/ 30 0.233 
Medical/ Surgical   38/ 44  
APACHE II  21 (3-38)  
Predicted mortality (%)  35.6 (1.2-92.6)  
SOFA score  7 (1-18)  
ICU Length of stay  6 (0.2-76.4)  
Hospital Length of stay  23 (0.4-508)  
Alive/ Dead  62/ 20  
    
Plasma    
C-reactive protein (mg/ l) <6 (<6-<6) 110 (<6-565) <0.001 
Albumin (g/ l) 44 (38-50) 18 (9-45) <0.001 
Cholesterol (mmol/ l) 5.40 (3.10-7.80) 2.10 (0.40-6.40) <0.001 
Triglycerides (mmol/ l) 1.25 (0.50-4.05) 1.06 (0.30-5.05) 0.218 
α-tocopherol (umol/ l) 29 (14-47) 15 (4-41) <0.001 
α-tocopherol/ cholesterol 
(µmol/ mmol) 
5.2 (3.5-8.7) 6.8 (3.6-15.7) <0.001 
α-tocopherol/ triglycerides 
(µmol/ mmol) 
22.3 (7.2-67.3) 12.8 (4.8-47.8) <0.001 
Red cell    
α-tocopherol (nmol/ gHb) 18.5 (12-28)a 18.6 (3.4-39.3) 0.852 
Median (range) 
a
n=26, bMann-Witney U test
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Table 6-2 Spearman correlations between plasma and red cell vitamin E concentrations in the controls 
(n=67) 
 Plasma α-
tocopherol/ 
cholesterol 
Plasma α-
tocopherol/ 
triglycerides 
Cholesterol Triglycerides Albumin Red cell 
α-tocopherol/ Hba 
Plasma       
α-tocopherol 0.68*** 0.00 0.35** 0.40** -0.46** 0.32 
α-tocopherol/ cholesterol  0.11 -0.39** 0.15 -0.50** 0.51** 
α-tocopherol/ triglycerides   -0.09 -0.88*** -0.06 0.26 
Cholesterol    0.26* 0.03 -0.07 
Triglycerides     -0.03 -0.10 
a
n=26, *P<0.05, **P<0.01, ***P<0.001
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Table 6-3 Spearman correlations between laboratory characteristics, plasma and red cell vitamin E concentrations in critically-ill patients 
on admission to ICU 
(n=82) 
 Plasma α-
tocopherol/ 
cholesterol 
Plasma α-
tocopherol/ 
triglycerides 
Plasma 
Cholesterol 
Plasma 
Triglycerides 
Plasma 
Albumin 
Red cell 
α-tocopherol/ Hb 
Plasma       
α-tocopherol -0.12 0.17 0.87*** 0.66*** 0.60*** 0.23* 
α-tocopherol/ cholesterol  -0.15 -0.55*** -0.02 -0.41*** 0.29* 
α-tocopherol/ triglycerides   0.22 -0.57*** 0.16 0.35** 
Cholesterol    0.54*** 0.72*** 0.07 
Triglycerides     0.37*** -0.04 
       *P<0.05, **P<0.01, ***P<0.001 
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Table 6-4 Characteristics and vitamin E concentrations in critically ill patients on 
admission and follow-up 
 Critically ill patients (n=53)  
 Admission  Follow-up p-valueb 
Age (yr) 61 (18-81)   
Sex (M/F) 37/ 16   
Patients (medical/ surgical) 25/ 28   
APACHE II 23 (7-38)   
Predicted mortality (%) 42.5 (4.3-92.6)   
SOFA score 7 (1-14) 7 (0-13) 0.212 
ICU length of stay 10.3 (0.90-76.4)   
Hospital length of stay 27.5 (6-253)   
Alive/ Dead 34/ 19   
    
Plasma    
C-reactive protein (mg/ l) 96 (26-565) 136 (20-356) 0.270 
Albumin (g/ l) 16 (9-45) 14 (9-29) 0.001 
Cholesterol (mmol/ l) 1.70 (0.53-5.20) 1.80 (0.60-4.40) 0.565 
Triglycerides (mmol/ l) 0.80 (0.30-3.40) 1.02 (0.20-3.20) 0.575 
α-tocopherol (µmol/ l) 14 (5-41) 16 (6-36) 0.081 
α-tocopherol/cholesterol (µmol/ mmol) 7.2 (3.6-15.7) 8.2 (3.4-12.9) 0.010 
α-tocopherol/ triglycerides (µmol/ mmol) 13.6 (4.8-47.8) 15.0 (3.7-60.1) 0.117 
Red cell    
α-tocopherol/ Hb (nmol/gHb) 19.04 (3.40-39.28) 21.86 (8.18-48.37) 0.066 
Median (range) 
bWilcoxon signed-rank test 
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7 The relationship between lipid peroxidation and lipid 
soluble vitamin antioxidants in critically ill patients 
7.1 Introduction 
During the systemic inflammatory response there is activation of white blood cells which 
secrete oxygen free radicals leading to oxidation of cell membrane lipids.  Polyunsaturated 
fatty acids are especially vulnerable to attack by free radicals and undergo lipid peroxidation.  
Indeed, products of this reaction such malondialdehyde (MDA) are routinely used as markers 
of free radical damage (Ogilvie et al. 1991; Grune & Berger 2007).  Furthermore, MDA may 
exacerbate oxidative stress since it is toxic to the cardiovascular system (Gutteridge 1995) and 
also mutagenic having potentially genotoxic interactions with DNA and proteins (Del Rio, 
Stewart & Pellegrini 2005). 
Vitamin E (α-tocopherol) and carotenoids have important antioxidant properties and are able 
to quench oxygen derived radicals and prevent lipid peroxidation (Bast et al. 1998; Galloway, 
McMillan & Sattar 2000).  However, there is increasing evidence which suggests that the 
systemic inflammatory response associated with acute injury and infection may lower plasma 
antioxidant concentrations independent of tissue stores (Rahman et al. 1998; Galloway, 
McMillan & Sattar 2000; Schweigert 2001; Roth, Manhart &Wessner 2004).  As part of this 
process, in acute inflammation there has been reported a transient decrease in plasma lipid 
soluble antioxidants such as α-tocopherol and carotenoids in healthy subjects (Galloway, 
McMillan & Sattar 2000; Kritchevsky et al. 2000; Gray et al. 2005) and medical patients 
(Curran et al. 2000; Chang et al. 2005).  In chronic inflammation there are also significant 
decreases in plasma lipid soluble antioxidants such as α-tocopherol and carotenoids (Talwar et 
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al. 1997; McMillan et al. 2002), even when expressed per mmol of plasma lipids (Talwar et al. 
1997; Leung et al. 2008). 
This inflammation-associated reduction in plasma lipid soluble vitamin anti-oxidants also 
appears to be relevant in the critically-ill patient (Goode & Webster 1993).  Quasim and 
colleagues (2003), in a small cross sectional study, reported that plasma concentrations of 
carotenoids (lutein, lycopene, α- and β-carotene) all appeared lower, compared with controls, 
even when expressed per mmol of cholesterol.  Also, supplementation with vitamins E and C 
appears to be beneficial to the critically ill patient, in reducing oxidative stress and the risk of 
the development of multiple organ dysfunction syndrome (Nathens et al. 2002). 
Clearly, if lipid soluble vitamin antioxidants were shown to be deficient in the critically-ill 
patient due to increased oxidative stress and were related to lipid peroxidation then they might 
provide an important therapeutic target in this difficult to treat group of patients.  
Alternatively, if lipid soluble vitamin antioxidants were shown to be related to vitamin A 
(retinol), which is very rarely deficient in Western populations (World Health Organisation 
1995) because of its large body stores but falls transiently during the systemic inflammatory 
response (Gray et al. 2005), then the value of using lipid soluble vitamins to protect from 
oxidative stress might be questioned.  
To date we are unaware of any studies that have examined the temporal plasma concentrations 
of MDA, retinol, α-tocopherol, and carotenoids in patients with critical illness.  Therefore, the 
aim of the present study was to examine the longitudinal inter-relationships between 
circulation concentrations of malondialdehyde (total and free) and the lipid vitamin 
antioxidants retinol, α-tocopherol, lutein, lycopene, α- and β-carotene in patients with critical 
illness.  
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7.2 Materials and methods 
7.2.1 Controls, patients and study design 
See paragraph 2.1.1 
7.2.2 Collection and preparation of blood samples 
Venous blood samples (EDTA) were withdrawn on admission (day 1) and on follow –up, 
median 4 (range 2-12) days for the analysis of plasma total and free malondialdehyde, retinol, 
α-tocopherol, lutein, lycopene, α-carotene and β-carotene, C-reactive protein, albumin, 
cholesterol and triglycerides.  The EDTA sample was centrifuged (500g, 4oC, 10mins) and 
plasma was removed into a plastic tube for vitamin determination.  All tubes were stored at -
70o C until analysis. All samples were assayed in a single batch for each analyte to minimise 
interbatch analytical variation. 
7.2.3 Analytical Methods 
7.2.3.1 Measurement of Malondialdehyde (MDA) 
See paragraph 2.1.2.9 
7.2.3.2 Measurement of lipid soluble antioxidants 
See paragraph 2.1.2.7 and 2.1.2.8 
7.2.3.3 Measurement of plasma proteins and lipids concentrations 
See paragraph 2.1.2.2 
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7.2.4 Statistics 
Comparisons between controls and critically ill patients were carried out using the Mann-
Whitney U test.  Data from critically ill patients groups are presented as median and range and 
Wilcoxon-signed rank test was used to test the longitudinal data.  Correlations were carried 
out using the Spearman rank correlation (rs).  Analysis was performed using SPSS software 
(SPSS Inc., version 15, Chicago, Illinois, U.S.A.). 
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7.3 Results 
In total, one hundred and twenty three critically ill (medical n=53, surgical n=70) patients and 
thirty eight controls were studied.  The characteristics of the controls and the critically-ill 
patients on admission are shown in Table 7-1.  The two groups were similar in terms of age 
and sex.  The majority of patients were male and over the age of fifty.  The majority of 
patients had a median APACHE II score greater than 20, with a predicted hospital mortality of 
34%, and a median SOFA score of 7.  One hundred patients survived and twenty three died in 
the ICU.  The patient group had significantly higher C-reactive protein concentrations 
(p<0.001) and significantly lower concentrations of total protein, albumin and cholesterol (all 
p<0.001) compared with the control group.  Free MDA and free MDA fraction were 
significantly higher in the critically ill patients, compared with the controls (p<0.05 and 
p=0.001, respectively) while more patients than controls had total MDA concentrations above 
1.0 umol/l (p<0.05; Table 7-2). 
Given that cholesterol concentrations in the critically ill patients were below the normal range 
and that carotenoids are lipophilic, associated with lipoproteins in plasma, and that cholesterol 
concentrations were significantly correlated with α-tocopherol (rs=0.84; p<0.001), lutein 
(rs=0.56, p<0.001), lycopene (rs=0.60, p<0.001), α-carotene (rs=0.40, p<0.001) and β-carotene 
(rs=0.45, p<0.001) their ratio to cholesterol concentrations were determined (Thurnham et al. 
1986).  Plasma concentrations of α-carotene were below the limit of detection in 30 (24%) of 
the critically-ill patients and therefore were not expressed per mmol of cholesterol.  Compared 
with the controls, α-tocopherol, lutein, lycopene, α- and β-carotene concentrations were 
significantly lower in the critically-ill patients (all p<0.001).  In contrast, when expressed per 
mmol of cholesterol, α-tocopherol concentrations were higher (p<0.001) while lutein, 
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lycopene and β-carotene concentrations remained significantly lower in the critically-ill 
patients (all p<0.001).   
The interrelations between lipid soluble vitamins and MDA concentrations in the control 
population are shown in Table 7-3.  Total MDA was directly associated with total MDA/g 
total protein (rs=0.97, p<0.001), free MDA (rs=0.81, p<0.001) and inversely associated with 
free MDA fraction (rs=-0.63, p<0.001).  Total MDA/g total protein was directly associated 
with free MDA (rs=0.77, p<0.001) and inversely associated with free MDA fraction (rs=-0.63, 
p<0.001).  Plasma lutein was directly associated with plasma α-carotene (rs=0.50, p<0.01).  
Concentrations of α-carotene were directly associated with concentrations of β-carotene 
(rs=0.49, p<0.001). 
The interrelations between lipid soluble vitamins and MDA concentrations in the patient 
population are shown in Tables 7-4 and 7-5.  Total MDA was directly associated with total 
MDA /g total protein (rs=0.81, p<0.001), free MDA (rs=0.30, p<0.01), plasma retinol (rs=0.40, 
p<0.001) and plasma α-tocopherol (rs=0.46, p<0.001).Total MDA/g total protein was directly 
associated with free MDA (rs=0.30, p<0.01).  Free MDA was directly associated with free 
MDA fraction (rs=0.82, p<0.001) and inversely associated with α-carotene (rs=-0.30, p<0.01).  
Free MDA fraction was inversely associated with plasma α-tocopherol (rs=-0.30, p<0.01), 
plasma lutein (rs=-0.30, p<0.01), plasma lycopene (rs=-0.34, p<0.01) and plasma α-carotene 
(rs=-0.29, p<0.01).  Plasma retinol was directly associated with plasma α-tocopherol (rs=0.63, 
p<0.001), plasma lutein (rs=0.59, p<0.001), plasma lycopene (rs=0.34, p<0.001), plasma α-
carotene (rs=0.45, p<0.001) and plasma β-carotene (rs=0.47, p<0.001).  Plasma α-tocopherol 
was directly associated with plasma lutein (rs=0.60, p<0.001), plasma lycopene (rs=0.58, 
p<0.001), plasma α-carotene (rs=0.39, p<0.001) and plasma β-carotene (rs=0.52, p<0.001).  
Plasma lutein was directly associated with plasma lycopene (rs=0.76, p<0.001), plasma α-
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carotene (rs=0.53, p<0.001) and plasma β-carotene (rs=0.63, p<0.001).  Plasma lycopene was 
directly associated with plasma α-carotene (rs=0.54, p<0.001) and plasma β-carotene (rs=0.62, 
p<0.001).  Plasma α-carotene was directly associated with plasma β-carotene (rs=0.69, 
p<0.001). 
Of the 123 patients that were admitted in the ICU, 59 had follow-up measurements (Table 7-
6).  On follow-up, the patients had significantly lower albumin (p=0.001) concentrations. 
The interrelations between the changes in lipid soluble antioxidants and MDA concentrations 
between admission to ICU and follow-up in critically ill patients (n=59) are shown in Tables 
7-7 and 7-8.  The change in total MDA was directly associated with the change in total MDA/ 
g total protein (rs=0.89, p<0.001).  The change in total MDA/g total protein was directly 
associated with the change in free MDA (rs=0.44, p<0.01).  The change in free MDA was 
directly associated with the change in free MDA fraction (rs=0.69, p<0.001).  The change in 
free MDA fraction was inversely associated with the change in plasma lutein (rs=-0.42, 
p<0.01).   
The change in plasma retinol was directly associated with the changes in plasma α-tocopherol 
(rs=0.63, p<0.001), plasma lutein (rs=0.54, p<0.001), plasma lycopene (rs=0.40, p<0.01), 
plasma α-carotene (rs=0.35, p<0.01) and plasma β-carotene (rs=0.40, p<0.001).  The change in 
plasma α-tocopherol was directly associated with the changes in plasma lutein (rs=0.68, 
p<0.001), plasma lycopene (rs=0.53, p<0.001), plasma α-carotene (rs=0.53, p<0.001) and 
plasma β-carotene (rs=0.47, p<0.001).  The change in .plasma lutein was directly associated 
with the changes in plasma lycopene (rs=0.70, p<0.001), plasma α-carotene (rs=0.55, p<0.001) 
and plasma β-carotene (rs=0.49, p<0.001).  The change in plasma lycopene was directly 
associated with the changes in plasma α-carotene (rs=0.67, p<0.001) and plasma β-carotene 
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(rs=0.55, p<0.001).  The change in plasma α-carotene was directly associated with the change 
in plasma β-carotene (rs=0.60, p<0.001). 
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7.4 Discusssion 
Increased production of reactive oxygen species (ROS) associated with the inflammatory 
response is normally buffered by cellular antioxidants. In humans, the carotenoids have an 
important role as chain-breaking antioxidants that can retard ROS proliferation (Halliwell 
1994). The mechanism by which carotenoids protect against ROS-mediated damage depends 
largely on physical quenching (Sies & Stahl 1995).  Their interaction with ROS results in 
fragmentation and loss of the carotenoid molecule (Tsuchiya et al. 1992; Boehm, Tinkler & 
Trusctott 1995).   
In the present study, on admission, the ICU patients had significantly higher total MDA/g total 
protein and free MDA fraction, and lower carotenoid concentrations compared with the 
control group.  The basis of such an increase in MDA to total protein and free MDA fraction 
in critically ill patients is not clear.  An elevated free MDA fraction, in the presence of normal 
total MDA concentrations, is likely to be due to decreased plasma protein binding of MDA 
since plasma protein concentrations were low, in particular albumin.  Furthermore, increased 
free MDA fraction may also have the potential to directly damage cellular proteins and DNA 
(Fleming et al. 1982; Cross et al. 1987; Hruszkewycz 1988). 
Previous studies have explored the clinical significance of measuring free MDA (Lee & 
Csallany 1987; Carbonneau et al. 1991; Draper et al. 1993; Cighetti et al. 2005; Hong et al. 
2000; Grotto et al. 2007). Indeed, Lee & Csallany (1987) showed that free MDA was 15 times 
higher but bound MDA was less than 2 times higher bound MDA in tissues of vitamin E 
deficient animals compared with vitamin E supplemented animals. Carbonneau and co-
workers (1991) showed that there is a significant increase in plasma free MDA in cancer and 
hemodialysis patients compared with healthy controls (by 4.9 and 4.1 times respectively, 
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p<0.001) where there was no difference in total MDA measurements between these three 
groups. Cighetti and co-workers (2005) showed that critically ill patients had 4 times higher 
concentrations of free MDA compared with controls (p<0.001).  Hong and co-workers (2000) 
showed that free MDA was not related to either bound or total MDA and that bound MDA 
plus free MDA were equal to total MDA in healthy subjects.  In the present study, free and 
total MDA concentrations were not significantly different between the critically ill patients 
and healthy controls.  A closer look to the data however showed that 32% of the patients had 
free MDA concentrations above the upper reference interval while none of the controls had 
free MDA concentrations above the reference interval (p<0.001). On the other had only 16% 
of the patients had total MDA concentrations above the reference interval while only 5% of 
the healthy controls had total MDA concentrations above the reference interval.  Furthermore, 
it was of interest that the critically ill patients had significantly higher free MDA fraction 
results compared with the controls (p=0.001), and that there were no correlations between the 
change in albumin and C-reactive protein concentrations, and the change in free MDA fraction 
between admission and follow-up.  In addition, free MDA fraction was only weakly related to 
albumin and cholesterol on admission to the ICU.  Therefore, from these results an increased 
free MDA fraction possibly reflects increased free radical damage rather than the effect of the 
systemic inflammatory response.   
Given that plasma α-tocopherol and carotenoids are lipophilic and associated with lipoproteins 
in plasma, their ratio to cholesterol concentrations was determined (Thurnham et al. 1986).  
However, it was of interest that, in the critically ill patients, the carotenoid concentrations, 
even when expressed per mmol of cholesterol, were low compared with the control group.  In 
contrast, α-tocopherol concentrations, when expressed per mmol of cholesterol, were higher 
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compared with the control group.  Therefore, in the critically ill patient, simply expressing per 
mmol of cholesterol is unlikely to reflect vitamin E and carotenoid status.   
The basis of the low concentrations of carotenoids after expressing them per mmol of 
cholesterol, in the present and previous studies of critically ill patients (Schweigert 2001; 
Quasim et al. 2003), is not clear.  It may be that many patients admitted to ICU are deficient in 
carotenoids and that carotenoids are utilized rapidly following injury.  Indeed, there is some 
evidence that patients admitted to the ICU have reduced antioxidant capacity (Ogilvie et al. 
1991; Goode et al. 1995; Borrelli et al. 1996; Cowley et al. 1996; Alonso de Vega et al. 2000; 
Alonso de Vega et al. 2002; Tsai et al. 2000).  In addition, it may be that there is some 
consumption that takes place in addition to redistribution.  It was also of interest that there was 
an inverse association between free MDA fraction and α-tocopherol and the majority of the 
carotenoids measured in the critically ill patients.  Thus, one interpretation of such data could 
be that these lipid soluble antioxidants are consumed during the lipid peroxidation process.  
However, the majority of patients had plasma retinol concentrations below the reference 
interval on admission to ICU and were directly and significantly related to α-tocopherol and 
the carotenoids.  Moreover, this relationship was maintained on follow-up.  Given that the 
hepatic stores of retinol are large and that deficiency is rare in Western populations (World 
Health Organisation 1995) this would suggest that the low concentrations of α-tocopherol and 
carotenoids, in addition to being consumed, maybe lowered by other factors. 
One such factor recognised to lower plasma lipid soluble antioxidant concentrations is the 
presence of a systemic inflammatory response.  Gray and coworkers (2005) showed that in 
patients undergoing elective surgery, there was a transient decrease in plasma α-tocopherol 
and carotenoid concentrations during the systemic inflammatory response, as evidenced by 
increasing concentrations of C-reactive protein and reducing concentrations of albumin.  
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Indeed, in the present study, both albumin and C-reactive protein were consistently associated 
with these lipid soluble antioxidant concentrations.  Therefore, the reduction of lipid soluble 
antioxidant concentrations, in particular carotenoids, is likely to be multifactorial and not 
solely dependent on consumption during lipid peroxidation. 
In summary, the results of the present study show that, on admission to ICU, total MDA tot 
total protein, free MDA and free MDA fraction were increased and carotenoid concentrations 
were low in patients with critical illness.  However, although increased free MDA fraction is 
likely to reflect primarily increased lipid peroxidation, low plasma carotenoid concentrations 
are unlikely to reflect primarily consumption. 
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Table 7-1 Characteristics and measurements of MDA and lipid soluble vitamins in 
controls and critically ill patients on admission to ICU 
 Reference 
Intervals 
Healthy controls 
(n=38) 
Critically ill 
patients (n=123) 
p-valuea 
Age (yr)  55 (43-73) 60 (20-100) 0.156 
Sex (M/F)  21/ 17 81/ 42 0.238 
Patients (medical/ surgical)   53/ 70  
APACHE II   21 (3-38)  
Predicted hospital mortality (%)   33.7 (0.2-92.6)  
SOFA score   7 (0-14)  
Total protein (g/ l) 60-80 73 (66-81) 46 (23-83) <0.001 
C-reactive protein (mg/ l) <6 <6 (<6-<6)  108 (<6-565) <0.001 
Albumin (g/ l) 32-45 44 (38-50) 17 (9-47) <0.001 
Cholesterol (mmol/ l) 3.5-5.5 5.45 (3.85-7.30) 2.19 (0.40-6.40) <0.001 
Triglycerides (mmol/l) <2.3 1.25 (0.50-4.05) 0.95 (0.30-5.05) 0.395 
Total MDA (µmol/l) 0.30-1.00 0.70 (0.36-1.10) 0.66 (0.22-14.27) 0.657 
Total MDA/ total protein (µmol/ g)  0.009 (0.00-0.02) 0.016 (0.01-0.53) <0.001 
Free MDA (µmol/ l) 0.04-0.10 0.08 (0.04-0.10) 0.09 (0.02-5.96) 0.030 
Free MDA fraction  0.11 (0.06-0.15) 0.14 (0.03-1.04) 0.001 
Retinol (µmol/l) 1.0-2.8 2.1 (1.3-3.6) 0.7 (0.02-4.2) <0.001 
α-tocopherol (µmol/ l) 14-39 30 (14-42) 14 (4-41) <0.001 
α-tocopherol/ chol (µmol/ mmol)  5.3 (3.5-8.4) 6.7 (2.1-15.7) <0.001 
Lutein (µg/ l) 82-202 130 (58-329) 22 (<5-246) <0.001 
Lutein/ chol (µg/ mmol)  23.4 (9.7-62.7) 12.6 (1.1-169) <0.001 
Lycopene (µg/l) 100-300 199 (64-505) 29 (<5-318) <0.001 
Lycopene/ chol (µg/ mmol)  39.3 (13.3-93.8) 17 (0.6-346) <0.001 
α-carotene (µg/ l) 14-60 17 (10-75) 9 (<5-173) <0.001 
β-carotene (µg/ l) 92-312 162 (57-708) 21 (<5-522) <0.001 
β-carotene/ chol (µg/ mmol)  30.9 (9.9-137.5) 10 (0.1-239) <0.001 
Median (range), aMann-Whitney U test 
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Table 7-2 Measurement categories of carotenoids and MDA concentrations in controls 
and critically ill patients on admission to ICU 
 Healthy controls 
(n= 38) 
Critically ill patients 
(n= 123) 
p-valuea 
Total protein (<60/ >60g/l) 0/ 38 96/ 27 <0.001 
C-reactive protein (<10/ >10mg/l) 38/ 0 18/ 104 <0.001 
Albumin (<35/ >35g/l) 0/ 38 114/ 9 <0.001 
Cholesterol (<3.5/ >3.5mmol/l) 0/ 38 91/ 26 <0.001 
Triglycerides (<2.3/ >2.3mmol/l) 29/ 2 103/ 12 0.505 
Total MDA(<1.0/ >1.0µmol/l) 36/ 2 81/ 20 0.037 
Free MDA (0.1</ >0.1µmol/l) 38/ 0 61/ 39 <0.001 
Retinol (<1.0/ >1.0 µmol/l) 0/ 38 80/ 43 <0.001 
α-tocopherol (<14/ >14 µmol/l) 1/ 37 63/ 60 <0.001 
Lutein (<82/ >82 µg/l) 6/ 32 112/ 11 <0.001 
Lycopene (<100/>100 µg/l) 3/ 35 99/ 24 <0.001 
α-carotene (<14/ >14 µg/l) 11/ 27 97/ 25 <0.001 
β-carotene (<92/ >92 µg/l) 4/ 34 104/ 19 <0.001 
aChi-square test
  154 
 
Table 7-3 Spearman correlations between lipid soluble vitamins and MDA concentrations in the control population 
(n=38) 
 Total MDA/ 
total protein 
Free 
MDA 
Free MDA 
fraction 
Retinol α-tocopherol Lutein Lycopene α-carotene β-carotene 
Total MDA 0.97*** 0.81*** -0.63*** 0.09 0.09 0.03 0.11 -0.18 -0.25 
Total MDA/ total protein  0.77*** -0.63*** 0.10 0.15 0.06 0.13 -0.12 -0.17 
Free MDA   -0.11 0.03 0.11 0.04 0.05 -0.10 -0.22 
Free MDA fraction    -0.09 -0.08 0.13 -0.06 0.30 0.17 
Retinol     -0.01 0.13 -0.06 -0.10 -0.39* 
α-tocopherol      0.23 0.06 0.16 0.34* 
Lutein       0.36* 0.50** 0.22 
Lycopene        0.25 0.12 
α-carotene         0.49** 
*p<0.05, **p<0.01, ***p<0.001 
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Table 7-4 Spearman correlations between laboratory characteristics, lipid soluble antioxidants and MDA concentrations in critically ill 
patients on admission to ICU 
(n=123) 
 Total protein CRP Albumin Cholesterol Triglycerides 
CRP -0.14     
Albumin 0.71*** -0.35***    
Cholesterol 0.62*** -0.39*** 0.69***   
Triglycerides 0.33*** -0.05 0.30** 0.50***  
Total MDA 0.31** -0.26** 0.37*** 0.53*** 0.38*** 
Total MDA/ total protein -0.25* -0.21* -0.01 0.19 0.24* 
Free MDA 0.05 0.07 -0.13 -0.10 0.04 
Free MDA fraction -0.20 0.22* -0.30** -0.35*** -0.19 
Retinol 0.47*** -0.50*** 0.58*** 0.65*** 0.34*** 
α-tocopherol 0.59*** -0.28** 0.59*** 0.84*** 0.62*** 
Lutein 0.43*** -0.35*** 0.60*** 0.56*** 0.09 
Lycopene 0.43*** -0.45*** 0.57*** 0.60*** 0.15 
α-carotene 0.29** -0.25** 0.33*** 0.40*** -0.00 
β-carotene 0.33*** -0.24** 0.37*** 0.45*** -0.00 
*p<0.05, **p<0.01, ***p<0.001 
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Table 7-5 Spearman correlations between laboratory characteristics, lipid soluble antioxidants and MDA concentrations in critically ill 
patients on admission to ICU 
(n=123) 
 Total MDA/ 
total protein 
Free MDA Free MDA 
fraction 
Retinol α-tocopherol Lutein Lycopene α-carotene β-carotene 
Total MDA 0.81*** 0.30** -0.24* 0.40*** 0.46*** 0.24* 0.22* 0.05 0.17 
Total MDA/  
Total protein 
 0.30** -0.17 0.17 0.14 -0.01 -0.02 -0.12 -0.03 
Free MDA   0.82*** -0.05 -0.08 -0.22* -0.25* -0.30** -0.17 
Free MDA 
fraction 
   -0.24* -0.30** -0.30** -0.34** -0.29** -0.22* 
Retinol     0.63*** 0.59*** 0.34*** 0.45*** 0.47*** 
α-tocopherol      0.60*** 0.58*** 0.39*** 0.52*** 
Lutein       0.76*** 0.53*** 0.63*** 
Lycopene        0.54*** 0.62*** 
α-carotene         0.69*** 
    *p<0.05, **p<0.01, ***p<0.001 
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Table 7-6 Characteristics, lipid soluble vitamin and MDA concentrations in critically ill 
patients on admission and follow-up 
 Critically ill patients (n=59)  
 Admission Follow up p-valuea 
Age (yr) 61 (20-86)   
Sex (M/F) 42/ 17   
BMI 26 (16-54)   
Patients (medical/ surgical) 25/ 34   
APACHE II 23 (7-38)   
Predicted mortality (%) 42.2 (4.3-92.6)   
SOFA score 7 (1-14) 7 (1-16) 0.106 
Total protein (g/ l) 41 (23-83) 42 (26-62) 0.018 
C-reactive protein (mg/ l) 100 (<6-565) 132 (20-356) 0.390 
Albumin (g/ l) 15 (9-45) 14 (9-29) <0.001 
Cholesterol (mmol/ l) 1.70 (0.53-5.20) 1.80 (0.60-4.40) 0.812 
Triglycerides (mmol/ l) 0.80 (0.30-4.50) 1.00 (0.20-3.20) 0.804 
Total Malondialdehyde (µmol/ l) 0.65 (0.22-14.27) 0.54 (0.32-20.40) 0.769 
Total Malondialdehyde/ total 
protein (µmol/ g) 
0.02 (0.01-0.53) 0.01 (0.01-0.57) 0.420 
Free Malondialdehyde (µmol/ l) 0.12 (0.04-5.96) 0.13 (0.03-9.41) 0.194 
Free Malondialdehyde fraction  0.12 (0.04-5.96) 0.13 (0.03-9.41) 0.509 
Lutein (µg/ l) 22 (2-246) 19 (4-107) 0.030 
Lycopene (µg/ l) 27 (1-291) 27 (2-176) 0.182 
α-carotene (µg/ l) 9 (1-173) 9 (1-143) 0.125 
β-carotene (µg/ l) 18 (<1-522) 27 (<1-248) 0.037 
Median (range) 
aWilcoxon signed rank test 
  158 
 
Table 7-7 Spearman correlations between the changes, between admission to ICU and follow-up, in laboratory characteristics, lipid 
soluble antioxidants and MDA concentrations in critically ill patients 
(n=59) 
 Total protein CRP Albumin Cholesterol Triglycerides 
CRP 0.02     
Albumin 0.62*** -0.11    
Cholesterol 0.53*** -0.41** 0.57***   
Triglycerides 0.50*** -0.20 0.67*** 0.64***  
Total MDA 0.32* 0.09 0.45** 0.30 0.57*** 
Total MDA/ total protein -0.01 0.03 0.26 0.09 0.34* 
Free MDA -0.14 0.09 0.11 -0.13 0.14 
Free MDA fraction -0.35* 0.03 -0.19 -0.28 -0.21 
Retinol 0.36** -0.64*** 0.47*** 0.59*** 0.42** 
α-tocopherol 0.58*** -0.27* 0.39** 0.81*** 0.59*** 
Lutein 0.60*** -0.33* 0.57*** 0.79*** 0.58*** 
Lycopene 0.38** -0.26 0.39** 0.62*** 0.30* 
α-carotene 0.44** -0.15 0.27* 0.58*** 0.19 
β-carotene 0.37** -0.17 0.17 0.43** 0.20 
      *p<0.05, **p<0.01, ***p<0.001
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Table 7-8 Spearman correlations between the changes, between admission to ICU and follow-up, in laboratory characteristics, lipid 
soluble antioxidants and MDA concentrations in critically ill patients 
(n=59) 
 Total MDA/ 
total protein 
Free 
MDA 
Free MDA 
fraction 
Retinol α-tocopherol Lutein Lycopene α-carotene β-carotene 
Total MDA 0.89*** 0.34* -0.31* 0.27 0.29 0.26 0.32* 0.27 0.06 
Total MDA/ 
total protein 
 0.44** -0.16 0.17 0.05 0.04 0.16 0.09 -0.06 
Free MDA   0.69*** 0.01 -0.10 -0.28 -0.07 -0.12 0.03 
Free MDA 
fraction 
   -0.15 -0.26 -0.42** -0.19 -0.35* -0.06 
Retinol     0.63*** 0.54*** 0.40** 0.35** 0.40*** 
α-tocopherol      0.68*** 0.53*** 0.53*** 0.47*** 
Lutein       0.70*** 0.55*** 0.49*** 
Lycopene        0.67*** 0.55*** 
α-carotene         0.60*** 
          *p<0.05, **p<0.01, ***p<0.001 
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8 The effect of B1, B2, B6 and C vitamin supplementation 
on plasma and intracellular vitamin concentrations in 
patients with critical illness  
8.1 Introduction 
It has been recognised for some time that during the systemic inflammatory response, plasma 
vitamin concentrations may not be responsive to supplementation.  Indeed, in 46 critically ill 
patients, Huang and co-workers (2002) showed that vitamin B6 supplementation (15 mg) was 
unable to increase plasma pyridoxal 5’-phosphate and pyridoxal concentrations and both 
markers decreased by approximately 20%.  In agreement it has been reported that, on 
supplementation (150mg), PLP concentrations were increased in red cells but not in plasma in 
critically ill patients (Talwar et al. 2003b). 
Vitamin C behaviour seems to follow similar patterns during the systemic inflammatory 
response.  In healthy patients with normal pre–operative plasma concentrations of ascorbic 
acid, a single oral supplementation with 1,000 mg of ascorbic acid was unable to prevent the 
fall in postoperative plasma concentrations (Rumelin et al. 2002).  In the same manner, 
supplementation of intravenous 1,000 mg vitamin C for 3 days was unable to prevent the fall 
of plasma concentrations to undetectable levels by day 12 in alcoholic critically ill patients 
(Mishra et al. 2005).  However, in critically ill surgical patients, very high amounts of a 
combined parenteral supplement of a-tocopherol (1000 IU/d) and ascorbic acid (1000 mg/d) 
eight times per day was able to increase plasma concentrations of these vitamins (Nathens et 
al. 2002).  White cell vitamin C has been found to decrease during the systemic inflammatory 
response by approximately 40% in patients undergoing orthopaedic surgery (Louw et al. 1992) 
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however to date there have been no studies examining the effect of ascorbic acid 
supplementation on white cell ascorbic acid concentrations in patients with critical illness. 
As plasma B and C vitamin concentrations seem to be less responsive to supplementation and 
also have been shown to fall transiently during the systemic inflammatory response trying to 
guide supplementation by interpretation of these values could be of questionable value.  In the 
previous chapters, we have shown that red and white cell B and C vitamin concentrations are 
more stable and less affected by the systemic inflammatory response syndrome, thus the 
question that arises is whether they reflect B and C vitamin supplementation and thus be 
alternative markers of vitamin status and be used to guide supplementation in patients with 
critical illness.  
The aim of the present study was to examine the effect of B and C vitamin supplementation on 
plasma and intracellular B and C vitamin concentrations in patients with critical illness.  
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8.2 Materials and Methods 
8.2.1 Patients and study design 
See paragraph 2.1.1 
8.2.2 Collection and preparation of blood samples 
An EDTA tube containing approximately 6 mL of whole blood was taken for each patient on 
admission and follow-up.  The EDTA sample was centrifuged (500g, 4oC, 10mins) and 500 
uL of plasma was removed into another plastic tube containing, metaphosphoric acid 6%, for 
plasma vitamin C determination.  After removing the buffy coat, the packed red cells were 
stored for red cell vitamin determination.  All tubes were stored at -70o C until analysis. All 
samples were assayed in a single batch for each of the analytes to minimise interbatch 
analytical variation. 
8.2.2.1 White cell preparation 
See paragraph 2.1.2.1 
Following the final brief centrifugation (10,000 rpm, 3mins), the supernatant was removed and 
the resulting pellet was dispersed in 125µL of deionised water and stabilized with 125uL of 
metaphosphoric acid 6% for the vitamin C analysis.  The cell suspension was stored at -80°C. 
Before analysis, the cell suspension was sonicated for 10 min to lyse the cell membranes. 
8.2.3 Analytical Methods 
8.2.3.1 Measurements of vitamins B1, B2 and B6 
See paragraph 2.1.2.3, 2.1.2.4 and 2.1.2.5 
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8.2.3.2 Measurement of vitamin C 
See paragraph 2.1.2.6 
8.2.4 Statistics 
Data from critically ill patient groups are presented as median and range.  Comparisons 
between the supplemented and not supplemented critically groups were performed with the 
use of the Mann-Whitney U test.  Data from different time points in the patient groups were 
tested for statistical significance with the use of the Wilcoxon’s signed-rank test. Correlations 
were carried out using the Spearman rank correlation (rs).  Because of the number of statistical 
comparisons, a P value of <0.01 was considered to be significant.  Analysis was performed 
with the use of SPSS software (version 15; SPSS Inc, Chicago, Illinois, U.S.A.). 
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8.3 Results 
In total, one hundred and twenty six patients were studied (Table 8.1 and 8.2).  Patients were 
initially grouped by whether or not they had recorded supplementation of B and C vitamins 
prior to ICU admission.  On admission, one hundred patients had no recorded supplementation 
and twenty six had received supplements of B and C vitamins prior to ICU admission.  Eleven 
out of the 26 patients were on chronic B vitamin supplementation in the community prior to 
ICU admission (B Co strong, contains: vitamin B1 5mg, vitamin B2 2mg and vitamin B6 
2mg).  The remaining 15 out of 26 patients had a record of receiving a median amount of 
Pabrinex doses equal to 5 (range 1-95) prior their admission in ICU.  The two groups did not 
differ in terms of age, sex, patient type, APACHE II and SOFA scores, ventilation days and 
ICU and hospital mortality.  The patients with recorded supplementation prior to admission in 
ICU, stayed in ICU significantly longer than the patients that did not (p<0.01).  In terms of 
vitamin B1, whole blood TDP was significantly higher on admission in patients that had 
recorded supplementation prior to ICU admission compared to the patients that did not 
(p<0.001).  In terms of vitamin B2, red cell FAD (p=0.001), red cell FMN (p=0.001), plasma 
riboflavin (p<0.001), red cell riboflavin (p<0.001) and white cell riboflavin (p=0.001), were 
significantly higher on admission in patients that had recorded supplementations prior to ICU 
admission compared to the patients that did not.  In terms of vitamin B6, red cell PLP 
(p<0.001), white cell PLP (p<0.01), plasma PL (p<0.001), red cell PL (p<0.001) and white 
cell PL (p<0.001) were significantly higher on admission in patients that had recorded 
supplementations prior to admission compared to the patients that did not.  In terms of vitamin 
C, white cell ascorbic acid was significantly higher on admission in patients that had recorded 
supplementations prior to admission compared to the patients that did not (p<0.01).  
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From the one hundred patients that had no recorded ICU supplementation prior to ICU 
admission, nineteen patients continued having no recorded supplementation until their follow-
up sample was taken (median 3 days, range 2-8; Table 8.3 and 8.4).  On follow up, there were 
no significant differences in plasma, red cell and white cell vitamin B1, B2, B6 and C 
concentrations. 
From the one hundred patients that had no recorded ICU supplementation prior to ICU 
admission, twenty two patients had record of supplementation in ICU (median 3 Pabrinex 
doses, range 1-12) until their follow-up sample was taken (median 4 days, range 2-5; Table 8.5 
and 8.6).  In terms of vitamin B1, on follow up, whole blood TDP was significantly higher 
compared with admission (p=0.001).  In terms of vitamin B2, on follow up, white cell FMN 
and white cell riboflavin were significantly higher compared with admission (both p<0.01).  In 
terms of vitamin B6 and vitamin C there were no significant differences between admission 
and follow up.   
The number of Pabrinex doses the patients received during their ICU stay, between admission 
and follow up sample, were significantly related with the follow-up concentrations of plasma 
riboflavin (rs=0.54, p=0.004), red cell FAD (rs=0.65, p<0.001), red cell riboflavin (rs=0.51, 
p=0.002), red cell PLP (rs=0.67, p<0.001), plasma PL (rs=0.50, p=0.003), red cell PL (rs=0.54, 
p=0.001) and white cell PL (rs=0.52, p=0.006) but were not related with the follow up 
concentrations of whole blood TDP (rs=0.38, p=0.020), plasma FAD (rs=-0.05, p=0.772), 
white cell FAD (rs=-0.08, p=0.684), plasma FMN (rs=0.27, p=0.448), red cell FMN (rs=0.46, 
p=0.013), white cell FMN (rs=-0.23, p=0.306), white cell riboflavin (rs=0.33, p=0.100), 
plasma PLP (rs=0.08, p=0.652), white cell PLP (rs=0.22, p=0.279), plasma vitamin C (rs=0.44, 
p=0.01) and white cell vitamin C (rs=0.53, p=0.023).   
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The number of Pabrinex doses the patients received during their ICU stay, between admission 
and follow up sample, were significantly related with the change in white cell ascorbic acid 
concentrations (rs=0.71, p=0.001) between admission and follow-up sample but not with the 
changes in whole blood TDP (rs=0.11, p=0.525), plasma FAD (rs=0.01, p=0.935), red cell 
FAD (rs=039, p=0.018), white cell FAD (rs=0.19, p=0.347), plasma FMN (rs=-0.78, p=0.225), 
red cell FMN (rs=0.16, p=0.400), white cell FMN (rs=-0.06, p=0.815), plasma riboflavin 
(rs=0.15, p=0.474), red cell riboflavin (rs=0.27, p=0.122), white cell riboflavin (rs=0.33, 
p=0.116), plasma PLP (rs=-0.19, p=0.262), red cell PLP (rs=0.16, p=0.346), white cell PLP 
(rs=0.10, p=0.632), plasma PL (rs=0.14, p=0.431), red cell PL (rs=-0.02, p=0.918), white cell 
PL (rs=0.22, p=0.304) and plasma ascorbic acid (rs=0.28, p=0.147) between admission and 
follow up.  
Tables 8.7 and 8.8 show the comparison between the characteristics and the change from 
baseline in plasma, red cell and white cell B and C vitamin concentrations between the 
patients that were admitted in ICU without prior recorded supplementation and either had 
records of ICU supplementation (n=22) or not (n=19).  The two groups were not different in 
terms of age, sex, type, APACHE II and SOFA scores, ventilation days, ICU and hospital 
length of stay and ICU and hospital mortality.  In terms of vitamin B1, the increase in whole 
blood TDP was significantly higher in the group that had recorded supplementation compared 
with the group that did not (p<0.001).  In terms of vitamin B2, white cell FMN decreased on 
follow-up in the non-supplemented group and increased in the supplemented group (p<0.01).   
Also the increase in white cell riboflavin was significantly higher in the group that had 
recorded supplementation compared with the group that did not (p<0.001).  In terms of 
vitamin B6, red cell PLP and red cell PL significantly decreased on follow-up in the non-
supplemented group and significantly increased in the supplemented group (p=0.001 and 
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p<0.01, respectively).  The increase in plasma PL and white cell PL was significantly higher in 
the group that had recorded supplementation compared with the group that did not (both 
p<0.01).     
There were only nine patients on admission with plasma FAD concentrations below the 
reference interval that had no recorded supplementation during their ICU stay and nineteen 
patients that on admission had plasma FAD concentrations below the reference interval and 
had recorded supplementation during their ICU stay (Table 8.9).  Statistical comparisons were 
not possible with the small numbers of the non-supplemented group.  Nevertheless, on follow-
up, apart from plasma FAD concentrations that remained below the reference interval, the rest 
of the vitamin B2 vitamers remained within the reference interval in the patients that were 
admitted with low plasma FAD concentrations and received no supplementation during their 
ICU stay.  On follow –up, only red cell FAD and red cell FMN concentrations significantly 
increased in the patients that were admitted with low plasma FAD concentrations and received 
supplementation during their ICU stay (both p<0.01).  Plasma FAD concentrations remained 
below the reference interval and plasma riboflavin concentrations remained above the 
reference interval, while the rest of the vitamers remained within the reference interval in this 
group of patients on follow-up.   
There was only one patient with red cell FAD concentrations below the reference interval on 
admission to ICU and this patient did not have follow up data.  
There were only three patients on admission with plasma FAD concentrations above the 
reference interval that had no recorded supplementation during their ICU stay and seven 
patients that on admission had plasma FAD concentrations below the reference interval and 
had recorded supplementation during their ICU stay (Table 8.10).  Statistical comparisons 
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were not possible with the small numbers of both the groups.  Nevertheless, on follow-up, 
apart from plasma FAD concentrations that remained above the reference interval, the rest of 
the vitamin B2 vitamers remained within the reference interval in the patients that were 
admitted with high plasma FAD concentrations whether they had recorded or not 
supplementation during their ICU stay.   
There were only eleven patients on admission with plasma PLP concentrations below the 
reference interval that had no recorded supplementation during their ICU stay and eleven 
patients that on admission had plasma PLP concentrations below the reference interval and 
had recorded supplementation during their ICU stay (Table 8.11).  There were no significant 
differences in all the B6 vitamers between admission and follow-up in the group that did not 
have recorded supplementation during ICU stay.  On follow-up, plasma PLP and red cell PLP 
concentrations remained below the reference interval and the rest of the vitamin B6 vitamers 
remained within the reference interval in the patients that were admitted with low plasma PLP 
concentrations and received no supplementation during their ICU stay.  On follow –up, only 
red cell PLP and plasma PL concentrations significantly increased in the patients that were 
admitted with low plasma PLP concentrations and received supplementation during their ICU 
stay (both p<0.01).  Plasma PLP concentrations showed a trend of increase from below the 
reference interval on admission to within the reference interval on follow up in the 
supplemented group (p=0.010).   Red cell PLP and plasma PL concentrations increased 
significantly from below the reference interval on admission to above the reference interval on 
follow up in the supplemented group (both p<0.01).    
In total fifty seven patients had low red cell PLP concentrations on admission to ICU.  There 
were thirteen patients with low red cell PLP concentrations on admission to ICU that had 
records of supplementation in ICU and thirteen that did not.  There was no significant 
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difference in plasma, red cell and white cell PLP concentrations in patients that did not receive 
supplementation in ICU.  Plasma PLP, red cell PLP and plasma PL concentrations 
significantly increased between admission and follow-up in patients that received 
supplementation with the medians of red cell PLP and plasma PL increasing above the 
reference interval on follow up.    
There were only four patients on admission with plasma PLP concentrations above the 
reference interval that had no recorded supplementation during their ICU stay and two patients 
that on admission had plasma PLP concentrations below the reference interval and had 
recorded supplementation during their ICU stay (Table 8.12).  Statistical comparisons were 
not possible with the small numbers of both the groups.  On follow-up, all the vitamin B6 
vitamers were within the reference interval in the patients that were admitted with high plasma 
PLP concentrations and did not have recorded supplementation during their ICU stay.  On 
follow-up, apart from plasma PLP that returned within the reference interval, all the vitamin 
B6 vitamers were above the reference interval in the patients that were admitted with high 
plasma PLP concentrations and had recorded supplementation during their ICU stay. 
There were only eleven patients on admission with plasma ascorbic acid concentrations below 
the reference interval that had no recorded supplementation during their ICU stay and nineteen 
patients that on admission had plasma ascorbic acid concentrations below the reference 
interval and had recorded supplementation during their ICU stay (Table 8.13).  Statistical 
comparisons were not possible with the small patient numbers of the non-supplemented group.  
Nevertheless, on follow-up, apart from plasma ascorbic acid concentrations that remained 
below the reference interval, white cell ascorbic acid concentrations remained within the 
reference interval in the patients that were admitted with low plasma ascorbic acid 
concentrations whether they had recorded supplementation during their ICU stay or not.   
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There were ten patients on admission to ICU with white cell ascorbic acid concentrations 
below the reference interval.  Three of these patients had follow up data.  Two patients did not 
receive supplementation in ICU and one did.  For both groups (supplemented and 
unsupplemented) both medians of plasma and white cell ascorbic acid concentrations 
remained below the reference interval.   
There was only one patient on admission with plasma ascorbic acid concentrations above the 
reference interval that had no recorded supplementation during their ICU stay and four 
patients that on admission had plasma ascorbic acid concentrations above the reference 
interval and had recorded supplementation during their ICU stay (Table 8.14).  Statistical 
comparisons were not possible with the small patient numbers in the two groups.  The patient 
that received no supplementation during ICU stay,  had plasma ascorbic acid concentrations 
below the reference interval (<10 umol/L) on follow up, while his white cell concentrations 
remained close to the upper reference interval on both admission and follow-up.  Also on 
follow up, there was no increase in the median of plasma ascorbic acid concentrations in the 
group that had recorded ICU supplementation while the median of white cell concentrations 
moved from within the reference range on admission to above the reference range in the 
patients that had high plasma ascorbic acid concentrations on admission to ICU and had 
recorded supplementation on follow up. 
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8.4 Discussion 
The results of the present study show a discrepancy in the behaviour of plasma and 
intracellular B2, B6 and C vitamin concentrations during supplementation in patients with 
critical illness.  Indeed, on admission to ICU, almost 1/3 of the patients had plasma vitamin 
B2, B6 and C concentrations below the reference interval.  This could be interpreted as 
indicating deficiency however it has been shown that plasma B and C vitamin concentrations 
can decrease transiently due to the effect of the systemic inflammatory response (Louw et al. 
1992; Gray et al. 2003; Mishra et al. 2005) and that supplementation is not reflected in plasma 
concentrations in these patients (Huang et al. 2002; Rumelin et al. 2002; Talwar et al. 2003b; 
Mishra et al. 2005; Quasim et al. 2005).  The longitudinal data presented in the current study 
are in agreement with these studies as plasma FAD, PLP and ascorbic acid concentrations did 
not increase with supplementation and remained below the reference interval on follow-up.   
In contrast, on admission to ICU, red cell FAD, red cell PLP and white cell ascorbic acid 
concentrations were significantly higher in the patients with records of prior supplementation 
compared with the patients without.  In addition, the medians of these intracellular vitamers 
were all significantly higher for the group with records of supplementation prior to ICU 
admission compared with the group without, while they were within the reference intervals for 
red cell FAD, above the reference interval for white cell ascorbic acid and below the reference 
interval for red cell PLP in the group that had records of supplementation prior to ICU.  
Moreover, in patients with plasma vitamin B2 and B6 concentrations below the reference 
interval and that did not have records of previous supplementation, red cell FAD and red cell 
PLP concentrations significantly increased after supplementation with their medians being 
above the reference interval on follow-up.  These results are in agreement with previous 
studies (Talwar et al. 2003b; Quasim et al. 2004; Huang et al. 2005). 
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Hustad et al. (2002) have proposed that both plasma riboflavin and red cell FAD could be 
valuable markers of vitamin B2 status compared with plasma FAD.  Indeed in the present 
study, both plasma riboflavin and red cell FAD concentrations were strongly related on follow 
up, to the number of supplementation doses, with red cell FAD concentrations having the 
strongest relationship.  The median of plasma riboflavin was above the reference interval in 
the group that had recorded supplementation prior to ICU admission while it was within the 
reference interval in the group that did not.  This may indicate that plasma riboflavin could be 
a good marker of vitamin B2 status in patients with critical illness.  However, in the present 
study, plasma riboflavin did not significantly increase with supplementation on follow up 
while red cell FAD concentrations did.   
Similar, findings were observed with plasma and red cell PL concentrations with their medians 
being above the reference interval in the group that had recorded supplementation prior to ICU 
admission.  This may indicate that plasma or red cell PL could be good markers of vitamin B6 
status in patients with critical illness.  Indeed in this study, both plasma and red cell PL 
concentrations were strongly related to number of supplementation doses on follow up.   
However, red cell PL did not reflect supplementation on follow up while both red cell PLP 
and plasma PL concentrations significantly increased with supplementation, in patients that 
were admitted in ICU with low plasma PLP concentrations.  In addition, PL is not the active 
vitamer of vitamin B6, thus its use in clinical practice for interpretation of vitamin B6 status is 
uncertain. 
In the present study, both white cell riboflavin and white cell PL were sensitive to 
supplementation.  Indeed, changes in white cell riboflavin and white cell PL concentrations 
between admission and follow up were significantly different between the groups that did not 
have record of supplementation prior to ICU admission and received, or not, supplementation 
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in ICU.  This possibly reflects that, within the short period between admission and follow up 
samples, white cells may more sensitively reflect changes in vitamin concentrations compared 
with either plasma or red cells.  Unfortunately, the number of longitudinal white cell riboflavin 
and white cell PL measurements was low in patients with low plasma FAD and low plasma 
PLP concentrations on admission, respectively, with recorded supplementation in ICU, and 
also reference intervals were not available from a control population in order to interpret the 
white cell riboflavin and white cell PL results.  This limits the interpretation of the value of 
white cell riboflavin and white cell PL as markers of vitamin B2 and B6 status, respectively, in 
patients with critical illness.    
In the present study, compared with plasma ascorbic acid, white cell ascorbic acid 
concentrations seemed to be a better marker of vitamin C status in patients with critical illness.  
Indeed, white cell ascorbic acid concentrations were above the reference interval in the group 
with evidence of prior ICU supplementation and their change between admission and follow 
up was related to the total number of supplementation doses received in ICU.  Previous studies 
have shown that, there is a good correlation between plasma and white cell vitamin C 
concentrations in healthy subjects (Bates 1977; Jacob, Skala & Omaye 1987; Omaye et al. 
1987) and also that, white cell ascorbic acid concentrations reflect cellular stores and vitamin 
C status (Omaye et al. 1987).   
There was no relationship between the number of Pabrinex doses and any of the change in 
vitamin B2 and B6 vitamers between admission and follow up.  This possibly means that the 
effect of supplementation may need longer to be evident at the intracellular compartment than 
the number of days between the admission and our follow up sample and possibly the 
relationship between the number of doses with the follow up measurements reflect a longer 
period of supplementation that many of these patients had starting prior to their ICU 
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admission.  Moreover, in the subgroups with records of ICU supplementation and plasma 
vitamin concentrations above the reference interval on admission, the medians of red cell PLP, 
plasma PL and red cell PL concentrations did not increase further, possibly suggesting that 
either saturation or increased utilisation and excretion or both took place between the 
admission and the follow up sample.  Such a metabolic effect could not be examined in the 
present study as there were no measurements of the relevant metabolic products in either urine 
or blood.  A recent previous study though has shown that there are increased pyridoxic acid 
concentrations in plasma and urine in patients with critical illness (Cheng et al. 2006).  Similar 
results were observed for the intracellular concentrations of FAD, FMN and riboflavin and 
also for white cell ascorbic acid concentrations in the subgroups with high plasma FAD and 
ascorbic acid concentrations on admission, respectively, that had records of supplementation 
in ICU.   
Low concentrations of both plasma and red cell PLP concentrations were identified in 
approximately half of the patients in this study, suggesting that true vitamin B6 deficiency 
may be more frequent in the critically ill patients and that supplementation may be essential.  
Vitamin B6 has been shown to be essential for immune function and recent research has been 
conducted to establish the effect and efficacy of vitamin B6 supplementation in patients with 
critical illness (Huang et al. 2005; Cheng et al. 2006). 
Taken together, these findings suggest that cellular concentrations of vitamins B2, B6 and C 
may be more accurate markers of their respective vitamin status and may be expected to be a 
more true reflection of the presence of supplementation than their respective plasma 
concentrations.  Also, from these data, critical illness could be related to true vitamin B6 and 
C deficiency and supplementation could be important for some patients admitted in ICU.
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Table 8-1 Characteristics and measurements of proteins in critically ill patients on 
admission to ICU that had either had or not recorded supplementation prior to ICU 
admission 
 Reference 
intervals 
No 
supplementation 
Admission 
(n=100) 
Supplementation 
Admission 
(n=26) 
p-value* 
Age (yr)  60 (18-100) 56 (33-81) 0.824 
Sex (M/F)  62/ 37 19/ 7 0.323 
Patients (medical/ surgical)  42/ 57 14/ 12 0.299 
ICU death (yes/ no)  19/ 80 5/ 21 0.996 
APACHE II  20 (3-34) 23 (11-38) 0.107 
Predicted hospital mortality (%)  31.5 (0.2-86.3) 46 (9.9-92.6) 0.025 
SOFA score  7 (0-18) 8 (2-14) 0.125 
Ventilation (days)  3 (0-60) 5 (0-75) 0.057 
ICU length of stay (days)  2.9 (0.2-59.5) 8.4 (0.8-76.4) 0.006 
Hospital length of stay (days)  19 (0.4-253) 31.3 (4-508) 0.072 
Hospital death (yes/ no)  24/ 75 8/ 18 0.499 
     
C-reactive protein (mg/ l) <6 109 (<6-434) 106 (<6-565) 0.961 
Albumin (g/ l) 32-45 18 (9-47) 14 (9-45) 0.210 
Median (range) 
*Mann-Whitney U-test 
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Table 8-2 Measurements of water and lipid soluble vitamins in critically ill patients on 
admission to ICU that had either had or not recorded supplementation prior to ICU 
admission 
 Reference 
intervals 
No supplementation 
Admission (n=100) 
Supplementation 
Admission (n=26) 
p-
value* 
Whole blood TDP (ng/ gHb) 275-675 690 (196-2552) 1703 (544-3650) <0.001 
Plasma FAD (nmol/ l) 51-160 43.6 (10.4-1179) 56.3 (10.3-1916) 0.310 
Red cell FAD (nmol/ gHb) 1.0-3.4 1.44 (0.97-2.58) 1.77 (1.23-2.30) 0.001 
White cell FAD (pmol/106 cells) NA (n=59)  
12.77 (7.89-90.15) 
(n=18) 
13.98 (6.58-18.25) 
0.057 
Plasma FMN (nmol/ l) 3.3-14.1** (n=18)  
16.95 (2.80-34.2) 
(n=8)  
15.05 (6.10-75.60) 
0.644 
Red cell FMN (nmol/ gHb) 0.04-0.44** (n=86)  
0.09 (0.05-0.48) 
(n=22)  
0.13 (0.07-0.28) 
0.001 
White cell FMN (pmol/ 106 cells) NA (n=51)  
0.62 (0.27-1.73) 
(n=15) 
0.74 (0.37-1.51) 
0.242 
Plasma riboflavin (nmol/ l) 4-34** (n=82) 
26 (3-374) 
(n=21) 
107 (7-748) 
<0.001 
Red cell riboflavin (nmol/ gHb) 0.01-0.13** (n=97) 
0.03 (0.00-0.23) 
(n=26) 
0.07 (0.00-0.22) 
<0.001 
White cell riboflavin (pmol/ 106 cells) NA (n=55) 
0.54 (0.23-3.27) 
(n=16) 
0.77 (0.28-1.32) 
0.001 
Plasma PLP (nmol/ l) 17-135 19 (<2-333) 30 (3-306) 0.015 
Red cell PLP (pmol/ gHb) 250-680 242 (32-27441) 2530 (111-25583) <0.001 
White cell PLP (pmol/ 106 cells) NA (n=57) 
2.12 (0.37-8.24) 
(n=16) 
2.96 (1.58-6.16) 
0.005 
Plasma PL (nmol/ l) 5-26 (n=96) 
9 (2-1112) 
(n=25) 
90 (2-1346) 
<0.001 
Red cell PL (pmol/ gHb) 25-195 (n=36) 
109 (12.24-8680) 
(n=17) 
1432 (15-28868) 
<0.001 
White cell PL (pmol/ 106 cells) NA (n=55) 
0.43 (0.7-7.78) 
(n=15) 
4.02 (0.44-10.29) 
<0.001 
Plasma ascorbic acid (µmol/ l) 15-40 (n=69 ) 
<10 (<10-58) 
(n=15) 
11 (<10-136) 
0.019 
White cell ascorbic acid (µmol/ 109 cells) 1.5-2.5*** (n=33) 
1.81 (0.46-3.30) 
(n=9) 
3.02 (1.47-8.77) 
0.002 
Median (range), *Mann-Whitney U-test, **Reference intervals from controls, ***Reference 
intervals Lee et al. (1982)
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Table 8-3 Characteristics and measurements of proteins between admission and follow 
up in critically ill patients that did not have recorded supplementation prior or within 
ICU 
  Critically ill patients (n=19) 
No supplementation 
 
 Reference 
intervals 
Admission Follow-up p-value* 
Age (yr)  67 (26-81)   
Sex (M/F)  14/ 5   
Patients (medical/ surgical)  6/ 13   
ICU death (yes/ no)  8/ 11   
APACHE II  20 (7-34)   
Predicted hospital mortality (%)  44.4 (4.8-86.3)   
SOFA score  7 (1-11)   
Ventilation (days)  12 (0-60)   
ICU length of stay (days)  10.7 (0.9-59.5)   
Hospital length of stay (days)  29 (11.1-253)   
Hospital death (yes/ no)  8/ 11   
     
C-reactive protein (mg/ l) <6 137 (<6-259) 149 (27-251) 0.845 
Albumin (g/ l) 32-45 19 (9-42) 14 (9-28) 0.016 
Median (range) 
*Wilcoxon signed rank test 
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Table 8-4 Measurements of water and lipid soluble vitamins between admission and 
follow up in critically ill patients that did not have recorded supplementation prior or 
within ICU 
  Critically ill patients (n=19) 
No supplementation 
 
 Reference 
intervals 
Admission Follow-up p-
value* 
Whole blood TDP (ng/ gHb) 275-675 800 (196-1379) 689 (207-1538) 0.904 
Plasma FAD (nmol/ l) 51-160 53 (25-1179) 56 (19-1225) 0.983 
Red cell FAD (nmol/ gHb) 1.0-3.4 1.31 (1.04-2.21) 1.33 (0.96-2.19) 1.000 
White cell FAD (pmol/106 cells) (n=14) NA 13.14 (11.22-15.81) 13.02 (10.47-16.25) 0.177 
Plasma FMN (nmol/ l) (n=6) 3.3-14.1** 10 (4-34) 6 (4-23) 0.046 
Red cell FMN (nmol/ gHb) 0.04-0.44** 0.10 (0.05-0.17) 0.10 (0.05-0.17) 0.904 
White cell FMN (pmol/ 106 cells) (n=14) NA 0.63 (0.43-0.82) 0.58 (0.37-0.90) 0.300 
Plasma riboflavin (nmol/ l) (n=13) 4-34** 20 (7-170) 17 (3-300) 0.753 
Red cell riboflavin (nmol/ gHb) 0.01-0.13** 0.03 (0.01-0.09) 0.03 (0.00-0.17) 0.841 
White cell riboflavin (pmol/ 106 cells) 
(n=14) 
NA 0.57 (0.33-0.83) 0.61 (0.38-0.81) 0.925 
Plasma PLP (nmol/ l) 17-135 17 (2-296) 10 (2-357) 0.133 
Red cell PLP (pmol/ gHb) 250-680 216 (149-721) 224 (78-514) 0.198 
White cell PLP (pmol/ 106 cells) (n=14) NA 1.96 (1.39-3.56) 1.93 (1.38-2.14) 0.510 
Plasma PL (nmol/ l) (n=16) 5-26** 5 (2-83) 5 (2-30) 0.048 
Red cell PL (pmol/ gHb) (n=15) 25-195** 50 (17-130) 54 (12-301) 0.211 
White cell PL (pmol/ 106 cells) (n=14) NA 0.54 (0.26-1.15) 0.66 (0.17-1.45) 0.026 
Plasma ascorbic acid (µmol/ l) (n=12) 15-40 <10 (<10-50) <10 (<10-18) 0.154 
White cell ascorbic acid (µmol/ 109 cells) 
(n=6) 
1.5-2.5*** 1.80 (0.60-2.45) 1.78 (0.67-3.12) 0.249 
Median (range) 
*Wilcoxon signed rank test, **Reference intervals from controls, ***Reference intervals Lee 
et al. (1982) 
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Table 8-5 Characteristics and measurements of proteins between admission and follow 
up in critically ill patients that had recorded supplementation only within ICU 
  Critically ill patients (n=22) 
Supplementation 
 
 Reference 
intervals 
Admission Follow-up p-
value
* 
Age (yr)  56 (18-86)   
Sex (M/F)  14/ 8   
Patients (medical/ surgical)  10/ 12   
ICU death (yes/ no)  7/ 15   
APACHE II  23 (9-33)   
Predicted hospital mortality (%)  38.6 (4.3-80.4)   
SOFA score  7 (1-14)    
Ventilation (days)  8 (0-49)   
ICU length of stay (days)  8.3 (1.9-48.1)   
Hospital length of stay (days)  26 (6-119)   
Hospital death (yes/ no)  9/ 13   
     
C-reactive protein (mg/ l) <6 58 (3-257) 144 (28-303) 0.055 
Albumin (g/ l) 32-45 16 (9-33) 15 (9-29) 0.055 
Median (range) 
*Wilcoxon signed rank test 
  180
 
Table 8-6 Measurements of water and lipid soluble vitamins between admission and 
follow up in critically ill patients that had recorded supplementation only within ICU 
  Critically ill patients (n=22) 
Supplementation 
 
 Reference 
intervals 
Admission Follow-up p-
value* 
Whole blood TDP (ng/ gHb) 275-675 685 (288-2287) 1646 (333-5491) 0.001 
Plasma FAD (nmol/ l)  51-160 37 (14-827) 43 (12-1698) 0.794 
Red cell FAD (nmol/ gHb) (n=21) 1.0-3.4 1.46 (1.13-2.56) 1.68 (1.24-2.63) 0.019 
White cell FAD (pmol/106 cells) (n=16) NA 12.63 (7.89-16.89) 13.64 (5.85-
29.25) 
0.163 
Plasma FMN (nmol/ l) (n=1) 3.3-14.1** NA NA  
Red cell FMN (nmol/ gHb) (n=16) 0.04-0.44** 0.09 (0.06-0.33) 0.11 (0.06-0.25) 0.034 
White cell FMN (pmol/ 106 cells) (n=11) NA 0.53 (0.27-0.84) 0.67 (0.34-0.94) 0.004 
Plasma riboflavin (nmol/ l) (n=13) 4-34** 24 (3-338) 44 (15-577) 0.221 
Red cell riboflavin (nmol/ gHb) (n=19) 0.01-0.13** 0.02 (0.01-0.21) 0.03 (0.01-0.28) 0.033 
White cell riboflavin (pmol/ 106 cells) (n=14) NA 0.49 (0.23-1.36) 0.67 (0.46-2.07) 0.003 
Plasma PLP (nmol/ l) 17-135 21 (<2-126) 34 (9-175) 0.158 
Red cell PLP (pmol/ gHb) (n=21) 250-680 241 (131-10788) 1000 (132-5881) 0.016 
White cell PLP (pmol/ 106 cells) (n=14) NA 2.62 (0.89-4.06) 3.39 (1.94-7.24) 0.041 
Plasma PL (nmol/ l) (n=18) 5-26** 9 (<2-912) 33 (7-1057) 0.058 
Red cell PL (pmol/ gHb) (n=15) 25-195** 39.74 (18.07-38223) 333 (83.33-8680) 0.088 
White cell PL (pmol/ 106 cells) (n=14) NA 0.43 (0.18-7.78) 3.02 (0.43-10.32) 0.016 
Plasma ascorbic acid (µmol/ l) (n=18) 15-40 <10 (<10-69) <10 (<10-69) 0.609 
White cell ascorbic acid (µmol/ 109 cells) 
(n=10) 
1.5-2.5*** 1.92 (0.46-2.93) 2.35 (1.02-5.80) 0.074 
Median (range) 
*Wilcoxon signed rank test, **Reference intervals from controls, ***Reference intervals Lee 
et al. (1982) 
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Table 8-7 Characteristics and changes in proteins between admission and follow up in 
critically ill patients that did not have recorded supplementation prior to ICU and did or 
did not have recorded supplementation within ICU 
 Critically ill patients   
 No 
supplementation 
(n=19) 
Changes 
Supplementation 
(n=22) 
 
Changes 
p-value* 
Age (yr) 67 (26-81) 56 (18-86) 0.440 
Sex (M/F) 14/ 5 14/ 8 0.496 
Patients (medical/ surgical) 6/ 13 10/ 12 0.370 
ICU death (yes/ no) 8/ 11 7/ 15 0.501 
APACHE II 20 (7-34) 23 (9-33) 0.896 
Predicted hospital mortality (%) 44.4 (4.8-86.3) 38.6 (4.3-80.4) 0.676 
SOFA score 7 (1-11) 7 (1-14)  0.460 
Ventilation (days) 12 (0-60) 8 (0-49) 0.885 
ICU length of stay (days) 10.7 (0.9-59.5) 8.3 (1.9-48.1) 0.906 
Hospital length of stay (days) 29 (11.1-253) 26 (6-119) 0.556 
Hospital death (yes/ no) 8/ 11 9/ 13 0.939 
    
C-reactive protein (mg/ l) -5 (-96 - +249) 62 (-184 - +276) 0.242 
Albumin (g/ l) -1 (-15 - +6) -3 (-15 - +18) 0.927 
     Change in median (change in range) 
    *Mann-Whitney U-test 
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Table 8-8 Changes water and lipid soluble vitamins between admission and follow up in 
critically ill patients that did not have recorded supplementation prior to ICU and did or 
did not have recorded supplementation within ICU 
 Critically ill patients  
 No supplementation 
(n=19) 
Supplementation 
(n=22) 
p-value* 
Whole blood TDP (ng/ gHb) 9 (-519 - +628) 885 (-1034 - +4600) <0.001 
Plasma FAD (nmol/ l)  2 (-200 - +845) 6 (-230 - +1377) 0.850 
Red cell FAD (nmol/ gHb)  -0.02 (-0.12 - +0.29) 0.10 (-0.36 - +1.50) 0.060 
White cell FAD (pmol/106 cells)  (n=14) 
-0.24 (-4.32 - +3.91) 
(n=16) 
0.85 (-3.28 - +12.50) 
0.022 
Plasma FMN (nmol/ l)  (n=6) 
-4 (-27 - +1) 
(n=1) 
NA 
NA 
Red cell FMN (nmol/ gHb)   
-0.00 (-0.02 - +0.02) 
(n=16) 
0.02 (-0.08 - +0.11) 
0.017 
White cell FMN (pmol/ 106 cells)  (n=14) 
-0.02 (-0.23- +0.18) 
(n=11) 
0.12 (-0.01- +0.24) 
0.003 
Plasma riboflavin (nmol/ l)  (n=13) 
1 (-17 - +130) 
(n=13) 
12 (-165 - +571) 
0.293 
Red cell riboflavin (nmol/ gHb)  (n=19) 
-0.00 (-0.03 - +0.07) 
(n=19) 
0.01 (-0.09 - +0.24) 
0.042 
White cell riboflavin (pmol/ 106 cells)  (n=14) 
0.001 (-0.19 - +0.16) 
(n=14) 
0.24 (-0.16 - +0.72) 
<0.001 
Plasma PLP (nmol/ l)  -2 (-147 - +62) 4.3 (-68 - +132) 0.150 
Red cell PLP (pmol/ gHb)  -53 (-274 - +352) 749 (-7038 - +5690) 0.001 
White cell PLP (pmol/ 106 cells)  (n=14) 
0.01 (-1.70 - +0.56) 
(n=14) 
1.26 (-1.53 - +4.98) 
0.054 
Plasma PL (nmol/ l)  (n=16) 
2 (-3 - +12) 
(n=18) 
15 (-857 - +1048) 
0.009 
Red cell PL (pmol/ gHb)  (n=15) 
-2.89 (-13.27 - +263) 
(n=15) 
292 (-34757 - +8653) 
0.007 
White cell PL (pmol/ 106 cells)  (n=14) 
0.01 (-1.70 - +0.56) 
(n=14) 
1.26 (-1.53 - +4.98) 
0.004 
Plasma ascorbic acid (µmol/ l)  (n=12) 
-0.55 (-47 - +2.10) 
(n=18) 
0.50 (-22 - +67) 
0.155 
White cell ascorbic acid (µmol/ 109 cells)  (n=6) 
0.09 (-0.46 - +0.66) 
(n=10) 
0.49 (-0.83 - +3.85) 
0.278 
   Change in median (change in range)  *Mann-Whitney U-test 
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Table 8-9 Plasma, red cell and white cell vitamin B2 concentrations in patients that had plasma FAD concentrations below the 
reference interval on admission to ICU and had or not recorded supplementation in ICU 
  Critically ill patients with low plasma FAD concentrations on admission 
 Reference 
intervals 
Admission 
(n=9) 
No supplementation 
Follow-up  (n=9) 
p-value* Admission  
(n=19) 
Supplementation 
Follow-up (n=19) 
p-value* 
Plasma FAD (nmol/ l)  51-160 30 (24-46) 33 (23-882) 0.327 23 (10-44) 36 (12-72) 0.020 
Red cell FAD (nmol/ gHb)  1.0-3.4 1.3 (1.13-2.21) 1.27 (1.08-2.19) 0.110 (n=18) 
1.54 (1.13-2.56) 
(n=18) 
1.83 (1.40-2.63) 
0.003 
White cell FAD (pmol/106 
cells)  
NA (n=5) 
15 (12-16) 
(n=5) 
12 (10-16) 
 (n=13) 
13 (8-17) 
(n=13) 
12 (6-29) 
0.221 
Plasma FMN (nmol/ l)  3.3-14.1** (n=4) 
6.6 (3.6-28.1) 
(n=4) 
4.8 (4.1-23.1) 
 (n=2) 
12.4 (2.8-21.9) 
(n=2) 
12.0 (4.6-19.3) 
0.655 
Red cell FMN (nmol/ gHb)  0.04-0.44** 0.08 (0.06-0.19) 0.08 (0.05-0.19)  (n=16) 
0.10 (0.06-0.33) 
(n=16) 
0.14 (0.08-0.25) 
0.008 
White cell FMN (pmol/ 106 
cells)  
NA (n=5) 
0.68 (0.49-0.78) 
(n=5) 
0.59 (0.38-0.90) 
 (n=11) 
0.43 (0.27-0.99) 
(n=11) 
0.51 (0.28-0.88) 
0.155 
Plasma riboflavin (nmol/ l)  4-34** (n=7) 
15 (7-34) 
(n=7) 
11 (3-40) 
 (n=16) 
43 (3-572) 
(n=16) 
86 (15-617) 
0.163 
Red cell riboflavin (nmol/ gHb)  0.01-0.13** 0.02 (0.01-0.08) 0.02 (0.01-0.07)  (n=17) 
0.03 (0.01-0.21) 
(n=17) 
0.06 (0.01-0.25) 
0.076 
White cell riboflavin (pmol/ 
106 cells)  
NA (n=5) 
0.55 (0.47-0.71) 
(n=5) 
0.53 (0.38-0.69) 
 (n=11) 
0.53 (0.23-1.36) 
(n=11) 
0.67 (0.52-2.07) 
0.013 
       Median (range), *Wilcoxon signed rank test, ** Reference intervals from controls 
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Table 8-10 Plasma, red cell and white cell vitamin B2 concentrations in patients that had plasma FAD concentrations above the 
reference interval on admission to ICU and had or not recorded supplementation in ICU 
  Critically ill patients with high plasma FAD concentrations on admission 
 Reference 
intervals 
Admission (n=3) No supplementation 
Follow-up  (n=3) 
p-value* Admission  
(n=7) 
Supplementation 
Follow-up (n=7) 
p-value* 
Plasma FAD (nmol/ l)  51-160 546 (322-1179) 414 (347-1225)  530 (170-1916) 908 (74-5479)  
Red cell FAD (nmol/ gHb)  1.0-3.4 1.85 (1.58-2.04) 2.15 (1.74-2.15)  1.86 (1.33-2.17) 2.02 (1.24-2.55)  
White cell FAD (pmol/106 cells)  NA 12.97 (11.22-13.08) 13.17 (12.86-15.13)  (n=6) 
14.87 (12.30-17.29) 
(n=6) 
13.56 (11.58-15.82) 
 
Plasma FMN (nmol/ l)  3.3-14.1** NA NA  NA NA  
Red cell FMN (nmol/ gHb)  0.04-0.44** 0.15 (0.10-0.17) 0.16 (0.11-0.17)  (n=4) 
0.13 (0.08-0.16) 
(n=4) 
0.15 (0.08-0.18) 
 
White cell FMN (pmol/ 106 cells)  NA 0.52 (0.52-0.82) 0.58 (0.56-0.76)  (n=3) 
0.81 (0.59-0.82) 
(n=3) 
0.64 (0.56-0.94) 
 
Plasma riboflavin (nmol/ l)  4-34** NA NA  NA NA  
Red cell riboflavin (nmol/ gHb)  0.01-0.13** 0.07 (0.07-0.09) 0.08 (0.06-0.17)  (n=6) 
0.12 (0.04-0.19) 
(n=6) 
0.10 (0.02-0.62) 
 
White cell riboflavin (pmol/ 106 
cells)  
NA 0.81 (0.54-0.82) 0.78 (0.58-0.81)  (n=6) 
0.84 (0.34-1.28) 
(n=6) 
0.85 (0.46-1.00) 
 
Median (range), *Wilcoxon signed rank test, ** Reference intervals from controls 
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Table 8-11 Plasma, red cell and white cell vitamin B6 concentrations in patients that had plasma PLP concentrations below the 
reference interval on admission to ICU and had or not recorded supplementation in ICU 
  Critically ill patients with low plasma PLP concentrations on admission 
 Reference 
intervals 
No supplementation 
Admission (n=11) 
No supplementation 
Follow-up (n=11) 
p-value* Supplementation 
Admission (n=11) 
Supplementation 
Follow-up (n=11) 
p-value* 
Plasma PLP (nmol/ l)  17-135 8 (2-17) 7 (2-12) 0.059 9 (<2-16) 22 (9-63) 0.010 
Red cell PLP (pmol/ gHb)  250-680 201 (111-625) 205 (51-399) 0.091 209 (131-1014) 1558 (185-22001) 0.008 
White cell PLP (pmol/ 106 
cells)  
 
NA 
(n=8) 
1.79 (1.39-2.34) 
(n=8) 
1.90 (1.38-2.09) 
0.779 (n=6) 
2.32 (0.89-3.47) 
(n=6) 
3.14 (1.94-5.18) 
0.249 
Plasma PL (nmol/ l)   
5-26** 
(n=10) 
5 (<2-10) 
(n=10) 
5 (2-12) 
0.123 (n=10) 
4 (<2-19) 
(n=10) 
44 (3-1057) 
0.007 
Red cell PL (pmol/ gHb)   
25-195** 
(n=8) 
25 (17-130) 
(n=8) 
46 (15-127) 
0.093 (n=9) 
39 (18-242) 
(n=9) 
824 (54-28868) 
0.011 
White cell PL (pmol/ 106 cells)   
NA 
(n=8) 
0.43 (0.26-1.15) 
(n=8) 
0.67 (0.17-1.45) 
0.069 (n=6) 
0.41 (0.18-1.22) 
(n=6) 
2.51 (0.42-7.17) 
0.075 
Median (range), *Wilcoxon signed rank test, **Reference intervals from controls 
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Table 8-12 Plasma, red cell and white cell vitamin B6 concentrations in patients that had plasma PLP concentrations above the 
reference interval on admission to ICU and had or not recorded supplementation in ICU 
  Critically ill patients with high plasma PLP concentrations on admission 
 Reference 
intervals 
No supplementation 
Admission (n=4) 
No supplementation 
Follow-up (n=4) 
p-value* Supplementation 
Admission (n=2) 
Supplementation 
Follow-up (n=2) 
p-value* 
Plasma PLP (nmol/ l)  17-135 162 (141-296) 24 (7-357)  252 (198-306) 73 (72-74)  
Red cell PLP (pmol/ gHb)  250-680 321 (205-13717) 301 (207-514)  18748 (11912-25583) 4250 (4233-4268)  
White cell PLP (pmol/ 106 
cells)  
NA 2.08 (1.74-3.98) 1.89 (1.81-2.14)  NA   
Plasma PL (nmol/ l)  5-26** 11 (3-865) 6 (<2-30)  NA   
Red cell PL (pmol/ gHb)   
25-195** 
(n=3) 
65 (50-12640) 
(n=3) 
71 (55-76) 
  
30122 (6765-53480) 
 
2232 (1747-2716) 
 
White cell PL (pmol/ 106 cells)  NA 0.64 (0.54-8.06) 0.64 (0.48-1.48)  NA   
Median (range), *Wilcoxon signed rank test, **Reference intervals from controls 
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Table 8-13 Plasma and white cell vitamin C concentrations in patients that had plasma ascorbic acid concentrations below the 
reference interval on admission to ICU and had or not recorded supplementation in ICU 
  Critically ill patients with low plasma vitamin C concentrations on admission 
 Reference 
intervals 
No supplementation 
Admission (n=11) 
No supplementation 
Follow-up 
(n=11) 
p-value* Supplementation 
Follow-up 
(n=19) 
p-value* 
Plasma ascorbic acid (µmol/ l)  15-40 <10 (<10-14) <10 (<10-10) 0.332 <10 (<10-69) 0.017 
White cell ascorbic acid (µmol/ 
109 cells)  
 
1.5-2.5** 
(n=27) 
1.6 (0.46-8.77) 
(n=5) 
1.45 (0.67-3.12) 
0.345 (n=10) 
2.20 (1.02-5.80) 
0.646 
Median (range), *Wilcoxon signed rank test, **Reference intervals from Lee et al. (1982) 
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Table 8-14 Plasma and white cell vitamin C concentrations in patients that had plasma ascorbic acid concentrations below the 
reference interval on admission to ICU and had or not recorded supplementation in ICU 
  Critically ill patients with low white cell vitamin C concentrations on admission 
 Reference 
intervals 
Admission 
(n=10) 
No supplementation 
Follow-up 
(n=2) 
p-
value* 
Supplementation 
Follow-up 
(n=1) 
p-value* 
Plasma ascorbic acid (µmol/ l)  15-40 <10 (<10-17) <10 (<10-<10) 0.317 NA NA 
White cell ascorbic acid (µmol/ 
109 cells)  
1.5-2.5** 0.87 (0.46-1.47) 0.76 (0.67-0.84) 0.180 NA NA 
Median (range), *Wilcoxon signed rank test, **Reference intervals from Lee et al. (1982) 
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9 The relationship between vitamin B2, B6, C, A, E and 
carotenoids’concentrations, lipid peroxidation and 
hospital mortality in patients with critical illness 
9.1 Introduction 
Nutritional support, in the form of parenteral and enteral nutrition, is a cornerstone of care for 
patients with critical illness.  The concept of feeding such patients is to maintain energy 
balance and micronutrient status (Kreymann et al. 2006).  In particular, micronutrients have 
been proposed to prevent cellular damage by reactive oxygen species, for example lipid 
peroxidations and malondialdehyde (MDA) formation, which have been linked to the 
development of multiple organ dysfunction syndrome and poor prognosis in patients with 
critical illness (Hill & Hill 1998; Mishra et al. 2005). 
Antioxidant status has been reported to be suboptimal in critical illness (Cowley et al. 1996; 
Alonso de Vega et al. 2000; Mishra et al. 2005; Doise et al. 2008).  Therefore, there is 
continuing interest in optimising micronutrient status for critically ill patients admitted to ICU 
(Heyland et al. 2005). 
Vitamin supplementation should be guided by the assessment of vitamin status.  However, 
reliable measurement of vitamin status in the critically ill is problematical.  In health, plasma 
concentrations of most vitamins have been shown to be associated with status (Fell & Talwar 
1998).  However, in the critically ill patient, plasma concentrations are often perturbed by the 
presence of systemic inflammatory response syndrome.  Indeed, there is evidence that plasma 
concentrations of water-soluble B (Hustad et al. 2002; Gray et al. 2004; Quasim et al. 2005) 
and C vitamins (Louw et al. 1992), and lipid-soluble retinol, α-tocopherol, and carotenoids 
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(Quasim et al. 2004; Gray et al. 2005) do not reflect status in the presence of a systemic 
inflammatory response.  Therefore, although low plasma concentrations are often used as the 
rationale for vitamin supplementation in the critically ill the basis for such supplementation is 
not well founded. 
Recently, there has been increasing evidence that intracellular vitamin concentrations in blood 
may be a more reliable measure of status in the patient with critical illness and systemic 
inflammatory response syndrome.  Red cell B2 and B6 have been reported to be more reliable 
indicators of status compared with plasma concentrations (Gray et al. 2004; Quasim et al. 
2005).  Also, red cell vitamin E and white cell vitamin C have also been reported to be more 
reliable indicators of status compared with plasma concentrations (Kitagawa, Nakagawa & 
Mino 1983; Omaye et al.1987; Lehmann et al. 1988; Louw et al. 1992). 
Therefore, the aim of the present study was to examine the relationships between MDA, water 
and lipid soluble vitamins and survival in patients with critical illness.  
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9.2 Materials and Methods 
9.2.1 Patients and study design 
See paragraph 2.1.1 
9.2.2 Collection and preparation of blood samples 
An EDTA tube containing approximately 6 mL of whole blood was taken for each patient on 
admission and follow-up.  The EDTA sample was centrifuged (500g, 4oC, 10mins) and 500 
uL of plasma was removed into another plastic tube containing, metaphosphoric acid 6%, for 
plasma vitamin C determination.  After removing the buffy coat, the packed red cells were 
stored for red cell vitamin determination.  All tubes were stored at -70o C until analysis. All 
samples were assayed in a single batch for each of the analytes to minimise interbatch 
analytical variation. 
9.2.2.1 White cell preparation 
See paragraph 2.1.2.1 
Following the final brief centrifugation (10,000 rpm, 3mins), the supernatant was removed and 
the resulting pellet was dispersed in 125µL of deionised water and stabilized with 125uL of 
metaphosphoric acid 6% for the vitamin C analysis.  The cell suspension was stored at -80°C. 
Before analysis, the cell suspension was sonicated for 10 min to lyse the cell membranes. 
9.2.3 Analytical Methods 
9.2.3.1 Measurements of vitamins B1, B2 and B6 
See paragraph 2.1.2.3, 2.1.2.4 and 2.1.2.5 
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9.2.3.2 Measurement of vitamin C 
See paragraph 2.1.2.6 
9.2.3.3 Measurement of plasma and red cell vitamin E and plasma carotenoids 
See paragraph 2.1.2.7 and 2.1.2.8 
9.2.3.4 Measurement of total and free malondialdehyde (MDA) 
See paragraph 2.1.2.9 
9.2.3.5 Measurement of whole blood and plasma proteins concentrations 
See paragraph 2.1.2.2 
9.2.4 Statistics 
Data from critically ill patient groups are presented as median and range.  Comparisons 
between critically groups were performed with the use of the Mann-Whitney U test.  
Correlations between variables in the critically ill group were performed with the use of the 
Spearman’s rank correlation (rs) and a P value of <0.01 was considered to be significant due to 
the number of observations.  Outcome data were analysed by binary logistic regression 
analysis.  Analysis was performed with the use of SPSS software (version 15; SPSS Inc, 
Chicago, Illinois, U.S.A.). 
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9.3 Results 
In total, one hundred and twenty six critically ill patients (medical n=56, surgical n=70) were 
studied.  The comparisons between the patients at the lowest APACHE II score quartile 
(n=33) and the patients at the highest APACHE II score quartile (n=34) are shown in Table 9-
1.  The patients in the lowest APACHE II score quartile were younger (p<0.001), mostly 
surgical (p<0.01), had lower hospital predicted mortality (p<0.001) and SOFA score (p<0.001) 
and stayed in the ICU for less days (p<0.01) compared with the patients in the highest quartile.  
Albumin, cholesterol and triglyceride concentrations were significantly lower in the group of 
patients at the highest APACHE II score quartile compared with the group at the lowest 
quartile (p<0.01, p<0.001 and p<0.01, respectively).  Free MDA fraction was significantly 
higher in the group of patients at the highest APACHE II score quartile compared with the 
group at the lowest quartile (p<0.01).  There were no significant differences in water soluble 
vitamin concentrations between the two groups (Table 9-2).  Plasma α-tocopherol was 
significantly lower in the group at the highest APACHE II score quartile compared with the 
group at the lowest quartile (Table 9-3, p<0.01).      
Ninety four patients survived and thirty two died in hospital after their ICU admission (Table 
9-4).  Non-survivors were older and had significantly higher APACHE II score (p<0.01), 
predicted hospital mortality (p<0.001), ventilation days (p<0.001) and ICU length of stay 
(p<0.001) compared with the survivors.  Survivors had significantly higher hospital length of 
stay compared with non-survivors (p<0.01).   
On admission, compared with survivors, free MDA and free MDA fraction were higher in the 
non-survivors (p<0.01 and p<0.001, respectively).  In contrast, plasma concentrations of 
albumin (p<0.01), retinol (p<0.05), α-tocopherol (p<0.05), lutein (p<0.01) and lycopene 
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(p<0.01) were significantly lower in the non-survivor critically ill patient group on admission 
to ICU (Tables 9-4, 9-5 and 9-6). 
The relationship between clinical pathological characteristics, vitamin status and hospital 
death in patients with critical illness on admission to ICU is shown in Table 9-7.  On 
multivariate logistic regression analysis of the individual significant parameters only albumin 
(p<0.05) and free MDA fraction (p<0.05) were independently associated with hospital death.  
When albumin was removed from the model, free MDA fraction (OR=55.20, 95% CI=3.88-
785, p=0.003) and lycopene (OR=0.98, 95% CI=0.97-1.00, p=0.033) were independently 
associated with hospital death. 
The interrelationships between outcome scores and concentrations of plasma proteins, lipids, 
free MDA fraction, plasma α-tocopherol and carotenoids in the critically-ill patients on 
admission to ICU are shown in Table 9-8.  APACHE II score was directly associated with age 
(rs=0.44, p<0.001), SOFA score (rs=0.50, p<0.001) and free MDA fraction (rs=0.34, p<0.01) 
and inversely associated with albumin (rs=-0.29, p<0.01), cholesterol (rs=-0.38, p<0.001), 
triglycerides (rs=-0.27, p<0.01), plasma α-tocopherol (rs=-0.32, p<0.001) and lycopene (rs=-
0.30, p<0.01).  Albumin was directly associated with cholesterol (rs=0.68, p<0.001), 
triglycerides (rs=0.28, p<0.01), retinol (rs=0.58, p<0.001), α-tocopherol (rs=0.58, p<0.001), 
lutein (rs=0.60, p<0.001) and lycopene (rs=0.57, p<0.001) and β-carotene (rs=0.37, p<0.001), 
and inversely associated with APACHE II (rs=-0.29, p<0.01), SOFA score (rs=-0.39, p<0.001) 
and free MDA fraction (rs=-0.29, p<0.01).  Free MDA fraction was directly associated with 
SOFA score (rs=0.41, p<0.001) inversely associated with cholesterol (rs=-0.34, p<0.01), 
plasma α-tocopherol (rs=-0.29, p<0.01), lutein (rs=-0.30, p<0.01) and lycopene (rs=-0.34, 
p<0.01). 
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9.4 Discussion 
In the present study, from the relationship between lipid peroxidation, water and lipid soluble 
vitamins and outcome in critically ill patients, it was shown that lipid peroxidation, as 
evidenced by elevated free MDA fraction, was most significantly associated with death in 
hospital.  This study included all the vitamers measured in all different blood compartments 
and tried to examine whether low plasma or intracellular vitamin concentrations are prognostic 
of outcome. 
In keeping with previous studies (Goode et al. 1995; Cowley et al. 1996), the results of this 
study show that plasma α-tocopherol concentrations on admission were related to the severity 
of illness, as measured by APACHE II score, in the critically ill patients.  However, taking 
into consideration that cholesterol and triglyceride concentrations also significantly decreased 
between the two quartiles and that plasma α-tocopherol concentrations were not significantly 
different between survivors and non-survivors, the clinical relevance of the association 
between plasma α-tocopherol concentrations and severity of illness is uncertain.  From these 
data, there was no relationship between plasma or intra-cellular vitamin concentrations and 
APACHE II scores in patients with critical illness. 
In the present study, serum albumin was found to be an independent predictor of hospital 
outcome in patients with critical illness, independent of severity of illness as assessed by 
APACHE II score.  Indeed, serum albumin has been found to be the best single indicator of 
concurrent sepsis and anergy and predictor of mortality in seriously ill hospitalized patients 
(Harvey et al., 1981).  An initial albumin of <2.2 g/dL has been associated with a greater than 
75% chance of having concurrent anergy and sepsis and dying during hospitalization (Harvey 
et al., 1981).  Surgery has been associated with a fall in serum albumin concentrations, which 
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persisted despite nutritional support (Harvey et al., 1981).  A decrease in serum albumin from 
concentrations greater than 46 g/L to less than 21 g/L was associated with an exponential 
increase in mortality rates from less than 1% to 29% and in morbidity rates from 10% to 65%, 
particularly sepsis and major infections, in surgical patients followed up for 30 days 
postoperatively (Gibbs et al., 1999). 
To date, the present study is the first to report the independent prognostic value of free MDA 
fraction in patients with critical illness.  It was of interest that, despite their recognised 
antioxidant role, the lipid soluble vitamins although associated with free MDA fraction, had 
no independent prognostic value.  One interpretation of these results would be that it is the 
degree of lipid peroxidation, rather than the depletion of lipid soluble vitamins, that 
determines outcome in patients with critical illness.  However, for most patients the 
concentrations of retinol and the carotenoids in the plasma were well below the reference 
intervals or were undetected and therefore may account for the lack of effect on outcome.  
This is further complicated by albumin being directly associated with the lipid soluble 
vitamins in the plasma, in particular retinol, α-tocopherol, lutein and lycopene, suggesting 
redistribution of these lipid soluble antioxidants.  Indeed, consistent with previous studies 
(Goldwasser & Felman, 1997; Vincent et al., 2003), albumin was shown to have prognostic 
value independent of APACHE II and when albumin was removed from the multivariate 
model, lycopene became an independent predictor of hospital death.  Taken together these 
results would suggest that low concentrations of lipid soluble vitamins may be partly due to 
redistribution in the same way as albumin concentrations fall as part of the systemic 
inflammatory response syndrome.  However, it remains to be established whether such low 
plasma concentrations are mainly due to increased consumption or redistribution or both. 
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Similarly, the present study showed that there was no significant difference in C-reactive 
protein concentrations between survivors and non-survivors.  For this reason, we decided not 
to include C-reactive protein in the univariate-multivariate model. These results are consistent 
with the results of Pettila and co-workers (2002) although changes in C-reactive protein 
concentrations have been shown to be predictive of outcome independently of severity of 
illness (Lobo et al. 2003; Ho et al. 2008). 
The basis of the present relationship between an elevated free MDA fraction and poor 
outcome is not clear.  However, it has previously been reported that elevated MDA has been 
associated with multiple organ dysfunction (Mishra et al. 2005).  Indeed, in the present study 
free MDA fraction was directly associated with APACHE II and SOFA scores on admission to 
ICU.  Therefore, it may be that free MDA fraction as well as being an important prognostic 
factor, may also provide a useful therapeutic target in patients with critical illness. 
In summary, the results of the present study have shown that free malondialdehyde fraction is 
an independent prosnostic factor for survival in the hospital after admission in the intensive 
care unit and could be used as a therapeutic target in patients with critical illness. 
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Table 9-1 Characteristics and measurements of proteins and malondialdehyde between 
critically ill patients at the lowest and those at the highest quartiles of APACHE II score 
on admission to ICU 
 Reference 
intervals 
APACHE II  
Lowest quartile  
(n=33) 
APACHE II 
Highest quartile 
(n=34) 
p-value* 
Age (yr)  43 (18-74) 63 (39-81) <0.001 
Sex (M/F)  20/ 13 23/ 11 0.551 
Patients (medical/ surgical)  10/ 23 22/ 12 0.005 
APACHE II score  12 (3-15) 31 (26-38) <0.001 
Predicted hospital mortality (%)  10.1 (0.2-27.4) 74.3 (4.4-92.6) <0.001 
SOFA score  4 (0-14) 8 (4-14) <0.001 
Ventilation (days)  2 (0-49) 6 (0-35) 0.017 
ICU death (yes/ no)  3/ 30 11/ 23 0.020 
ICU length of stay (days)  2.3 (0.2-48.1) 7.0 (0.9-34.6) 0.003 
Hospital death (yes/ no)  4/ 29 13/ 21 0.015 
Hospital length of stay (days)  14 (0.4-77) 24.5 (1.8-240) 0.259 
     
C-reactive protein (mg/ l) <6 48 (<6-434) 138 (3-565) 0.030 
Albumin (g/ l) 35-75 22 (10-47) 15 (9-33) 0.005 
Total protein (g/ l) 60-80 48 (32-75) 44 (25-73) 0.236 
Cholesterol (mmol/ l) 3.5-5.5 (n=30)  
2.7 (0.9-6.4) 
 
1.6 (0.4-5.0) 
 
<0.001 
Triglycerides (mmol/ l) <2.3 (n=30) 
1.2 (0.3-4.7) 
(n=33) 
0.8 (0.3-2.4) 
 
0.005 
Total Malondialdehyde  
(umol/ l) 
0.30-1.00 (n=27) 
0.77 (0.24-1.65) 
(n=29) 
0.65 (0.22-2.34) 
 
0.142 
Total Malondialdehyde/  
Total protein (µmol/ g) 
 (n=27) 
0.017 (0.01-0.03) 
(n=29) 
0.014 (0.01-0.09) 
 
0.329 
Free Malondialdehyde (µmol/ l) 0.04-0.10 (n=26) 
0.07 (0.02-0.38) 
(n=29) 
0.12 (0.02-0.62) 
 
0.017 
Free Malondialdehyde fraction  (n=26) 
0.10 (0.04-0.37) 
(n=29) 
0.19 (0.03-0.58) 
 
0.002 
Median (range), *Mann-Whitney U test 
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Table 9-2 Measurements of water soluble vitamins between critically ill patients at the 
lowest and those at the highest quartiles of APACHE II score on admission to ICU 
 Reference 
intervals 
APACHE II  
Lowest quartile (n=33) 
APACHE II 
Highest quartile (n=34) 
p-value* 
Whole blood TDP (ng/ gHb) 275-675 697 (257-2574) 863 (300-3650) 0.087 
Plasma FAD (nmol/ l) 51-160  
46 (18-290) 
(n=33) 
41 (10-1916) 
 
0.773 
Red cell FAD (nmol/ gHb) 1.0-3.4 (n=32) 
1.46 (1.02-2.10) 
 
1.65 (1.06-2.56) 
 
0.186 
White cell FAD (pmol/106 cells) NA (n=19) 
12.69 (8.40-90.15) 
(n=20) 
13.03 (9.24-17.29) 
 
0.482 
Plasma FMN (nmol/ l) 3.3-14.1** (n=11) 
17 (5-29) 
(n=4) 
30 (22-76) 
 
0.013 
Red cell FMN (nmol/ gHb) 0.04-0.44** (n=28) 
0.08 (0.05-0.48) 
(n=33) 
0.11 (0.05-0.33) 
 
0.256 
White cell FMN (pmol/ 106 cells) NA (n=16) 
0.67 (0.38-1.73) 
(n=20) 
0.60 (0.37-0.94) 
 
0.504 
Plasma riboflavin (nmol/ l) 4-34** (n=32) 
29 (6-279) 
(n=23) 
34 (4-748) 
 
0.384 
Red cell riboflavin (nmol/ gHb) 0.01-0.13** (n=32) 
0.02 (0.01-0.22) 
(n=33) 
0.04 (0.00-0.21) 
 
0.208 
White cell riboflavin (pmol/ 106 cells) NA (n=16) 
0.60 (0.33-1.04) 
(n=20) 
0.58 (0.36-1.36) 
 
0.236 
Plasma PLP (nmol/ l) 17-135 21 (<9-198) 29 (<9-333) 0.306 
Red cell PLP (pmol/ gHb) 250-680 (n=32) 
248 (105-25583) 
 
321 (32-27441) 
 
0.140 
White cell PLP (pmol/ 106 cells) NA (n=17) 
2.07 (1.30-6.16) 
(n=20) 
2.01 (0.37-5.18) 
 
0.345 
Plasma PL (nmol/ l) 5-26  
9 (<9-301) 
(n=33) 
10 (<9-1346) 
 
0.114 
Red cell PL (pmol/ gHb) 25-195 (n=29) 
50.0 (6.4-53480) 
(n=31) 
64.9 (12.0-38223) 
 
0.300 
White cell PL (pmol/ 106 cells) NA (n=17) 
0.43 (0.17-10.29) 
(n=20) 
0.58 (0.07-9.79) 
 
0.223 
Plasma ascorbic acid (µmol/ l) 15-40 (n=23) 
<9 (<9-136) 
(n=21) 
<9 (<9-102) 
 
0.315 
White cell ascorbic acid (µmol/ 109 
cells) 
1.5-2.5*** (n=11) 
1.79 (0.74-2.57) 
(n=11) 
1.70 (0.60-8.77) 
 
0.718 
Median (range), * Mann-Whitney U test, ** Reference intervals from controls, ***Lee et al. (1982) 
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Table 9-3 Measurements of lipid soluble vitamins between critically ill patients at the 
lowest and those at the highest quartiles of APACHE II score on admission to ICU 
 Reference 
intervals 
APACHE II  
Lowest quartile  
(n=33) 
APACHE II 
Highest quartile 
(n=34) 
p-value* 
Plasma retinol (µmol/l) 1.0-2.8 0.75 (0.09-3.10) 0.61 (0.02-2.50) 0.269 
Plasma α-tocopherol (µmol/ l) 14-39 17 (6-36) 12 (4-23) 0.004 
Red cell α-tocopherol (nmol/gHb)  
12-28** 
(n=16) 
16.9 (11.3-25.3) 
(n=23) 
18.5 (12.4-29.8) 
 
0.123 
Lutein (µg/ l) 82-202 (n=32) 
30 (<9-106) 
 
19 (<9-142) 
 
0.036 
Lycopene (µg/ l) 100-300 (n=32) 
50 (<9-318) 
 
18 (<9-291) 
 
0.016 
α-carotene (µg/ l) 14-60 (n=32) 
9 (<9-44) 
(n=33) 
9 (<9-29) 
 
0.157 
β-carotene (µg/ l) 92-312 (n=32) 
15 (<9-518) 
 
15 (<9-201) 
 
0.126 
 
Median (range), *Mann-Whitney U test 
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Table 9-4 Characteristics and measurements of proteins and malondialdehyde between 
survivor and non-survivor critically ill patients on admission to ICU 
 Reference 
intervals 
Survivors  
(n=94) 
Non-survivors 
(n=32) 
p-value* 
Age (yr)  56 (22-100) 67 (18-81) 0.014 
Sex (M/F)  61/ 33 21/ 11 0.940 
Patients (medical/ surgical)  42/ 52 14/ 18 0.927 
APACHE II  19 (3-38) 24 (10-34) 0.003 
Predicted hospital mortality (%)  25.4 (0.2-92.6) 53.3 (11.7-86.3) <0.001 
SOFA score  6 (0-18) 8 (1-14) 0.027 
Ventilation (days)  2 (0-35) 12 (0-75) <0.001 
ICU length of stay (days)  3 (1-36) 11 (1-77) <0.001 
Hospital length of stay (days)  24 (1-508) 12 (2-123) 0.002 
     
C-reactive protein (mg/ l) <6 97 (<6-434) 119 (2-565) 0.577 
Albumin (g/ l) 32-45 19 (9-47) 14 (9-33) 0.002 
Total protein (g/ l) 60-80 47 (23-83) 43 (26-73) 0.364 
Cholesterol (mmol/ l) 3.5-5.5 2.20 (0.53-6.40) 1.90 (0.40-5.20) 0.072 
Triglycerides (mmol/ l) <2.3 1.10 (0.30-5.05) 0.80 (0.30-2.80) 0.041 
Total Malondialdehyde  
(umol/ l) 
0.30-1.00 0.69 (0.24-2.34) 
(n=75) 
0.59 (0.22-14.27) 
(n=29) 
0.090 
Total Malondialdehyde/  
Total protein (µmol/ g) 
 0.02 (0.01-0.09) 
(n=75) 
0.01 (0.01-0.53) 
0.02 (n=29) 
0.121 
Free Malondialdehyde (µmol/ l) 0.04-0.10 0.08 (0.02-1.37) 
(n=74) 
0.12 (0.04-5.96) 
(n=29) 
0.007 
Free Malondialdehyde fraction  0.13 (0.03-1.00) 
(n=74) 
0.21 (0.05-1.04) 
(n=29) 
<0.001 
Median (range), *Mann-Whitney U-test 
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Table 9-5 Measurements of water soluble vitamins between survivor and non-survivor 
critically ill patients on admission to ICU 
 Reference 
intervals 
Survivors  
(n=94) 
Non-survivors  
(n=32) 
p-
value* 
Whole blood TDP (ng/ gHb) 275-675 778 (257-3650) 
(n=93) 
728 (196-3524) 0.157 
Plasma FAD (nmol/ l) 51-160 44 (14-1916) 
(n=92) 
56 (10-1179) 0.263 
Red cell FAD (nmol/ gHb) 1.0-3.4 1.49 (0.97-2.58) 1.46 (1.04-2.30) 0.788 
White cell FAD (pmol/106 cells)  13 (7-90) 
(n=55) 
13 (8-18) 
(n=22) 
0.558 
Plasma FMN (nmol/ l) 3.3-14.1** 17 (3-76) 
(n=23) 
19 (12-31) 
(n=3) 
0.446 
Red cell FMN (nmol/ gHb) 0.04-0.44** 0.09 (0.05-0.48) 
(n=80) 
0.09 (0.05-0.19) 
(n=29) 
0.773 
White cell FMN (pmol/ 106 cells)  0.68 (0.37-1.73) 
(n=46) 
0.54 (0.27-1.51) 
(n=20) 
0.132 
Plasma riboflavin (nmol/ l) 4-34** 30 (3-458) 
(n=85) 
35 (4-748) 
(n=19) 
0.480 
Red cell riboflavin (nmol/ gHb) 0.01-0.13** 0.03 (0.00-0.23) 0.04 (0.01-0.17) 
(n=31) 
0.676 
White cell riboflavin (pmol/ 106 cells)  0.61 (0.31-3.27) 
(n=49) 
0.59 (0.23-1.32) 
(n=22) 
0.728 
Plasma PLP (nmol/ l) 17-135 22 (<10-333) 16 (<10-296) 0.064 
Red cell PLP (pmol/ gHb) 250-680 50 (<10-53480) 
(n=93) 
60 (12-13499) 0.995 
White cell PLP (pmol/ 106 cells)  2.31 (1.02-8.24) 
(n=51) 
2.08 (0.37-6.15) 
(n=22) 
0.186 
Plasma PL (nmol/ l) 5-26** <10 (<10-1346) 
(n=90) 
<10 (<10-286) 0.189 
Red cell PL (pmol/ gHb) 25-195** 50 (<10-53480) 
(n=83) 
60 (12-13499) 
(n=28) 
0.664 
White cell PL (pmol/ 106 cells)  0.49 (0.17-10.29) 
(n=49) 
0.54 (0.07-6.15) 
(n=21) 
0.833 
Plasma ascorbic acid (µmol/ l) 15-40 5 (1-136) 
(n=64) 
4 (1-102) 
(n=20) 
0.441 
White cell ascorbic acid (µmol/ 109 cells) 1.5-2.5*** 1.92 (0.96-8.77) 
(n=28) 
1.83 (0.46-3.06) 
(n=14) 
0.571 
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Table 9-6 Measurements of water and lipid soluble vitamins between survivor and non-
survivor critically ill patients on admission to ICU 
Plasma retinol (µmol/l) 1.0-2.8 0.80 (0.09-3.10) 0.40 (0.02-4.20) 0.019 
Plasma α-tocopherol (µmol/ l) 14-39 15 (5-41) 12 (4-34) 0.020 
Red cell α-tocopherol (nmol/gHb) 12-28 18.35 (3.40-31.49) 
(n=58) 
19.14 (11.30-39.28) 
(n=24) 
0.210 
Lutein (µg/ l) 82-202 28 (<5-168) 
(n=92) 
14 (<5-246) 
(n=31) 
0.003 
Lycopene (µg/ l) 100-300 42 (<5-318) 
(n=92) 
19 (<5-103) 
(n=31) 
0.009 
α-carotene (µg/ l) 14-60 9 (<5-173) 
(n=91) 
9 (<5-44) 
(n=31) 
0.626 
β-carotene (µg/ l) 92-312 25 (<5-402) 
(n=92) 
16 (<5-522) 
(n=31) 
0.060 
Median (range) * Mann-Whitney U test, ** Reference intervals from controls, ***Lee et al. (1982) 
  204
 
Table 9-7 The relationship between clinical characteristics, vitamin status and hospital 
death in patients with critical illness on admission to ICU 
Univariate and multivariate binary logistic regression analysis 
 Univariate analysis p-value Multivariate analysis p-value 
 Odds ratio (95% CI)  Odds ratio (95% CI)  
Age 1.03 (1.00-1.06) 0.041*  0.896 
APACHE II 1.09 (1.03-1.16) 0.004* 1.07 (1.00-1.15) 0.069 
SOFA score 1.11 (0.99-1.24) 0.071*  0.995 
Albumin 0.92 (0.86-0.98) 0.006* 0.92 (0.85-0.99) 0.025 
Cholesterol 0.72 (0.51-1.01) 0.059*  0.660 
Triglycerides 0.49 (0.25-0.97) 0.040*  0.637 
Free MDA 4.10 (0.44-38.42) 0.217   
Free MDA fraction 41.35 (3.23-529.34) 0.004* 12.59 (1.13-140.18) 0.039 
Retinol 0.55 (0.28-1.08) 0.084*  0.400 
Plasma α-tocopherol 0.93 (0.87-0.99) 0.022*  0.603 
Plasma lutein 0.98 (0.97-1.00) 0.073*  0.874 
Plasma lycopene 0.98 (0.97-1.00) 0.011*  0.311 
Plasma β-carotene 1.00 (1.00-1.01) 0.933   
*Variables included in the multivariate model.  
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Table 9-8 Spearman correlations between outcome scores and concentrations of plasma proteins, lipids, free MDA fraction, plasma α-
tocopherol and carotenoids in the critically-ill patients on admission to ICU 
(n=126) 
 APACHE II SOFA Albumin Cholesterol Trigly- 
cerides 
Free MDA 
fraction 
Retinol α-
tocopherol 
Lutein Lycopene β-
carotene 
Age 0.44*** 0.11 -0.21* -0.15 0.23* 0.16 -0.03 -0.09 -0.08 -0.25** -0.06 
APACHE II  0.50*** -0.29** -0.38*** -0.27** 0.34** -0.14 -0.32*** -0.22* -0.30** -0.15 
SOFA   -0.39*** -0.49*** -0.17 0.41*** -0.41*** -0.43*** -0.39*** -0.45*** -0.36*** 
Albumin    0.68*** 0.28** -0.29** 0.58*** 0.58*** 0.60*** 0.57*** 0.37*** 
Cholesterol     0.48*** -0.34** 0.65*** 0.84*** 0.56*** 0.60*** 0.45*** 
Triglycerides      -0.17 0.30** 0.60*** 0.09 0.15 -0.01 
Free MDA 
fraction 
      -0.24* -0.29** -0.30** -0.34** -0.22* 
Retinol        0.63*** 0.59*** 0.59*** 0.45*** 
α-tocopherol         0.60*** 0.58*** 0.52*** 
Lutein          0.76*** 0.63*** 
Lycopene           0.62*** 
*P<0.05, **P<0.01, ***P<0.001 
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10 Discussion 
The aims of the thesis were to examine whether intracellular vitamin concentrations, as 
measured in blood cells, are a more reliable measure of status in patients with critical illness, 
and also, to examine the relationship between plasma and intracellular vitamin concentrations 
and hospital mortality in patients with critical illness.  These were addressed by a prospective 
longitudinal study that examined the relationship between plasma and intracellular 
concentrations of a number of vitamins (both water and lipid soluble) and outcome in patients 
with critical illness. 
The major findings of the study were: 
1. Intracellular vitamin measurements may be more reliable in assessing vitamin status 
and in guiding supplementation in patients with systemic inflammatory response.  
Assessment of vitamin status by measuring plasma concentrations is discouraged in 
patients with evidence of systemic inflammatory response syndrome. 
2. True vitamin B6 deficiency may be more frequent in the critically ill patient and thus 
vitamin B6 supplementation may be essential.  
3. Neither plasma nor intracellular vitamin B2 nor B6 nor C concentrations were related 
to severity of illness and hospital mortality in patients with critical illness. 
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10.1 Accurate and reliable assessment of vitamin status in patients 
with critical illness  
Clinical assessment of the general nutritional status of the critically ill patients can be 
addressed by the use of different tools such as reported recent weight changes, dietary 
assessment, clinical signs of vitamins deficiency, functional and anthropometric 
measurements.  In the clinical setting, there is a discrepancy between nutritional screening and 
nutritional assessment with the first including tools for identification of malnourished patients 
while the second aims to help with the understanding of the present nutritional status and the 
calculation of current nutritional needs and requirements.  Biochemical vitamin measurements 
are one of the methods traditionally used to assess patient vitamin status in the clinical setting 
and one of the key pieces of the vitamin status puzzle. 
10.1.1 Assessment of plasma vitamin concentrations 
A good marker of vitamin status should be able to reflect deficiency and supplementation.  On 
admission to ICU, almost 1/3 of the critically ill patients had plasma vitamin B2, B6 and C 
concentrations below the reference interval and remained below the reference interval on 
follow-up.  This could be interpreted as indicating deficiency.  However it has been shown 
that plasma B and C vitamin concentrations can decrease transiently due to the effect of the 
systemic inflammatory response (Louw et al. 1992; Gray et al. 2003; Mishra et al. 2005) and 
that supplementation is not reflected in plasma concentrations in these patients (Huang et al. 
2002; Rumelin et al. 2002; Talwar et al. 2003b; Mishra et al. 2005; Quasim et al. 2005) and 
the data of the current study are in agreement with these results as plasma concentrations of 
these vitamins did not increase with supplementation on follow up.   
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Compared with control subjects, the critically ill patients had lower plasma α-tocopherol 
concentrations even when expressed per mmol of triglycerides.  In contrast, α-tocopherol 
concentrations were higher when expressed per mmol of cholesterol (although these patients 
did not receive vitamin E supplementation).  Moreover, neither plasma α-tocopherol nor 
plasma α-tocopherol expressed per mmol of plasma lipids were strongly correlated with red 
cell α-tocopherol concentrations in the critically ill patients. 
Plasma carotenoid concentrations, even when expressed per mmol of cholesterol, remained 
low compared with the control group.  One interpretation of such data could be that these lipid 
soluble antioxidant vitamins may be consumed during the lipid peroxidation process.  
However, the majority of patients had plasma retinol concentrations below the reference 
interval on admission to ICU and these were directly and significantly related to alpha-
tocopherol and the carotenoids.  Moreover, this relationship was maintained on follow-up.  
Given that the hepatic stores of retinol are large and that deficiency is rare in Western 
populations (World Health Organisation 1995) this would suggest that the low concentrations 
of alpha-tocopherol and carotenoids, in addition to being consumed, maybe lowered by other 
factors.  Indeed, in the present study, there was no or only a weak relationship between the 
different carotenoids and between the carotenoids and retinol in control subjects.  In contrast, 
in patients with critical illness, the correlations between the different carotenoids became 
significant and particularly stong illustrating the effect of the systemic inflammatory response 
and redistribution in these carotenoid concentrations. 
10.1.2 Assessment of red cell vitamin concentrations 
In contrast, on admission to ICU, red cell FAD and red cell PLP concentrations were 
significantly higher in the patients with records of prior supplementation compared with the 
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patients without.  Moreover, in patients with plasma vitamin B2 and B6 concentrations below 
the reference interval, who did not have records of previous supplementation, red cell FAD 
and red cell PLP concentrations significantly increased after supplementation, in agreement 
with previous studies (Talwar et al. 2003b; Quasim et al. 2004; Huang et al. 2005). 
The critically ill patients of the present study did not receive vitamin E supplementation and 
their median red cell vitamin E concentrations were found to be similar to healthy subjects. 
10.1.3 Assessment of white cell vitamin concentrations 
White cell B2 and B6 vitamin concentrations seemed to also be able to reflect supplementation 
in the present study, with both white cell riboflavin and white cell PL being sensitive to 
supplementation.  Indeed, changes in white cell riboflavin and white cell PL concentrations 
between admission and follow up were significantly different between the groups that received 
(group 1), or not (group 2), supplementation in ICU (and did not have record of 
supplementation prior to ICU admission).  This possibly reflects that, within the short period 
between admission and follow up samples, white cells may more sensitively reflect vitamin 
B2 and vitamin B6 supplementation compared with either plasma or red cells.  Unfortunately, 
the number of longitudinal white cell riboflavin and white cell PL measurements was low in 
patients with low plasma FAD and low plasma PLP concentrations on admission, respectively, 
with recorded supplementation in ICU, and also reference intervals were not available from a 
control population in order to interpret the white cell riboflavin and white cell PL results.  This 
limits the interpretation of the value of white cell riboflavin and white cell PL as markers of 
vitamin B2 and B6 status, respectively, in patients with critical illness. 
Also, in the present study, compared with plasma ascorbic acid, white cell ascorbic acid 
concentrations seemed to be a better marker of vitamin C status in patients with critical illness.  
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On admission to ICU, white cell ascorbic acid concentrations were significantly higher in the 
patients with records of prior supplementation compared with the patients without.  Indeed, 
white cell ascorbic acid concentrations were above the reference interval in the group with 
evidence of prior ICU supplementation and their change between admission and follow up 
was related to the total number of supplementation doses received in ICU.  Previous studies 
have shown that, there is a good correlation between plasma and white cell vitamin C 
concentrations in healthy subjects (Bates 1977; Jacob, Skala & Omaye 1987; Omaye et al. 
1987) and also that, white cell ascorbic acid concentrations reflect cellular stores and vitamin 
C status (Omaye et al. 1987). 
Taken together, these findings suggest that intra-cellular concentrations of vitamins B2, B6, C 
and E may be more accurate markers of their respective vitamin status in patients with critical 
illness. 
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10.2 The importance of supplementation in patients with critical 
illness 
Low concentrations of both plasma and red cell PLP concentrations were identified in 
approximately half of the patients in this study, although a number of these patients had 
records of supplementation prior to ICU admission, suggesting that true vitamin B6 deficiency 
may be more frequent in the critically ill patients and that supplementation may be essential.  
Vitamin B6 has been shown to be essential for immune function and recent research has been 
conducted to establish the effect and efficacy of vitamin B6 supplementation in patients with 
critical illness (Huang et al. 2005; Cheng et al. 2006).  Similarly, approximately 1 in 4 patients 
admitted in ICU had low white cell ascorbic acid concentrations, also suggesting that some of 
these patients may have true vitamin C deficiency on their admission.  In contrast, there was 
only one patient with red cell FAD concentrations just below the reference interval on 
admission to ICU, suggesting that vitamin B2 deficiency may not be so common in patients 
with critical illness and that vitamin B2 supplementation may be unnecessary in these patients. 
On admission to ICU, intracellular B2, B6 and C vitamin concentrations and more 
specifically, red cell FAD, red cell PLP and white cell ascorbic acid concentrations were 
significantly higher in the patients with records of prior supplementation compared with the 
patients without.  In addition, the medians of these intracellular vitamers were all significantly 
higher for the group with records of supplementation prior to ICU admission compared with 
the group without, while they were within the reference intervals for red cell FAD, above the 
reference interval for white cell ascorbic acid and below the reference interval for red cell PLP 
in the group that had records of supplementation prior to ICU.  Moreover, in patients with 
plasma vitamin B2 and B6 concentrations below the reference interval and that did not have 
records of previous supplementation, red cell FAD and red cell PLP concentrations 
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significantly increased after supplementation with their medians being above the reference 
interval on follow-up.  These results are in agreement with previous studies (Talwar et al. 
2003b; Quasim et al. 2004; Huang et al. 2005). 
There was no relationship between the number of Pabrinex doses and the change in any of the 
changes in vitamin B2 and B6 vitamers between admission and follow up.  This possibly 
means that the effect of supplementation may need longer to be evident at the intracellular 
compartment than the number of days between the admission and our follow up sample and 
possibly that the relationship between the number of doses with the follow up measurements 
reflect a longer period of supplementation that many of these patients had starting prior to 
their ICU admission.  Moreover, in the subgroups with records of ICU supplementation and 
plasma vitamin concentrations above the reference interval on admission, the medians of red 
cell PLP, plasma PL and red cell PL concentrations did not increase further, possibly 
suggesting that either saturation or increased utilisation and excretion or both took place 
between the admission and the follow up sample.  Such a metabolic effect could not be 
examined in the present study as there were no measurements of the relevant metabolic 
products in either urine or blood.  A recent previous study though has shown that there are 
increased pyridoxic acid concentrations in plasma and urine in patients with critical illness 
(Cheng et al. 2006).  Similar results were observed for the intracellular concentrations of FAD, 
FMN and riboflavin and also for white cell ascorbic acid concentrations in the subgroups with 
high plasma FAD and ascorbic acid concentrations on admission, respectively, that had 
records of supplementation in ICU. 
Taken together, these findings suggest that cellular concentrations of vitamins B2, B6 and C 
may be expected to be a more true reflection of the presence of supplementation than their 
respective plasma concentrations.  Also, from these data, critical illness seems to be associated 
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with vitamin B6 and possibly vitamin C deficiency without these though to be important for 
patient severity of illness, as measured by APACHE II score, or survival.  Still, correction of 
vitamin deficiency could be important for some of the patients admitted in ICU and 
intracellular measurements of these vitamins, from the results of this study, could identify 
patient vitamin status and guide supplementation in ICU. 
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10.3 The relationship between intracellular vitamin 
concentrations, the magnitude of injury and outcome in 
patients with critical illness 
The relationship between admission plasma and intracellular blood concentrations of vitamins 
B2, B6, C and E and outcome in patients with critical illness was examined.  Neither plasma 
nor intracellular concentrations of B2, B6, C and E were significantly and independently 
associated with hospital mortality (p>0.10).  These results would suggest that these vitamins 
may not play a major role in determining outcome in patients with critical illness. 
A higher APACHE II score was associated with lower plasma α-tocopherol concentrations in 
patients with critical illness at the highest APACHE II quartile compared with the patients at 
the lowest APACHE II quartile.  Taken though into consideration, that at the same time 
plasma lipids (cholesterol and triglyceride) concentrations were also significantly lower in 
patients at the highest APACHE II quartile compared with the patients at the lowest and that 
plasma α-tocopherol concentrations were not related to red cell α-tocopherol concentrations in 
patients with critical illness or plasma α-tocopherol concentrations in healthy controls, and that 
plasma α-tocopherol concentrations have been shown to transiently fall in the presence of a 
systemic inflammatory response (Louw et al. 1992; Gray et al. 2005), the clinical relevance of 
such an observation is questionable.  Neither plasma carotenoids nor plasma nor intracellular 
concentrations of B2, B6 and C vitamins nor red cell E vitamin were significantly related with 
severity of illness in the patients of the present study as assessed by APACHE II score. 
Free MDA fraction was also found to be an independent prognostic factor of outcome 
prognosis in patients with critical illness.  This relationship and clinical significance of this 
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finding is not clear especially when neither total MDA nor free MDA were significantly 
related to hospital mortality in patients with critical illness.   
From the data of the present study, it would appear that outcome depends more on the severity 
of the insult, which lead to the state of critical illness, and its effect on metabolism rather than 
the presence of low plasma or intra-cellular vitamin concentrations. 
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10.4 Limitations of the study 
In the present study, biochemical measurements in three different blood compartments were 
used to assess vitamin status in patients with critical illness.  Other methods for assessing 
general nutritional status exist such as anthropometric measurements (changes in weight, BMI, 
muscle mass, skinfold thickness) and previous diet history (24h hour recall, 7 day food diary, 
food frequency questionnaires) however most of the above methods of assessing nutritional 
status are often of limited value in the critically ill patient, bringing challenge to the 
assessment of vitamin status (Manning & Shenkin 1995; Winkler & Malone 2004).  The 
critically ill patients are a heterogenous group with different medical backgrounds, and are 
usually unable to provide a dietary history due to sedation/confusion, weight measurements 
may be erroneous after fluid resuscitation and/ or oedema, and anthropometric measurements 
are not easily attainable, may be erroneous due to oedema, have been shown to be less 
sensitive to acute changes of status (Harvey et al. 1981; Winkler & Malone 2004).  In 
addition, clinical symptoms occur at the final stages of vitamin deficiency thus their value as 
markers of vitamin deficiency and predictors of outcome in patients with critical illness comes 
possibly too late for the clinician and the patient. 
One limitation of the present work was that a number of the critically ill patients had received 
intravenously B and C vitamin supplementation either before their admission to ICU and/ or 
during their ICU stay.  Clearly, since these patients received vitamin supplementation this may 
have had a confounding effect on some of the results obtained.  For example, it meant that few 
patients had evidence of intracellular B vitamin deficiency on admission limiting the 
conclusions of the study on whether low intracellular B vitamin concentrations may be related 
to poor outcome. 
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Examining the effect of supplementation in the specific study was challenging as some of our 
patients had records of supplementation prior to ICU admission.  Also,  the upper range of 
some of the vitamins in the non-supplemented group prior to ICU admission were very high 
suggesting that some of these patients had recently received B and C vitamin supplementation 
prior to their admission to ICU but to our knowledge there were no records of this in the 
medical files. 
Also, in the present study, there were no control values for white cell vitamin concentrations.  
In the first 6 months of this study, I had identified approximately 100 anonymous patient 
blood samples from the Haematology department in which I extracted the white cells and 
analysed white cell B2 and B6 vitamin concentrations in order to calculate a non-critically ill 
population reference range.  On the completion of this, I was advised that these results could 
not be used for such a purpose as the majority of the patients admitted in the hospital would be 
under systemic inflammatory response and thus the vitamin concentrations could be biased. 
Another limitation was the smaller number of plasma and white cell vitamin C samples.  There 
was a problem in stabilising the blood samples for vitamin C analysis soon enough as 
stabilisation has to take place within the first 12 hours of the sample extracted.  A number of 
patients were admitted in the ICU directly from theatre in the evening hours resulting in a big 
number of samples being unsuitable for vitamin C analysis.  In addition, some patients had 
very low white cell numbers resulting in insufficient white cell pellets during extraction which 
further compromised the number of white cell vitamin C samples.  Thus, these small numbers 
may have compromised the significance of plasma and white cell vitamin C concentrations in 
terms of outcome. 
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A problem with numbers of observations also occurred during the analysis of some of the 
vitamers especially FMN.  The chromatogram produced had split peaks which did not allow 
the calculation of the vitamer concentration in the sample.  That lead to the difference in 
numbers between the vitamers in the same matrix. 
There was no vitamin E or carotenoid supplementation in the critically ill patients admitted in 
the intensive care unit.  Thus the effect of supplementation on red cell vitamin E or plasma 
carotenoid concentrations could not be examined. 
Also it remains to be determined, in patients with critical illness, whether red or white cell 
concentrations of B2, B6, C and E reflect those in other tissues before a definitive statement 
can be made as to their value in measuring whole body status.  However, given the clinical 
and ethical problems of removing tissue samples from the critically-ill this issue may remain 
unresolved for some time.  
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10.5 Future studies 
Future research is required both to confirm these results and also to further investigate the 
clinical value of the intracellular blood vitamin measurements in patient management.   
10.5.1 Studies to confirm the usefulness of intracellular vitamin measurements 
The relationship between intracellular vitamin status and tissue stores could be investigated by 
analysing tissue (liver and muscle being the major stores) obtained from these patients. 
Removing tissue from critically ill patients has major ethical implications.  One way this could 
be achieved without compromising the health of the patient and without further invasive 
procedures would be to collect liver biopsy specimens at the time of laparotomy for intra-
abdominal sepsis.   
Establishing reference intervals for vitamins B2 and B6 in white cells would be required in 
order to examine whether white cell vitamin concentrations are more reliable than red cell 
vitamin concentrations. 
10.5.2 Intervention studies 
Further examination of the effect of supplementation on white cell vitamin C concentrations in 
patients with critical illness is required with a bigger number of longitudinal samples.  Such a 
task would require longer term patient recruitment, sample collection and white cell extraction 
than the duration of this study. 
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10.5.3 Studies that examine the effect of vitamin supplementation on mortality 
Studies examining the importance of normal intracellular vitamin concentrations, in terms of 
outcome for the critically ill patient, could further examine the differences in outcome between 
patients who receive supplementation and those that they do not.  For example, a subgroup of 
patient samples from the Accident and Emergency Unit could be identified at the 
Haematology Department immediately after the patients are admitted and consented in the 
ICU and analysed for vitamin concentrations.  It is expected that these samples would be free 
of IV or oral hospital supplementation treatments.  Also, future studies could include results 
from different centres where vitamin supplementation protocols differ. 
More specifically, future studies could examine the effect of vitamin E and carotenoid 
supplementation on red cell vitamin E and plasma carotenoids in patients with critical illness.  
Interestingly, in the present study, plasma lycopene was independently associated with 
hospital mortality when albumin was removed from the multivariate analysis model.  Taking 
into consideration, the established role of poor antioxidant status and adverse outcome in 
patients with critical illness (Borrelli et al. 1996; Tsai et al. 2000; Alonso de Vega et al. 2002; 
Nathens et al. 2002; Crimi et al. 2004), a study examining the role of carotenoid 
supplementation in improving hospital mortality in patients with critical illness would be of 
substantial interest. 
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10.6 Final comments 
This work, to my knowledge, is the most detailed systematic examination of how best to 
assess vitamin status and its role in outcome in large cohort of patients with critical illness.  
These results have led to changes in the methodology and practice of vitamin analysis in the 
Scottish Trace Elements and Micronutrients Reference Laboratory, Glasgow Royal Infirmary.  
In particular, analysis of vitamins B2 and B6 for assessing their status is now carried out in red 
cells rather than plasma in the acutely ill patient in Glasgow Royal Infirmary.  In these patients 
such measurements may be more informative and clinically relevant.  Furthermore, such 
measurements may be more reliable in guiding supplementation in patients with systemic 
inflammatory response.  Assessment of vitamin status by measuring plasma concentrations is 
discouraged in patients with evidence of systemic inflammatory response syndrome. 
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12.1 Appendix 1 Data collection proforma 
Intensive Care Proforma 
 
 Admission (1) (2) (3) Discharge 
Dates - Time 
 
    
Tube coding for 
routine     
Tube coding 
 
    
APACHE II 
 
    
Predicted mortality 
(%)     
MOF 
(systems)     
E/P Nutrition 
(sort/rate) 
 
    
Vitamin supplements 
 
    
Oral anticoagulants 
(warfarin/enoxaparin)     
Weight (kg)  Height (m)  
Smoker (yes/no)  Cigar/day  
Alcohol intake/Drugs  
Diagnosis for ICU 
admission 
 
 
Did the patient die? 
(Y/N) Date  
Pabrinex or oral B 
vitamin 
supplementation 
(Number/timing) 
Prior to 
admission (1) 
Prior to sample (2) Prior to sample (3) 
CRP 
 
    
Albumin 
 
    
WBC 
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12.2 Appendix 2 Consent form for participation in the study 
Patient Identification Number for this study: 
19th June 2006 
CONSENT FORM 
 
The relationship between the systemic inflammatory response, micronutrient status and 
outcome in patients with critical illness 
(Version 2A) 
Name of Researcher: Dr John Kinsella 
 
I confirm that I have read and understand the information sheet dated 5th June 2006 (version 
2A) for the above study and have had the opportunity to ask questions. 
 
I understand that my participation is voluntary and that I am free to withdraw at any time, 
without giving a reason, without my medical care or legal rights being affected. 
 
I give my permission for my GP to be informed about my participation in the above study. 
 
I understand that the blood samples taken from me for routine purposes will be kept and 
analysed for research purposes which include vitamin and trace element concentrations in 
different blood compartments. I understand that these samples will not be returned to me.  
 
 I understand that the sections of any of my medical notes may be looked at by responsible 
individuals from the research team where it is relevant to my taking part in research. I give 
permission for these individuals to have access to my records. 
 
I agree to take part in the above study. 
 
_____________________          ________________        ________________________ 
Name of patient                          Date                                 Signature 
 
-----------------------------------          --------------------------        ------------------------------ 
Name of welfare guardian or        Date                                Signature 
Next of kin 
 
Nearest relative:  Yes /  No           If yes, relationship to patient:__________________ 
 
Welfare guardian: Yes  /  No 
 
_____________________           ________________       _________________________ 
Name of person taking consent    Date                               Signature     
(if different from researcher) 
__________________            _____________       _______________________ 
Researcher                             Date                            Signature 
 
1 for patient, 1 for researcher, 1 to be kept with hospital notes 
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12.3 Appendix 3 Information leaflet for patients and relatives 
19th June 2006 
 
PATIENT INFORMATION SHEET 
 
The relationship between the systemic inflammatory response, micronutrient status and 
outcome inpatients with critical illness 
(Version 2A) 
 
You are being invited to take part in a research study. Before you decide it is important for 
you to understand why the research is being done and what it will involve. Please take time to 
read the following information carefully and discuss it with friends, relatives and your GP if 
you wish. Ask us if there is anything that is not clear or if you would like more information. 
Take time to decide whether or not you wish to take part. 
 
Consumers for Ethics in Research (CERES) publish a leaflet entitled ‘Medical Research and 
You.’ This leaflet gives more information about medical research and looks at some questions 
you may want to ask. If you would like to have a copy we will provide one. 
 
Thank you for reading this. 
 
What is the Purpose of the Study? 
We wish to investigate the changes that occur in the concentrations of vitamins and other 
micronutrients in the blood during and after critical illness. This will require the further 
analysis of some of the blood samples that were routinely taken during your illness and a 
further blood sample after you have left intensive care.  
We will also ask you some questions about your state of health and your diet. From this 
information we intend to establish the best method of assessing the vitamin and trace element 
nutritional status in critically ill patients.  
 
Why have I been chosen?  
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All patients admitted to Glasgow Royal Infirmary ICU are being considered for admission into 
this study. 
 
Do I have to take part?  
It is up to you to decide whether or not to take part. If you decide to take part you will be 
given this information sheet to keep and be asked to sign a consent form. If you decide to take 
part you are still free to withdraw at any time and without giving a reason. This will not affect 
the standard of care you receive. 
 
What will happen to me if I take part?  
Your treatment will not be altered by taking part to the study.  
Phase 1 - When in the intensive care unit we would like to run some extra tests on your blood 
samples that have already been taken from you as part of routine. We will not ask you for 
anything else other than your consent to measure the vitamin and trace element concentrations 
in different compartments of your blood. This assessment is not done routinely and it will help 
us better assess the health of other patients admitted in the intensive care unit. 
Phase 2 - If you agree to that we will also ask you to give us one more blood sample at clinic, 
and an interview about your health 3 – 6 months after your discharge from the intensive care 
unit. At this time we would also like you to provide us with a 7 day food diary that you will 
complete before coming to see us.   
 
What do I have to do?  
You don’t have to do anything while in hospital (phase 1).  If you agree to take part in phase 2 
(at clinic) you only have to complete a 7 day food diary before visiting the surgical clinic. 
Please try not to change your usual eating habits when completing the diary. You should also 
follow your doctor’s instructions and take your medication as prescribed.  
 
Will any of my travel expenses be covered?  
Travel expenses for routine hospital visits will not be covered. However, if you have to come 
to the hospital just for the purposes of the study your travel expenses will be covered in full. 
 
What are the side effects of taking part?  
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There are no side effects of taking part in this study. It is purely an observational study does 
not include drug or nutritional intervention. In addition, if at any point you become concerned 
in any way please contact Dr John Kinsella, Consultant in Critical Care, tel. 0141 211 4625.  
 
What are the possible disadvantages and risks of taking part?  
There are no disadvantages or risks of taking part to this study.  
 
What are the possible benefits of taking part?  
As your treatment will be unchanged, there is no intended clinical benefit from taking part in 
the study. However, the information that we collect may help us to improve the treatment of 
future patients admitted to the intensive care unit. 
 
What happens when the study stops? 
Your treatment and follow up will continue as normal. 
 
What if something goes wrong?  
We have seen that the study will be absolutely safe for the patient as being observational in 
nature. If you are harmed by taking part in this study, there are no special compensation 
arrangements. Standard NHS indemnity does, however, apply in any case of adverse event. If 
you are harmed due to someone’s negligence, then you may have grounds for legal action but 
you may have to pay for it. Regardless of this, if you wish to complain, or have any concerns 
about any aspect of the way you have been approached or treated during the course of this 
study, the normal National Health Service complaints mechanisms should be available to you. 
 
Will my taking part in this study be kept confidential?  
Yes. All information, which is collected about you during the course of research, will be kept 
strictly confidential. All the information required for the study will be kept strictly within the 
hospital departments. We have also set up a coding system so that your name will be replaced 
by a unique number and all of your information and results will be matched to this unique 
number and not your name.  
If you agree, we will write to your GP and inform them of your participation in the study.  
 
What will happen to the results of the research study?  
  
249
The results of the study will be in large part to PhD thesis studies and may be published in 
scientific journals. Moreover, some of the results may also be presented in scientific meetings, 
e.g. conferences. We expect to publish our first results in 2007.  If you wish you can obtain a 
copy of the published material from the University Department of Anaesthesia.  
It is important to understand that at no publication or presentation of the results your name 
and/or personal details about your health will be identified. 
 
Who is organizing and funding the research?  
The funding of this research is from collaborative group of clinicians and scientists in the 
Glasgow Royal Infirmary. 
 
Who has reviewed the study?  
The study has been reviewed and approved by the Local Research Ethics Committee of the 
Royal Infirmary of Glasgow and the MREC for Scotland, Committee A. 
 
Contact for Further Information  
If you have any further questions or wish to obtain more information, please do not hesitate to 
contact the chief investigator – 
Dr John Kinsella 
Consultant 
University Department of Anaesthesia 
Royal Infirmary 
Tel - 0141 211 4625 
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12.4 Appendix 4 Information leaflet for General Practitioner 
Patient Name: ………………………………… 
19th June 2006 
GENERAL PRACTIONER INFORMATION SHEET 
The relationship between the systemic inflammatory response, micronutrient status and 
outcome inpatients with critical illness 
(Version 2) 
We would like to inform you that your patient has consented to take part to the study 
mentioned above while in Intensive Care Unit in Glasgow Royal Infirmary.  
This is an observational study that aims to investigate the changes in micronutrient status that 
occur during and after critical illness. This will require the further analysis of some of the 
samples that were routinely taken during your patient’s illness and a further blood sample after 
the patient has left intensive care.  
There are no side effects or benefits of taking part in this study. It is purely an observational 
study does not include drug or nutritional intervention.  
The study has been reviewed and approved by the Local Research Ethics Committee of the 
Royal Infirmary of Glasgow and the MREC for Scotland, Committee A. 
Contact for Further Information  
If you have any further questions or wish to obtain more information, please do not hesitate to 
contact Dr John Kinsella, tel. 0141 211 4625. 
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12.5 Appendix 5 Development of a white cell extraction method 
First of all I had to stabilize the technique of separating a good proportion (> 40%) of white 
cells from small quantities (2 mL) of fresh whole blood. To do that I used anonymous blood 
samples from haematology. I started with the technique that T.P. Chang had developed for his 
summer projected but found that severe clotting, and platelets and haemoglobin concentrations 
were in my final preparations. Reading papers that described white cell separation, I found out 
that using the water bath at 37oC and centrifuging my tubes at room temperature were creating 
these clots (Hinks, Colmsee & Delves 1982). Instead, I used cold temperatures to avoid 
clotting. Together with Dr Dinesh Talwar, we established a method of bringing our blood to 
the right temperature (2-3oC) without freezing it and we show that this solved the problem of 
clotting and removed all the haemoglobin that was contaminating our white cells. Moreover, I 
centrifuge the tubes at 4-5oC. Instead of using NH4Cl, as described in the previous method, I 
read that there would be less clumping and better separation of mononuclear cells from 
platelets if our lysing solution contained EDTA, as EDTA prevents platelet binding to 
leukocytes (Milne, Ralston & Wallwork 1985). Ammonium chloride has the disadvantage that 
associated changes in pH can damage and destroy the white cells, thus producing low yields of 
a final leucocyte preparation that may not be representative tissue (Hinks, Colmsee & Delves 
1982). Our red blood cells’ lysing solution (described in the methods in the following pages) 
has a pH of 7.4 so white cell losses have been minimized. The last problem was how to 
remove the platelets. The method of T.P. Chang was describing three centrifugations of the 
tubes at 1000 rpm. Centrifugation of the samples for the third time at 500 rpm rather than 1000 
rmp was able to remove all platelets as they are lighter and remain in the supernatant so they 
are removed easily. The method provided a white cell extraction yield of 63% (n=76, 50-93%) 
containing mainly neutrophils (>90%). 
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Because of the clumping problems I performed protein determination of my white cell 
samples together with a white cell count, using the Bradford reagent and measuring 
absorbance after 15 minutes incubation at 595 nm (method described in the following pages). 
The rational behind this is that the machine that does the cell count can only measure intact 
cells. So cells that might have burst will not be detected. However, a protein determination 
would give us more robust results as it is not affected by cell integrity. Our cell counts 
correlated extremely well with the protein determination results (see figure 8-1). 
White cell extraction method description 
For the white cell extraction conical plastic tubes (15 ml) were used. All reagents and 
centrifugation were kept at a temperature of approximately 4oC.  This temperature prevented 
the white cells from forming clots and aided in the removal of haemoglobin.  Two hundred µL 
of whole blood were transferred into Eppendorff tubes (1.9 mL) to be used for comparison of 
white cells in the count machine.  Two mL of whole blood were put in a conical plastic tube 
and 9 mL of diluted sterile red blood cell lysing solution was added.  The tubes were then 
gently mixed by a roller for 2 minutes and stored in the freezer for five minutes.  Mixing by 
the roller and freezing for the same timings was repeated for once more, then the tubes were 
mixed again for 2 minutes and kept in the fridge for 15 minutes.  The tubes were centrifuged 
at 1,000 rpm for 10 minutes at 4-5oC.  The supernatant was carefully removed so as not to 
disturb the white cell pellet.  Ten mL of cold PBS solution (Invitrogen, Paisley, UK) were 
added to the pellet of each tube and the latter was resuspended by mixing.  The tubes were 
again centrifuged, supernatant was removed and the pellet was resuspended for once more as 
described above.  The tubes were finally centrifuged at 500 rpm for 10 minutes at 4-5oC, the 
supernatant was removed and 1 mL of PBS solution was added to the final pellet.  The pellet 
was well resuspended in the solution and the final mixture was transferred to Eppendorff tubes 
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(1.9 mL).  The samples were taken to the blood count machine (KX – 21N, Sysmex, UK Ltd) 
and both the whole blood samples and white cell samples were assessed.  The white cell 
samples were then centrifuged at 10,000 rpm for 3 minutes, the supernatant was removed and 
the pellet was resuspended by adding 500 µL of cold water. 
Protein Determination 
Standard 3.1 mL Assay Protocol 
Dilute 100 mg BSA to 10 mL of H2O (10 mg/mL) – stock solution. 
Take 1 mL of stock solution to 9 mL of H2O (1 mg/mL) – tube A. 
Take 1 mL of tube A to fresh tube and add 1 mL of H2O (0.5 mg/mL) – tube B. 
Take 1 mL of tube B to fresh tube and add 1 mL of H2O (0.25 mg/mL) – tube C. 
Take 1 mL of tube C to fresh tube and add 1 mL of H2O (0.125 mg/mL) – tube D. 
Take 100 µL of each tube to new tubes and add 3 mL Bradford Reagent. 
To make blank tube: take 100 µL of H2O and add 3 mL Bradford Reagent – tube E. 
Vortex gently but thoroughly all tubes and let them incubate at room temperature for 20 
minutes. 
Transfer the samples into cuvets and measure the absorbance at 595 nm. 
 
Micro 2 mL Assay Protocol 
Dilute 100 mg BSA to 10 mL of H2O (10 mg/mL) – stock solution. 
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Take 1 mL of stock solution to 9 mL of H2O (1 mg/mL) – tube O. 
Take 100 µL of tube O to 9.9 mL of H2O (10 µg/mL) – tube A. 
Take 2 mL of tube A to fresh tube and add 2 mL of H2O (5 µg/mL) – tube B. 
Take 2 mL of tube B to fresh tube and add 2 mL of H2O (2.5 µg/mL) – tube C. 
Take 2 mL of tube C to fresh tube and add 2 mL of H2O (1.25 µg/mL) – tube D. 
Take 1 mL of each tube to new tubes and add 1 mL Bradford Reagent. 
To make blank tube: take 1 mL of H2O and add 1 mL Bradford Reagent – tube E. 
Vortex gently but thoroughly all tubes and let them incubate at room temperature for 20 
minutes. 
Transfer the samples into cuvets and measure the absorbance at 595 nm. 
 
Unknown sample protein determination 
To the frozen samples add 275 µL of H2O and mix well to redistribute the pallet.  
Put in the freezer to –50oC for 15 minutes. 
Thaw the samples and mix them well. 
Sonicate them for 20 minutes. 
Mix them well with the vortex mixer. 
Take 25 µL into fresh glass tube and add 75 µL of H2O. Add 3 mL of Bradford Reagent. 
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Take 25 µL into fresh glass tube and add 975 µL of H2O. Add 1 mL of Bradford Reagent. 
 
Reagents 
1. Bradford solution 
2. Sterile Red Blood Cell Lysing Solution 
Sterile RBC Lysing Solution has a reagent formula = 155 mM NH4Cl, 10 mM NaHCO3, 0.1 
mM EDTA; pH = 7.4.  The solution is used cold at 2-8 C and has a shelf life of six months 
when made and kept sterile.  For the white cell extraction a dilution with water 1:10 was 
prepared and used. 
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Linear Regression
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WC = 0.04 + 9.75 * PRWC
R-Square = 0.91
 
Figure 12-1 The relationship between white cell counts (WC) and white cell protein (PR 
WC) in anonymous hospital samples (n=76) 
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12.6 Appendix 6 Data coding 
Pre-ICU Pabrinex doses: Doses of recorded vitamin B and C supplementation each patient 
received prior to their admission to the intensive care unit. The number 1000 is a code and 
refers to B vitamin supplementation prescribed to the patient on a regular basis in the 
community. 
Pre + ICU Pabrinex doses: The total recorded vitamin B and C supplementation doses the 
patient received by the time the follow-up sample was taken. 
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12.7 Appendix 7 Chapter 3 data 
Appendix 7. Characteristics and biochemical measurements of controls (Chapter 3) 
Control 
No. 
Age Male/ 
Female 
(0/1) 
C-reactive 
protein 
(mg/l) 
Plasma 
FAD 
(nmol/l) 
Plasma 
FMN 
(nmol/l) 
Plasma 
riboflavin 
(nmol/l) 
Plasma 
FAD/ 
Riboflavi
n 
Red cell 
FAD 
(pmol/g Hb) 
Red cell 
FMN 
(pmol/g Hb) 
Red cell 
riboflavin 
(pmol/g 
Hb) 
Red cell 
FAD/ 
Riboflavin 
1.00 45.00 0.00 6.00 82.00 6.60 9.00 9.11 0.70 -- 0.03 24.14 
2.00 47.00 1.00 6.00 117.00 7.20 8.00 14.63 0.90 0.05 0.02 50.00 
3.00 51.00 1.00 6.00 92.00 4.40 12.00 7.67 1.00 0.11 0.02 45.45 
4.00 39.00 0.00 6.00 67.00 3.90 4.00 16.75 1.10 0.13 0.08 13.58 
5.00 53.00 1.00 6.00 88.00 4.90 7.00 12.57 1.10 0.15 0.03 37.93 
6.00 47.00 1.00 6.00 68.00 5.70 7.00 9.71 1.20 0.13 0.02 54.55 
7.00 54.00 1.00 6.00 145.00 7.20 10.00 14.50 1.20 0.05 -- -- 
8.00 50.00 1.00 6.00 150.00 8.40 34.00 4.41 1.20 0.05 -- -- 
9.00 71.00 0.00 6.00 63.00 -- 5.00 12.60 1.30 0.07 0.01 108.33 
10.00 58.00 1.00 6.00 89.00 5.10 4.00 22.25 1.30 0.05 0.01 92.86 
11.00 48.00 0.00 6.00 94.00 7.20 17.00 5.53 1.30 0.04 -- -- 
12.00 68.00 1.00 6.00 124.00 9.30 23.00 5.39 1.30 0.07 -- -- 
13.00 73.00 1.00 6.00 130.00 6.00 20.00 6.50 1.30 0.04 0.02 76.47 
14.00 61.00 1.00 6.00 69.00 8.30 5.00 13.80 1.40 0.15 0.03 42.42 
15.00 45.00 0.00 6.00 102.00 4.80 15.00 6.80 1.40 0.07 0.01 100.00 
16.00 44.00 0.00 6.00 107.00 7.50 10.00 10.70 1.40 0.08 0.02 77.78 
17.00 73.00 1.00 6.00 126.00 10.00 28.00 4.50 1.40 0.07 -- -- 
18.00 60.00 1.00 6.00 127.00 5.40 12.00 10.58 1.40 0.07 0.11 13.21 
19.00 68.00 0.00 6.00 60.00 13.80 5.00 12.00 1.50 -- 0.03 44.12 
20.00 58.00 0.00 6.00 69.00 -- 7.00 9.86 1.50 0.09 -- -- 
21.00 42.00 0.00 6.00 75.00 -- 12.00 6.25 1.50 0.12 0.02 78.95 
22.00 60.00 0.00 6.00 88.00 5.40 8.00 11.00 1.50 0.06 -- -- 
23.00 65.00 1.00 6.00 100.00 6.60 21.00 4.76 1.50 0.06 -- -- 
24.00 48.00 0.00 6.00 103.00 -- 11.00 9.36 1.50 0.12 0.05 30.61 
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Control 
No. 
Age Male/ 
Female 
(0/1) 
C-reactive 
protein 
(mg/l) 
Plasma 
FAD 
(nmol/l) 
Plasma 
FMN 
(nmol/l) 
Plasma 
riboflavin 
(nmol/l) 
Plasma 
FAD/ 
Riboflavi
n 
Red cell 
FAD 
(pmol/g Hb) 
Red cell 
FMN 
(pmol/g Hb) 
Red cell 
riboflavin 
(pmol/g 
Hb) 
Red cell 
FAD/ 
Riboflavin 
25.00 41.00 0.00 6.00 73.00 3.90 4.00 18.25 1.60 0.17 0.03 51.61 
26.00 53.00 1.00 6.00 87.00 4.00 7.00 12.43 1.60 -- 0.02 106.67 
27.00 66.00 1.00 6.00 87.00 -- 10.00 8.70 1.60 0.13 0.03 64.00 
28.00 42.00 0.00 6.00 94.00 10.50 15.00 6.27 1.60 0.09 0.05 32.65 
29.00 42.00 0.00 6.00 96.00 4.50 7.00 13.71 1.60 0.08 0.01 123.08 
30.00 56.00 0.00 6.00 101.00 6.90 9.00 11.22 1.60 0.06 0.01 123.08 
31.00 55.00 0.00 6.00 107.00 -- 14.00 7.64 1.60 0.07 -- -- 
32.00 61.00 0.00 6.00 109.00 3.90 7.00 15.57 1.60 0.05 -- -- 
33.00 41.00 1.00 6.00 122.00 8.40 7.00 17.43 1.60 0.13 0.09 17.58 
34.00 38.00 0.00 6.00 148.00 9.90 23.00 6.43 1.60 0.12 0.03 59.26 
35.00 70.00 0.00 6.00 57.00 6.00 8.00 7.13 1.70 0.05 0.02 100.00 
36.00 64.00 1.00 6.00 69.00 6.30 13.00 5.31 1.70 0.09 0.02 89.47 
37.00 64.00 0.00 6.00 92.00 4.40 7.00 13.14 1.70 0.16 0.02 100.00 
38.00 47.00 1.00 6.00 94.00 5.00 11.00 8.55 1.70 0.07 -- -- 
39.00 59.00 1.00 6.00 98.00 5.40 16.00 6.13 1.70 0.21 0.03 68.00 
40.00 40.00 0.00 6.00 117.00 7.50 23.00 5.09 1.70 0.08 0.01 121.43 
41.00 61.00 1.00 6.00 138.00 5.40 6.00 23.00 1.70 0.05 -- -- 
42.00 72.00 1.00 6.00 170.00 12.60 27.00 6.30 1.70 0.09 0.01 130.77 
43.00 62.00 0.00 6.00 73.00 5.70 13.00 5.62 1.80 0.11 0.01 180.00 
44.00 39.00 0.00 6.00 77.00 5.70 5.00 15.40 1.80 0.09 0.02 78.26 
45.00 43.00 1.00 6.00 77.00 3.30 5.00 15.40 1.80 0.11 -- -- 
46.00 72.00 1.00 6.00 81.00 4.20 7.00 11.57 1.80 0.12 0.01 150.00 
47.00 71.00 1.00 6.00 87.00 5.10 9.00 9.67 1.80 0.15 0.02 100.00 
48.00 45.00 0.00 6.00 92.00 3.80 8.00 11.50 1.80 0.06 0.06 28.13 
49.00 49.00 1.00 6.00 93.00 7.20 13.00 7.15 1.80 0.08 -- -- 
50.00 48.00 1.00 6.00 100.00 5.90 13.00 7.69 1.80 0.05 0.01 180.00 
51.00 48.00 0.00 6.00 100.00 6.30 19.00 5.26 1.80 0.12 0.04 45.00 
52.00 46.00 1.00 6.00 102.00 4.80 4.00 25.50 1.80 0.14 0.02 105.88 
53.00 39.00 0.00 6.00 103.00 3.60 10.00 10.30 1.80 0.07 0.02 100.00 
54.00 70.00 0.00 6.00 116.00 6.60 6.00 19.33 1.80 0.15 0.06 32.73 
55.00 39.00 0.00 6.00 118.00 5.40 4.00 29.50 1.80 -- 0.01 150.00 
56.00 47.00 1.00 6.00 120.00 8.40 19.00 6.32 1.80 0.09 -- -- 
57.00 51.00 0.00 6.00 121.00 6.30 10.00 12.10 1.80 0.13 0.02 105.88 
58.00 41.00 1.00 6.00 140.00 6.90 23.00 6.09 1.80 0.08 0.02 81.82 
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Control 
No. 
Age Male/ 
Female 
(0/1) 
C-reactive 
protein 
(mg/l) 
Plasma 
FAD 
(nmol/l) 
Plasma 
FMN 
(nmol/l) 
Plasma 
riboflavin 
(nmol/l) 
Plasma 
FAD/ 
Riboflavi
n 
Red cell 
FAD 
(pmol/g Hb) 
Red cell 
FMN 
(pmol/g Hb) 
Red cell 
riboflavin 
(pmol/g 
Hb) 
Red cell 
FAD/ 
Riboflavin 
59.00 38.00 0.00 6.00 71.00 6.60 19.00 3.74 1.90 -- 0.01 158.33 
60.00 57.00 0.00 6.00 77.00 5.70 9.00 8.56 1.90 0.05 0.01 135.71 
61.00 35.00 0.00 6.00 83.00 5.10 8.00 10.38 1.90 0.05 0.02 126.67 
62.00 67.00 1.00 6.00 93.00 5.10 10.00 9.30 1.90 0.20 0.06 29.69 
63.00 72.00 1.00 6.00 95.00 5.90 11.00 8.64 1.90 0.27 0.08 23.46 
64.00 45.00 1.00 6.00 140.00 7.50 8.00 17.50 1.90 0.09 -- -- 
65.00 54.00 1.00 6.00 77.00 6.00 7.00 11.00 2.00 0.11 -- -- 
66.00 58.00 1.00 6.00 77.00 4.80 6.00 12.83 2.00 0.15 0.03 64.52 
67.00 58.00 0.00 6.00 85.00 6.90 9.00 9.44 2.00 0.14 -- -- 
68.00 57.00 0.00 6.00 115.00 7.20 8.00 14.38 2.00 0.07 0.03 60.61 
69.00 38.00 0.00 6.00 116.00 5.40 9.00 12.89 2.00 0.06 0.02 125.00 
70.00 47.00 1.00 6.00 117.00 7.20 10.00 11.70 2.00 0.08 0.02 133.33 
71.00 53.00 0.00 6.00 143.00 5.40 8.00 17.88 2.00 0.08 0.04 51.28 
72.00 47.00 0.00 6.00 94.00 7.80 9.00 10.44 2.10 0.13 0.03 67.74 
73.00 51.00 1.00 6.00 106.00 6.70 19.00 5.58 2.10 0.12 0.02 116.67 
74.00 63.00 1.00 6.00 112.00 6.00 19.00 5.89 2.10 0.22 0.02 105.00 
75.00 51.00 0.00 6.00 71.00 3.30 4.00 17.75 2.20 0.17 0.04 57.89 
76.00 63.00 1.00 6.00 77.00 9.60 20.00 3.85 2.20 0.10 0.02 146.67 
77.00 52.00 0.00 6.00 88.00 -- 13.00 6.77 2.20 0.16 0.10 21.57 
78.00 69.00 0.00 6.00 89.00 4.80 8.00 11.13 2.20 0.11 0.02 146.67 
79.00 49.00 0.00 6.00 98.00 -- 15.00 6.53 2.20 0.11 0.02 100.00 
80.00 57.00 0.00 6.00 101.00 6.70 12.00 8.42 2.20 0.14 0.02 91.67 
81.00 53.00 0.00 6.00 118.00 7.00 10.00 11.80 2.20 0.09 0.03 75.86 
82.00 67.00 1.00 6.00 119.00 7.40 12.00 9.92 2.20 0.09 0.02 91.67 
83.00 53.00 1.00 6.00 132.00 11.10 22.00 6.00 2.20 0.14 0.03 70.97 
84.00 57.00 0.00 6.00 137.00 14.10 28.00 4.89 2.20 0.31 0.04 61.11 
85.00 57.00 0.00 6.00 108.00 6.00 28.00 3.86 2.30 0.44 0.13 17.42 
86.00 48.00 0.00 6.00 122.00 7.80 15.00 8.13 2.30 0.06 0.03 67.65 
87.00 59.00 0.00 6.00 78.00 4.80 12.00 6.50 2.40 0.23 0.03 72.73 
88.00 66.00 0.00 6.00 79.00 3.90 4.00 19.75 2.40 0.06 -- -- 
89.00 43.00 0.00 6.00 80.00 8.10 25.00 3.20 2.40 0.11 0.01 171.43 
90.00 60.00 0.00 6.00 105.00 5.70 18.00 5.83 2.40 0.25 0.05 50.00 
91.00 70.00 0.00 6.00 137.00 10.80 31.00 4.42 2.40 0.30 0.07 32.43 
92.00 62.00 0.00 6.00 70.00 3.70 8.00 8.75 2.60 0.10 0.02 136.84 
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Control 
No. 
Age Male/ 
Female 
(0/1) 
C-reactive 
protein 
(mg/l) 
Plasma 
FAD 
(nmol/l) 
Plasma 
FMN 
(nmol/l) 
Plasma 
riboflavin 
(nmol/l) 
Plasma 
FAD/ 
Riboflavi
n 
Red cell 
FAD 
(pmol/g Hb) 
Red cell 
FMN 
(pmol/g Hb) 
Red cell 
riboflavin 
(pmol/g 
Hb) 
Red cell 
FAD/ 
Riboflavin 
93.00 37.00 0.00 6.00 110.00 6.10 19.00 5.79 2.60 0.08 0.02 108.33 
94.00 45.00 0.00 6.00 115.00 4.80 5.00 23.00 2.60 0.19 0.03 100.00 
95.00 50.00 0.00 6.00 100.00 6.60 8.00 12.50 2.70 0.07 0.01 225.00 
96.00 62.00 1.00 6.00 116.00 7.70 19.00 6.11 2.70 0.14 0.03 79.41 
97.00 58.00 1.00 6.00 140.00 5.00 19.00 7.37 2.70 0.05 0.01 225.00 
98.00 69.00 1.00 6.00 94.00 5.50 6.00 15.67 2.80 0.07 0.01 280.00 
99.00 51.00 0.00 6.00 96.00 6.00 25.00 3.84 2.80 0.22 0.03 100.00 
100.00 49.00 1.00 6.00 119.00 -- 19.00 6.26 2.80 0.18 0.03 96.55 
101.00 55.00 1.00 6.00 123.00 8.10 14.00 8.79 2.80 0.13 0.02 147.37 
102.00 66.00 1.00 6.00 95.00 5.90 9.00 10.56 2.90 0.10 0.01 241.67 
103.00 57.00 0.00 6.00 139.00 -- 17.00 8.18 2.90 0.11 0.03 93.55 
104.00 53.00 0.00 6.00 86.00 4.80 13.00 6.62 3.00 0.20 0.03 111.11 
105.00 70.00 0.00 6.00 96.00 7.20 8.00 12.00 3.00 0.21 0.03 88.24 
106.00 55.00 0.00 6.00 102.00 5.70 19.00 5.37 3.00 0.24 0.03 111.11 
107.00 44.00 1.00 6.00 108.00 6.70 4.00 27.00 3.00 0.10 0.03 111.11 
108.00 44.00 0.00 6.00 120.00 6.90 14.00 8.57 3.00 0.21 0.04 81.08 
109.00 54.00 0.00 6.00 87.00 3.60 4.00 21.75 3.10 0.26 0.02 182.35 
110.00 47.00 0.00 6.00 106.00 6.90 12.00 8.83 3.10 0.24 0.02 129.17 
111.00 45.00 1.00 6.00 116.00 7.50 16.00 7.25 3.10 0.08 -- -- 
112.00 66.00 0.00 6.00 121.00 9.90 12.00 10.08 3.10 0.20 0.04 81.58 
113.00 63.00 0.00 6.00 82.00 4.20 10.00 8.20 3.30 0.26 0.03 126.92 
114.00 71.00 0.00 6.00 105.00 11.80 14.00 7.50 3.30 0.08 0.02 220.00 
115.00 56.00 1.00 6.00 121.00 6.80 16.00 7.56 3.30 0.15 0.03 122.22 
116.00 48.00 1.00 6.00 124.00 7.10 13.00 9.54 3.30 0.11 0.01 275.00 
117.00 70.00 1.00 6.00 130.00 9.90 12.00 10.83 3.70 0.13 0.02 154.17 
118.00 38.00 0.00 6.00 159.00 9.30 21.00 7.57 3.70 0.15 0.01 264.29 
119.00 45.00 1.00 6.00 150.00 9.10 23.00 6.52 3.80 0.14 0.03 131.03 
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Appendix 7. Characteristics and biochemical measurements of patients (Chapter 3) 
Patient 
No. 
Age Male/ 
Female 
(0/1) 
APACHE 
II 
Predicted 
Mortality 
(%) 
Medical/ 
Surgical 
(0/1) 
Pro-ICU 
Pabrinex 
(doses) 
Pro + ICU 
Pabrinex 
doses 
ICU 
Death 
ICU stay 
(days) 
SOFA 
score 
admission 
SOFA 
score 
follow-up 
Follow-up 
sample 
(days) 
12.00 61.00 0.00 29.00 76.60 0.00 0.00 0.00 0.00 7.40 7.00 7.00 2.00 
13.00 43.00 1.00 12.00 11.70 1.00 0.00 2.00 0.00 48.10 5.00 9.00 3.00 
14.00 71.00 1.00 18.00 28.90 1.00 0.00 0.00 1.00 12.90 8.00 9.00 2.00 
15.00 53.00 1.00 19.00 32.20 0.00 0.00 1.00 0.00 4.80 8.00 2.00 5.00 
16.00 61.00 0.00 23.00 28.50 0.00 0.00 -- 0.00 1.00 6.00 -- -- 
17.00 18.00 0.00 12.00 20.20 0.00 0.00 3.00 1.00 6.20 2.00 0.00 4.00 
18.00 67.00 0.00 18.00 44.40 1.00 0.00 0.00 1.00 59.50 10.00 10.00 4.00 
19.00 50.00 0.00 21.00 38.90 0.00 0.00 3.00 1.00 46.30 10.00 9.00 4.00 
21.00 61.00 0.00 34.00 76.80 1.00 0.00 -- 0.00 2.00 8.00 -- -- 
22.00 52.00 0.00 13.00 9.90 0.00 95.00 101.00 0.00 3.70 2.00 3.00 4.00 
23.00 71.00 0.00 23.00 42.50 1.00 9.00 10.00 1.00 20.90 8.00 4.00 7.00 
24.00 77.00 1.00 21.00 35.00 0.00 0.00 -- 0.00 2.00 4.00 -- -- 
27.00 76.00 1.00 23.00 46.00 0.00 1.00 3.00 0.00 21.70 5.00 4.00 3.00 
29.00 70.00 0.00 16.00 20.20 1.00 4.00 10.00 0.00 5.10 4.00 4.00 4.00 
30.00 73.00 1.00 25.00 53.30 1.00 0.00 2.00 1.00 15.50 11.00 7.00 3.00 
31.00 62.00 0.00 19.00 27.10 1.00 0.00 -- 0.00 0.50 11.00 -- -- 
32.00 55.00 1.00 15.00 21.00 1.00 0.00 -- 0.00 2.20 6.00 -- -- 
33.00 80.00 1.00 31.00 84.20 1.00 0.00 0.00 1.00 12.00 7.00 8.00 5.00 
34.00 53.00 0.00 26.00 68.60 1.00 6.00 7.00 0.00 29.40 6.00 7.00 4.00 
35.00 20.00 0.00 18.00 39.70 1.00 0.00 1.00 1.00 44.00 10.00 7.00 3.00 
36.00 43.00 1.00 38.00 92.60 0.00 5.00 10.00 0.00 25.50 13.00 10.00 4.00 
37.00 60.00 0.00 27.00 63.10 0.00 0.00 0.00 0.00 21.80 10.00 9.00 4.00 
38.00 74.00 0.00 20.00 23.00 1.00 0.00 -- 0.00 1.00 4.00 -- -- 
40.00 47.00 0.00 22.00 28.50 1.00 0.00 2.00 0.00 1.90 9.00 4.00 3.00 
41.00 76.00 1.00 29.00 79.90 1.00 0.00 -- 0.00 1.40 8.00 -- -- 
42.00 79.00 0.00 21.00 30.90 1.00 0.00 3.00 0.00 3.20 4.00 6.00 4.00 
44.00 81.00 0.00 34.00 86.30 0.00 0.00 0.00 1.00 16.10 7.00 3.00 8.00 
45.00 74.00 0.00 33.00 75.20 0.00 0.00 0.00 1.00 16.00 11.00 5.00 5.00 
46.00 41.00 1.00 8.00 15.60 1.00 0.00 -- 0.00 0.80 1.00 -- -- 
47.00 76.00 0.00 29.00 77.20 1.00 0.00 0.00 1.00 34.60 7.00 7.00 2.00 
48.00 67.00 0.00 31.00 68.10 1.00 1,000.00 1,007.00 1.00 18.40 6.00 11.00 4.00 
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Patient 
No. 
Age Male/ 
Female 
(0/1) 
APACHE 
II 
Predicted 
Mortality 
(%) 
Medical/ 
Surgical 
(0/1) 
Pro-ICU 
Pabrinex 
(doses) 
Pro + ICU 
Pabrinex 
doses 
ICU 
Death 
ICU stay 
(days) 
SOFA 
score 
admission 
SOFA 
score 
follow-up 
Follow-up 
sample 
(days) 
50.00 60.00 0.00 19.00 48.00 1.00 0.00 0.00 0.00 6.20 7.00 4.00 6.00 
51.00 46.00 1.00 24.00 49.70 0.00 1,000.00 1,006.00 1.00 4.60 14.00 16.00 3.00 
52.00 61.00 0.00 33.00 78.60 0.00 7.00 10.00 1.00 7.70 11.00 11.00 3.00 
53.00 67.00 1.00 18.00 21.20 0.00 0.00 0.00 1.00 11.10 11.00 10.00 3.00 
55.00 80.00 1.00 31.00 73.30 0.00 0.00 3.00 1.00 8.20 8.00 8.00 4.00 
56.00 40.00 1.00 6.00 10.20 1.00 0.00 -- 0.00 0.40 6.00 -- -- 
57.00 60.00 0.00 27.00 60.20 1.00 0.00 -- 1.00 1.80 10.00 -- -- 
58.00 41.00 0.00 21.00 17.80 1.00 0.00 0.00 0.00 19.70 4.00 12.00 2.00 
59.00 68.00 0.00 20.00 32.30 0.00 0.00 -- 0.00 0.80 5.00 -- -- 
60.00 57.00 0.00 24.00 67.00 0.00 0.00 -- 0.00 6.50 3.00 -- -- 
61.00 76.00 1.00 18.00 14.40 0.00 0.00 -- 0.00 0.70 5.00 -- -- 
62.00 74.00 0.00 20.00 19.90 1.00 0.00 0.00 0.00 0.90 1.00 2.00 3.00 
63.00 62.00 0.00 18.00 44.40 1.00 1,000.00 -- 0.00 1.00 2.00 -- -- 
64.00 66.00 0.00 34.00 81.00 0.00 0.00 -- 0.00 22.40 13.00 -- -- 
65.00 38.00 1.00 17.00 26.20 0.00 0.00 -- 0.00 18.90 9.00 -- -- 
67.00 68.00 1.00 31.00 80.30 0.00 1,000.00 0.00 0.00 5.00 4.00 4.00 5.00 
68.00 74.00 0.00 24.00 49.70 0.00 0.00 7.00 0.00 10.70 14.00 12.00 5.00 
69.00 61.00 0.00 22.00 54.90 1.00 1,000.00 1,004.00 0.00 76.40 10.00 13.00 4.00 
71.00 25.00 0.00 17.00 1.20 0.00 0.00 -- 0.00 2.00 3.00 -- -- 
72.00 51.00 0.00 21.00 12.40 0.00 1.00 1.00 0.00 15.50 11.00 7.00 12.00 
73.00 69.00 0.00 12.00 20.20 0.00 0.00 -- 0.00 5.80 3.00 -- -- 
74.00 65.00 0.00 33.00 80.40 0.00 0.00 7.00 0.00 19.60 6.00 11.00 4.00 
75.00 28.00 1.00 14.00 18.50 1.00 0.00 -- 0.00 0.60 10.00 -- -- 
77.00 54.00 1.00 17.00 1.20 0.00 0.00 -- 0.00 0.80 7.00 -- -- 
78.00 45.00 0.00 12.00 5.50 1.00 0.00 -- 0.00 0.90 4.00 -- -- 
79.00 41.00 0.00 7.00 7.60 1.00 0.00 0.00 0.00 9.30 4.00 3.00 3.00 
80.00 38.00 0.00 16.00 23.30 1.00 1,000.00 -- 0.00 0.80 9.00 -- -- 
81.00 71.00 0.00 25.00 35.90 1.00 0.00 1.00 0.00 8.30 5.00 6.00 3.00 
82.00 80.00 1.00 17.00 12.70 0.00 0.00 1.00 0.00 10.30 1.00 1.00 2.00 
83.00 46.00 1.00 11.00 10.30 1.00 0.00 -- 0.00 2.90 4.00 -- -- 
84.00 56.00 0.00 28.00 63.90 0.00 1,000.00 1,006.00 0.00 15.40 13.00 10.00 3.00 
85.00 73.00 0.00 18.00 44.40 1.00 0.00 0.00 0.00 1.40 6.00 7.00 2.00 
87.00 34.00 1.00 12.00 12.40 1.00 0.00 -- 0.00 2.30 6.00 -- -- 
88.00 81.00 0.00 17.00 23.60 1.00 1,000.00 1,004.00 1.00 9.30 9.00 9.00 5.00 
  
264 
Patient 
No. 
Age Male/ 
Female 
(0/1) 
APACHE 
II 
Predicted 
Mortality 
(%) 
Medical/ 
Surgical 
(0/1) 
Pro-ICU 
Pabrinex 
(doses) 
Pro + ICU 
Pabrinex 
doses 
ICU 
Death 
ICU stay 
(days) 
SOFA 
score 
admission 
SOFA 
score 
follow-up 
Follow-up 
sample 
(days) 
89.00 22.00 1.00 10.00 9.50 1.00 0.00 -- 0.00 0.20 2.00 -- -- 
90.00 53.00 0.00 32.00 60.90 1.00 0.00 2.00 0.00 3.00 10.00 7.00 4.00 
91.00 62.00 0.00 22.00 58.90 1.00 0.00 -- 0.00 1.70 9.00 -- -- 
94.00 32.00 1.00 25.00 53.30 0.00 0.00 -- 0.00 17.30 18.00 -- -- 
96.00 63.00 1.00 18.00 4.80 0.00 0.00 0.00 0.00 1.90 3.00 2.00 3.00 
99.00 37.00 0.00 13.00 16.50 1.00 0.00 -- 0.00 2.10 5.00 -- -- 
100.00 50.00 1.00 26.00 38.20 0.00 0.00 12.00 0.00 2.60 4.00 4.00 3.00 
102.00 26.00 0.00 23.00 45.70 1.00 0.00 -- 0.00 2.30 4.00 2.00 2.00 
103.00 52.00 0.00 16.00 12.20 1.00 0.00 0.00 0.00 2.00 2.00 1.00 3.00 
104.00 38.00 0.00 3.00 2.70 0.00 0.00 -- 0.00 0.30 2.00 -- -- 
105.00 39.00 0.00 34.00 87.50 0.00 1,000.00 1,001.00 0.00 3.00 11.00 8.00 2.00 
107.00 45.00 1.00 12.00 6.60 1.00 0.00 -- 0.00 3.10 8.00 -- -- 
108.00 44.00 1.00 6.00 0.90 0.00 0.00 -- 0.00 0.80 3.00 -- -- 
110.00 48.00 1.00 26.00 35.20 0.00 0.00 8.00 1.00 4.90 7.00 12.00 5.00 
111.00 23.00 0.00 9.00 4.30 1.00 0.00 7.00 0.00 9.20 7.00 2.00 5.00 
112.00 45.00 1.00 24.00 22.40 1.00 0.00 0.00 1.00 10.70 1.00 10.00 4.00 
113.00 70.00 0.00 27.00 47.70 0.00 0.00 2.00 1.00 6.50 4.00 5.00 3.00 
114.00 65.00 1.00 24.00 65.70 1.00 0.00 3.00 0.00 32.80 9.00 8.00 4.00 
115.00 47.00 0.00 10.00 1.50 0.00 0.00 -- 0.00 0.60 2.00 -- -- 
116.00 61.00 0.00 13.00 10.60 0.00 0.00 -- 0.00 2.40 1.00 -- -- 
117.00 48.00 0.00 13.00 8.50 1.00 0.00 2.00 0.00 4.20 3.00 3.00 4.00 
118.00 59.00 0.00 23.00 39.90 1.00 0.00 1.00 0.00 12.10 9.00 12.00 2.00 
119.00 67.00 1.00 18.00 14.40 0.00 0.00 -- 0.00 1.30 2.00 -- -- 
121.00 86.00 0.00 22.00 42.20 1.00 0.00 3.00 0.00 6.60 7.00 4.00 5.00 
123.00 60.00 0.00 16.00 14.60 0.00 1,000.00 1,004.00 0.00 3.10 7.00 6.00 3.00 
124.00 33.00 0.00 14.00 27.40 1.00 1.00 4.00 0.00 4.70 7.00 6.00 2.00 
126.00 68.00 0.00 27.00 46.00 0.00 1,000.00 -- 0.00 1.60 5.00 -- -- 
127.00 100.00 0.00 25.00 64.60 1.00 0.00 -- 0.00 3.50 12.00 -- -- 
128.00 80.00 1.00 30.00 56.90 1.00 0.00 -- 0.00 2.90 7.00 -- -- 
129.00 31.00 0.00 19.00 44.00 0.00 0.00 -- 0.00 2.90 12.00 -- -- 
131.00 65.00 0.00 21.00 55.30 1.00 0.00 -- 0.00 6.70 8.00 -- -- 
133.00 35.00 0.00 14.00 7.20 1.00 0.00 -- 0.00 0.90 0.00 -- -- 
135.00 41.00 1.00 16.00 14.30 1.00 0.00 -- 0.00 0.60 2.00 -- -- 
137.00 69.00 1.00 19.00 32.00 1.00 0.00 -- 0.00 0.80 4.00 -- -- 
  
265 
Patient 
No. 
Age Male/ 
Female 
(0/1) 
APACHE 
II 
Predicted 
Mortality 
(%) 
Medical/ 
Surgical 
(0/1) 
Pro-ICU 
Pabrinex 
(doses) 
Pro + ICU 
Pabrinex 
doses 
ICU 
Death 
ICU stay 
(days) 
SOFA 
score 
admission 
SOFA 
score 
follow-up 
Follow-up 
sample 
(days) 
139.00 54.00 1.00 23.00 55.80 1.00 0.00 -- 0.00 2.60 8.00 -- -- 
140.00 74.00 0.00 21.00 41.60 1.00 0.00 -- 0.00 2.10 8.00 -- -- 
141.00 67.00 0.00 32.00 78.00 1.00 0.00 -- 0.00 19.60 10.00 2.00 11.00 
143.00 52.00 0.00 10.00 17.40 1.00 0.00 -- 1.00 9.80 2.00 -- -- 
146.00 38.00 0.00 18.00 24.20 1.00 6.00 21.00 0.00 10.30 6.00 5.00 6.00 
147.00 70.00 0.00 20.00 35.50 1.00 0.00 0.00 0.00 1.50 7.00 3.00 2.00 
148.00 71.00 0.00 25.00 53.30 0.00 0.00 -- 0.00 0.80 5.00 -- -- 
149.00 74.00 0.00 15.00 -- 1.00 0.00 -- 1.00 13.80 5.00 -- -- 
150.00 62.00 0.00 21.00 38.90 0.00 0.00 -- 0.00 35.20 11.00 -- -- 
151.00 36.00 0.00 8.00 8.60 1.00 -- -- 0.00 1.20 0.00 -- -- 
152.00 47.00 0.00 11.00 7.60 0.00 0.00 -- 0.00 2.00 3.00 -- -- 
153.00 77.00 1.00 27.00 46.00 0.00 -- -- 0.00 3.10 4.00 -- -- 
154.00 49.00 0.00 26.00 4.40 0.00 0.00 -- 0.00 0.90 4.00 -- -- 
155.00 43.00 0.00 25.00 3.80 0.00 0.00 -- 0.00 0.80 8.00 -- -- 
156.00 41.00 0.00 33.00 78.60 0.00 0.00 -- 1.00 1.80 12.00 -- -- 
157.00 61.00 0.00 31.00 81.40 1.00 0.00 -- 0.00 11.40 14.00 -- -- 
158.00 56.00 0.00 11.00 22.30 1.00 -- -- 0.00 9.00 3.00 -- -- 
159.00 60.00 1.00 19.00 11.30 1.00 0.00 -- 0.00 1.50 4.00 -- -- 
163.00 77.00 1.00 26.00 56.70 1.00 0.00 -- 0.00 1.40 10.00 -- -- 
164.00 62.00 1.00 14.00 9.70 0.00 0.00 -- 0.00 7.00 10.00 -- -- 
165.00 35.00 0.00 5.00 0.20 0.00 0.00 -- 0.00 1.00 1.00 -- -- 
166.00 63.00 0.00 13.00 13.40 1.00 0.00 -- 0.00 0.60 8.00 -- -- 
167.00 56.00 0.00 32.00 76.00 0.00 1.00 -- 0.00 2.10 8.00 -- -- 
168.00 52.00 1.00 26.00 56.90 0.00 3.00 -- 0.00 34.10 10.00 -- -- 
169.00 39.00 1.00 13.00 24.60 1.00 66.00 -- 0.00 24.60 14.00 -- -- 
171.00 67.00 0.00 27.00 60.50 0.00 0.00 -- 0.00 2.30 14.00 -- -- 
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Patient 
No. 
C-reactive 
protein 
admission 
(mg/l) 
C-reactive 
protein 
follow-up 
(mg/l) 
Albumin 
admission 
(g/l) 
Albumin 
follow-up 
(g/l) 
Globulins 
admission 
(g/l) 
Globulins 
follow-up 
(g/l) 
Plasma FAD 
admission 
(nmol/l) 
Plasma FAD 
follow-up 
(nmol/l) 
Plasma FMN 
admission 
(nmol/l) 
Plasma 
FMN 
follow-up 
(nmol/l) 
12.00 126.00 156.00 24.00 23.00 22.00 22.00 77.20 79.90 -- -- 
13.00 22.00 261.00 27.00 22.00 28.00 25.00 111.70 63.50 -- -- 
14.00 220.00 124.00 12.00 10.00 33.00 27.00 81.20 56.80 -- -- 
15.00 257.00 73.00 23.00 16.00 40.00 38.00 375.90 145.60 -- -- 
16.00 122.00 -- 28.00 -- 44.00 -- 75.00 -- -- -- 
17.00 3.00 55.00 33.00 26.00 40.00 23.00 289.60 73.70 -- -- 
18.00 152.00 64.00 10.00 10.00 21.00 20.00 29.80 62.20 -- -- 
19.00 143.00 101.00 12.00 14.00 56.00 24.00 133.40 1,510.30 -- -- 
21.00 23.00 -- 10.00 -- 15.00 -- 195.90 -- -- -- 
22.00 20.00 67.00 27.00 15.00 44.00 25.00 58.70 55.00 18.50 4.70 
23.00 125.00 216.00 10.00 13.00 29.00 35.00 87.00 157.00 -- -- 
24.00 81.00 -- 35.00 -- 39.00 -- 70.30 -- -- -- 
27.00 103.00 133.00 23.00 17.00 31.00 29.00 170.10 307.10 -- -- 
29.00 59.00 20.00 9.00 10.00 16.00 29.00 22.80 33.20 -- -- 
30.00 26.00 179.00 16.00 11.00 28.00 31.00 826.50 1,697.50 -- -- 
31.00 50.00 -- 22.00 -- 24.00 -- 42.40 -- -- -- 
32.00 434.00 -- 17.00 -- 22.00 -- 58.80 -- -- -- 
33.00 259.00 173.00 17.00 10.00 24.00 25.00 41.30 25.30 -- -- 
34.00 404.00 336.00 30.00 15.00 26.00 24.00 658.40 908.30 -- -- 
35.00 119.00 303.00 9.00 13.00 18.00 23.00 36.70 42.50 -- -- 
36.00 132.00 70.00 14.00 14.00 21.00 25.00 1,915.70 911.30 -- -- 
37.00 81.00 35.00 12.00 12.00 33.00 27.00 321.50 414.40 -- -- 
38.00 127.00 -- 14.00 -- 42.00 -- 41.90 -- -- -- 
40.00 15.00 234.00 20.00 18.00 19.00 23.00 67.40 51.70 -- -- 
41.00 184.00 -- 19.00 -- 14.00 -- 37.60 -- -- -- 
42.00 8.00 149.00 17.00 18.00 15.00 19.00 29.90 28.90 -- -- 
44.00 151.00 55.00 10.00 16.00 27.00 27.00 546.20 346.50 -- -- 
45.00 258.00 164.00 14.00 14.00 27.00 31.00 37.00 881.50 -- -- 
46.00 250.00 -- 11.00 -- 21.00 -- 31.10 -- -- -- 
47.00 64.00 72.00 24.00 24.00 34.00 29.00 1,179.40 1,224.70 -- -- 
48.00 119.00 123.00 10.00 9.00 47.00 38.00 529.60 5,478.50 -- -- 
50.00 180.00 141.00 23.00 15.00 8.00 27.00 52.40 58.20 34.20 6.90 
51.00 56.00 58.00 14.00 19.00 29.00 28.00 53.70 89.60 11.50 7.10 
  
267 
Patient 
No. 
C-reactive 
protein 
admission 
(mg/l) 
C-reactive 
protein 
follow-up 
(mg/l) 
Albumin 
admission 
(g/l) 
Albumin 
follow-up 
(g/l) 
Globulins 
admission 
(g/l) 
Globulins 
follow-up 
(g/l) 
Plasma FAD 
admission 
(nmol/l) 
Plasma FAD 
follow-up 
(nmol/l) 
Plasma FMN 
admission 
(nmol/l) 
Plasma 
FMN 
follow-up 
(nmol/l) 
52.00 565.00 257.00 9.00 9.00 34.00 35.00 67.20 100.40 -- -- 
53.00 148.00 131.00 9.00 9.00 25.00 24.00 61.80 56.30 -- -- 
55.00 107.00 71.00 13.00 9.00 28.00 26.00 30.40 43.80 -- 3.60 
56.00 37.00 -- 16.00 -- 17.00 -- 28.60 -- 4.90 -- 
57.00 181.00 -- 10.00 -- 27.00 -- 10.40 -- -- -- 
58.00 6.00 36.00 19.00 12.00 20.00 27.00 35.60 22.70 7.70 5.20 
59.00 32.00 -- 36.00 -- 30.00 -- 69.30 -- -- -- 
60.00 166.00 -- 26.00 -- 49.00 -- 52.70 -- -- -- 
61.00 380.00 -- 26.00 -- 39.00 -- 58.70 -- -- -- 
62.00 88.00 180.00 12.00 14.00 26.00 29.00 28.70 32.80 5.40 4.30 
63.00 117.00 -- 14.00 -- 13.00 -- 18.80 -- -- -- 
64.00 311.00 -- 18.00 -- 46.00 -- 31.00 -- -- -- 
65.00 163.00 -- 23.00 -- 31.00 -- 41.20 -- -- -- 
67.00 438.00 52.00 20.00 16.00 15.00 20.00 24.10 26.70 -- -- 
68.00 67.00 139.00 11.00 11.00 26.00 25.00 19.60 38.90 -- 8.20 
69.00 179.00 356.00 14.00 16.00 22.00 25.00 10.30 36.00 -- 10.70 
71.00 2.00 -- 38.00 -- 37.00 -- 42.20 -- -- -- 
72.00 40.00 89.00 32.00 15.00 26.00 41.00 78.20 86.30 6.10 12.10 
73.00 2.00 -- 31.00 -- 31.00 -- 38.20 -- -- -- 
74.00 77.00 28.00 15.00 13.00 33.00 29.00 -- 115.40 -- 6.80 
75.00 184.00 -- 11.00 -- 26.00 -- 28.70 -- -- -- 
77.00 2.00 -- 20.00 -- 27.00 -- 33.20 -- -- -- 
78.00 177.00 -- 27.00 -- 34.00 -- 53.00 -- -- -- 
79.00 2.00 251.00 24.00 21.00 20.00 23.00 77.60 51.10 12.40 6.90 
80.00 126.00 -- 14.00 -- 44.00 -- 54.50 -- -- -- 
81.00 8.00 284.00 10.00 21.00 13.00 23.00 43.60 68.70 -- -- 
82.00 4.00 86.00 29.00 29.00 31.00 33.00 19.20 57.30 2.80 4.60 
83.00 318.00 -- 21.00 -- 27.00 -- 42.20 -- -- -- 
84.00 63.00 80.00 9.00 9.00 20.00 23.00 27.40 26.70 21.90 19.30 
85.00 176.00 198.00 11.00 9.00 15.00 18.00 25.30 34.80 3.60 4.10 
87.00 110.00 -- 18.00 -- 22.00 -- 39.30 -- 24.40 -- 
88.00 108.00 104.00 12.00 11.00 39.00 40.00 29.50 43.90 -- -- 
89.00 31.00 -- 16.00 -- 17.00 -- 41.90 -- -- -- 
90.00 159.00 38.00 11.00 29.00 30.00 9.00 20.90 39.70 -- -- 
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Patient 
No. 
C-reactive 
protein 
admission 
(mg/l) 
C-reactive 
protein 
follow-up 
(mg/l) 
Albumin 
admission 
(g/l) 
Albumin 
follow-up 
(g/l) 
Globulins 
admission 
(g/l) 
Globulins 
follow-up 
(g/l) 
Plasma FAD 
admission 
(nmol/l) 
Plasma FAD 
follow-up 
(nmol/l) 
Plasma FMN 
admission 
(nmol/l) 
Plasma 
FMN 
follow-up 
(nmol/l) 
91.00 268.00 -- 14.00 -- 26.00 -- -- -- -- -- 
94.00 147.00 -- 14.00 -- 33.00 -- 61.40 -- -- -- 
96.00 76.00 27.00 29.00 28.00 35.00 28.00 46.40 55.00 -- -- 
99.00 287.00 -- 22.00 -- 30.00 -- 33.40 -- -- -- 
100.00 253.00 171.00 13.00 9.00 28.00 24.00 20.30 12.80 -- -- 
102.00 28.00 198.00 19.00 19.00 19.00 20.00 26.20 26.20 28.10 23.10 
103.00 -- 69.00 42.00 27.00 31.00 22.00 53.10 35.00 -- -- 
104.00 1.00 -- 34.00 -- 37.00 -- 73.40 -- 28.40 -- 
105.00 25.00 23.00 30.00 29.00 36.00 28.00 25.50 19.10 29.30 -- 
107.00 261.00 -- 17.00 -- 22.00 -- 45.30 -- -- -- 
108.00 48.00 -- 35.00 -- 35.00 -- 44.90 -- 28.70 -- 
110.00 199.00 153.00 13.00 11.00 35.00 23.00 18.20 71.80 -- 16.70 
111.00 6.00 245.00 28.00 13.00 25.00 24.00 42.70 25.50 -- -- 
112.00 2.00 165.00 20.00 9.00 22.00 17.00 64.70 18.70 19.40 -- 
113.00 14.00 205.00 31.00 19.00 29.00 24.00 51.40 24.10 30.70 -- 
114.00 49.00 98.00 16.00 9.00 21.00 18.00 30.40 12.40 -- 34.10 
115.00 1.00 -- 39.00 -- 24.00 -- 67.80 -- 17.30 -- 
116.00 3.00 -- 24.00 -- 24.00 -- 34.90 -- 6.80 -- 
117.00 9.00 88.00 32.00 23.00 23.00 22.00 64.40 36.00 19.60 -- 
118.00 252.00 204.00 12.00 9.00 21.00 19.00 16.60 22.10 -- -- 
119.00 2.00 -- 25.00 -- 25.00 -- 68.20 -- 16.60 -- 
121.00 203.00 88.00 15.00 15.00 22.00 24.00 13.70 30.50 -- -- 
123.00 2.00 207.00 45.00 28.00 38.00 30.00 85.80 50.50 7.70 -- 
124.00 97.00 149.00 15.00 14.00 25.00 30.00 18.00 39.40 11.60 -- 
126.00 3.00 -- 21.00 -- 25.00 -- 158.60 -- 75.60 -- 
127.00 316.00 -- 17.00 -- 42.00 -- 17.40 -- -- -- 
128.00 51.00 -- 16.00 -- 30.00 -- 34.60 -- -- -- 
129.00 63.00 -- 20.00 -- 33.00 -- 37.80 -- -- -- 
131.00 165.00 -- 21.00 -- 26.00 -- 19.90 -- -- -- 
133.00 35.00 -- 16.00 -- 20.00 -- 47.70 -- 7.20 -- 
135.00 221.00 -- 18.00 -- 40.00 -- 40.50 -- -- -- 
137.00 218.00 -- 11.00 -- 23.00 -- 43.70 -- -- -- 
139.00 72.00 -- 14.00 -- 19.00 -- 48.30 -- -- -- 
140.00 51.00 -- 9.00 -- 17.00 -- 99.80 -- -- -- 
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Patient 
No. 
C-reactive 
protein 
admission 
(mg/l) 
C-reactive 
protein 
follow-up 
(mg/l) 
Albumin 
admission 
(g/l) 
Albumin 
follow-up 
(g/l) 
Globulins 
admission 
(g/l) 
Globulins 
follow-up 
(g/l) 
Plasma FAD 
admission 
(nmol/l) 
Plasma FAD 
follow-up 
(nmol/l) 
Plasma FMN 
admission 
(nmol/l) 
Plasma 
FMN 
follow-up 
(nmol/l) 
141.00 143.00 80.00 9.00 9.00 31.00 33.00 40.10 56.20 -- -- 
143.00 39.00 -- 14.00 -- 46.00 -- 61.50 -- -- -- 
146.00 73.00 22.00 26.00 18.00 12.00 27.00 58.00 85.50 -- -- 
147.00 203.00 216.00 32.00 24.00 24.00 27.00 57.60 59.90 -- -- 
148.00 17.00 -- 23.00 -- 31.00 -- 78.40 -- -- -- 
149.00 94.00 -- 13.00 -- 27.00 -- 26.10 -- -- -- 
150.00 295.00 -- 24.00 -- 31.00 -- 41.80 -- -- -- 
151.00 229.00 -- 13.00 -- 34.00 -- 41.80 -- -- -- 
152.00 26.00 -- 35.00 -- 30.00 -- 100.40 -- -- -- 
153.00 45.00 -- 19.00 -- 31.00 -- 52.80 -- -- -- 
154.00 39.00 -- 33.00 -- 29.00 -- 84.50 -- -- -- 
155.00 52.00 -- 19.00 -- 49.00 -- 45.30 -- -- -- 
156.00 316.00 -- 20.00 -- 53.00 -- 48.00 -- -- -- 
157.00 294.00 -- 13.00 -- 31.00 -- 21.40 -- -- -- 
158.00 163.00 -- 10.00 -- 24.00 -- 45.80 -- -- -- 
159.00 137.00 -- 15.00 -- 24.00 -- 43.00 -- -- -- 
163.00 269.00 -- 12.00 -- 26.00 -- 34.60 -- -- -- 
164.00 291.00 -- 24.00 -- 34.00 -- 45.80 -- -- -- 
165.00 0.60 -- 47.00 -- 28.00 -- 87.60 -- -- -- 
166.00 75.00 -- 13.00 -- 24.00 -- 66.90 -- -- -- 
167.00 74.00 -- 23.00 -- 20.00 -- 58.90 -- -- -- 
168.00 131.00 -- 11.00 -- 27.00 -- 39.40 -- -- -- 
169.00 273.00 -- 14.00 -- 36.00 -- 75.80 -- -- -- 
171.00 203.00 -- 20.00 -- 32.00 -- 49.50 -- -- -- 
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Patient 
No. 
Plasma 
riboflavin 
admission 
(nmol/l) 
Plasma 
riboflavin 
follow-up 
(nmol/l) 
Plasma FAD/ 
Riboflavin 
admission 
Plasma FAD/ 
Riboflavin 
follow-up 
Red cell 
FAD 
admission 
(pmol/g 
Hb) 
Red cell FAD 
follow-up 
(pmol/g Hb) 
Red cell 
FMN 
admission 
(pmol/g Hb) 
Red cell 
FMN follow-
up (pmol/g 
Hb) 
Red cell 
riboflavin 
admission 
(pmol/g Hb) 
Red cell 
riboflavin 
follow-up 
(pmol/g Hb) 
12.00 32.70 39.50 2.36 2.02 1.76 1.70 0.14 0.14 0.05 0.05 
13.00 42.70 103.90 2.62 0.61 1.53 1.54 0.16 0.14 0.06 0.05 
14.00 170.30 300.00 0.48 0.19 1.82 1.91 0.14 0.12 0.09 0.08 
15.00 -- -- -- -- 1.46 1.42 -- -- 0.03 -- 
16.00 77.20 -- 0.97 -- 1.05 -- 0.08 -- 0.03 -- 
17.00 -- -- -- -- 1.33 1.24 0.08 0.08 0.04 0.02 
18.00 7.80 3.00 3.82 20.73 1.13 1.08 0.07 0.06 0.01 0.01 
19.00 -- -- -- -- 1.69 1.90 -- -- 0.04 0.12 
21.00 53.00 -- 3.70 -- 1.42 -- 0.09 -- 0.03 -- 
22.00 279.00 172.10 0.21 0.32 2.09 2.00 0.22 0.21 0.22 0.14 
23.00 -- -- -- -- 1.63 1.67 0.09 0.09 0.02 0.03 
24.00 62.70 -- 1.12 -- 2.29 -- -- -- 0.05 -- 
27.00 -- -- -- -- 1.63 1.88 -- -- 0.10 0.10 
29.00 198.70 66.20 0.11 0.50 1.57 1.86 0.11 0.13 0.07 0.06 
30.00 -- -- -- -- 1.97 2.02 -- -- 0.14 0.27 
31.00 13.50 -- 3.14 -- 1.30 -- 0.08 -- 0.03 -- 
32.00 18.20 -- 3.23 -- 1.38 -- 0.09 -- 0.03 -- 
33.00 -- -- -- -- 1.20 1.26 0.08 0.08 0.01 0.01 
34.00 -- -- -- -- 1.86 2.04 0.13 0.18 0.19 0.10 
35.00 -- -- -- -- 1.35 1.68 0.09 0.10 0.01 0.01 
36.00 -- -- -- -- 2.17 2.03 0.14 0.13 0.17 0.06 
37.00 -- -- -- -- 1.58 1.74 0.10 0.11 0.07 0.08 
38.00 45.60 -- 0.92 -- 1.70 -- 0.11 -- 0.06 -- 
40.00 -- -- -- -- 1.41 1.33 0.09 0.09 0.01 0.01 
41.00 -- -- -- -- 1.20 -- 0.06 -- 0.04 -- 
42.00 43.00 40.10 0.70 0.72 1.29 -- 0.08 -- 0.02 -- 
44.00 -- -- -- -- 2.04 2.15 0.17 0.17 0.07 0.06 
45.00 -- -- -- -- 2.21 2.19 0.14 0.15 0.02 0.06 
46.00 31.90 -- 0.97 -- 1.21 -- 0.08 -- 0.01 -- 
47.00 -- -- -- -- 1.85 2.15 0.15 0.16 0.09 0.17 
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Patient 
No. 
Plasma 
riboflavin 
admission 
(nmol/l) 
Plasma 
riboflavin 
follow-up 
(nmol/l) 
Plasma FAD/ 
Riboflavin 
admission 
Plasma FAD/ 
Riboflavin 
follow-up 
Red cell 
FAD 
admission 
(pmol/g 
Hb) 
Red cell FAD 
follow-up 
(pmol/g Hb) 
Red cell 
FMN 
admission 
(pmol/g Hb) 
Red cell 
FMN follow-
up (pmol/g 
Hb) 
Red cell 
riboflavin 
admission 
(pmol/g Hb) 
Red cell 
riboflavin 
follow-up 
(pmol/g Hb) 
48.00 -- -- -- -- 2.14 2.55 0.16 0.18 0.11 0.62 
50.00 44.30 29.10 1.18 2.00 1.49 1.46 0.10 0.10 0.04 0.02 
51.00 106.50 330.60 0.50 0.27 1.80 1.89 0.16 0.15 0.11 0.17 
52.00 748.10 910.80 0.09 0.11 2.30 2.30 0.11 0.10 0.17 0.24 
53.00 -- -- -- -- 1.04 0.96 0.05 0.05 0.01 0.00 
55.00 4.10 237.70 7.41 0.18 1.22 2.00 0.08 0.14 -- 0.12 
56.00 16.60 -- 1.72 -- 1.45 -- 0.07 -- 0.14 -- 
57.00 52.50 -- 0.20 -- 1.33 -- 0.13 -- 0.04 -- 
58.00 15.40 12.40 2.31 1.83 1.16 1.14 0.07 0.07 0.02 0.02 
59.00 53.70 -- 1.29 -- 1.22 -- 0.07 -- 0.01 -- 
60.00 11.80 -- 4.47 -- 1.17 -- 0.05 -- 0.00 -- 
61.00 38.00 -- 1.54 -- 1.21 -- 0.06 -- 0.01 -- 
62.00 6.60 9.60 4.35 3.42 1.20 1.09 0.06 0.05 0.01 0.01 
63.00 48.00 -- 0.39 -- 1.80 -- 0.26 -- 0.09 -- 
64.00 10.00 -- 3.10 -- 1.06 -- 0.06 -- 0.01 -- 
65.00 57.30 -- 0.72 -- 1.91 -- 0.36 -- 0.03 -- 
67.00 34.00 39.80 0.71 0.67 1.72 1.68 0.19 0.19 0.08 0.07 
68.00 5.90 577.10 3.32 0.07 1.54 2.30 0.11 0.17 0.02 0.20 
69.00 571.90 616.80 0.02 0.06 1.34 2.26 0.12 0.22 0.03 0.25 
71.00 8.60 -- 4.91 -- 0.97 -- 0.05 -- 0.01 -- 
72.00 55.70 559.90 1.40 0.15 1.78 2.40 0.09 0.13 0.03 0.21 
73.00 40.70 -- 0.94 -- 1.38 -- 0.14 -- 0.05 -- 
74.00 -- 1,166.10 -- 0.10 1.44 1.96 0.13 0.17 0.04 0.28 
75.00 53.90 -- 0.53 -- 2.10 -- 0.48 -- 0.09 -- 
77.00 24.80 -- 1.34 -- 1.81 -- 0.13 -- 0.03 -- 
78.00 139.00 -- 0.38 -- 1.93 -- 0.17 -- 0.06 -- 
79.00 18.40 17.40 4.22 2.94 1.24 1.21 0.07 0.07 0.01 0.01 
80.00 140.80 -- 0.39 -- 2.23 -- 0.28 -- 0.14 -- 
81.00 7.10 33.00 6.14 2.08 1.56 1.66 0.09 0.09 0.01 0.03 
82.00 3.00 14.50 6.40 3.95 1.31 1.68 0.08 0.11 0.01 0.02 
83.00 7.80 -- 5.41 -- 1.49 -- 0.08 -- 0.01 -- 
84.00 62.00 356.00 0.44 0.08 1.75 2.51 0.14 0.20 0.04 0.17 
85.00 6.70 8.00 3.78 4.35 1.30 1.33 0.09 0.10 0.05 0.03 
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Patient 
No. 
Plasma 
riboflavin 
admission 
(nmol/l) 
Plasma 
riboflavin 
follow-up 
(nmol/l) 
Plasma FAD/ 
Riboflavin 
admission 
Plasma FAD/ 
Riboflavin 
follow-up 
Red cell 
FAD 
admission 
(pmol/g 
Hb) 
Red cell FAD 
follow-up 
(pmol/g Hb) 
Red cell 
FMN 
admission 
(pmol/g Hb) 
Red cell 
FMN follow-
up (pmol/g 
Hb) 
Red cell 
riboflavin 
admission 
(pmol/g Hb) 
Red cell 
riboflavin 
follow-up 
(pmol/g Hb) 
87.00 65.60 -- 0.60 -- 1.62 -- 0.12 -- 0.03 -- 
88.00 43.30 401.00 0.68 0.11 1.35 2.21 0.07 0.14 0.03 0.15 
89.00 6.80 -- 6.16 -- 1.17 -- 0.08 -- 0.01 -- 
90.00 11.70 74.30 1.79 0.53 2.06 1.88 0.11 0.11 0.03 0.06 
91.00 -- -- -- -- 1.25 -- 0.08 -- 0.04 -- 
94.00 14.30 -- 4.29 -- 1.87 -- 0.14 -- 0.02 -- 
96.00 20.20 11.20 2.30 4.91 2.12 2.00 0.15 0.14 0.06 0.06 
99.00 43.40 -- 0.77 -- 1.48 -- 0.09 -- 0.01 -- 
100.00 337.50 172.10 0.06 0.07 2.56 2.50 0.33 0.25 0.21 0.12 
102.00 27.00 36.80 0.97 0.71 1.31 1.27 0.08 0.07 0.02 0.02 
103.00 43.10 26.30 1.23 1.33 1.59 1.59 0.16 0.16 0.07 0.07 
104.00 33.80 -- 2.17 -- 1.31 -- 0.06 -- 0.02 -- 
105.00 133.80 114.20 0.19 0.17 1.80 1.70 0.19 0.19 0.19 0.13 
107.00 29.60 -- 1.53 -- 1.67 -- 0.17 -- 0.06 -- 
108.00 11.80 -- 3.81 -- 1.23 -- 0.05 -- 0.01 -- 
110.00 -- 516.30 -- 0.14 1.13 2.63 0.06 0.17 0.01 0.16 
111.00 24.30 20.90 1.76 1.22 1.37 1.80 0.06 0.11 0.01 0.02 
112.00 28.60 54.00 2.26 0.35 1.15 1.33 0.12 0.14 0.03 0.05 
113.00 68.60 62.20 0.75 0.39 1.31 1.37 0.06 0.06 0.01 0.01 
114.00 -- 66.20 -- 0.19 1.14 1.40 0.06 0.08 0.01 0.02 
115.00 7.30 -- 9.29 -- 1.02 -- 0.05 -- 0.01 -- 
116.00 13.60 -- 2.57 -- 1.29 -- -- -- 0.01 -- 
117.00 39.90 44.00 1.61 0.82 1.53 1.58 -- -- 0.02 0.03 
118.00 193.10 29.00 0.09 0.76 1.85 1.48 -- -- 0.04 0.02 
119.00 24.00 -- 2.84 -- 1.33 -- 0.08 -- 0.02 -- 
121.00 14.00 26.20 0.98 1.16 1.54 1.79 0.14 0.16 0.03 0.05 
123.00 115.00 69.40 0.75 0.73 1.77 1.88 -- -- 0.05 0.06 
124.00 55.80 97.90 0.32 0.40 1.56 1.78 -- -- 0.02 0.01 
126.00 458.00 -- 0.35 -- 1.23 -- -- -- 0.04 -- 
127.00 374.20 -- 0.05 -- 2.58 -- -- -- 0.23 -- 
128.00 14.30 -- 2.42 -- 1.75 -- 0.09 -- 0.03 -- 
129.00 188.00 -- 0.20 -- 1.88 -- -- -- 0.04 -- 
131.00 69.70 -- 0.29 -- 1.68 -- -- -- 0.04 -- 
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Patient 
No. 
Plasma 
riboflavin 
admission 
(nmol/l) 
Plasma 
riboflavin 
follow-up 
(nmol/l) 
Plasma FAD/ 
Riboflavin 
admission 
Plasma FAD/ 
Riboflavin 
follow-up 
Red cell 
FAD 
admission 
(pmol/g 
Hb) 
Red cell FAD 
follow-up 
(pmol/g Hb) 
Red cell 
FMN 
admission 
(pmol/g Hb) 
Red cell 
FMN follow-
up (pmol/g 
Hb) 
Red cell 
riboflavin 
admission 
(pmol/g Hb) 
Red cell 
riboflavin 
follow-up 
(pmol/g Hb) 
133.00 40.20 -- 1.19 -- 1.55 -- -- -- 0.02 -- 
135.00 81.50 -- 0.50 -- 1.91 -- -- -- 0.03 -- 
137.00 4.50 -- 9.71 -- 1.84 -- 0.10 -- 0.12 -- 
139.00 48.60 -- 0.99 -- 2.02 -- 0.11 -- 0.03 -- 
140.00 21.90 -- 4.56 -- 2.13 -- 0.13 -- 0.09 -- 
141.00 9.20 199.10 4.36 0.28 1.53 2.11 0.08 0.14 0.02 0.08 
143.00 34.60 -- 1.78 -- 1.84 -- 0.12 -- 0.08 -- 
146.00 196.30 288.50 0.30 0.30 2.13 2.22 0.13 0.13 0.07 0.07 
147.00 6.50 7.50 8.86 7.99 1.23 1.17 0.06 0.06 0.01 0.02 
148.00 26.20 -- 2.99 -- 1.54 -- 0.09 -- 0.01 -- 
149.00 27.60 -- 0.95 -- 1.36 -- 0.08 -- 0.04 -- 
150.00 5.50 -- 7.60 -- 1.42 -- 0.07 -- 0.01 -- 
151.00 5.50 -- 7.60 -- 1.24 -- 0.06 -- 0.01 -- 
152.00 18.60 -- 5.40 -- 1.29 -- 0.07 -- 0.03 -- 
153.00 23.00 -- 2.30 -- 1.37 -- 0.07 -- 0.00 -- 
154.00 90.50 -- 0.93 -- 1.82 -- 0.15 -- 0.11 -- 
155.00 26.50 -- 1.71 -- 1.44 -- 0.09 -- 0.03 -- 
156.00 7.80 -- 6.15 -- 1.22 -- 0.06 -- 0.01 -- 
157.00 228.60 -- 0.09 -- 1.37 -- 0.08 -- 0.02 -- 
158.00 62.20 -- 0.74 -- 1.58 -- 0.12 -- 0.09 -- 
159.00 21.10 -- 2.04 -- 1.43 -- 0.07 -- 0.01 -- 
163.00 9.40 -- 3.68 -- 1.15 -- 0.05 -- 0.00 -- 
164.00 10.60 -- 4.32 -- 1.47 -- 0.08 -- 0.01 -- 
165.00 19.80 -- 4.42 -- 1.27 -- 0.06 -- 0.01 -- 
166.00 29.20 -- 2.29 -- 1.47 -- 0.09 -- 0.05 -- 
167.00 7.30 -- 8.07 -- 1.39 -- 0.09 -- 0.02 -- 
168.00 307.40 -- 0.13 -- 1.82 -- 0.11 -- 0.05 -- 
169.00 85.60 -- 0.89 -- 1.77 -- 0.14 -- 0.07 -- 
171.00 20.30 -- 2.44 -- 1.77 -- 0.13 -- 0.06 -- 
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Patient 
No. 
Red cell 
FAD/ 
Riboflavin 
admission 
Red cell 
FAD/ 
Riboflavin 
follow-up 
Alkaline 
phosphatase 
admission 
(IU/l) 
Alkaline 
phosphatase 
follow-up 
(IU/l) 
Haemoglobin 
admission 
(g/dl) 
Haemoglobin 
follow-up 
(g/dl) 
12.00 33.86 37.79 115.00 120.00 13.90 12.60 
13.00 27.66 29.59 277.00 206.00 9.90 7.30 
14.00 20.93 23.13 538.00 406.00 7.50 9.20 
15.00 41.92 -- 146.00 241.00 10.10 10.90 
16.00 32.81 -- 234.00 -- 12.30 -- 
17.00 33.13 51.80 344.00 213.00 14.90 10.00 
18.00 85.21 104.25 253.00 177.00 12.90 9.90 
19.00 41.67 16.08 184.00 159.00 7.10 8.40 
21.00 46.66 -- 1,221.00 -- 10.10 -- 
22.00 9.65 14.49 226.00 136.00 10.10 -- 
23.00 91.75 58.88 170.00 307.00 6.70 10.20 
24.00 42.46 -- 250.00 -- 12.80 -- 
27.00 16.21 18.26 261.00 441.00 12.10 10.80 
29.00 21.92 30.03 168.00 204.00 8.90 9.00 
30.00 14.41 7.61 1,089.00 659.00 10.10 7.80 
31.00 44.84 -- 126.00 -- 12.20 -- 
32.00 45.98 -- 331.00 -- 9.80 -- 
33.00 133.75 105.61 107.00 280.00 12.00 10.60 
34.00 9.80 21.12 96.00 220.00 12.50 8.70 
35.00 226.38 201.10 69.00 121.00 9.50 8.70 
36.00 12.84 34.75 238.00 543.00 8.70 9.50 
37.00 23.42 22.66 264.00 255.00 13.30 13.50 
38.00 29.93 -- 398.00 -- 9.20 -- 
40.00 143.02 114.52 35.00 39.00 7.20 8.90 
41.00 33.49 -- 54.00 -- 11.60 -- 
42.00 65.15 -- 26.00 41.00 9.30 10.50 
44.00 29.73 34.91 31.00 88.00 10.90 10.00 
45.00 135.91 37.48 158.00 564.00 7.70 10.10 
46.00 108.60 -- 71.00 -- 8.80 -- 
47.00 19.89 12.91 276.00 264.00 8.50 8.60 
48.00 19.16 4.13 121.00 86.00 9.60 10.10 
50.00 40.72 74.07 36.00 94.00 -- 9.60 
51.00 16.12 11.12 24.00 99.00 8.90 9.70 
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Patient 
No. 
Red cell 
FAD/ 
Riboflavin 
admission 
Red cell 
FAD/ 
Riboflavin 
follow-up 
Alkaline 
phosphatase 
admission 
(IU/l) 
Alkaline 
phosphatase 
follow-up 
(IU/l) 
Haemoglobin 
admission 
(g/dl) 
Haemoglobin 
follow-up 
(g/dl) 
52.00 13.33 9.58 111.00 258.00 8.40 7.20 
53.00 134.75 200.75 96.00 158.00 9.40 8.20 
55.00 -- 16.54 70.00 116.00 8.20 8.50 
56.00 10.42 -- 42.00 -- 8.60 -- 
57.00 35.49 -- 43.00 -- 9.40 -- 
58.00 56.95 69.23 36.00 22.00 10.00 8.30 
59.00 94.88 -- 52.00 -- 15.20 -- 
60.00 320.24 -- 85.00 -- -- -- 
61.00 81.90 -- 76.00 -- 9.40 -- 
62.00 136.29 92.98 48.00 55.00 9.20 10.30 
63.00 19.38 -- 67.00 -- 9.90 -- 
64.00 133.48 -- 83.00 -- 8.70 -- 
65.00 59.53 -- 58.00 -- 9.10 -- 
67.00 20.64 24.97 212.00 125.00 9.80 11.80 
68.00 77.10 11.38 28.00 125.00 11.00 8.80 
69.00 39.69 9.18 47.00 81.00 9.10 9.30 
71.00 127.88 -- 95.00 -- 15.50 -- 
72.00 52.28 11.53 79.00 181.00 10.50 8.20 
73.00 28.38 -- 97.00 -- 10.70 -- 
74.00 36.32 7.01 820.00 644.00 11.80 11.50 
75.00 22.09 -- 51.00 -- 7.70 -- 
77.00 57.88 -- 46.00 -- 8.90 -- 
78.00 32.69 -- 148.00 -- 10.00 -- 
79.00 85.25 86.13 47.00 76.00 13.30 12.00 
80.00 15.44 -- 183.00 -- 7.90 -- 
81.00 144.55 65.14 27.00 52.00 9.20 7.90 
82.00 88.89 72.64 72.00 72.00 11.10 9.80 
83.00 234.07 -- 81.00 -- 11.80 -- 
84.00 48.45 14.62 124.00 127.00 11.20 11.10 
85.00 25.33 52.65 16.00 17.00 11.70 -- 
87.00 63.46 -- 79.00 -- 7.40 -- 
88.00 51.28 14.72 77.00 91.00 -- 9.00 
89.00 88.75 -- 67.00 -- 9.40 -- 
90.00 75.43 33.11 69.00 81.00 8.50 7.90 
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Patient 
No. 
Red cell 
FAD/ 
Riboflavin 
admission 
Red cell 
FAD/ 
Riboflavin 
follow-up 
Alkaline 
phosphatase 
admission 
(IU/l) 
Alkaline 
phosphatase 
follow-up 
(IU/l) 
Haemoglobin 
admission 
(g/dl) 
Haemoglobin 
follow-up 
(g/dl) 
91.00 30.68 -- 55.00 -- 10.70 -- 
94.00 77.64 -- 108.00 -- 9.20 -- 
96.00 36.20 32.32 86.00 108.00 9.70 9.00 
99.00 113.55 -- 105.00 -- 13.70 -- 
100.00 12.43 20.64 183.00 132.00 7.60 8.40 
102.00 63.03 76.31 39.00 60.00 8.50 7.70 
103.00 21.34 22.36 71.00 80.00 13.20 -- 
104.00 64.97 -- 88.00 -- 11.70 -- 
105.00 9.51 13.25 94.00 98.00 7.00 7.70 
107.00 30.24 -- 71.00 -- 10.50 -- 
108.00 141.58 -- 66.00 -- 12.70 -- 
110.00 175.86 16.87 31.00 113.00 9.00 8.20 
111.00 153.26 94.66 99.00 52.00 16.20 6.80 
112.00 37.01 28.02 64.00 43.00 15.40 8.90 
113.00 207.10 242.66 64.00 40.00 14.90 10.00 
114.00 81.40 62.45 100.00 86.00 10.70 7.70 
115.00 124.49 -- 67.00 -- 14.20 -- 
116.00 111.09 -- 50.00 -- 9.70 -- 
117.00 95.05 46.82 69.00 54.00 12.90 9.30 
118.00 46.45 90.92 88.00 86.00 8.10 9.20 
119.00 77.68 -- 73.00 -- 11.60 -- 
121.00 50.16 39.37 56.00 166.00 10.00 10.20 
123.00 32.94 29.32 148.00 80.00 10.50 10.20 
124.00 94.48 161.65 83.00 107.00 7.00 -- 
126.00 29.57 -- 74.00 -- 9.20 -- 
127.00 11.43 -- 278.00 -- 8.50 -- 
128.00 60.10 -- 73.00 -- 8.80 -- 
129.00 48.96 -- 265.00 -- 11.30 -- 
131.00 47.94 -- 74.00 -- 10.60 -- 
133.00 86.30 -- 102.00 -- 11.00 -- 
135.00 58.77 -- 399.00 -- 7.30 -- 
137.00 15.50 -- 155.00 -- -- -- 
139.00 59.24 -- 28.00 -- -- -- 
140.00 23.42 -- 2,326.00 -- -- -- 
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Patient 
No. 
Red cell 
FAD/ 
Riboflavin 
admission 
Red cell 
FAD/ 
Riboflavin 
follow-up 
Alkaline 
phosphatase 
admission 
(IU/l) 
Alkaline 
phosphatase 
follow-up 
(IU/l) 
Haemoglobin 
admission 
(g/dl) 
Haemoglobin 
follow-up 
(g/dl) 
141.00 65.92 26.96 104.00 143.00 -- -- 
143.00 22.29 -- 178.00 -- -- -- 
146.00 30.59 33.65 61.00 73.00 -- -- 
147.00 92.69 65.28 51.00 46.00 -- -- 
148.00 111.33 -- 68.00 -- -- -- 
149.00 35.46 -- 68.00 -- -- -- 
150.00 99.38 -- 106.00 -- -- -- 
151.00 214.18 -- 143.00 -- -- -- 
152.00 51.09 -- 153.00 -- -- -- 
153.00 410.25 -- 91.00 -- -- -- 
154.00 16.53 -- 88.00 -- -- -- 
155.00 54.92 -- 66.00 -- -- -- 
156.00 97.23 -- 97.00 -- -- -- 
157.00 81.14 -- 58.00 -- -- -- 
158.00 17.04 -- 57.00 -- -- -- 
159.00 108.24 -- 154.00 -- -- -- 
163.00 423.55 -- 75.00 -- -- -- 
164.00 135.30 -- 56.00 -- -- -- 
165.00 94.76 -- 69.00 -- -- -- 
166.00 27.63 -- 283.00 -- -- -- 
167.00 65.81 -- 56.00 -- -- -- 
168.00 34.76 -- 73.00 -- -- -- 
169.00 24.09 -- 418.00 -- -- -- 
171.00 27.89 -- 34.00 -- -- -- 
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12.8 Appendix 8 Chapter 4 data 
Appendix 8. Characteristics and biochemical measurements of controls (Chapter 4) 
Control 
No. 
Age 
(yrs) 
Male/ 
Female 
(0/1) 
C-reactive 
protein 
(mg/l) 
Plasma 
PLP 
(nmol/l) 
Plasma PL 
(nmol/l) 
Plasma 
PLP/PL 
Red cell PLP 
(pmol/g Hb) 
Red cell PL 
(pmol/g Hb) 
Red Cell 
PLP/PL 
1.00 66.00 1.00 6.00 40.00 7.00 5.71 391.00 71.00 5.51 
2.00 48.00 1.00 6.00 65.00 14.00 4.64 504.00 105.00 4.80 
3.00 62.00 1.00 6.00 43.00 8.00 5.38 365.00 101.00 3.61 
4.00 53.00 1.00 6.00 44.00 10.00 4.40 372.00 61.00 6.10 
5.00 67.00 1.00 6.00 67.00 12.00 5.58 538.00 97.00 5.55 
6.00 38.00 1.00 6.00 92.00 16.00 5.75 563.00 97.00 5.80 
7.00 61.00 1.00 6.00 98.00 20.00 4.90 551.00 83.00 6.64 
8.00 35.00 1.00 6.00 66.00 15.00 4.40 505.00 55.00 9.18 
9.00 53.00 1.00 6.00 33.00 6.00 5.50 351.00 53.00 6.62 
10.00 72.00 1.00 6.00 30.00 7.00 4.29 342.00 53.00 6.45 
11.00 35.00 1.00 6.00 97.00 23.00 4.22 510.00 114.00 4.47 
12.00 67.00 1.00 6.00 114.00 23.00 4.96 626.00 148.00 4.23 
13.00 70.00 1.00 6.00 42.00 8.00 5.25 336.00 56.00 6.00 
14.00 58.00 1.00 6.00 40.00 8.00 5.00 280.00 33.00 8.48 
15.00 58.00 1.00 6.00 80.00 19.00 4.21 411.00 43.00 9.56 
16.00 58.00 1.00 6.00 75.00 14.00 5.36 463.00 57.00 8.12 
17.00 64.00 1.00 6.00 30.00 5.00 6.00 278.00 33.00 8.42 
18.00 51.00 1.00 6.00 36.00 9.00 4.00 301.00 72.00 4.18 
19.00 39.00 1.00 6.00 79.00 15.00 5.27 499.00 119.00 4.19 
20.00 53.00 1.00 6.00 74.00 15.00 4.93 557.00 134.00 4.16 
21.00 55.00 1.00 6.00 69.00 12.00 5.75 465.00 150.00 3.10 
22.00 47.00 1.00 6.00 74.00 19.00 3.89 466.00 83.00 5.61 
23.00 31.00 1.00 6.00 162.00 33.00 4.91 746.00 248.00 3.01 
24.00 69.00 1.00 6.00 68.00 12.00 5.67 475.00 156.00 3.04 
25.00 39.00 1.00 6.00 107.00 19.00 5.63 501.00 109.00 4.60 
26.00 45.00 1.00 6.00 40.00 7.00 5.71 391.00 62.00 6.31 
27.00 72.00 1.00 6.00 49.00 10.00 4.90 387.00 72.00 5.38 
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Control 
No. 
Age 
(yrs) 
Male/ 
Female 
(0/1) 
C-reactive 
protein 
(mg/l) 
Plasma 
PLP 
(nmol/l) 
Plasma PL 
(nmol/l) 
Plasma 
PLP/PL 
Red cell PLP 
(pmol/g Hb) 
Red cell PL 
(pmol/g Hb) 
Red Cell 
PLP/PL 
28.00 48.00 1.00 6.00 54.00 15.00 3.60 413.00 73.00 5.66 
29.00 44.00 1.00 6.00 41.00 10.00 4.10 394.00 49.00 8.04 
30.00 43.00 1.00 6.00 33.00 7.00 4.71 317.00 40.00 7.93 
31.00 47.00 1.00 6.00 55.00 11.00 5.00 279.00 39.00 7.15 
32.00 49.00 1.00 6.00 35.00 9.00 3.89 351.00 57.00 6.16 
33.00 71.00 1.00 6.00 41.00 10.00 4.10 347.00 84.00 4.13 
34.00 51.00 1.00 6.00 41.00 10.00 4.10 341.00 25.00 13.64 
35.00 49.00 1.00 6.00 194.00 40.00 4.85 815.00 150.00 5.43 
36.00 56.00 1.00 6.00 60.00 11.00 5.45 356.00 99.00 3.60 
37.00 47.00 1.00 6.00 46.00 9.00 5.11 447.00 85.00 5.26 
38.00 45.00 1.00 6.00 49.00 12.00 4.08 369.00 75.00 4.92 
39.00 66.00 1.00 6.00 130.00 30.00 4.33 723.00 201.00 3.60 
40.00 63.00 1.00 6.00 34.00 9.00 3.78 417.00 118.00 3.53 
41.00 73.00 1.00 6.00 37.00 14.00 2.64 339.00 75.00 4.52 
42.00 47.00 1.00 6.00 55.00 18.00 3.06 403.00 119.00 3.39 
43.00 41.00 1.00 6.00 40.00 9.00 4.44 351.00 59.00 5.95 
44.00 60.00 1.00 6.00 30.00 6.00 5.00 308.00 73.00 4.22 
45.00 54.00 1.00 6.00 32.00 8.00 4.00 329.00 76.00 4.33 
46.00 68.00 1.00 6.00 38.00 9.00 4.22 340.00 49.00 6.94 
47.00 50.00 1.00 6.00 44.00 10.00 4.40 350.00 33.00 10.61 
48.00 45.00 1.00 6.00 50.00 10.00 5.00 382.00 59.00 6.47 
49.00 41.00 1.00 6.00 70.00 13.00 5.38 467.00 97.00 4.81 
50.00 73.00 1.00 6.00 30.00 7.00 4.29 307.00 58.00 5.29 
51.00 47.00 1.00 6.00 35.00 7.00 5.00 307.00 62.00 4.95 
52.00 65.00 1.00 6.00 140.00 32.00 4.38 742.00 221.00 3.36 
53.00 61.00 1.00 6.00 44.00 7.00 6.29 371.00 27.00 13.74 
54.00 54.00 1.00 6.00 49.00 9.00 5.44 381.00 33.00 11.55 
55.00 46.00 1.00 6.00 36.00 7.00 5.14 318.00 31.00 10.26 
56.00 63.00 1.00 6.00 37.00 8.00 4.63 339.00 44.00 7.70 
57.00 72.00 1.00 6.00 19.00 7.00 2.71 234.00 54.00 4.33 
58.00 38.00 1.00 6.00 64.00 22.00 2.91 402.00 75.00 5.36 
59.00 59.00 1.00 6.00 35.00 9.00 3.89 329.00 58.00 5.67 
60.00 50.00 0.00 6.00 39.00 10.00 3.90 350.00 67.00 5.22 
61.00 52.00 0.00 6.00 38.00 15.00 2.53 318.00 26.00 12.23 
  
280 
Control 
No. 
Age 
(yrs) 
Male/ 
Female 
(0/1) 
C-reactive 
protein 
(mg/l) 
Plasma 
PLP 
(nmol/l) 
Plasma PL 
(nmol/l) 
Plasma 
PLP/PL 
Red cell PLP 
(pmol/g Hb) 
Red cell PL 
(pmol/g Hb) 
Red Cell 
PLP/PL 
62.00 48.00 0.00 6.00 53.00 19.00 2.79 403.00 105.00 3.84 
63.00 53.00 0.00 6.00 33.00 9.00 3.67 318.00 86.00 3.70 
64.00 45.00 0.00 6.00 78.00 27.00 2.89 477.00 144.00 3.31 
65.00 38.00 0.00 6.00 65.00 14.00 4.64 445.00 97.00 4.59 
66.00 57.00 0.00 6.00 154.00 32.00 4.81 774.00 227.00 3.41 
67.00 48.00 0.00 6.00 49.00 13.00 3.77 370.00 26.00 14.23 
68.00 57.00 0.00 6.00 43.00 14.00 3.07 371.00 27.00 13.74 
69.00 39.00 0.00 6.00 36.00 10.00 3.60 328.00 33.00 9.94 
70.00 64.00 0.00 6.00 58.00 11.00 5.27 413.00 53.00 7.79 
71.00 57.00 0.00 6.00 87.00 11.00 7.91 530.00 78.00 6.79 
72.00 37.00 0.00 6.00 70.00 14.00 5.00 466.00 93.00 5.01 
73.00 57.00 0.00 6.00 34.00 8.00 4.25 318.00 112.00 2.84 
74.00 47.00 0.00 6.00 62.00 11.00 5.64 424.00 59.00 7.19 
75.00 71.00 0.00 6.00 26.00 7.00 3.71 297.00 34.00 8.74 
76.00 42.00 0.00 6.00 32.00 8.00 4.00 318.00 33.00 9.64 
77.00 49.00 0.00 6.00 45.00 11.00 4.09 372.00 42.00 8.86 
78.00 35.00 0.00 6.00 33.00 10.00 3.30 318.00 33.00 9.64 
79.00 69.00 0.00 6.00 40.00 10.00 4.00 349.00 84.00 4.15 
80.00 62.00 0.00 6.00 32.00 6.00 5.33 318.00 51.00 6.24 
81.00 71.00 0.00 6.00 51.00 10.00 5.10 381.00 91.00 4.19 
82.00 38.00 0.00 6.00 129.00 10.00 12.90 688.00 105.00 6.55 
83.00 62.00 0.00 6.00 33.00 8.00 4.13 318.00 44.00 7.23 
84.00 58.00 0.00 6.00 31.00 8.00 3.88 318.00 44.00 7.23 
85.00 66.00 0.00 6.00 42.00 10.00 4.20 360.00 42.00 8.57 
86.00 53.00 0.00 6.00 65.00 11.00 5.91 435.00 69.00 6.30 
87.00 38.00 0.00 6.00 49.00 11.00 4.45 382.00 93.00 4.11 
88.00 57.00 0.00 6.00 62.00 10.00 6.20 424.00 92.00 4.61 
89.00 51.00 0.00 6.00 44.00 11.00 4.00 360.00 52.00 6.92 
90.00 40.00 0.00 6.00 164.00 23.00 7.13 657.00 100.00 6.57 
91.00 45.00 0.00 6.00 39.00 6.00 6.50 349.00 92.00 3.79 
92.00 39.00 0.00 6.00 57.00 10.00 5.70 413.00 84.00 4.92 
93.00 48.00 0.00 6.00 41.00 16.00 2.56 465.00 80.00 5.81 
94.00 70.00 0.00 6.00 64.00 15.00 4.27 345.00 75.00 4.60 
95.00 42.00 0.00 6.00 66.00 13.00 5.08 356.00 38.00 9.37 
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Control 
No. 
Age 
(yrs) 
Male/ 
Female 
(0/1) 
C-reactive 
protein 
(mg/l) 
Plasma 
PLP 
(nmol/l) 
Plasma PL 
(nmol/l) 
Plasma 
PLP/PL 
Red cell PLP 
(pmol/g Hb) 
Red cell PL 
(pmol/g Hb) 
Red Cell 
PLP/PL 
96.00 55.00 0.00 6.00 49.00 10.00 4.90 391.00 27.00 14.48 
97.00 48.00 0.00 6.00 49.00 12.00 4.08 342.00 35.00 9.77 
98.00 61.00 0.00 6.00 30.00 8.00 3.75 272.00 38.00 7.16 
99.00 60.00 0.00 6.00 52.00 10.00 5.20 311.00 27.00 11.52 
100.00 57.00 0.00 6.00 52.00 9.00 5.78 316.00 46.00 6.87 
101.00 42.00 0.00 6.00 87.00 17.00 5.12 489.00 49.00 9.98 
102.00 38.00 0.00 6.00 42.00 10.00 4.20 360.00 34.00 10.59 
103.00 39.00 0.00 6.00 60.00 9.00 6.67 424.00 59.00 7.19 
104.00 68.00 0.00 6.00 46.00 8.00 5.75 371.00 26.00 14.27 
105.00 45.00 0.00 6.00 130.00 29.00 4.48 699.00 84.00 8.32 
106.00 56.00 0.00 6.00 48.00 10.00 4.80 371.00 78.00 4.76 
107.00 70.00 0.00 6.00 73.00 6.00 12.17 476.00 129.00 3.69 
108.00 39.00 0.00 6.00 50.00 6.00 8.33 381.00 44.00 8.66 
109.00 70.00 0.00 6.00 82.00 8.00 10.25 508.00 119.00 4.27 
110.00 41.00 0.00 6.00 104.00 5.00 20.80 582.00 142.00 4.10 
111.00 44.00 0.00 6.00 101.00 20.00 5.05 573.00 85.00 6.74 
112.00 51.00 0.00 6.00 134.00 3.00 44.67 700.00 53.00 13.21 
113.00 43.00 0.00 6.00 63.00 11.00 5.73 434.00 69.00 6.29 
114.00 53.00 0.00 6.00 62.00 6.00 10.33 434.00 68.00 6.38 
115.00 44.00 0.00 6.00 55.00 11.00 5.00 402.00 62.00 6.48 
116.00 70.00 0.00 6.00 100.00 8.00 12.50 572.00 91.00 6.29 
117.00 55.00 0.00 6.00 154.00 8.00 19.25 775.00 243.00 3.19 
118.00 51.00 0.00 6.00 74.00 11.00 6.73 476.00 112.00 4.25 
119.00 47.00 0.00 6.00 66.00 8.00 8.25 445.00 82.00 5.43 
120.00 54.00 0.00 6.00 100.00 12.00 8.33 572.00 108.00 5.30 
121.00 63.00 0.00 6.00 72.00 7.00 10.29 466.00 76.00 6.13 
122.00 66.00 0.00 6.00 76.00 9.00 8.44 478.00 82.00 5.83 
123.00 58.00 0.00 6.00 64.00 10.00 6.40 423.00 51.00 8.29 
124.00 59.00 0.00 6.00 58.00 7.00 8.29 403.00 42.00 9.60 
125.00 45.00 0.00 6.00 74.00 9.00 8.22 467.00 116.00 4.03 
126.00 60.00 0.00 6.00 60.00 11.00 5.45 402.00 33.00 12.18 
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Appendix 8. Clinical and biochemical characteristics of critically ill patients (Chapter 4) 
Patient 
No. 
Age 
(yrs) 
Male/ 
Female 
(0/1) 
APACHE 
II score 
Predicted 
Mortality 
(%) 
Medical/
Surgical 
(0/1) 
Pro ICU 
Pabrinex 
doses 
Pro+ICU 
Pabrinex 
doses 
ICU 
Alive/Dead 
(0/1) 
ICU stay 
(days) 
Day of 
follow-up 
sample 
12.00 61.00 0.00 29.00 76.60 0.00 0.00 0.00 0.00 7.40 2.00 
13.00 43.00 1.00 12.00 11.70 1.00 0.00 2.00 0.00 48.10 3.00 
14.00 71.00 1.00 18.00 28.90 1.00 0.00 0.00 1.00 12.90 2.00 
15.00 53.00 1.00 19.00 32.20 0.00 0.00 1.00 0.00 4.80 5.00 
16.00 61.00 0.00 23.00 28.50 0.00 0.00  0.00 1.00  
17.00 18.00 0.00 12.00 20.20 0.00 0.00 3.00 1.00 6.20 4.00 
18.00 67.00 0.00 18.00 44.40 1.00 0.00 0.00 1.00 59.50 4.00 
19.00 50.00 0.00 21.00 38.90 0.00 0.00 3.00 1.00 46.30 4.00 
21.00 61.00 0.00 34.00 76.80 1.00 0.00  0.00 2.00  
22.00 52.00 0.00 13.00 9.90 0.00 95.00 101.00 0.00 3.70 4.00 
23.00 71.00 0.00 23.00 42.50 1.00 9.00 10.00 1.00 20.90 7.00 
24.00 77.00 1.00 21.00 35.00 0.00 0.00  0.00 2.00  
27.00 76.00 1.00 23.00 46.00 0.00 1.00 3.00 0.00 21.70 3.00 
29.00 70.00 0.00 16.00 20.20 1.00 4.00 10.00 0.00 5.10 4.00 
30.00 73.00 1.00 25.00 53.30 1.00 0.00 2.00 1.00 15.50 3.00 
31.00 62.00 0.00 19.00 27.10 1.00 0.00  0.00 0.50  
32.00 55.00 1.00 15.00 21.00 1.00 0.00  0.00 2.20  
33.00 80.00 1.00 31.00 84.20 1.00 0.00 0.00 1.00 12.00 5.00 
34.00 53.00 0.00 26.00 68.60 1.00 6.00 7.00 0.00 29.40 4.00 
35.00 20.00 0.00 18.00 39.70 1.00 0.00 1.00 1.00 44.00 3.00 
36.00 43.00 1.00 38.00 92.60 0.00 5.00 10.00 0.00 25.50 4.00 
37.00 60.00 0.00 27.00 63.10 0.00 0.00 0.00 0.00 21.80 4.00 
38.00 74.00 0.00 20.00 23.00 1.00 0.00  0.00 1.00  
40.00 47.00 0.00 22.00 28.50 1.00 0.00 2.00 0.00 1.90 3.00 
41.00 76.00 1.00 29.00 79.90 1.00 0.00  0.00 1.40  
42.00 79.00 0.00 21.00 30.90 1.00 0.00 3.00 0.00 3.20 4.00 
44.00 81.00 0.00 34.00 86.30 0.00 0.00 0.00 1.00 16.10 8.00 
45.00 74.00 0.00 33.00 75.20 0.00 0.00 0.00 1.00 16.00 5.00 
46.00 41.00 1.00 8.00 15.60 1.00 0.00  0.00 0.80  
47.00 76.00 0.00 29.00 77.20 1.00 0.00 0.00 1.00 34.60 2.00 
48.00 67.00 0.00 31.00 68.10 1.00 1,000.00 1,007.00 1.00 18.40 4.00 
50.00 60.00 0.00 19.00 48.00 1.00 0.00 0.00 0.00 6.20 6.00 
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Patient 
No. 
Age 
(yrs) 
Male/ 
Female 
(0/1) 
APACHE 
II score 
Predicted 
Mortality 
(%) 
Medical/
Surgical 
(0/1) 
Pro ICU 
Pabrinex 
doses 
Pro+ICU 
Pabrinex 
doses 
ICU 
Alive/Dead 
(0/1) 
ICU stay 
(days) 
Day of 
follow-up 
sample 
51.00 46.00 1.00 24.00 49.70 0.00 1,000.00 1,006.00 1.00 4.60 3.00 
52.00 61.00 0.00 33.00 78.60 0.00 7.00 10.00 1.00 7.70 3.00 
53.00 67.00 1.00 18.00 21.20 0.00 0.00 0.00 1.00 11.10 3.00 
55.00 80.00 1.00 31.00 73.30 0.00 0.00 3.00 1.00 8.20 4.00 
56.00 40.00 1.00 6.00 10.20 1.00 0.00  0.00 0.40  
57.00 60.00 0.00 27.00 60.20 1.00 0.00  1.00 1.80  
58.00 41.00 0.00 21.00 17.80 1.00 0.00 0.00 0.00 19.70 2.00 
59.00 68.00 0.00 20.00 32.30 0.00 0.00  0.00 0.80  
60.00 57.00 0.00 24.00 67.00 0.00 0.00  0.00 6.50  
61.00 76.00 1.00 18.00 14.40 0.00 0.00  0.00 0.70  
62.00 74.00 0.00 20.00 19.90 1.00 0.00 0.00 0.00 0.90 3.00 
63.00 62.00 0.00 18.00 44.40 1.00 1,000.00  0.00 1.00  
64.00 66.00 0.00 34.00 81.00 0.00 0.00  0.00 22.40  
65.00 38.00 1.00 17.00 26.20 0.00 0.00  0.00 8.90  
67.00 68.00 1.00 31.00 80.30 0.00 1,000.00 0.00 0.00 5.00 5.00 
68.00 74.00 0.00 24.00 49.70 0.00 0.00 7.00 0.00 10.70 5.00 
69.00 61.00 0.00 22.00 54.90 1.00 1,000.00 1,004.00 0.00 76.40 4.00 
71.00 25.00 0.00 17.00 1.20 0.00 0.00  0.00 2.00  
72.00 51.00 0.00 21.00 12.40 0.00 1.00 1.00 0.00 15.50 12.00 
73.00 69.00 0.00 12.00 20.20 0.00 0.00  0.00 5.80  
74.00 65.00 0.00 33.00 80.40 0.00 0.00 7.00 0.00 19.60 4.00 
75.00 28.00 1.00 14.00 18.50 1.00 0.00  0.00 0.60  
77.00 54.00 1.00 17.00 1.20 0.00 0.00  0.00 0.80  
78.00 45.00 0.00 12.00 5.50 1.00 0.00  0.00 0.90  
79.00 41.00 0.00 7.00 7.60 1.00 0.00 0.00 0.00 9.30 3.00 
80.00 38.00 0.00 16.00 23.30 1.00 1,000.00  0.00 0.80  
83.00 46.00 1.00 11.00 10.30 1.00 0.00  0.00 2.90  
85.00 73.00 0.00 18.00 44.40 1.00 0.00 0.00 0.00 1.40 2.00 
87.00 34.00 1.00 12.00 12.40 1.00 0.00  0.00 2.30  
88.00 81.00 0.00 17.00 23.60 1.00 1,000.00 1,004.00 1.00 9.30 5.00 
89.00 22.00 1.00 10.00 9.50 1.00 0.00  0.00 0.20  
90.00 53.00 0.00 32.00 60.90 1.00 0.00 2.00 0.00 3.00 4.00 
91.00 62.00 0.00 22.00 58.90 1.00 0.00  0.00 1.70  
94.00 32.00 1.00 25.00 53.30 0.00 0.00  0.00 17.30  
96.00 63.00 1.00 18.00 4.80 0.00 0.00 0.00 0.00 1.90 3.00 
99.00 37.00 0.00 13.00 16.50 1.00 0.00  0.00 2.10  
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Patient 
No. 
Age 
(yrs) 
Male/ 
Female 
(0/1) 
APACHE 
II score 
Predicted 
Mortality 
(%) 
Medical/
Surgical 
(0/1) 
Pro ICU 
Pabrinex 
doses 
Pro+ICU 
Pabrinex 
doses 
ICU 
Alive/Dead 
(0/1) 
ICU stay 
(days) 
Day of 
follow-up 
sample 
100.00 50.00 1.00 26.00 38.20 0.00 0.00 12.00 0.00 2.60 3.00 
101.00 35.00 1.00 9.00 4.70 1.00 0.00  0.00 0.80  
102.00 26.00 0.00 23.00 45.70 1.00 0.00  0.00 2.30 2.00 
103.00 52.00 0.00 16.00 12.20 1.00 0.00 0.00 0.00 2.00 3.00 
104.00 38.00 0.00 3.00 2.70 0.00 0.00  0.00 0.30  
105.00 39.00 0.00 34.00 87.50 0.00 1,000.00 1,001.00 0.00 3.00 2.00 
107.00 45.00 1.00 12.00 6.60 1.00 0.00  0.00 3.10  
108.00 44.00 1.00 6.00 0.90 0.00 0.00  0.00 0.80  
110.00 48.00 1.00 26.00 35.20 0.00 0.00 8.00 1.00 4.90 5.00 
111.00 23.00 0.00 9.00 4.30 1.00 0.00 7.00 0.00 9.20 5.00 
112.00 45.00 1.00 24.00 22.40 1.00 0.00 0.00 1.00 10.70 4.00 
113.00 70.00 0.00 27.00 47.70 0.00 0.00 2.00 1.00 6.50 3.00 
114.00 65.00 1.00 24.00 65.70 1.00 0.00 3.00 1.00 6.50 4.00 
115.00 47.00 0.00 10.00 1.50 0.00 0.00  0.00 0.60  
116.00 61.00 0.00 13.00 10.60 0.00 0.00  0.00 2.40  
117.00 48.00 0.00 13.00 8.50 1.00 0.00 2.00 0.00 4.20 4.00 
118.00 59.00 0.00 23.00 39.90 1.00 0.00 1.00 0.00 12.10 2.00 
119.00 67.00 1.00 18.00 14.40 0.00 0.00  0.00 1.30  
121.00 86.00 0.00 22.00 42.20 1.00 0.00 3.00 0.00 6.60 5.00 
123.00 60.00 0.00 16.00 14.60 0.00 1,000.00 1,004.00 0.00 3.10 3.00 
124.00 33.00 0.00 14.00 27.40 1.00 1.00 4.00 0.00 4.70 2.00 
126.00 68.00 0.00 27.00 46.00 0.00 1,000.00  0.00 1.60  
127.00 100.00 0.00 25.00 64.60 1.00 0.00  0.00 3.50  
128.00 80.00 1.00 30.00 56.90 1.00 0.00  0.00 2.90  
129.00 31.00 0.00 19.00 44.00 0.00 0.00  0.00 2.90  
131.00 65.00 0.00 21.00 55.30 1.00 0.00  0.00 6.70  
133.00 35.00 0.00 14.00 7.20 1.00 0.00  0.00 0.90  
135.00 41.00 1.00 16.00 14.30 1.00 0.00  0.00 0.60  
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Patient 
No. 
C-reactive 
protein 
admission 
(mg/l) 
C-reactive 
protein 
follow-up 
(mg/l) 
Albumin 
admission 
(g/l) 
Albumin 
follow-up 
(g/l) 
White cell 
counts 
admission 
(10 (9) cells) 
White cell 
counts 
follow-up 
(10 (9) cells) 
Plasma 
PLP 
admission 
(nmol/l) 
Plasma PLP 
follow-up 
(nmol/l) 
Plasma PL 
admission 
(nmol/l) 
Plasma PL 
follow-up 
(nmol/l) 
Plasma 
PLP/PL 
admission 
Plasma 
PLP/PL 
follow-up 
12.00 126.00 156.00 24.00 23.00 23.00  16.90 12.10 3.00 4.70 5.63 2.57 
13.00 22.00 261.00 27.00 22.00 5.00 8.00 49.20 17.60 10.00 6.60 4.92 2.67 
14.00 220.00 124.00 12.00 10.00 24.90 17.60 5.10 3.10 9.80 12.00 0.52 0.26 
15.00 257.00 73.00 23.00 16.00 11.40 6.60 48.20 37.40 359.20 14.30 0.13 2.62 
16.00 122.00  28.00  5.70  67.80  1,111.60  0.06  
17.00 3.00 55.00 33.00 26.00 11.40 7.70 98.00 30.00 9.00  10.89  
18.00 152.00 64.00 10.00 10.00 12.10 25.00 8.50 6.60 12.00  0.71  
19.00 143.00 101.00 12.00 14.00 17.00 8.00 13.10 59.10 3.80 41.10 3.45 1.44 
21.00 23.00  10.00  14.00  332.60  27.60  12.05  
22.00 20.00 67.00 27.00 15.00 24.80  197.50 71.50 246.30 87.60 0.80 0.82 
23.00 125.00 216.00 10.00 13.00 8.30 10.70 15.80 9.30 4.70 3.40 3.36 2.74 
24.00 81.00  35.00  31.00  39.40  6.90  5.71  
27.00 103.00 133.00 23.00 17.00 3.80 13.70 21.70 30.30 2.30 12.20 9.43 2.48 
29.00 59.00 20.00 9.00 10.00 10.60 22.00 26.70 19.80 75.10 18.40 0.36 1.08 
30.00 26.00 179.00 16.00 11.00 16.70 18.30 12.60 15.10 14.80 42.60 0.85 0.35 
31.00 50.00  22.00  9.20  17.20  3.10  5.55  
32.00 434.00  17.00  14.70  3.80  4.10  0.93  
33.00 259.00 173.00 17.00 10.00 10.00 19.40 6.80 2.30 0.90 3.10 7.56 0.74 
34.00 404.00 336.00 30.00 15.00 10.10 8.70 69.10 19.70 89.80 42.10 0.77 0.47 
35.00 119.00 303.00 9.00 13.00 6.30 8.40 6.90 11.60 1.60 7.50 4.31 1.55 
36.00 132.00 70.00 14.00 14.00 13.80 29.50 33.10 7.60 155.10 20.10 0.21 0.38 
37.00 81.00 35.00 12.00 12.00 31.30 22.00 141.40 27.00 2.90 5.70 48.76 4.74 
38.00 127.00  14.00    6.00  0.60  10.00  
40.00 15.00 234.00 20.00 18.00 3.80 8.00 13.90 30.30 2.70 10.90 5.15 2.78 
41.00 184.00  19.00  16.40  9.00  9.50  0.95  
42.00 8.00 149.00 17.00 18.00 10.00  21.40 45.90 4.70 16.30 4.55 2.82 
44.00 151.00 55.00 10.00 16.00 10.70 17.40 37.10 26.20 5.50 10.40 6.75 2.52 
45.00 258.00 164.00 14.00 14.00 18.90 10.60 154.40 7.20 2.50 6.00 61.76 1.20 
46.00 250.00  11.00  20.20  4.80  2.40  2.00  
47.00 64.00 72.00 24.00 24.00 12.80 13.30 295.70 357.20 18.30 30.30 16.16 11.79 
48.00 119.00 123.00 10.00 9.00  23.50 9.40 16.90 19.20 752.70 0.49 0.02 
50.00 180.00 141.00 23.00 15.00 8.90 17.70 7.90 5.00 0.50 2.10 15.80 2.38 
  
286 
Patient 
No. 
C-reactive 
protein 
admission 
(mg/l) 
C-reactive 
protein 
follow-up 
(mg/l) 
Albumin 
admission 
(g/l) 
Albumin 
follow-up 
(g/l) 
White cell 
counts 
admission 
(10 (9) cells) 
White cell 
counts 
follow-up 
(10 (9) cells) 
Plasma 
PLP 
admission 
(nmol/l) 
Plasma PLP 
follow-up 
(nmol/l) 
Plasma PL 
admission 
(nmol/l) 
Plasma PL 
follow-up 
(nmol/l) 
Plasma 
PLP/PL 
admission 
Plasma 
PLP/PL 
follow-up 
51.00 56.00 58.00 14.00 19.00  10.10 28.80 45.50 285.50 634.50 0.10 0.07 
52.00 565.00 257.00 9.00 9.00 48.60 66.00 38.10 70.10 109.70 259.20 0.35 0.27 
53.00 148.00 131.00 9.00 9.00 4.40 6.10 1.70 1.50 1.30 2.00 1.31 0.75 
55.00 107.00 71.00 13.00 9.00  24.00 1.20 22.00 0.90 109.90 1.33 0.20 
56.00 37.00  16.00  9.60  4.00  1.00  4.00  
57.00 181.00  10.00  6.60  10.30  8.90  1.16  
58.00 6.00 36.00 19.00 12.00   37.40 28.10 6.50 3.90 5.75 7.21 
59.00 32.00  36.00  11.10  151.80  1,106.40  0.14  
60.00 166.00  26.00  12.90  13.20  5.30  2.49  
61.00 380.00  26.00    10.90  6.10  1.79  
62.00 88.00 180.00 12.00 14.00 12.50 12.10 6.40 6.00 8.10 6.10 0.79 0.98 
63.00 117.00  14.00  5.60  15.90  7.10  2.24  
64.00 311.00  18.00  11.60  34.40  2.20  15.64  
65.00 163.00  23.00  16.10  63.10  12.60  5.01  
67.00 438.00 52.00 20.00 16.00 7.30  2.60 9.30 1.30 6.60 2.00 1.41 
68.00 67.00 139.00 11.00 11.00 3.60  9.20 13.10 0.90 250.60 10.22 0.05 
69.00 179.00 356.00 14.00 16.00 2.00  17.60 121.70 2.40 134.50 7.33 0.90 
71.00 2.00  38.00  11.50  89.80  3.60  24.94  
72.00 40.00 89.00 32.00 15.00 35.40 37.60 169.60 20.60 864.70 1.20 0.20 17.17 
73.00 2.00  31.00    27.30  9.00  3.03  
74.00 77.00 28.00 15.00 13.00 7.70 8.70 45.60 42.50 9.00 114.60 5.07 0.37 
75.00 184.00  11.00  4.10  20.70  0.70  29.57  
77.00 2.00  20.00  7.10  43.80  5.00  8.76  
78.00 177.00  27.00  13.20  30.60  1.70  18.00  
79.00 2.00 251.00 24.00 21.00 8.40 16.00 65.20 26.70 1.80 4.10 36.22 6.51 
80.00 126.00  14.00  34.20  21.10  9.50  2.22  
83.00 318.00  21.00  8.70  8.60  2.90  2.97  
85.00 176.00 198.00 11.00 9.00 3.70 7.20 10.40 10.20 6.10 4.70 1.70 2.17 
87.00 110.00  18.00  7.30  9.60  2.00  4.80  
88.00 108.00 104.00 12.00 11.00 11.20 19.30 17.90 24.30 117.20 28.60 0.15 0.85 
89.00 31.00  16.00  11.90  6.80  2.60  2.62  
90.00 159.00 38.00 11.00 29.00   2.20 45.20 9.00 46.00 0.24 0.98 
91.00 268.00  14.00    14.10  3.00  4.70  
  
287 
Patient 
No. 
C-reactive 
protein 
admission 
(mg/l) 
C-reactive 
protein 
follow-up 
(mg/l) 
Albumin 
admission 
(g/l) 
Albumin 
follow-up 
(g/l) 
White cell 
counts 
admission 
(10 (9) cells) 
White cell 
counts 
follow-up 
(10 (9) cells) 
Plasma 
PLP 
admission 
(nmol/l) 
Plasma PLP 
follow-up 
(nmol/l) 
Plasma PL 
admission 
(nmol/l) 
Plasma PL 
follow-up 
(nmol/l) 
Plasma 
PLP/PL 
admission 
Plasma 
PLP/PL 
follow-up 
94.00 147.00  14.00  17.60  23.00  9.00  2.56  
96.00 76.00 27.00 29.00 28.00   9.00 9.00 9.00 9.00 1.00 1.00 
99.00 287.00  22.00  16.40  111.00  258.00  0.43  
100.00 253.00 171.00 13.00 9.00 15.30 29.50 49.00 44.00 912.00 55.00 0.05 0.80 
101.00 231.00  25.00  5.70  9.00  9.00  1.00  
102.00 28.00 198.00 19.00 19.00   33.00 54.00 9.00  3.67  
103.00  69.00 42.00 27.00 10.70 11.40 34.00 84.00 15.00  2.27  
104.00 1.00  34.00    28.00  10.00  2.80  
105.00 25.00 23.00 30.00 29.00 11.60 11.30 50.00 101.00 45.00 160.00 1.11 0.63 
107.00 261.00  17.00  13.60  9.00  9.00  1.00  
108.00 48.00  35.00  14.30  9.00  9.00  1.00  
110.00 199.00 153.00 13.00 11.00 31.20 22.00 9.00 63.00 9.00 1,057.00 1.00 0.06 
111.00 6.00 245.00 28.00 13.00 11.90 3.90 126.00 93.00 9.00 15.00 14.00 6.20 
112.00 2.00 165.00 20.00 9.00 19.30  16.00 9.00 9.00 9.00 1.78 1.00 
113.00 14.00 205.00 31.00 19.00   25.00 24.00 9.00 22.00 2.78 1.09 
114.00 49.00 98.00 16.00 9.00 13.10 22.50 19.00 9.00 8.00 122.00 2.38 0.07 
115.00 1.00  39.00  12.50  9.00  9.00  1.00  
116.00 3.00  24.00  7.80  31.00  12.00  2.58  
117.00 9.00 88.00 32.00 23.00 15.20 5.60 60.00 155.00 9.00 25.00 6.67 6.20 
118.00 252.00 204.00 12.00 9.00 13.70 9.00 20.00 10.00 30.00 9.00 0.67 1.11 
119.00 2.00  25.00    18.00  9.00  2.00  
121.00 203.00 88.00 15.00 15.00   12.00 28.00 9.00  1.33  
123.00 2.00 207.00 45.00 28.00 9.70 8.30 306.00 74.00 519.00  0.59  
124.00 97.00 149.00 15.00 14.00 16.20 33.30 38.00 37.00 11.00 19.00 3.45 1.95 
126.00 3.00  21.00    127.00  1,346.00  0.09  
127.00 316.00  17.00    9.00  9.00  1.00  
128.00 51.00  16.00  24.70  9.00  9.00  1.00  
129.00 63.00  20.00    22.00  744.00  0.03  
131.00 165.00  21.00    15.00  9.00  1.67  
133.00 35.00  16.00    155.00  84.00  1.85  
135.00 221.00  18.00  16.00  9.00  9.00  1.00  
 
  
288 
Patient 
No. 
Red cell PLP 
admission 
(pmol/g Hb) 
Red cell PLP 
follow-up 
(pmol/g Hb) 
Red cell PL 
admission 
(pmol/g 
Hb) 
Red Cell 
PLP/PL 
admission 
Red cell 
PLP/PL 
follow-up 
Red cell PL 
Follow-up 
(pmol/g Hb) 
White cell PLP 
admission 
(pmol/10 (6) 
cells) 
White cell PLP 
follow-up 
(pmol/10 (6) 
cells) 
White cell PL 
admission 
(pmol/ 10 (6) 
cells) 
White cell PL 
follow-up 
(pmol/10 (6) 
cells) 
12.00 348.39 270.11 59.14 5.89 3.41 79.31 1.98 1.97 0.75 0.77 
13.00 345.35 446.74 70.93 4.87 2.13 209.78 2.67 2.55 0.79 1.31 
14.00 624.69 398.84 129.63 4.82 3.15 126.74 2.30 2.09 1.15 1.45 
15.00 2,282.98 131.76 12,431.91 0.18 1.29 102.35 4.06 2.69 6.88 0.68 
16.00 7,870.37  23,635.80 0.33   8.24  5.35  
17.00 331.03 168.67 101.15 3.27 2.00 84.34 3.29 2.48 0.48 0.43 
18.00 216.30 155.91 54.35 3.98 2.38 65.59 2.34 2.08 0.70 0.73 
19.00 334.18 1,558.43 45.57 7.33 1.74 894.38 2.22 5.18 0.43 4.34 
21.00 563.10  279.76 2.01   3.01  1.30  
22.00 25,583.33 4,232.91 53,479.76 0.48 1.56 2,716.46 6.16  10.29  
23.00 396.30 196.20 101.23 3.91 3.60 54.43 3.13 2.15 0.66 0.42 
24.00 241.98  103.70 2.33   2.52  1.03  
27.00 116.28 548.28 39.53 2.94 1.24 442.53 2.19 2.35 0.73 1.71 
29.00 2,274.16 1,725.93 4,038.20 0.56 1.88 918.52 4.38 3.57 6.08 3.58 
30.00 173.91 1,204.49 90.22 1.93 1.46 823.60 2.42 4.09 1.22 7.17 
31.00 158.89  36.67 4.33   2.31  0.32  
32.00 317.24  40.23 7.89   1.30  0.24  
33.00 176.25 204.88 18.75 9.40 3.82 53.66 1.39 1.95 0.34 0.98 
34.00 3,922.58 2,146.15 3,627.96 1.08 1.19 1,798.72 5.18 5.88 5.29 3.52 
35.00 131.03 184.72 35.63 3.68 2.22 83.33 1.93 2.79 0.38 0.69 
36.00 2,983.13 853.01 7,756.63 0.38 2.11 403.61 2.46 2.12 9.79 3.07 
37.00 205.26 280.52 50.00 4.11 3.93 71.43 1.74 1.90 0.56 0.73 
38.00 310.26  32.05 9.68       
40.00 155.42 346.51 18.07 8.60 2.98 116.28 3.47 1.94 0.35 0.56 
41.00 198.77  30.86 6.44   2.18  0.34  
42.00 240.45  41.57 5.78   2.64  0.38  
44.00 720.99 447.06 97.53 7.39 4.75 94.12 1.85 2.07 0.60 1.04 
45.00 325.93 207.32 105.56 3.09   2.05 1.88 0.72 0.48 
46.00 211.63  26.74 7.91   1.75  0.34  
47.00 316.88 514.08 64.94 4.88 9.36 54.93 2.12 2.14 0.54 0.55 
48.00 1,013.92 22,001.47 241.77 4.19 0.76 28,867.65  3.81  9.22 
50.00 313.92 304.29     1.50 1.62 0.52 0.60 
51.00 11,113.89 33,797.44 13,498.61 0.82 1.31 25,896.15 6.15 4.85 4.66 7.28 
  
289 
Patient 
No. 
Red cell PLP 
admission 
(pmol/g Hb) 
Red cell PLP 
follow-up 
(pmol/g Hb) 
Red cell PL 
admission 
(pmol/g 
Hb) 
Red Cell 
PLP/PL 
admission 
Red cell 
PLP/PL 
follow-up 
Red cell PL 
Follow-up 
(pmol/g Hb) 
White cell PLP 
admission 
(pmol/10 (6) 
cells) 
White cell PLP 
follow-up 
(pmol/10 (6) 
cells) 
White cell PL 
admission 
(pmol/ 10 (6) 
cells) 
White cell PL 
follow-up 
(pmol/10 (6) 
cells) 
52.00 7,519.74 2,924.32 3,788.16 1.99 2.04 1,432.43 1.97 1.54 6.15 5.95 
53.00 168.67 142.86 28.92 5.83 6.00 23.81 1.44 1.48 0.26 0.37 
55.00 191.80 5,881.43   1.17 5,027.14  4.67  6.65 
56.00 260.98  23.17 11.26   1.64  0.17  
57.00 208.33  15.48 13.46   0.37  0.07  
58.00 241.05 186.79 58.95 4.09 3.81 49.06     
59.00 8,840.00  22,254.44 0.40   7.21  4.39  
60.00 138.71  21.51 6.45   1.68  0.18  
61.00 181.25  27.50 6.59       
62.00 176.74 78.16     1.94 1.38 0.27 0.17 
63.00 321.35  51.69 6.22   2.79  0.56  
64.00 139.74  24.36 5.74   1.35  0.31  
65.00 642.50  166.25 3.86   1.46  1.04  
67.00 111.39 51.09 17.72 6.29   1.58  0.44  
68.00 213.98 5,347.31 26.88 7.96 0.62 8,679.57 1.32    
69.00 265.88 2,214.63 24.71 10.76 1.36 1,624.39 1.76    
71.00 103.57  14.29 7.25   2.49  0.30  
72.00 13,716.88 321.43 12,640.26 1.09 4.22 76.19 3.98 1.81 8.06 1.48 
73.00 150.00  57.14 2.63       
74.00 254.55 3,167.47     2.26 7.24 0.28 6.46 
75.00 153.85  6.41 24.00   2.07  0.37  
77.00 263.46  44.23 5.96   2.57  0.24  
78.00 279.07  44.19 6.32   2.05  0.38  
79.00 157.14 109.18 25.51 6.16 8.92 12.24 3.56 1.86 0.53 0.54 
80.00 798.80  90.36 8.84   2.68  1.09  
83.00 104.55  31.82 3.29   1.65  0.17  
85.00 201.20 241.57   7.96 30.34 1.64 1.84 0.34 0.40 
87.00 177.89  26.32 6.76   1.36  0.20  
88.00 2,785.37 2,453.25 2,850.00 0.98 2.30 1,067.53 3.83 2.68 4.02 3.93 
89.00 204.85  41.75 4.91   2.05  0.43  
90.00 241.46 1,728.74 39.02 6.19 0.86 2,013.79     
91.00 209.00  28.00 7.46       
94.00 243.68      1.02    
  
290 
Patient 
No. 
Red cell PLP 
admission 
(pmol/g Hb) 
Red cell PLP 
follow-up 
(pmol/g Hb) 
Red cell PL 
admission 
(pmol/g 
Hb) 
Red Cell 
PLP/PL 
admission 
Red cell 
PLP/PL 
follow-up 
Red cell PL 
Follow-up 
(pmol/g Hb) 
White cell PLP 
admission 
(pmol/10 (6) 
cells) 
White cell PLP 
follow-up 
(pmol/10 (6) 
cells) 
White cell PL 
admission 
(pmol/ 10 (6) 
cells) 
White cell PL 
follow-up 
(pmol/10 (6) 
cells) 
96.00 245.83 118.18 16.67 14.75 3.96 29.87     
99.00 2,581.63  4,807.14 0.54   6.10  7.13  
100.00 10,787.95 3,750.00 38,222.89 0.28 1.08 3,465.91 3.63 5.70 7.78 10.32 
101.00           
102.00 177.89 123.96 35.79 4.97 4.10 30.21     
103.00 149.44 501.18 38.20 3.91 1.66 301.18 2.64 2.14 0.46 1.37 
104.00 219.15  60.64 3.61       
105.00 808.79 1,734.83 263.74 3.07 0.81 2,152.81 2.14 4.80 0.97 4.41 
107.00 232.98      1.89  0.53  
108.00 147.47  75.76 1.95   2.32  0.50  
110.00 186.21 2,019.44   0.68 2,950.00 0.89 3.48 0.18 5.35 
111.00 300.00 1,230.00 38.82 7.73 3.71 331.25 3.20 3.43 0.49 1.18 
112.00 160.67 224.71 21.35 7.53 5.97 37.65 2.47  0.53  
113.00 265.22 732.04 40.22 6.59 2.20 333.01     
114.00 196.77 1,715.46   0.88 1,959.79 1.43 3.34 0.33 6.95 
115.00 127.00  23.00 5.52   2.18  0.35  
116.00 383.87          
117.00 222.68 651.96         
118.00 594.38 210.34         
119.00 127.55  21.43 5.95       
121.00 209.30 958.62 29.07 7.20 2.18 440.23     
123.00 11,912.94 4,267.71         
124.00 846.15 1,089.66         
126.00 21,893.41          
127.00 342.68          
128.00 285.23      1.63  0.35  
129.00 23,853.33          
131.00 348.31          
133.00 1,989.00          
135.00 454.88          
  
291 
 
Patient 
No. 
White cell 
PLP/PL 
admission 
White cell 
PLP/PL 
follow-up 
Alkaline 
phosphatase 
admission 
(U/l) 
Alkaline 
phosphatase 
follow-up 
(U/l) 
Haemoglobin 
admission 
(g/dl) 
Haemoglobin 
follow-up 
(g/dl) 
12.00 2.64 2.55 115.00 120.00 13.90 12.60 
13.00 3.36 1.94 277.00 206.00 9.90 7.30 
14.00 1.99 1.44 538.00 406.00 7.50 9.20 
15.00 0.59 3.96 146.00 241.00 10.10 10.90 
16.00 1.54  234.00  12.30  
17.00 6.91 5.70 344.00 213.00 14.90 10.00 
18.00 3.34 2.83 253.00 177.00 12.90 9.90 
19.00 5.14 1.20 184.00 159.00 7.10 8.40 
21.00 2.32  1,221.00  10.10  
22.00 0.60  226.00 136.00 10.10  
23.00 4.72 5.11 170.00 307.00 6.70 10.20 
24.00 2.45  250.00  12.80  
27.00 3.00 1.38 261.00 441.00 12.10 10.80 
29.00 0.72 1.00 168.00 204.00 8.90 9.00 
30.00 1.99 0.57 1,089.00 659.00 10.10 7.80 
31.00 7.21  126.00  12.20  
32.00 5.45  331.00  9.80  
33.00 4.08 1.98 107.00 280.00 12.00 10.60 
34.00 0.98 1.67 96.00 220.00 12.50 8.70 
35.00 5.07 4.06 69.00 121.00 9.50 8.70 
36.00 0.25 0.69 238.00 543.00 8.70 9.50 
37.00 3.11 2.61 264.00 255.00 13.30 13.50 
38.00   398.00  9.20  
40.00 9.83 3.49 35.00 39.00 7.20 8.90 
41.00 6.38  54.00  11.60  
42.00 7.05  26.00 41.00 9.30 10.50 
44.00 3.08 1.98 31.00 88.00 10.90 10.00 
45.00 2.84 3.96 158.00 564.00 7.70 10.10 
46.00 5.12  71.00  8.80  
47.00 3.94 3.92 276.00 264.00 8.50 8.60 
48.00  0.41 121.00 86.00 9.60 10.10 
50.00 2.88 2.70 36.00 94.00  9.60 
  
292 
Patient 
No. 
White cell 
PLP/PL 
admission 
White cell 
PLP/PL 
follow-up 
Alkaline 
phosphatase 
admission 
(U/l) 
Alkaline 
phosphatase 
follow-up 
(U/l) 
Haemoglobin 
admission 
(g/dl) 
Haemoglobin 
follow-up 
(g/dl) 
51.00 1.32 0.67 24.00 99.00 8.90 9.70 
52.00 0.32 0.26 111.00 258.00 8.40 7.20 
53.00 5.57 4.04 96.00 158.00 9.40 8.20 
55.00  0.70 70.00 116.00 8.20 8.50 
56.00 9.42  42.00  8.60  
57.00 5.25  43.00  9.40  
58.00   36.00 22.00 10.00 8.30 
59.00 1.64  52.00  15.20  
60.00 9.54  85.00    
61.00   76.00  9.40  
62.00 7.18 8.07 48.00 55.00 9.20 10.30 
63.00 4.97  67.00  9.90  
64.00 4.36  83.00  8.70  
65.00 1.40  58.00  9.10  
67.00 3.56  212.00 125.00 9.80 11.80 
68.00   28.00 125.00 11.00 8.80 
69.00   47.00 81.00 9.10 9.30 
71.00 8.35  95.00  15.50  
72.00 0.49 1.22 79.00 181.00 10.50 8.20 
73.00   97.00  10.70  
74.00 7.96 1.12 820.00 644.00 11.80 11.50 
75.00 5.55  51.00  7.70  
77.00 10.65  46.00  8.90  
78.00 5.47  148.00  10.00  
79.00 6.66 3.43 47.00 76.00 13.30 12.00 
80.00 2.46  183.00  7.90  
83.00 9.81  81.00  11.80  
85.00 4.82 4.55 16.00 17.00 11.70  
87.00 6.91  79.00  7.40  
88.00 0.95 0.68 77.00 91.00  9.00 
89.00 4.75  67.00  9.40  
90.00   69.00 81.00 8.50 7.90 
91.00   55.00  10.70  
  
293 
Patient 
No. 
White cell 
PLP/PL 
admission 
White cell 
PLP/PL 
follow-up 
Alkaline 
phosphatase 
admission 
(U/l) 
Alkaline 
phosphatase 
follow-up 
(U/l) 
Haemoglobin 
admission 
(g/dl) 
Haemoglobin 
follow-up 
(g/dl) 
94.00   108.00  9.20  
96.00   86.00 108.00 9.70 9.00 
99.00 0.86  105.00  13.70  
100.00 0.47 0.55 183.00 132.00 7.60 8.40 
101.00   40.00  10.10  
102.00   39.00 60.00 8.50 7.70 
103.00 5.75 1.56 71.00 80.00 13.20  
104.00   88.00  11.70  
105.00 2.21 1.09 94.00 98.00 7.00 7.70 
107.00 3.55  71.00  10.50  
108.00 4.69  66.00  12.70  
110.00 5.07 0.65 31.00 113.00 9.00 8.20 
111.00 6.53 2.90 99.00 52.00 16.20 6.80 
112.00 4.68  64.00 43.00 15.40 8.90 
113.00   64.00 40.00 14.90 10.00 
114.00 4.33 0.48 100.00 86.00 10.70 7.70 
115.00 6.31  67.00  14.20  
116.00   50.00  9.70  
117.00   69.00 54.00 12.90 9.30 
118.00   88.00 86.00 8.10 9.20 
119.00   73.00  11.60  
121.00   56.00 166.00 10.00 10.20 
123.00   148.00 80.00 10.50 10.20 
124.00   83.00 107.00 7.00  
126.00   74.00  9.20  
127.00   278.00  8.50  
128.00 4.71  73.00  8.80  
129.00   265.00  11.30  
131.00   74.00  10.60  
133.00   102.00  11.00  
135.00   399.00  7.30  
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12.9 Appendix 9 Chapter 5 data 
Appendix 9. Characteristics and biochemical measurements of controls (Chapter 5) 
Control 
no. 
Age Male/ 
Female 
(0/1) 
C-reactive 
protein 
(mg/l) 
Albumin 
(g/l) 
Total 
protein 
(g/l) 
Plasma α-
tocopherol 
(umol/l) 
Plasma β-
carotene 
(ug/l) 
Free MDA 
(umol/l) 
MDA/ Total 
Protein 
(umol/g) 
Plasma 
ascorbic 
acid 
(umol/l) 
1.00 51.00 0.00 6.00 46.00 77.00 24.00 100.00 0.04 0.01 3 
2.00 53.00 1.00 6.00 41.00 73.00 29.00 272.00 0.04 0.01 57 
3.00 43.00 0.00 6.00 45.00 76.00 25.00 186.00 0.05 0.00 23 
4.00 47.00 0.00 6.00 48.00 78.00 23.00 344.00 0.05 0.00 21 
5.00 55.00 1.00 6.00 44.00 76.00 27.00 150.00 0.05 0.01 34 
6.00 59.00 0.00 6.00 41.00 70.00 38.00 249.00 0.05 0.01 . 
7.00 69.00 1.00 6.00 38.00 71.00 40.00 312.00 0.05 0.01 . 
8.00 45.00 1.00 6.00 45.00 78.00 21.00 271.00 0.06 0.01 48 
9.00 48.00 0.00 8.00 44.00 73.00 31.00 122.00 0.07 0.01 35 
10.00 57.00 0.00 6.00 43.00 72.00 23.00 146.00 0.07 0.01 24 
11.00 58.00 1.00 6.00 48.00 76.00 37.00 157.00 0.07 0.01 71 
12.00 73.00 1.00 6.00 39.00 69.00 37.00 210.00 0.07 0.01 29 
13.00 51.00 0.00 6.00 44.00 74.00 26.00 708.00 0.07 0.01 6 
14.00 62.00 0.00 6.00 41.00 70.00 31.00 258.00 0.07 0.01 57 
15.00 44.00 0.00 6.00 42.00 69.00 33.00 155.00 0.07 0.01 9 
16.00 64.00 1.00 6.00 41.00 76.00 41.00 288.00 0.07 0.01 . 
17.00 59.00 1.00 6.00 43.00 72.00 42.00 595.00 0.08 0.01 43 
18.00 57.00 1.00 6.00 44.00 73.00 29.00 167.00 0.08 0.01 20 
19.00 45.00 1.00 6.00 47.00 70.00 30.00 157.00 0.08 0.01 41 
20.00 52.00 0.00 6.00 43.00 72.00 20.00 152.00 0.08 0.01 24 
21.00 64.00 0.00 6.00 43.00 72.00 31.00 328.00 0.08 0.01 . 
22.00 51.00 1.00 6.00 42.00 71.00 24.00 109.00 0.08 0.01 82 
23.00 50.00 0.00 6.00 44.00 70.00 37.00 100.00 0.08 0.01 54 
24.00 60.00 0.00 6.00 49.00 80.00 27.00 123.00 0.08 0.01 51 
25.00 47.00 0.00 6.00 44.00 72.00 22.00 147.00 0.08 0.01 3 
26.00 53.00 0.00 6.00 46.00 71.00 31.00 102.00 0.09 0.01 10 
27.00 55.00 1.00 6.00 43.00 72.00 33.00 314.00 0.09 0.01 20 
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Control 
no. 
Age Male/ 
Female 
(0/1) 
C-reactive 
protein 
(mg/l) 
Albumin 
(g/l) 
Total 
protein 
(g/l) 
Plasma α-
tocopherol 
(umol/l) 
Plasma β-
carotene 
(ug/l) 
Free MDA 
(umol/l) 
MDA/ Total 
Protein 
(umol/g) 
Plasma 
ascorbic 
acid 
(umol/l) 
28.00 44.00 0.00 6.00 48.00 80.00 24.00 73.00 0.09 0.01 43 
29.00 44.00 1.00 6.00 50.00 80.00 28.00 80.00 0.09 0.01 2 
30.00 56.00 0.00 6.00 47.00 81.00 28.00 87.00 0.09 0.01 47 
31.00 49.00 1.00 6.00 47.00 78.00 31.00 126.00 0.09 0.01 18 
32.00 55.00 1.00 6.00 46.00 76.00 14.00 228.00 0.09 0.01 4 
33.00 52.00 0.00 6.00 41.00 69.00 32.00 202.00 0.09 0.01 43 
34.00 57.00 1.00 6.00 45.00 76.00 25.00 134.00 0.09 0.01 4 
35.00 56.00 0.00 6.00 44.00 74.00 29.00 57.00 0.09 0.01 5 
36.00 71.00 1.00 6.00 41.00 70.00 33.00 255.00 0.09 0.01 . 
37.00 61.00 0.00 6.00 44.00 77.00 37.00 188.00 0.10 0.01 . 
38.00 56.00 0.00 6.00 43.00 66.00 39.00 366.00 0.10 0.02 41 
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Appendix 9. Characteristics and biochemical measurements of patients (Chapter 5) 
Patient No. Age Male/ 
Female (0/1) 
APACHE II Predicte 
mortality 
(%) 
Medical/ 
Surgical (0/1) 
Pro-ICU 
Pabrinex 
(doses) 
Pro+ICU 
Pabrinex 
(doses) 
ICU Death SOFA score 
admission 
SOFA score 
follow-up 
Follow-up 
sample 
(days) 
13.00 43.00 1.00 12.00 11.70 1.00 0.00 2.00 0.00 5.00 9.00 3.00 
14.00 71.00 1.00 18.00 28.90 1.00 0.00 0.00 1.00 8.00 9.00 2.00 
15.00 53.00 1.00 19.00 32.20 0.00 0.00 1.00 0.00 8.00 2.00 5.00 
16.00 61.00 0.00 23.00 28.50 0.00 0.00 -- 0.00 6.00 -- -- 
18.00 67.00 0.00 18.00 44.40 1.00 0.00 0.00 1.00 10.00 10.00 4.00 
19.00 50.00 0.00 21.00 38.90 0.00 0.00 3.00 1.00 10.00 9.00 4.00 
21.00 61.00 0.00 34.00 76.80 1.00 0.00 -- 0.00 8.00 -- -- 
22.00 52.00 0.00 13.00 9.90 0.00 95.00 101.00 0.00 2.00 3.00 4.00 
23.00 71.00 0.00 23.00 42.50 1.00 9.00 10.00 1.00 8.00 4.00 7.00 
24.00 77.00 1.00 21.00 35.00 0.00 0.00 -- 0.00 4.00 -- -- 
27.00 76.00 1.00 23.00 46.00 0.00 1.00 3.00 0.00 5.00 4.00 3.00 
30.00 73.00 1.00 25.00 53.30 1.00 0.00 2.00 1.00 11.00 7.00 3.00 
31.00 62.00 0.00 19.00 27.10 1.00 0.00 -- 0.00 11.00 -- -- 
32.00 55.00 1.00 15.00 21.00 1.00 0.00 -- 0.00 6.00 -- -- 
33.00 80.00 1.00 31.00 84.20 1.00 0.00 0.00 1.00 7.00 8.00 5.00 
34.00 53.00 0.00 26.00 68.60 1.00 6.00 7.00 0.00 6.00 7.00 4.00 
35.00 20.00 0.00 18.00 39.70 1.00 0.00 1.00 1.00 10.00 7.00 3.00 
36.00 43.00 1.00 38.00 92.60 0.00 5.00 10.00 0.00 13.00 10.00 4.00 
40.00 47.00 0.00 22.00 28.50 1.00 0.00 2.00 0.00 9.00 4.00 3.00 
41.00 76.00 1.00 29.00 79.90 1.00 0.00 -- 0.00 8.00 -- -- 
42.00 79.00 0.00 21.00 30.90 1.00 0.00 3.00 0.00 4.00 6.00 4.00 
45.00 74.00 0.00 33.00 75.20 0.00 0.00 0.00 1.00 11.00 5.00 5.00 
47.00 76.00 0.00 29.00 77.20 1.00 0.00 0.00 1.00 7.00 7.00 2.00 
50.00 60.00 0.00 19.00 48.00 1.00 0.00 0.00 0.00 7.00 4.00 6.00 
51.00 46.00 1.00 24.00 49.70 0.00 1,000.00 1,006.00 1.00 14.00 16.00 3.00 
52.00 61.00 0.00 33.00 78.60 0.00 7.00 10.00 1.00 11.00 11.00 3.00 
53.00 67.00 1.00 18.00 21.20 0.00 0.00 0.00 1.00 11.00 10.00 3.00 
56.00 40.00 1.00 6.00 10.20 1.00 0.00 -- 0.00 6.00 -- -- 
60.00 57.00 0.00 24.00 67.00 0.00 0.00 -- 0.00 3.00 -- -- 
62.00 74.00 0.00 20.00 19.90 1.00 0.00 0.00 0.00 1.00 2.00 3.00 
63.00 62.00 0.00 18.00 44.40 1.00 1,000.00 -- 0.00 2.00 -- -- 
64.00 66.00 0.00 34.00 81.00 0.00 0.00 -- 0.00 13.00 -- -- 
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Patient No. Age Male/ 
Female (0/1) 
APACHE II Predicte 
mortality 
(%) 
Medical/ 
Surgical (0/1) 
Pro-ICU 
Pabrinex 
(doses) 
Pro+ICU 
Pabrinex 
(doses) 
ICU Death SOFA score 
admission 
SOFA score 
follow-up 
Follow-up 
sample 
(days) 
65.00 38.00 1.00 17.00 26.20 0.00 0.00 -- 0.00 9.00 -- -- 
67.00 68.00 1.00 31.00 80.30 0.00 1,000.00 0.00 0.00 4.00 4.00 5.00 
71.00 25.00 0.00 17.00 1.20 0.00 0.00 -- 0.00 3.00 -- -- 
72.00 51.00 0.00 21.00 12.40 0.00 1.00 1.00 0.00 11.00 7.00 12.00 
73.00 69.00 0.00 12.00 20.20 0.00 0.00 -- 0.00 3.00 -- -- 
74.00 65.00 0.00 33.00 80.40 0.00 0.00 7.00 0.00 6.00 11.00 4.00 
75.00 28.00 1.00 14.00 18.50 1.00 0.00 -- 0.00 10.00 -- -- 
79.00 41.00 0.00 7.00 7.60 1.00 0.00 0.00 0.00 4.00 3.00 3.00 
80.00 38.00 0.00 16.00 23.30 1.00 1,000.00 -- 0.00 9.00 -- -- 
81.00 71.00 0.00 25.00 35.90 1.00 0.00 1.00 0.00 5.00 6.00 3.00 
82.00 80.00 1.00 17.00 12.70 0.00 0.00 1.00 0.00 1.00 1.00 2.00 
83.00 46.00 1.00 11.00 10.30 1.00 0.00 -- 0.00 4.00 -- -- 
84.00 56.00 0.00 28.00 63.90 0.00 1,000.00 1,006.00 0.00 13.00 10.00 3.00 
85.00 73.00 0.00 18.00 44.40 1.00 0.00 0.00 0.00 6.00 7.00 2.00 
87.00 34.00 1.00 12.00 12.40 1.00 0.00 -- 0.00 6.00 -- -- 
89.00 22.00 1.00 10.00 9.50 1.00 0.00 -- 0.00 2.00 -- -- 
99.00 37.00 0.00 13.00 16.50 1.00 0.00 -- 0.00 5.00 -- -- 
100.00 50.00 1.00 26.00 38.20 0.00 0.00 12.00 0.00 4.00 4.00 3.00 
101.00 35.00 1.00 9.00 4.70 1.00 0.00 -- 0.00 5.00 -- -- 
102.00 26.00 0.00 23.00 45.70 1.00 0.00 -- 0.00 4.00 2.00 2.00 
103.00 52.00 0.00 16.00 12.20 1.00 0.00 0.00 0.00 2.00 1.00 3.00 
104.00 38.00 0.00 3.00 2.70 0.00 0.00 -- 0.00 2.00 -- -- 
105.00 39.00 0.00 34.00 87.50 0.00 1,000.00 1,001.00 0.00 11.00 8.00 2.00 
107.00 45.00 1.00 12.00 6.60 1.00 0.00 -- 0.00 8.00 -- -- 
108.00 44.00 1.00 6.00 0.90 0.00 0.00 -- 0.00 3.00 -- -- 
110.00 48.00 1.00 26.00 35.20 0.00 0.00 8.00 1.00 7.00 12.00 5.00 
111.00 23.00 0.00 9.00 4.30 1.00 0.00 7.00 0.00 7.00 2.00 5.00 
113.00 70.00 0.00 27.00 47.70 0.00 0.00 2.00 1.00 4.00 5.00 3.00 
114.00 65.00 1.00 24.00 65.70 1.00 0.00 3.00 0.00 9.00 8.00 4.00 
115.00 47.00 0.00 10.00 1.50 0.00 0.00 -- 0.00 2.00 -- -- 
116.00 61.00 0.00 13.00 10.60 0.00 0.00 -- 0.00 1.00 -- -- 
117.00 48.00 0.00 13.00 8.50 1.00 0.00 2.00 0.00 3.00 3.00 4.00 
118.00 59.00 0.00 23.00 39.90 1.00 0.00 1.00 0.00 9.00 12.00 2.00 
119.00 67.00 1.00 18.00 14.40 0.00 0.00 -- 0.00 2.00 -- -- 
121.00 86.00 0.00 22.00 42.20 1.00 0.00 3.00 0.00 7.00 4.00 5.00 
123.00 60.00 0.00 16.00 14.60 0.00 1,000.00 1,004.00 0.00 7.00 6.00 3.00 
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Patient No. Age Male/ 
Female (0/1) 
APACHE II Predicte 
mortality 
(%) 
Medical/ 
Surgical (0/1) 
Pro-ICU 
Pabrinex 
(doses) 
Pro+ICU 
Pabrinex 
(doses) 
ICU Death SOFA score 
admission 
SOFA score 
follow-up 
Follow-up 
sample 
(days) 
126.00 68.00 0.00 27.00 46.00 0.00 1,000.00 -- 0.00 5.00 -- -- 
128.00 80.00 1.00 30.00 56.90 1.00 0.00 -- 0.00 7.00 -- -- 
133.00 35.00 0.00 14.00 7.20 1.00 0.00 -- 0.00 0.00 -- -- 
135.00 41.00 1.00 16.00 14.30 1.00 0.00 -- 0.00 2.00 -- -- 
137.00 69.00 1.00 19.00 32.00 1.00 0.00 -- 0.00 4.00 -- -- 
139.00 54.00 1.00 23.00 55.80 1.00 0.00 -- 0.00 8.00 -- -- 
140.00 74.00 0.00 21.00 41.60 1.00 0.00 -- 0.00 8.00 -- -- 
141.00 67.00 0.00 32.00 78.00 1.00 0.00 -- 0.00 10.00 2.00 11.00 
143.00 52.00 0.00 10.00 17.40 1.00 0.00 -- 1.00 2.00 -- -- 
147.00 70.00 0.00 20.00 35.50 1.00 0.00 0.00 0.00 7.00 3.00 2.00 
150.00 62.00 0.00 21.00 38.90 0.00 0.00 -- 0.00 11.00 -- -- 
154.00 49.00 0.00 26.00 4.40 0.00 0.00 -- 0.00 4.00 -- -- 
155.00 43.00 0.00 25.00 3.80 0.00 0.00 -- 0.00 8.00 -- -- 
157.00 61.00 0.00 31.00 81.40 1.00 0.00 -- 0.00 14.00 -- -- 
164.00 62.00 1.00 14.00 9.70 0.00 0.00 -- 0.00 10.00 -- -- 
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Patient No. C-reactive 
protein 
admission 
(mg/l) 
C-reactive 
protein 
follow-up 
(mg/l) 
Albumin 
admission 
(g/l) 
Albumin 
follow-up 
(g/l) 
Total protein 
admission 
(g/l) 
Total protein 
follow-up 
(g/l) 
White cell 
counts 
admission 
(10 (9) cells) 
White cell 
counts 
follow-up (10 
(9) cells) 
Plasma α-
tocopherol 
admission 
(umol/l) 
Red cell α-
tocopherol 
admission 
(umol/g Hb) 
Plasma α-
tocopherol 
follow-up 
(umol/l) 
Red cell α-
tocopherol 
follow-up 
(umol/g Hb) 
13.00 22.00 261.00 27.00 22.00 55.00 47.00 5.00 8.00 15.35 11.30 11.98 11.53 
14.00 220.00 124.00 12.00 10.00 45.00 37.00 24.90 17.60 16.26 22.20 10.49 22.17 
15.00 257.00 73.00 23.00 16.00 63.00 54.00 11.40 6.60 14.48 3.40 26.88 25.78 
16.00 122.00 -- 28.00 -- 72.00 -- 5.70 -- 15.68 16.48 -- -- 
18.00 152.00 64.00 10.00 10.00 31.00 30.00 12.10 25.00 6.27 16.01 14.47 11.94 
19.00 143.00 101.00 12.00 14.00 68.00 38.00 17.00 8.00 17.70 18.62 15.40 12.15 
21.00 23.00 -- 10.00 -- 25.00 -- 14.00 -- 16.03 16.00 -- -- 
22.00 20.00 67.00 27.00 15.00 71.00 40.00 24.80 -- 13.74 18.73 16.90 -- 
23.00 125.00 216.00 10.00 13.00 39.00 48.00 8.30 10.70 7.93 13.47 18.48 18.62 
24.00 81.00 -- 35.00 -- 74.00 -- 31.00 -- 26.95 22.18 -- -- 
27.00 103.00 133.00 23.00 17.00 54.00 46.00 3.80 13.70 24.42 19.14 21.91 25.37 
30.00 26.00 179.00 16.00 11.00 44.00 42.00 16.70 18.30 33.79 39.28 23.73 36.95 
31.00 50.00 -- 22.00 -- 46.00 -- 9.20 -- 14.80 17.83 -- -- 
32.00 434.00 -- 17.00 -- 39.00 -- 14.70 -- 10.30 11.39 -- -- 
33.00 259.00 173.00 17.00 10.00 41.00 35.00 10.00 19.40 11.83 16.94 13.34 19.80 
34.00 404.00 336.00 30.00 15.00 56.00 39.00 10.10 8.70 19.65 15.33 23.17 34.15 
35.00 119.00 303.00 9.00 13.00 27.00 36.00 6.30 8.40 10.16 26.99 16.07 21.66 
36.00 132.00 70.00 14.00 14.00 35.00 39.00 13.80 29.50 6.44 12.38 14.56 27.64 
40.00 15.00 234.00 20.00 18.00 39.00 41.00 3.80 8.00 17.38 21.05 21.31 20.02 
41.00 184.00 -- 19.00 -- 33.00 -- 16.40 -- 10.05 25.22 -- -- 
42.00 8.00 149.00 17.00 18.00 32.00 37.00 10.00 -- 12.37 15.59 14.77 22.05 
45.00 258.00 164.00 14.00 14.00 41.00 45.00 18.90 10.60 15.25 16.23 19.08 19.03 
47.00 64.00 72.00 24.00 24.00 58.00 53.00 12.80 13.30 14.47 18.55 12.24 18.77 
50.00 180.00 141.00 23.00 15.00 31.00 42.00 8.90 17.70 9.98 18.10 15.88 15.54 
51.00 56.00 58.00 14.00 19.00 43.00 47.00 -- 10.10 8.40 -- 12.09 -- 
52.00 565.00 257.00 9.00 9.00 43.00 44.00 48.60 66.00 7.83 16.99 8.64 11.91 
53.00 148.00 131.00 9.00 9.00 34.00 33.00 4.40 6.10 16.34 20.19 19.99 23.66 
56.00 37.00 -- 16.00 -- 33.00 -- 9.60 -- 11.20 17.05 -- -- 
60.00 166.00 -- 26.00 -- 75.00 -- 12.90 -- 30.79 21.47 -- -- 
62.00 88.00 180.00 12.00 14.00 38.00 43.00 12.50 12.10 14.40 18.07 17.15 14.28 
63.00 117.00 -- 14.00 -- 27.00 -- 5.60 -- 9.63 13.00 -- -- 
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Patient No. C-reactive 
protein 
admission 
(mg/l) 
C-reactive 
protein 
follow-up 
(mg/l) 
Albumin 
admission 
(g/l) 
Albumin 
follow-up 
(g/l) 
Total protein 
admission 
(g/l) 
Total protein 
follow-up 
(g/l) 
White cell 
counts 
admission 
(10 (9) cells) 
White cell 
counts 
follow-up (10 
(9) cells) 
Plasma α-
tocopherol 
admission 
(umol/l) 
Red cell α-
tocopherol 
admission 
(umol/g Hb) 
Plasma α-
tocopherol 
follow-up 
(umol/l) 
Red cell α-
tocopherol 
follow-up 
(umol/g Hb) 
64.00 311.00 -- 18.00 -- 64.00 -- 11.60 -- 19.42 20.23 -- -- 
65.00 163.00 -- 23.00 -- 54.00 -- 16.10 -- 10.05 20.07 -- -- 
67.00 438.00 52.00 20.00 16.00 35.00 36.00 7.30 -- 12.43 29.75 25.83 48.37 
71.00 2.00 -- 38.00 -- 75.00 -- 11.50 -- 21.98 17.68 -- -- 
72.00 40.00 89.00 32.00 15.00 58.00 56.00 35.40 37.60 16.40 9.77 33.61 38.31 
73.00 2.00 -- 31.00 -- 62.00 -- -- -- 19.99 16.66 -- -- 
74.00 77.00 28.00 15.00 13.00 48.00 42.00 7.70 8.70 11.23 13.46 12.79 23.73 
75.00 184.00 -- 11.00 -- 37.00 -- 4.10 -- 20.40 17.85 -- -- 
79.00 2.00 251.00 24.00 21.00 44.00 44.00 8.40 16.00 17.25 25.28 21.55 24.34 
80.00 126.00 -- 14.00 -- 58.00 -- 34.20 -- 11.19 -- -- -- 
81.00 8.00 284.00 10.00 21.00 23.00 44.00 5.30 7.60 6.08 21.71 16.42 28.07 
82.00 4.00 86.00 29.00 29.00 60.00 62.00 20.00 21.40 33.45 21.44 24.02 23.52 
83.00 318.00 -- 21.00 -- 48.00 -- 8.70 -- 17.97 12.79 -- -- 
84.00 63.00 80.00 9.00 9.00 29.00 32.00 7.80 19.60 5.33 16.02 8.20 8.18 
85.00 176.00 198.00 11.00 9.00 26.00 27.00 3.70 7.20 8.06 22.33 8.94 20.74 
87.00 110.00 -- 18.00 -- 40.00 -- 7.30 -- 16.63 18.91 -- -- 
89.00 31.00 -- 16.00 -- 33.00 -- 11.90 -- 19.22 19.83 -- -- 
99.00 287.00 -- 22.00 -- 52.00 -- 16.40 -- 15.00 11.60 -- -- 
100.00 253.00 171.00 13.00 9.00 41.00 33.00 15.30 29.50 19.00 22.67 12.00 30.64 
101.00 231.00 -- 25.00 -- 46.00 -- 5.70 -- 15.00 16.68 -- -- 
102.00 28.00 198.00 19.00 19.00 38.00 39.00 -- -- 11.00 23.38 14.00 15.70 
103.00 -- 69.00 42.00 27.00 73.00 49.00 10.70 11.40 41.00 31.49 29.00 38.97 
104.00 1.00 -- 34.00 -- 71.00 -- -- -- 36.00 13.43 -- -- 
105.00 25.00 23.00 30.00 29.00 66.00 57.00 11.60 11.30 13.00 21.66 10.00 8.76 
107.00 261.00 -- 17.00 -- 39.00 -- 13.60 -- 16.00 12.87 -- -- 
108.00 48.00 -- 35.00 -- 70.00 -- 14.30 -- 23.00 -- -- -- 
110.00 199.00 153.00 13.00 11.00 48.00 34.00 31.20 22.00 17.00 23.88 27.00 19.26 
111.00 6.00 245.00 28.00 13.00 53.00 37.00 11.90 3.90 26.00 22.55 18.00 22.30 
113.00 14.00 205.00 31.00 19.00 60.00 43.00 -- -- 17.00 13.13 9.00 14.98 
114.00 49.00 98.00 16.00 9.00 37.00 27.00 13.10 22.50 15.00 16.57 10.00 23.03 
115.00 1.00 -- 39.00 -- 63.00 -- 12.50 -- 24.00 -- -- -- 
116.00 3.00 -- 24.00 -- 48.00 -- 7.80 -- 12.00 -- -- -- 
117.00 9.00 88.00 32.00 23.00 55.00 45.00 15.20 5.60 36.00 -- 29.00 -- 
118.00 252.00 204.00 12.00 9.00 33.00 28.00 13.70 9.00 7.00 16.69 9.00 16.45 
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Patient No. C-reactive 
protein 
admission 
(mg/l) 
C-reactive 
protein 
follow-up 
(mg/l) 
Albumin 
admission 
(g/l) 
Albumin 
follow-up 
(g/l) 
Total protein 
admission 
(g/l) 
Total protein 
follow-up 
(g/l) 
White cell 
counts 
admission 
(10 (9) cells) 
White cell 
counts 
follow-up (10 
(9) cells) 
Plasma α-
tocopherol 
admission 
(umol/l) 
Red cell α-
tocopherol 
admission 
(umol/g Hb) 
Plasma α-
tocopherol 
follow-up 
(umol/l) 
Red cell α-
tocopherol 
follow-up 
(umol/g Hb) 
119.00 2.00 -- 25.00 -- 50.00 -- -- -- 32.00 -- -- -- 
121.00 203.00 88.00 15.00 15.00 37.00 39.00 -- -- 8.00 -- 15.00 -- 
123.00 2.00 207.00 45.00 28.00 83.00 58.00 9.70 8.30 27.00 19.07 24.00 22.45 
126.00 3.00 -- 21.00 -- 46.00 -- -- -- 20.00 -- -- -- 
128.00 51.00 -- 16.00 -- 46.00 -- 24.70 -- 17.00 -- -- -- 
133.00 35.00 -- 16.00 -- 36.00 -- -- -- 6.00 -- -- -- 
135.00 221.00 -- 18.00 -- 58.00 -- 16.00 -- 25.00 -- -- -- 
137.00 218.00 -- 11.00 -- 34.00 -- -- -- 20.00 -- -- -- 
139.00 72.00 -- 14.00 -- 33.00 -- -- -- 6.00 -- -- -- 
140.00 51.00 -- 9.00 -- 26.00 -- -- -- 5.00 -- -- -- 
141.00 143.00 80.00 9.00 9.00 40.00 42.00 -- -- 6.00 -- 22.00 -- 
143.00 39.00 -- 14.00 -- 60.00 -- -- -- 22.00 -- -- -- 
147.00 203.00 216.00 32.00 24.00 56.00 51.00 -- -- 12.00 -- 11.00 -- 
150.00 295.00 -- 24.00 -- 55.00 -- -- -- 12.00 -- -- -- 
154.00 39.00 -- 33.00 -- 62.00 -- -- -- 23.00 -- -- -- 
155.00 52.00 -- 19.00 -- 68.00 -- -- -- 11.00 -- -- -- 
157.00 294.00 -- 13.00 -- 44.00 -- -- -- 6.00 -- -- -- 
164.00 291.00 -- 24.00 -- 58.00 -- -- -- 12.00 -- -- -- 
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Patient No. Plasma β-
carotene 
admission 
(ug/l) 
Plasma β-
carotene 
follow-up 
(ug/l) 
Free MDA 
admission 
(umol/l) 
Free MDA 
follow-up 
(umol/l) 
MDA/Total 
Protein 
admission 
(umol/g) 
MDA/Total 
Protein 
follow-up 
(umol/g) 
Plasma 
ascorbic 
acid 
admission 
(umol/l) 
Plasma 
ascorbic 
acid 
follow-up 
(umol/l) 
White cell 
ascorbic 
acid 
admission 
(umol/10 
(9)  cells) 
White cell 
ascorbic 
acid 
follow-up 
(umol/10 
(9)  cells) 
13.00 0.50 10.90 0.16 0.17 0.02 0.01 24 2 1.9 2.64 
14.00 8.90 0.60 0.58 0.16 0.01 0.02 0.9 3 2.45 3.12 
15.00 3.90 0.40 0.17 0.14 0.02 0.01 16 0.9 2.93 2.1 
16.00 20.40 -- 0.20 -- 0.01 -- 1 . 1.39 . 
18.00 0.30 2.80 0.19 0.17 0.03 0.02 4 3 1.91 1.45 
19.00 117.90 60.30 0.26 0.40 0.01 0.03 37 15 1.76 2.17 
21.00 10.20 -- 0.62 -- 0.09 -- 2 . 0.69 . 
22.00 39.00 39.00 0.38 -- 0.01 -- 136 25 2.57 . 
23.00 28.30 115.40 0.19 0.11 0.01 0.01 20 10 3.02 1.11 
24.00 115.60 -- 0.37 -- 0.02 -- 21 . 1.81 . 
27.00 67.60 183.50 0.22 0.25 0.02 0.02 13 28 3.39 1.41 
30.00 40.10 25.30 0.97 0.56 0.02 0.02 11 . 1.56 . 
31.00 66.90 -- 0.21 -- 0.01 -- 3 . 1.91 . 
32.00 9.30 -- 0.23 -- 0.02 -- 3 . 1.32 . 
33.00 39.00 57.80 0.31 0.61 0.02 0.03 8 5 1.7 2.1 
34.00 0.60 69.50 0.14 0.13 0.01 0.01 59 25 2.91 2.69 
35.00 34.30 54.40 5.96 9.41 0.53 0.57 0.9 4 2.63 2.5 
36.00 14.40 30.40 0.20 0.33 0.02 0.04 59 16 3.81 3.53 
40.00 31.70 11.10 0.06 0.03 0.01 0.01 20 11 1.93 2.2 
41.00 45.20 -- 0.05 -- 0.01 -- 19 . 3.3 . 
42.00 57.10 76.40 -- -- -- -- 0.9 4 1.82 . 
45.00 15.60 50.20 0.06 0.08 0.01 0.01 1 2 0.75 0.84 
47.00 31.20 22.50 0.07 0.13 0.01 0.01 0.9 0.9 0.6 0.67 
50.00 25.90 23.30 0.15 0.09 0.01 0.01 50 3 2.35 2.43 
51.00 23.90 46.70 0.10 0.13 0.01 0.01 11 7 3.06 4.86 
52.00 0.60 0.40 0.18 0.21 0.01 0.01 102 60 . . 
53.00 0.90 1.50 0.10 0.09 0.01 0.01 0.9 1 . . 
56.00 29.70 -- -- -- 0.01 -- 4 . . . 
60.00 85.00 -- 0.07 -- 0.01 -- 12 . . . 
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Patient No. Plasma β-
carotene 
admission 
(ug/l) 
Plasma β-
carotene 
follow-up 
(ug/l) 
Free MDA 
admission 
(umol/l) 
Free MDA 
follow-up 
(umol/l) 
MDA/Total 
Protein 
admission 
(umol/g) 
MDA/Total 
Protein 
follow-up 
(umol/g) 
Plasma 
ascorbic 
acid 
admission 
(umol/l) 
Plasma 
ascorbic 
acid 
follow-up 
(umol/l) 
White cell 
ascorbic 
acid 
admission 
(umol/10 
(9)  cells) 
White cell 
ascorbic 
acid 
follow-up 
(umol/10 
(9)  cells) 
62.00 53.10 85.00 0.05 0.71 0.02 0.02 0.9 . . . 
63.00 20.90 -- 0.06 -- 0.02 -- 0.9 . . . 
64.00 65.60 -- 0.02 -- 0.01 -- 4 . . . 
65.00 -- -- 0.08 -- 0.01 -- 14 . . . 
67.00 22.00 126.00 0.26 0.08 0.02 0.02 11 9 . . 
71.00 16.00 -- 0.04 -- 0.01 -- 6 . . . 
72.00 0.50 187.20 -- -- -- -- 79 . . . 
73.00 51.50 -- 0.05 -- 0.02 -- 0.9 . . . 
74.00 0.30 0.50 -- -- -- -- 2 69 . . 
75.00 18.20 -- 0.18 -- 0.03 -- 0.9 . . . 
79.00 41.90 22.10 -- -- -- -- 0.9 2 . . 
80.00 10.60 -- -- -- -- -- 2 . 1.47 . 
81.00 14.60 21.60 0.08 0.07 0.02 0.01 10 6 1.54 1.46 
82.00 401.80 248.20 -- -- -- -- 0.9 22 . . 
83.00 91.60 -- 0.04 -- 0.02 -- 1 . 1.6 . 
84.00 0.70 14.40 0.13 0.15 0.03 0.03 1 16 1.57 1.42 
85.00 9.00 13.40 -- -- -- -- 1 0.9 . . 
87.00 141.30 -- 0.02 -- 0.01 -- 3 . . . 
89.00 62.60 -- -- -- -- -- 12 . 1.94 . 
99.00 9.00 -- 0.05 -- 0.01 -- 29 . 1.79 . 
100.00 9.00 9.00 0.19 0.12 0.02 0.01 2 24 1.95 5.8 
101.00 46.00 -- 0.07 -- 0.01 -- 17 . 2.12 . 
102.00 44.00 56.00 -- -- -- -- 9 5 . . 
103.00 167.00 218.00 -- -- -- -- 35 18 . . 
104.00 32.00 -- -- -- -- -- 0.9 . . . 
105.00 52.00 32.00 0.15 0.17 0.01 0.01 5 0.9 8.77 1.9 
107.00 311.00 -- 0.08 -- 0.02 -- 16 . . . 
108.00 48.00 -- 0.10 -- 0.01 -- 3 . 1.42 . 
110.00 11.00 16.00 0.09 0.12 0.01 0.02 5 17 1.5 2.54 
111.00 50.00 50.00 -- -- -- -- 2 3 1.99 4.08 
113.00 25.00 9.00 0.35 0.05 0.03 0.01 2 2 . . 
114.00 53.00 18.00 0.12 0.16 0.02 0.02 0.9 2 0.46 1.02 
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Patient No. Plasma β-
carotene 
admission 
(ug/l) 
Plasma β-
carotene 
follow-up 
(ug/l) 
Free MDA 
admission 
(umol/l) 
Free MDA 
follow-up 
(umol/l) 
MDA/Total 
Protein 
admission 
(umol/g) 
MDA/Total 
Protein 
follow-up 
(umol/g) 
Plasma 
ascorbic 
acid 
admission 
(umol/l) 
Plasma 
ascorbic 
acid 
follow-up 
(umol/l) 
White cell 
ascorbic 
acid 
admission 
(umol/10 
(9)  cells) 
White cell 
ascorbic 
acid 
follow-up 
(umol/10 
(9)  cells) 
115.00 51.00 -- 0.05 -- 0.02 -- 17 . 0.99 . 
116.00 9.00 -- 0.06 -- 0.02 -- 0.9 . 0.74 . 
117.00 16.00 15.00 0.06 0.06 0.03 0.01 2 2 . . 
118.00 9.00 9.00 0.05 0.17 0.02 0.02 0.9 0.9 . . 
119.00 140.00 -- 0.06 -- 0.03 -- 11 . . . 
121.00 9.00 27.00 0.08 0.06 0.02 0.01 2 7 . . 
123.00 24.00 73.00 0.04 0.10 0.01 0.01 2 20 . . 
126.00 14.00 -- 0.06 -- 0.01 -- 10 . . . 
128.00 39.00 -- 0.10 -- 0.02 -- 2 . . . 
133.00 9.00 -- 0.08 -- 0.02 -- 17 . . . 
135.00 176.00 -- 0.06 -- 0.01 -- 5 . 2.04 . 
137.00 48.00 -- 0.04 -- 0.01 -- 4 . . . 
139.00 9.00 -- 0.04 -- 0.02 -- 11 . . . 
140.00 9.00 -- 0.08 -- 0.02 -- 1 . . . 
141.00 9.00 13.00 0.12 0.11 0.02 0.01 0.9 0.9 . . 
143.00 518.00 -- 0.08 -- 0.01 -- 3 . . . 
147.00 23.00 24.00 0.05 0.05 0.01 0.01 12 10 . . 
150.00 9.00 -- 0.06 -- 0.01 -- 5 . . . 
154.00 10.00 -- 0.09 -- 0.01 -- 58 . . . 
155.00 92.00 -- 0.19 -- 0.02 -- 28 . . . 
157.00 9.00 -- 0.22 -- 0.01 -- 29 . . . 
164.00 8.00 -- 0.05 -- 0.01 -- 0.9 . . . 
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12.10 Appendix 10 Chapter 6 data 
Appendix 10. Characteristics and biochemical measurements of controls (Chapter 6) 
Control 
no. 
Age 
(yrs) 
Male/ 
Female 
(0/1) 
C-reactive 
protein 
(mg/l) 
Albumin 
(g/l) 
Triglycerides 
(mmol/l) 
Cholesterol 
(mmol/l) 
Plasma α-
tocopherol 
admission 
(umol/l) 
Plasma α-
tocopherol/ 
cholesterol 
admission 
(umol/mmol) 
Plasma α-
tocopherol/ 
triglycerides 
admission 
(umol/mmol) 
1.00 42.00 0.00 6.00 44.00 0.70 4.20 20.00 4.76 28.57 
2.00 42.00 0.00 6.00 44.00 1.60 5.90 27.00 4.58 16.88 
3.00 42.00 0.00 6.00 45.00 1.25 4.95 24.00 4.85 19.20 
4.00 43.00 0.00 6.00 45.00 0.50 5.40 25.00 4.63 50.00 
5.00 44.00 1.00 6.00 50.00 1.50 6.40 28.00 4.38 18.67 
6.00 44.00 0.00 6.00 42.00 2.00 5.85 33.00 5.64 16.50 
7.00 44.00 0.00 6.00 48.00 1.35 4.80 24.00 5.00 17.78 
8.00 45.00 1.00 6.00 45.00 0.55 4.25 21.00 4.94 38.18 
9.00 45.00 1.00 6.00 47.00 1.25 6.15 30.00 4.88 24.00 
10.00 47.00 0.00 6.00 48.00 0.65 5.80 23.00 3.97 35.38 
11.00 47.00 0.00 6.00 44.00 1.05 5.65 22.00 3.89 20.95 
12.00 48.00 0.00 8.00 44.00 1.45 5.75 31.00 5.39 21.38 
13.00 49.00 1.00 6.00 47.00 2.50 5.05 31.00 6.14 12.40 
14.00 50.00 0.00 6.00 44.00 0.55 5.55 37.00 6.67 67.27 
15.00 51.00 1.00 6.00 42.00 1.25 4.50 24.00 5.33 19.20 
16.00 51.00 0.00 6.00 44.00 0.55 5.15 26.00 5.05 47.27 
17.00 51.00 0.00 6.00 46.00 1.00 4.85 24.00 4.95 24.00 
18.00 52.00 0.00 6.00 43.00 1.35 5.40 20.00 3.70 14.81 
19.00 52.00 0.00 6.00 41.00 1.70 5.35 32.00 5.98 18.82 
20.00 53.00 0.00 6.00 46.00 1.25 6.10 31.00 5.08 24.80 
21.00 53.00 1.00 6.00 41.00 0.75 5.00 29.00 5.80 38.67 
22.00 55.00 1.00 6.00 44.00 2.10 5.20 27.00 5.19 12.86 
23.00 55.00 1.00 6.00 46.00 0.50 3.85 14.00 3.64 28.00 
24.00 55.00 1.00 6.00 43.00 0.95 4.50 33.00 7.33 34.74 
25.00 56.00 0.00 6.00 47.00 1.50 5.55 28.00 5.05 18.67 
26.00 56.00 0.00 6.00 44.00 4.05 5.75 29.00 5.04 7.16 
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Control 
no. 
Age 
(yrs) 
Male/ 
Female 
(0/1) 
C-reactive 
protein 
(mg/l) 
Albumin 
(g/l) 
Triglycerides 
(mmol/l) 
Cholesterol 
(mmol/l) 
Plasma α-
tocopherol 
admission 
(umol/l) 
Plasma α-
tocopherol/ 
cholesterol 
admission 
(umol/mmol) 
Plasma α-
tocopherol/ 
triglycerides 
admission 
(umol/mmol) 
27.00 56.00 0.00 6.00 43.00 1.65 6.15 39.00 6.34 23.64 
28.00 57.00 0.00 6.00 43.00 0.85 6.50 23.00 3.54 27.06 
29.00 57.00 1.00 6.00 45.00 1.45 5.90 25.00 4.24 17.24 
30.00 57.00 1.00 6.00 44.00 0.65 5.25 29.00 5.52 44.62 
31.00 58.00 1.00 6.00 48.00 1.30 5.25 37.00 7.05 28.46 
32.00 59.00 1.00 6.00 43.00 0.90 6.90 42.00 6.09 46.67 
33.00 59.00 0.00 6.00 41.00 -- 4.90 38.00 7.76 -- 
34.00 60.00 0.00 6.00 49.00 1.05 7.30 27.00 3.70 25.71 
35.00 61.00 0.00 6.00 44.00 -- 5.50 37.00 6.73 -- 
36.00 62.00 0.00 6.00 41.00 1.20 6.20 31.00 5.00 25.83 
37.00 64.00 1.00 6.00 41.00 -- 4.90 41.00 8.37 -- 
38.00 64.00 0.00 6.00 43.00 -- 5.35 31.00 5.79 -- 
39.00 69.00 1.00 6.00 38.00 -- 6.10 40.00 6.56 -- 
40.00 71.00 1.00 6.00 41.00 -- 5.70 33.00 5.79 -- 
41.00 73.00 1.00 6.00 39.00 -- 5.30 37.00 6.98 -- 
42.00 29.00 1.00 -- -- 1.10 5.30 24.00 4.53 21.82 
43.00 33.00 1.00 -- -- 1.10 4.80 25.00 5.21 22.73 
44.00 60.00 1.00 -- -- 2.35 5.30 29.00 5.47 12.34 
45.00 66.00 0.00 -- -- 1.20 7.00 25.00 3.57 20.83 
46.00 58.00 0.00 -- -- 2.30 6.40 30.00 4.69 13.04 
47.00 30.00 1.00 -- -- 1.50 5.20 27.00 5.19 18.00 
48.00 51.00 0.00 -- -- 1.70 4.10 30.00 7.32 17.65 
49.00 50.00 1.00 -- -- 0.60 5.70 24.00 4.21 40.00 
50.00 47.00 0.00 -- -- 0.65 6.40 30.00 4.69 46.15 
51.00 41.00 1.00 -- -- 1.25 4.80 28.00 5.83 22.40 
52.00 47.00 0.00 -- -- 1.35 6.40 24.00 3.75 17.78 
53.00 61.00 0.00 -- -- 1.60 6.30 29.00 4.60 18.13 
54.00 31.00 0.00 -- -- 1.20 3.70 18.00 4.86 15.00 
55.00 60.00 0.00 -- -- 1.40 7.80 31.00 3.97 22.14 
56.00 69.00 1.00 -- -- 1.50 5.10 30.00 5.88 20.00 
57.00 61.00 0.00 -- -- 2.80 7.50 41.00 5.47 14.64 
58.00 71.00 1.00 -- -- 1.10 4.50 26.00 5.78 23.64 
59.00 56.00 1.00 -- -- 1.18 7.80 47.00 6.03 39.83 
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Control 
no. 
Age 
(yrs) 
Male/ 
Female 
(0/1) 
C-reactive 
protein 
(mg/l) 
Albumin 
(g/l) 
Triglycerides 
(mmol/l) 
Cholesterol 
(mmol/l) 
Plasma α-
tocopherol 
admission 
(umol/l) 
Plasma α-
tocopherol/ 
cholesterol 
admission 
(umol/mmol) 
Plasma α-
tocopherol/ 
triglycerides 
admission 
(umol/mmol) 
60.00 57.00 1.00 -- -- 0.70 4.30 24.00 5.58 34.29 
61.00 79.00 0.00 -- -- 1.10 5.90 36.00 6.10 32.73 
62.00 47.00 0.00 -- -- 1.60 6.70 27.00 4.03 16.88 
63.00 69.00 1.00 -- -- 1.30 4.50 31.00 6.89 23.85 
64.00 75.00 1.00 -- -- 1.00 3.80 27.00 7.11 27.00 
65.00 69.00 1.00 -- -- 1.20 5.70 27.00 4.74 22.50 
66.00 73.00 1.00 -- -- 1.30 3.10 27.00 8.71 20.77 
67.00 51.00 0.00 -- -- 3.60 7.30 40.00 5.48 11.11 
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Appendix 10. Characteristics and biochemical measurements of patients (Chapter 6) 
Patient 
no. 
Age 
(yrs) 
Male/ 
Female 
(0/1) 
APACHE 
II 
Predicted 
Mortality 
(%) 
Medical/ 
Surgical 
(0/1) 
Pro-ICU 
Pabrinex 
(doses) 
Pro+ICU 
Pabrinex 
(doses) 
ICU 
Death 
ICU stay 
(days) 
Hospital 
stay 
(days) 
12.00 61.00 0.00 29.00 76.60 0.00 0.00 0.00 0.00 7.40 13.40 
13.00 43.00 1.00 12.00 11.70 1.00 0.00 2.00 0.00 48.10 50.10 
14.00 71.00 1.00 18.00 28.90 1.00 0.00 0.00 1.00 12.90 12.90 
15.00 53.00 1.00 19.00 32.20 0.00 0.00 1.00 0.00 4.80 10.80 
16.00 61.00 0.00 23.00 28.50 0.00 0.00 -- 0.00 1.00 10.00 
17.00 18.00 0.00 12.00 20.20 0.00 0.00 3.00 1.00 6.20 6.20 
18.00 67.00 0.00 18.00 44.40 1.00 0.00 0.00 1.00 59.50 59.50 
19.00 50.00 0.00 21.00 38.90 0.00 0.00 3.00 1.00 46.30 46.30 
21.00 61.00 0.00 34.00 76.80 1.00 0.00 -- 0.00 2.00 53.00 
22.00 52.00 0.00 13.00 9.90 0.00 95.00 101.00 0.00 3.70 77.00 
23.00 71.00 0.00 23.00 42.50 1.00 9.00 10.00 1.00 20.90 20.90 
24.00 77.00 1.00 21.00 35.00 0.00 0.00 -- 0.00 2.00 6.00 
27.00 76.00 1.00 23.00 46.00 0.00 1.00 3.00 0.00 21.70 21.70 
29.00 70.00 0.00 16.00 20.20 1.00 4.00 10.00 0.00 5.10 85.00 
30.00 73.00 1.00 25.00 53.30 1.00 0.00 2.00 1.00 15.50 15.50 
31.00 62.00 0.00 19.00 27.10 1.00 0.00 -- 0.00 0.50 25.00 
32.00 55.00 1.00 15.00 21.00 1.00 0.00 -- 0.00 2.20 22.20 
33.00 80.00 1.00 31.00 84.20 1.00 0.00 0.00 1.00 12.00 12.00 
34.00 53.00 0.00 26.00 68.60 1.00 6.00 7.00 0.00 29.40 85.00 
35.00 20.00 0.00 18.00 39.70 1.00 0.00 1.00 1.00 44.00 44.00 
36.00 43.00 1.00 38.00 92.60 0.00 5.00 10.00 0.00 25.50 27.50 
37.00 60.00 0.00 27.00 63.10 0.00 0.00 0.00 0.00 21.80 29.00 
38.00 74.00 0.00 20.00 23.00 1.00 0.00 -- 0.00 1.00 150.00 
40.00 47.00 0.00 22.00 28.50 1.00 0.00 2.00 0.00 1.90 19.90 
41.00 76.00 1.00 29.00 79.90 1.00 0.00 -- 0.00 1.40 21.40 
42.00 79.00 0.00 21.00 30.90 1.00 0.00 3.00 0.00 3.20 27.00 
44.00 81.00 0.00 34.00 86.30 0.00 0.00 0.00 1.00 16.10 16.10 
45.00 74.00 0.00 33.00 75.20 0.00 0.00 0.00 1.00 16.00 16.00 
47.00 76.00 0.00 29.00 77.20 1.00 0.00 0.00 1.00 34.60 36.80 
48.00 67.00 0.00 31.00 68.10 1.00 1,000.00 1,007.00 1.00 18.40 18.40 
50.00 60.00 0.00 19.00 48.00 1.00 0.00 0.00 0.00 6.20 124.20 
52.00 61.00 0.00 33.00 78.60 0.00 7.00 10.00 1.00 7.70 7.70 
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Patient 
no. 
Age 
(yrs) 
Male/ 
Female 
(0/1) 
APACHE 
II 
Predicted 
Mortality 
(%) 
Medical/ 
Surgical 
(0/1) 
Pro-ICU 
Pabrinex 
(doses) 
Pro+ICU 
Pabrinex 
(doses) 
ICU 
Death 
ICU stay 
(days) 
Hospital 
stay 
(days) 
53.00 67.00 1.00 18.00 21.20 0.00 0.00 0.00 1.00 11.10 11.10 
55.00 80.00 1.00 31.00 73.30 0.00 0.00 3.00 1.00 8.20 8.20 
56.00 40.00 1.00 6.00 10.20 1.00 0.00 -- 0.00 0.40 0.40 
57.00 60.00 0.00 27.00 60.20 1.00 0.00 -- 1.00 1.80 1.80 
58.00 41.00 0.00 21.00 17.80 1.00 0.00 0.00 0.00 19.70 36.70 
59.00 68.00 0.00 20.00 32.30 0.00 0.00 -- 0.00 0.80 12.00 
60.00 57.00 0.00 24.00 67.00 0.00 0.00 -- 0.00 6.50 59.50 
61.00 76.00 1.00 18.00 14.40 0.00 0.00 -- 0.00 0.70 22.70 
62.00 74.00 0.00 20.00 19.90 1.00 0.00 0.00 0.00 0.90 253.00 
63.00 62.00 0.00 18.00 44.40 1.00 1,000.00 -- 0.00 1.00 508.00 
64.00 66.00 0.00 34.00 81.00 0.00 0.00 -- 0.00 22.40 46.00 
65.00 38.00 1.00 17.00 26.20 0.00 0.00 -- 0.00 18.90 37.00 
67.00 68.00 1.00 31.00 80.30 0.00 1,000.00 0.00 0.00 5.00 8.00 
68.00 74.00 0.00 24.00 49.70 0.00 0.00 7.00 0.00 10.70 27.70 
69.00 61.00 0.00 22.00 54.90 1.00 1,000.00 1,004.00 0.00 76.40 122.40 
71.00 25.00 0.00 17.00 1.20 0.00 0.00 -- 0.00 2.00 3.50 
72.00 51.00 0.00 21.00 12.40 0.00 1.00 1.00 0.00 15.50 40.00 
73.00 69.00 0.00 12.00 20.20 0.00 0.00 -- 0.00 5.80 23.00 
74.00 65.00 0.00 33.00 80.40 0.00 0.00 7.00 0.00 19.60 40.00 
75.00 28.00 1.00 14.00 18.50 1.00 0.00 -- 0.00 0.60 58.00 
77.00 54.00 1.00 17.00 1.20 0.00 0.00 -- 0.00 0.80 12.00 
79.00 41.00 0.00 7.00 7.60 1.00 0.00 0.00 0.00 9.30 19.00 
81.00 71.00 0.00 25.00 35.90 1.00 0.00 1.00 0.00 8.30 20.00 
82.00 80.00 1.00 17.00 12.70 0.00 0.00 1.00 0.00 10.30 29.00 
83.00 46.00 1.00 11.00 10.30 1.00 0.00 -- 0.00 2.90 10.00 
84.00 56.00 0.00 28.00 63.90 0.00 1,000.00 1,006.00 0.00 15.40 35.00 
85.00 73.00 0.00 18.00 44.40 1.00 0.00 0.00 0.00 1.40 160.00 
87.00 34.00 1.00 12.00 12.40 1.00 0.00 -- 0.00 2.30 12.00 
88.00 81.00 0.00 17.00 23.60 1.00 1,000.00 1,004.00 1.00 9.30 10.00 
89.00 22.00 1.00 10.00 9.50 1.00 0.00 -- 0.00 0.20 1.00 
90.00 53.00 0.00 32.00 60.90 1.00 0.00 2.00 0.00 3.00 36.00 
91.00 62.00 0.00 22.00 58.90 1.00 0.00 -- 0.00 1.70 14.00 
94.00 32.00 1.00 25.00 53.30 0.00 0.00 -- 0.00 17.30 24.00 
96.00 63.00 1.00 18.00 4.80 0.00 0.00 0.00 0.00 1.90 15.00 
99.00 37.00 0.00 13.00 16.50 1.00 0.00 -- 0.00 2.10 11.00 
100.00 50.00 1.00 26.00 38.20 0.00 0.00 12.00 0.00 2.60 119.00 
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Patient 
no. 
Age 
(yrs) 
Male/ 
Female 
(0/1) 
APACHE 
II 
Predicted 
Mortality 
(%) 
Medical/ 
Surgical 
(0/1) 
Pro-ICU 
Pabrinex 
(doses) 
Pro+ICU 
Pabrinex 
(doses) 
ICU 
Death 
ICU stay 
(days) 
Hospital 
stay 
(days) 
101.00 35.00 1.00 9.00 4.70 1.00 0.00 -- 0.00 0.80 6.00 
102.00 26.00 0.00 23.00 45.70 1.00 0.00 -- 0.00 2.30 77.00 
103.00 52.00 0.00 16.00 12.20 1.00 0.00 0.00 0.00 2.00 48.00 
104.00 38.00 0.00 3.00 2.70 0.00 0.00 -- 0.00 0.30 5.00 
105.00 39.00 0.00 34.00 87.50 0.00 1,000.00 1,001.00 0.00 3.00 58.00 
107.00 45.00 1.00 12.00 6.60 1.00 0.00 -- 0.00 3.10 48.00 
110.00 48.00 1.00 26.00 35.20 0.00 0.00 8.00 1.00 4.90 6.00 
111.00 23.00 0.00 9.00 4.30 1.00 0.00 7.00 0.00 9.20 48.00 
112.00 45.00 1.00 24.00 22.40 1.00 0.00 0.00 1.00 10.70 12.00 
113.00 70.00 0.00 27.00 47.70 0.00 0.00 2.00 1.00 6.50 7.00 
114.00 65.00 1.00 24.00 65.70 1.00 0.00 3.00 0.00 32.80 61.00 
118.00 59.00 0.00 23.00 39.90 1.00 0.00 1.00 0.00 12.10 24.00 
123.00 60.00 0.00 16.00 14.60 0.00 1,000.00 1,004.00 0.00 3.10 23.00 
129.00 31.00 0.00 19.00 44.00 0.00 0.00 -- 0.00 2.90 54.00 
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Patient no. SOFA 
score 
admission 
SOFA 
score 
follow-up 
Follow-up 
sample 
(days) 
C-reactive 
protein 
admission 
(mg/l) 
C-reactive 
protein 
follow-up 
(mg/l) 
Albumin 
admission 
(g/l) 
Albumin 
follow-up 
(g/l) 
Triglycerides 
admission 
(mmol/l) 
Triglycerides 
follow-up 
(mmol/l) 
Cholesterol 
admission 
(mmol/l) 
Cholesterol 
follow-up 
(mmol/l) 
12.00 7.00 7.00 2.00 126.00 156.00 24.00 23.00 0.61 0.43 1.70 1.73 
13.00 5.00 9.00 3.00 22.00 261.00 27.00 22.00 2.80 1.95 4.27 2.08 
14.00 8.00 9.00 2.00 220.00 124.00 12.00 10.00 1.55 0.82 2.19 1.28 
15.00 8.00 2.00 5.00 257.00 73.00 23.00 16.00 1.52 -- 2.75 -- 
16.00 6.00 -- -- 122.00 -- 28.00 -- 0.75 -- 3.76 -- 
17.00 2.00 0.00 4.00 3.00 55.00 33.00 26.00 0.71 1.93 2.83 2.27 
18.00 10.00 10.00 4.00 152.00 64.00 10.00 10.00 0.80 2.75 0.55 1.47 
19.00 10.00 9.00 4.00 143.00 101.00 12.00 14.00 0.72 1.77 3.06 2.09 
21.00 8.00 -- -- 23.00 -- 10.00 -- 1.60 -- 2.60 -- 
22.00 2.00 3.00 4.00 20.00 67.00 27.00 15.00 1.10 -- 3.00 -- 
23.00 8.00 4.00 7.00 125.00 216.00 10.00 13.00 0.50 0.80 1.10 1.60 
24.00 4.00 -- -- 81.00 -- 35.00 -- 0.80 -- 4.90 -- 
27.00 5.00 4.00 3.00 103.00 133.00 23.00 17.00 1.80 0.80 3.90 2.50 
29.00 4.00 4.00 4.00 59.00 20.00 9.00 10.00 0.80 1.10 0.90 1.80 
30.00 11.00 7.00 3.00 26.00 179.00 16.00 11.00 1.20 0.60 3.80 3.20 
31.00 11.00 -- -- 50.00 -- 22.00 -- 0.60 -- 2.50 -- 
32.00 6.00 -- -- 434.00 -- 17.00 -- 1.10 -- 2.00 -- 
33.00 7.00 8.00 5.00 259.00 173.00 17.00 10.00 0.80 1.00 2.10 1.70 
34.00 6.00 7.00 4.00 404.00 336.00 30.00 15.00 2.01 1.31 1.25 1.94 
35.00 10.00 7.00 3.00 119.00 303.00 9.00 13.00 0.70 1.28 1.27 1.74 
36.00 13.00 10.00 4.00 132.00 70.00 14.00 14.00 0.68 1.02 0.53 1.94 
37.00 10.00 9.00 4.00 81.00 35.00 12.00 12.00 0.38 0.65 0.84 1.35 
38.00 4.00 -- -- 127.00 -- 14.00 -- 1.66 -- 2.40 -- 
40.00 9.00 4.00 3.00 15.00 234.00 20.00 18.00 -- 2.10 -- 2.00 
41.00 8.00 -- -- 184.00 -- 19.00 -- 0.64 -- 1.51 -- 
42.00 4.00 6.00 4.00 8.00 149.00 17.00 18.00 0.50 0.80 2.10 2.40 
44.00 7.00 3.00 8.00 151.00 55.00 10.00 16.00 0.44 1.18 0.98 3.44 
45.00 11.00 5.00 5.00 258.00 164.00 14.00 14.00 0.69 1.18 2.41 2.07 
47.00 7.00 7.00 2.00 64.00 72.00 24.00 24.00 0.80 0.70 2.20 1.80 
48.00 6.00 11.00 4.00 119.00 123.00 10.00 9.00 0.70 0.80 0.90 0.90 
50.00 7.00 4.00 6.00 180.00 141.00 23.00 15.00 1.20 1.10 1.50 1.50 
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Patient no. SOFA 
score 
admission 
SOFA 
score 
follow-up 
Follow-up 
sample 
(days) 
C-reactive 
protein 
admission 
(mg/l) 
C-reactive 
protein 
follow-up 
(mg/l) 
Albumin 
admission 
(g/l) 
Albumin 
follow-up 
(g/l) 
Triglycerides 
admission 
(mmol/l) 
Triglycerides 
follow-up 
(mmol/l) 
Cholesterol 
admission 
(mmol/l) 
Cholesterol 
follow-up 
(mmol/l) 
52.00 11.00 11.00 3.00 565.00 257.00 9.00 9.00 0.70 0.90 1.00 1.40 
53.00 11.00 10.00 3.00 148.00 131.00 9.00 9.00 2.50 2.60 1.70 1.90 
55.00 8.00 8.00 4.00 107.00 71.00 13.00 9.00 0.30 0.20 1.10 0.60 
56.00 6.00 -- -- 37.00 -- 16.00 -- 1.07 -- 1.42 -- 
57.00 10.00 -- -- 181.00 -- 10.00 -- 0.55 -- 0.40 -- 
58.00 4.00 12.00 2.00 6.00 36.00 19.00 12.00 0.95 0.39 2.12 1.13 
59.00 5.00 -- -- 32.00 -- 36.00 -- 5.05 -- 4.23 -- 
60.00 3.00 -- -- 166.00 -- 26.00 -- 2.53 -- 4.56 -- 
61.00 5.00 -- -- 380.00 -- 26.00 -- 2.13 -- 4.60 -- 
62.00 1.00 2.00 3.00 88.00 180.00 12.00 14.00 -- 0.93 -- 2.10 
63.00 2.00 -- -- 117.00 -- 14.00 -- 1.34 -- 1.49 -- 
64.00 13.00 -- -- 311.00 -- 18.00 -- 1.47 -- 1.68 -- 
65.00 9.00 -- -- 163.00 -- 23.00 -- 1.12 -- 1.36 -- 
67.00 4.00 4.00 5.00 438.00 52.00 20.00 16.00 0.87 1.40 1.21 2.47 
68.00 14.00 12.00 5.00 67.00 139.00 11.00 11.00 1.68 1.48 1.44 1.93 
69.00 10.00 13.00 4.00 179.00 356.00 14.00 16.00 0.53 1.63 0.71 0.96 
71.00 3.00 -- -- 2.00 -- 38.00 -- 2.10 -- 3.20 -- 
72.00 11.00 7.00 12.00 40.00 89.00 32.00 15.00 3.40 1.50 3.30 3.10 
73.00 3.00 -- -- 2.00 -- 31.00 -- 1.80 -- 3.30 -- 
74.00 6.00 11.00 4.00 77.00 28.00 15.00 13.00 0.90 1.00 1.30 3.80 
75.00 10.00 -- -- 184.00 -- 11.00 -- 2.80 -- 2.00 -- 
77.00 7.00 -- -- 2.00 -- 20.00 -- 0.50 -- 2.10 -- 
79.00 4.00 3.00 3.00 2.00 251.00 24.00 21.00 -- 1.00 -- 1.80 
81.00 5.00 6.00 3.00 8.00 284.00 10.00 21.00 0.60 1.90 1.10 2.20 
82.00 1.00 1.00 2.00 4.00 86.00 29.00 29.00 0.70 0.40 4.00 2.60 
83.00 4.00 -- -- 318.00 -- 21.00 -- 0.80 -- 3.10 -- 
84.00 13.00 10.00 3.00 63.00 80.00 9.00 9.00 0.90 2.20 0.90 1.10 
85.00 6.00 7.00 2.00 176.00 198.00 11.00 9.00 0.30 0.50 1.20 1.20 
87.00 6.00 -- -- 110.00 -- 18.00 -- 0.70 -- 2.60 -- 
88.00 9.00 9.00 5.00 108.00 104.00 12.00 11.00 0.80 0.60 1.70 1.70 
89.00 2.00 -- -- 31.00 -- 16.00 -- 1.50 -- 2.70 -- 
90.00 10.00 7.00 4.00 159.00 38.00 11.00 29.00 1.60 1.80 1.60 1.90 
91.00 9.00 -- -- 268.00 -- 14.00 -- 1.30 -- 1.60 -- 
94.00 18.00 -- -- 147.00 -- 14.00 -- 2.60 -- 1.90 -- 
  
313 
Patient no. SOFA 
score 
admission 
SOFA 
score 
follow-up 
Follow-up 
sample 
(days) 
C-reactive 
protein 
admission 
(mg/l) 
C-reactive 
protein 
follow-up 
(mg/l) 
Albumin 
admission 
(g/l) 
Albumin 
follow-up 
(g/l) 
Triglycerides 
admission 
(mmol/l) 
Triglycerides 
follow-up 
(mmol/l) 
Cholesterol 
admission 
(mmol/l) 
Cholesterol 
follow-up 
(mmol/l) 
96.00 3.00 2.00 3.00 76.00 27.00 29.00 28.00 1.60 1.10 4.40 4.40 
99.00 5.00 -- -- 287.00 -- 22.00 -- 1.06 -- 2.50 -- 
100.00 4.00 4.00 3.00 253.00 171.00 13.00 9.00 2.40 0.50 2.30 1.40 
101.00 5.00 -- -- 231.00 -- 25.00 -- 0.70 -- 2.20 -- 
102.00 4.00 2.00 2.00 28.00 198.00 19.00 19.00 0.60 2.40 1.70 1.80 
103.00 2.00 1.00 3.00 -- 69.00 42.00 27.00 3.30 -- 4.10 -- 
104.00 2.00 -- -- 1.00 -- 34.00 -- 4.70 -- 6.40 -- 
105.00 11.00 8.00 2.00 25.00 23.00 30.00 29.00 1.00 0.60 2.00 1.90 
107.00 8.00 -- -- 261.00 -- 17.00 -- -- -- -- -- 
110.00 7.00 12.00 5.00 199.00 153.00 13.00 11.00 1.10 3.20 1.60 2.10 
111.00 7.00 2.00 5.00 6.00 245.00 28.00 13.00 2.00 2.10 4.00 1.60 
112.00 1.00 10.00 4.00 2.00 165.00 20.00 9.00 1.20 0.80 5.20 1.70 
113.00 4.00 5.00 3.00 14.00 205.00 31.00 19.00 1.30 0.40 2.70 1.40 
114.00 9.00 8.00 4.00 49.00 98.00 16.00 9.00 1.40 0.70 2.20 1.00 
118.00 9.00 12.00 2.00 252.00 204.00 12.00 9.00 0.70 1.10 0.70 1.00 
123.00 7.00 6.00 3.00 2.00 207.00 45.00 28.00 1.90 0.80 4.80 3.90 
129.00 12.00 -- -- 63.00 -- 20.00 -- -- -- -- -- 
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Patient no. Plasma α-
tocopherol 
admission 
(umol/l) 
Plasma α-
tocopherol/ 
cholesterol 
admission 
(umol/mmol) 
Plasma α-
tocopherol/ 
triglycerides 
admission 
(umol/mmol) 
Red cell α-
tocopherol 
admission 
(pmol/g Hb) 
Plasma α-
tocopherol 
follow-up 
(umol/l) 
Plasma α-
tocopherol/ 
cholesterol 
follow-up 
(umol/mmol) 
Plasma α-
tocopherol/ 
triglycerides 
follow-up 
(umol/mmol) 
Red cell α-
tocopherol 
follow-up 
(pmol/g Hb) 
12.00 14.36 8.45 23.54 17.58 12.70 7.34 29.53 19.51 
13.00 15.35 3.59 5.48 11.30 11.98 5.76 6.14 11.53 
14.00 16.26 7.42 10.49 22.20 10.49 8.20 12.79 22.17 
15.00 14.48 5.27 9.53 3.40 26.88 -- -- 25.78 
16.00 15.68 4.17 20.91 16.48 -- -- -- -- 
17.00 17.00 6.01 23.94 19.66 17.00 7.49 8.81 13.93 
18.00 6.27 11.40 7.84 16.01 14.47 9.84 5.26 11.94 
19.00 17.70 5.78 24.58 18.62 15.40 7.37 8.70 12.15 
21.00 16.03 6.17 10.02 16.00 -- -- -- -- 
22.00 13.74 4.58 12.49 18.73 16.90 -- -- -- 
23.00 7.93 7.21 15.86 13.47 18.48 11.55 23.10 18.62 
24.00 26.95 5.50 33.69 22.18 -- -- -- -- 
27.00 24.42 6.26 13.57 19.14 21.91 8.76 27.39 25.37 
29.00 10.91 12.12 13.64 19.67 16.56 9.20 15.05 21.26 
30.00 33.79 8.89 28.16 39.28 23.73 7.42 39.55 36.95 
31.00 14.80 5.92 24.67 17.83 -- -- -- -- 
32.00 10.30 5.15 9.36 11.39 -- -- -- -- 
33.00 11.83 5.63 14.79 16.94 13.34 7.85 13.34 19.80 
34.00 19.65 15.72 9.78 15.33 23.17 11.94 17.69 34.15 
35.00 10.16 8.00 14.51 26.99 16.07 9.24 12.55 21.66 
36.00 6.44 12.15 9.47 12.38 14.56 7.51 14.27 27.64 
37.00 6.25 7.44 16.45 16.08 10.86 8.04 16.71 19.80 
38.00 20.99 8.75 12.64 18.59 -- -- -- -- 
40.00 17.38 -- -- 21.05 21.31 10.66 10.15 20.02 
41.00 10.05 6.66 15.70 25.22 -- -- -- -- 
42.00 12.37 5.89 24.74 15.59 14.77 6.15 18.46 22.05 
44.00 8.31 8.48 18.89 18.50 35.61 10.35 30.18 26.89 
45.00 15.25 6.33 22.10 16.23 19.08 9.22 16.17 19.03 
47.00 14.47 6.58 18.09 18.55 12.24 6.80 17.49 18.77 
48.00 8.06 8.96 11.51 24.40 7.13 7.92 8.91 15.01 
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Patient no. Plasma α-
tocopherol 
admission 
(umol/l) 
Plasma α-
tocopherol/ 
cholesterol 
admission 
(umol/mmol) 
Plasma α-
tocopherol/ 
triglycerides 
admission 
(umol/mmol) 
Red cell α-
tocopherol 
admission 
(pmol/g Hb) 
Plasma α-
tocopherol 
follow-up 
(umol/l) 
Plasma α-
tocopherol/ 
cholesterol 
follow-up 
(umol/mmol) 
Plasma α-
tocopherol/ 
triglycerides 
follow-up 
(umol/mmol) 
Red cell α-
tocopherol 
follow-up 
(pmol/g Hb) 
50.00 9.98 6.65 8.32 18.10 15.88 10.59 14.44 15.54 
52.00 7.83 7.83 11.19 16.99 8.64 6.17 9.60 11.91 
53.00 16.34 9.61 6.54 20.19 19.99 10.52 7.69 23.66 
55.00 8.12 7.38 27.07 26.96 7.12 11.87 35.60 24.43 
56.00 11.20 7.89 10.47 17.05 -- -- -- -- 
57.00 3.55 8.88 6.45 21.03 -- -- -- -- 
58.00 11.37 5.36 11.97 17.17 5.95 5.27 15.26 18.57 
59.00 33.30 7.87 6.59 21.69 -- -- -- -- 
60.00 30.79 6.75 12.17 21.47 -- -- -- -- 
61.00 31.14 6.77 14.62 27.94 -- -- -- -- 
62.00 14.40 -- -- 18.07 17.15 8.17 18.44 14.28 
63.00 9.63 6.46 7.19 13.00 -- -- -- -- 
64.00 19.42 11.56 13.21 20.23 -- -- -- -- 
65.00 10.05 7.39 8.97 20.07 -- -- -- -- 
67.00 12.43 10.27 14.29 29.75 25.83 10.46 18.45 48.37 
68.00 10.01 6.95 5.96 19.01 18.30 9.48 12.36 30.88 
69.00 5.31 7.48 10.02 16.86 11.39 11.86 6.99 15.25 
71.00 21.98 6.87 10.47 17.68 -- -- -- -- 
72.00 16.40 4.97 4.82 9.77 33.61 10.84 22.41 38.31 
73.00 19.99 6.06 11.11 16.66 -- -- -- -- 
74.00 11.23 8.64 12.48 13.46 12.79 3.37 12.79 23.73 
75.00 20.40 10.20 7.29 17.85 -- -- -- -- 
77.00 13.23 6.30 26.46 26.49 -- -- -- -- 
79.00 17.25 -- -- 25.28 21.55 11.97 21.55 24.34 
81.00 6.08 5.53 10.13 21.71 16.42 7.46 8.64 28.07 
82.00 33.45 8.36 47.79 21.44 24.02 9.24 60.05 23.52 
83.00 17.97 5.80 22.46 12.79 -- -- -- -- 
84.00 5.33 5.92 5.92 16.02 8.20 7.45 3.73 8.18 
85.00 8.06 6.72 26.87 22.33 8.94 7.45 17.88 20.74 
87.00 16.63 6.40 23.76 18.91 -- -- -- -- 
88.00 12.70 7.47 15.88 23.14 17.83 10.49 29.72 32.48 
89.00 19.22 7.12 12.81 19.83 -- -- -- -- 
90.00 15.93 9.96 9.96 22.65 17.29 9.10 9.61 27.27 
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Patient no. Plasma α-
tocopherol 
admission 
(umol/l) 
Plasma α-
tocopherol/ 
cholesterol 
admission 
(umol/mmol) 
Plasma α-
tocopherol/ 
triglycerides 
admission 
(umol/mmol) 
Red cell α-
tocopherol 
admission 
(pmol/g Hb) 
Plasma α-
tocopherol 
follow-up 
(umol/l) 
Plasma α-
tocopherol/ 
cholesterol 
follow-up 
(umol/mmol) 
Plasma α-
tocopherol/ 
triglycerides 
follow-up 
(umol/mmol) 
Red cell α-
tocopherol 
follow-up 
(pmol/g Hb) 
91.00 15.56 9.73 11.97 18.69 -- -- -- -- 
94.00 14.00 7.37 5.38 13.45 -- -- -- -- 
96.00 27.00 6.14 16.88 29.52 27.00 6.14 24.55 29.33 
99.00 15.00 6.00 14.15 11.60 -- -- -- -- 
100.00 19.00 8.26 7.92 22.67 12.00 8.57 24.00 30.64 
101.00 15.00 6.82 21.43 16.68 -- -- -- -- 
102.00 11.00 6.47 18.33 23.38 14.00 7.78 5.83 15.70 
103.00 41.00 10.00 12.42 31.49 29.00 -- -- 38.97 
104.00 36.00 5.63 7.66 13.43 -- -- -- -- 
105.00 13.00 6.50 13.00 21.66 10.00 5.26 16.67 8.76 
107.00 16.00 -- -- 12.87 -- -- -- -- 
110.00 17.00 10.63 15.45 23.88 27.00 12.86 8.44 19.26 
111.00 26.00 6.50 13.00 22.55 18.00 11.25 8.57 22.30 
112.00 28.00 5.38 23.33 24.97 12.00 7.06 15.00 25.82 
113.00 17.00 6.30 13.08 13.13 9.00 6.43 22.50 14.98 
114.00 15.00 6.82 10.71 16.57 10.00 10.00 14.29 23.03 
118.00 7.00 10.00 10.00 16.69 9.00 9.00 8.18 16.45 
123.00 27.00 5.63 14.21 19.07 24.00 6.15 30.00 22.45 
129.00 12.00 -- -- 5.15 -- -- -- -- 
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12.11 Appendix 11 Chapter 7 data 
Appendix 11. Characteristics and biochemical measurements of controls (Chapter 7) 
Control 
no. 
Age 
(yrs) 
Male/ 
Female 
(0/1) 
C-reactive 
protein 
(mg/l) 
Albumin 
(g/l) 
Total 
protein 
(g/l) 
Triglycerides 
(mmol/l) 
Cholesterol 
(mmol/l) 
Plasma 
retinol 
(umol/l) 
Plasma α-
tocopherol 
(umol/l) 
Plasma α-
tocopherol/ 
cholesterol 
(umol/mmol) 
1.00 59.00 1.00 6.00 43.00 72.00 0.90 6.90 1.30 42.00 6.09 
2.00 53.00 1.00 6.00 41.00 73.00 0.75 5.00 1.60 29.00 5.80 
3.00 45.00 1.00 6.00 45.00 78.00 0.55 4.25 1.60 21.00 4.94 
4.00 48.00 0.00 8.00 44.00 73.00 1.45 5.75 1.60 31.00 5.39 
5.00 57.00 1.00 6.00 44.00 73.00 0.65 5.25 1.60 29.00 5.52 
6.00 52.00 0.00 6.00 43.00 72.00 1.35 5.40 1.60 20.00 3.70 
7.00 71.00 1.00 6.00 41.00 70.00 -- 5.70 1.60 33.00 5.79 
8.00 55.00 1.00 6.00 43.00 72.00 0.95 4.50 1.70 33.00 7.33 
9.00 55.00 1.00 6.00 46.00 76.00 0.50 3.85 1.70 14.00 3.64 
10.00 57.00 1.00 6.00 45.00 76.00 1.45 5.90 1.70 25.00 4.24 
11.00 53.00 0.00 6.00 46.00 71.00 1.25 6.10 1.80 31.00 5.08 
12.00 61.00 0.00 6.00 44.00 77.00 -- 5.50 1.80 37.00 6.73 
13.00 73.00 1.00 6.00 39.00 69.00 -- 5.30 1.90 37.00 6.98 
14.00 51.00 0.00 6.00 44.00 74.00 0.55 5.15 1.90 26.00 5.05 
15.00 64.00 0.00 6.00 43.00 72.00 -- 5.35 1.90 31.00 5.79 
16.00 51.00 0.00 6.00 46.00 77.00 1.00 4.85 2.00 24.00 4.95 
17.00 47.00 0.00 6.00 48.00 78.00 0.65 5.80 2.00 23.00 3.97 
18.00 69.00 1.00 6.00 38.00 71.00 -- 6.10 2.00 40.00 6.56 
19.00 64.00 1.00 6.00 41.00 76.00 -- 4.90 2.10 41.00 8.37 
20.00 44.00 1.00 6.00 50.00 80.00 1.50 6.40 2.10 28.00 4.38 
21.00 56.00 0.00 6.00 47.00 81.00 1.50 5.55 2.10 28.00 5.05 
22.00 44.00 0.00 6.00 48.00 80.00 1.35 4.80 2.20 24.00 5.00 
23.00 56.00 0.00 6.00 43.00 66.00 1.65 6.15 2.20 39.00 6.34 
24.00 55.00 1.00 6.00 44.00 76.00 2.10 5.20 2.30 27.00 5.19 
25.00 59.00 0.00 6.00 41.00 70.00 -- 4.90 2.30 38.00 7.78 
26.00 44.00 0.00 6.00 42.00 69.00 2.00 5.85 2.30 33.00 5.64 
27.00 52.00 0.00 6.00 41.00 69.00 1.70 5.35 2.40 32.00 5.98 
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Control 
no. 
Age 
(yrs) 
Male/ 
Female 
(0/1) 
C-reactive 
protein 
(mg/l) 
Albumin 
(g/l) 
Total 
protein 
(g/l) 
Triglycerides 
(mmol/l) 
Cholesterol 
(mmol/l) 
Plasma 
retinol 
(umol/l) 
Plasma α-
tocopherol 
(umol/l) 
Plasma α-
tocopherol/ 
cholesterol 
(umol/mmol) 
28.00 43.00 0.00 6.00 45.00 76.00 0.50 5.40 2.50 25.00 4.63 
29.00 51.00 1.00 6.00 42.00 71.00 1.25 4.50 2.50 24.00 5.33 
30.00 58.00 1.00 6.00 48.00 76.00 1.30 5.25 2.60 37.00 7.05 
31.00 47.00 0.00 6.00 44.00 72.00 1.05 5.65 2.70 22.00 3.89 
32.00 49.00 1.00 6.00 47.00 78.00 2.50 5.05 2.70 31.00 6.14 
33.00 62.00 0.00 6.00 41.00 70.00 1.20 6.20 2.80 31.00 5.00 
34.00 56.00 0.00 6.00 44.00 74.00 4.05 5.75 2.80 29.00 5.04 
35.00 57.00 0.00 6.00 43.00 72.00 0.85 6.50 2.90 23.00 3.54 
36.00 45.00 1.00 6.00 47.00 70.00 1.25 6.15 3.30 30.00 4.88 
37.00 50.00 0.00 6.00 44.00 70.00 0.55 5.55 3.40 37.00 6.67 
38.00 60.00 0.00 6.00 49.00 80.00 1.05 7.30 3.60 27.00 3.70 
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Control 
no. 
Plasma 
lutein 
(ug/l) 
Plasma 
lutein/ 
cholesterol 
(ug/mmol) 
Plasma 
lycopene 
(ug/l) 
Plasma 
lycopene/ 
cholesterol 
(ug/mmol) 
Plasma α-
carotene 
(ug/l) 
Plasma α-
carotene/ 
cholesterol 
(ug/mmol) 
Plasma β-
carotene 
(ug/l) 
Plasma β-
carotene/ 
cholesterol 
(ug/mmol) 
Total 
MDA 
(umol/l) 
Free MDA 
(umol/l) 
Free/ 
Total 
MDA  
MDA/ 
Total 
Protein 
(umol/g) 
1.00 329.00 47.68 277.00 40.14 27.00 3.91 595.00 86.23 0.95 0.08 0.08 0.01 
2.00 118.00 23.60 245.00 49.00 14.00 2.80 272.00 54.40 0.59 0.04 0.07 0.01 
3.00 82.00 19.29 171.00 40.24 39.00 9.18 271.00 63.76 0.47 0.06 0.13 0.01 
4.00 149.00 25.91 207.00 36.00 19.00 3.30 122.00 21.22 0.53 0.07 0.12 0.01 
5.00 229.00 43.62 286.00 54.48 27.00 5.14 167.00 31.81 0.60 0.08 0.13 0.01 
6.00 58.00 10.74 181.00 33.52 14.00 2.59 152.00 28.15 0.66 0.08 0.12 0.01 
7.00 89.00 15.61 168.00 29.47 11.00 1.93 255.00 44.74 0.89 0.09 0.10 0.01 
8.00 174.00 38.67 379.00 84.22 55.00 12.22 314.00 69.78 0.71 0.09 0.12 0.01 
9.00 137.00 35.58 189.00 49.09 26.00 6.75 228.00 59.22 1.00 0.09 0.09 0.01 
10.00 115.00 19.49 268.00 45.42 10.00 1.69 134.00 22.71 0.71 0.09 0.13 0.01 
11.00 135.00 22.13 304.00 49.84 17.00 2.79 102.00 16.72 0.71 0.09 0.12 0.01 
12.00 81.00 14.73 144.00 26.18 11.00 2.00 188.00 34.18 1.10 0.10 0.09 0.01 
13.00 97.00 18.30 179.00 33.77 12.00 2.26 210.00 39.62 0.65 0.07 0.10 0.01 
14.00 138.00 26.80 483.00 93.79 63.00 12.23 708.00 137.48 0.47 0.07 0.15 0.01 
15.00 188.00 35.14 211.00 39.44 18.00 3.36 328.00 61.31 0.73 0.08 0.11 0.01 
16.00 69.00 14.23 178.00 36.70 10.00 2.06 100.00 20.62 0.60 0.04 0.06 0.01 
17.00 130.00 22.41 138.00 23.79 40.00 6.90 344.00 59.31 0.36 0.05 0.13 0.00 
18.00 105.00 17.21 171.00 28.03 16.00 2.62 312.00 51.15 0.44 0.05 0.12 0.01 
19.00 110.00 22.45 185.00 37.76 23.00 4.69 288.00 58.78 0.61 0.07 0.12 0.01 
20.00 62.00 9.69 180.00 28.13 15.00 2.34 80.00 12.50 0.95 0.09 0.09 0.01 
21.00 129.00 23.24 218.00 39.28 16.00 2.88 87.00 15.68 0.71 0.09 0.12 0.01 
22.00 301.00 62.71 64.00 13.33 10.00 2.08 73.00 15.21 0.89 0.09 0.10 0.01 
23.00 207.00 33.66 187.00 30.41 75.00 12.20 366.00 59.51 1.06 0.10 0.09 0.02 
24.00 111.00 21.35 93.00 17.88 10.00 1.92 150.00 28.85 0.40 0.05 0.13 0.01 
25.00 116.00 23.67 199.00 40.61 15.00 3.06 249.00 50.82 0.65 0.05 0.08 0.01 
26.00 85.00 14.53 153.00 26.15 15.00 2.56 155.00 26.50 0.53 0.07 0.13 0.01 
27.00 268.00 50.09 224.00 41.87 26.00 4.86 202.00 37.76 0.70 0.09 0.13 0.01 
28.00 185.00 34.26 228.00 42.22 23.00 4.26 186.00 34.44 0.37 0.05 0.12 0.00 
29.00 165.00 36.67 139.00 30.89 65.00 14.44 109.00 24.22 0.83 0.08 0.10 0.01 
30.00 278.00 52.95 248.00 47.24 18.00 3.43 157.00 29.90 0.61 0.07 0.11 0.01 
31.00 71.00 12.57 339.00 60.00 10.00 1.77 147.00 26.02 0.96 0.08 0.09 0.01 
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Control 
no. 
Plasma 
lutein 
(ug/l) 
Plasma 
lutein/ 
cholesterol 
(ug/mmol) 
Plasma 
lycopene 
(ug/l) 
Plasma 
lycopene/ 
cholesterol 
(ug/mmol) 
Plasma α-
carotene 
(ug/l) 
Plasma α-
carotene/ 
cholesterol 
(ug/mmol) 
Plasma β-
carotene 
(ug/l) 
Plasma β-
carotene/ 
cholesterol 
(ug/mmol) 
Total 
MDA 
(umol/l) 
Free MDA 
(umol/l) 
Free/ 
Total 
MDA  
MDA/ 
Total 
Protein 
(umol/g) 
32.00 98.00 19.41 199.00 39.41 10.00 1.98 126.00 24.95 0.87 0.09 0.10 0.01 
33.00 207.00 33.39 215.00 34.68 50.00 8.06 258.00 41.61 0.55 0.07 0.13 0.01 
34.00 75.00 13.04 104.00 18.09 10.00 1.74 57.00 9.91 0.83 0.09 0.11 0.01 
35.00 102.00 15.69 257.00 39.54 18.00 2.77 146.00 22.46 0.70 0.07 0.09 0.01 
36.00 181.00 29.43 87.00 14.15 16.00 2.60 157.00 25.53 0.63 0.08 0.12 0.01 
37.00 182.00 32.79 266.00 47.93 65.00 11.71 100.00 18.02 0.84 0.08 0.10 0.01 
38.00 219.00 30.00 505.00 69.18 10.00 1.37 123.00 16.85 0.98 0.08 0.08 0.01 
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Appendix 11. Characteristics and biochemical measurements of patients (Chapter 7) 
Patient No. Age 
(yrs) 
Male/ 
Female 
(0/1) 
APACH
E II 
Predicted 
mortality 
(%) 
Medical/ 
Surgical 
(0/1) 
SOFA score 
admission 
SOFA score 
follow-up 
Follow-up 
sample 
(days) 
C-reactive 
protein 
admission 
(mg/l) 
C-reactive 
protein 
follow-up 
(mg/l) 
12.00 61.00 0.00 29.00 76.60 0.00 7.00 7.00 2.00 126.00 156.00 
13.00 43.00 1.00 12.00 11.70 1.00 5.00 9.00 3.00 22.00 261.00 
14.00 71.00 1.00 18.00 28.90 1.00 8.00 9.00 2.00 220.00 124.00 
15.00 53.00 1.00 19.00 32.20 0.00 8.00 2.00 5.00 257.00 73.00 
16.00 61.00 0.00 23.00 28.50 0.00 6.00 -- -- 122.00 -- 
18.00 67.00 0.00 18.00 44.40 1.00 10.00 10.00 4.00 152.00 64.00 
19.00 50.00 0.00 21.00 38.90 0.00 10.00 9.00 4.00 143.00 101.00 
21.00 61.00 0.00 34.00 76.80 1.00 8.00 -- -- 23.00 -- 
22.00 52.00 0.00 13.00 9.90 0.00 2.00 3.00 4.00 20.00 67.00 
23.00 71.00 0.00 23.00 42.50 1.00 8.00 4.00 7.00 125.00 216.00 
24.00 77.00 1.00 21.00 35.00 0.00 4.00 -- -- 81.00 -- 
27.00 76.00 1.00 23.00 46.00 0.00 5.00 4.00 3.00 103.00 133.00 
29.00 70.00 0.00 16.00 20.20 1.00 4.00 4.00 4.00 59.00 20.00 
30.00 73.00 1.00 25.00 53.30 1.00 11.00 7.00 3.00 26.00 179.00 
31.00 62.00 0.00 19.00 27.10 1.00 11.00 -- -- 50.00 -- 
32.00 55.00 1.00 15.00 21.00 1.00 6.00 -- -- 434.00 -- 
33.00 80.00 1.00 31.00 84.20 1.00 7.00 8.00 5.00 259.00 173.00 
34.00 53.00 0.00 26.00 68.60 1.00 6.00 7.00 4.00 404.00 336.00 
35.00 20.00 0.00 18.00 39.70 1.00 10.00 7.00 3.00 119.00 303.00 
36.00 43.00 1.00 38.00 92.60 0.00 13.00 10.00 4.00 132.00 70.00 
37.00 60.00 0.00 27.00 63.10 0.00 10.00 9.00 4.00 81.00 35.00 
38.00 74.00 0.00 20.00 23.00 1.00 4.00 -- -- 127.00 -- 
40.00 47.00 0.00 22.00 28.50 1.00 9.00 4.00 3.00 15.00 234.00 
41.00 76.00 1.00 29.00 79.90 1.00 8.00 -- -- 184.00 -- 
42.00 79.00 0.00 21.00 30.90 1.00 4.00 6.00 4.00 8.00 149.00 
44.00 81.00 0.00 34.00 86.30 0.00 7.00 3.00 8.00 151.00 55.00 
45.00 74.00 0.00 33.00 75.20 0.00 11.00 5.00 5.00 258.00 164.00 
46.00 41.00 1.00 8.00 15.60 1.00 1.00 -- -- 250.00 -- 
47.00 76.00 0.00 29.00 77.20 1.00 7.00 7.00 2.00 64.00 72.00 
48.00 67.00 0.00 31.00 68.10 1.00 6.00 11.00 4.00 119.00 123.00 
50.00 60.00 0.00 19.00 48.00 1.00 7.00 4.00 6.00 180.00 141.00 
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Patient No. Age 
(yrs) 
Male/ 
Female 
(0/1) 
APACH
E II 
Predicted 
mortality 
(%) 
Medical/ 
Surgical 
(0/1) 
SOFA score 
admission 
SOFA score 
follow-up 
Follow-up 
sample 
(days) 
C-reactive 
protein 
admission 
(mg/l) 
C-reactive 
protein 
follow-up 
(mg/l) 
51.00 46.00 1.00 24.00 49.70 0.00 14.00 16.00 3.00 56.00 58.00 
52.00 61.00 0.00 33.00 78.60 0.00 11.00 11.00 3.00 565.00 257.00 
53.00 67.00 1.00 18.00 21.20 0.00 11.00 10.00 3.00 148.00 131.00 
55.00 80.00 1.00 31.00 73.30 0.00 8.00 8.00 4.00 107.00 71.00 
56.00 40.00 1.00 6.00 10.20 1.00 6.00 -- -- 37.00 -- 
57.00 60.00 0.00 27.00 60.20 1.00 10.00 -- -- 181.00 -- 
58.00 41.00 0.00 21.00 17.80 1.00 4.00 12.00 2.00 6.00 36.00 
59.00 68.00 0.00 20.00 32.30 0.00 5.00 -- -- 32.00 -- 
60.00 57.00 0.00 24.00 67.00 0.00 3.00 -- -- 166.00 -- 
61.00 76.00 1.00 18.00 14.40 0.00 5.00 -- -- 380.00 -- 
62.00 74.00 0.00 20.00 19.90 1.00 1.00 2.00 3.00 88.00 180.00 
63.00 62.00 0.00 18.00 44.40 1.00 2.00 -- -- 117.00 -- 
64.00 66.00 0.00 34.00 81.00 0.00 13.00 -- -- 311.00 -- 
67.00 68.00 1.00 31.00 80.30 0.00 4.00 4.00 5.00 438.00 52.00 
68.00 74.00 0.00 24.00 49.70 0.00 14.00 12.00 5.00 67.00 139.00 
69.00 61.00 0.00 22.00 54.90 1.00 10.00 13.00 4.00 179.00 356.00 
71.00 25.00 0.00 17.00 1.20 0.00 3.00 -- -- 2.00 -- 
72.00 51.00 0.00 21.00 12.40 0.00 11.00 7.00 12.00 40.00 89.00 
73.00 69.00 0.00 12.00 20.20 0.00 3.00 -- -- 2.00 -- 
74.00 65.00 0.00 33.00 80.40 0.00 6.00 11.00 4.00 77.00 28.00 
75.00 28.00 1.00 14.00 18.50 1.00 10.00 -- -- 184.00 -- 
77.00 54.00 1.00 17.00 1.20 0.00 7.00 -- -- 2.00 -- 
78.00 45.00 0.00 12.00 5.50 1.00 4.00 -- -- 177.00 -- 
79.00 41.00 0.00 7.00 7.60 1.00 4.00 3.00 3.00 2.00 251.00 
80.00 38.00 0.00 16.00 23.30 1.00 9.00 -- -- 126.00 -- 
81.00 71.00 0.00 25.00 35.90 1.00 5.00 6.00 3.00 8.00 284.00 
82.00 80.00 1.00 17.00 12.70 0.00 1.00 1.00 2.00 4.00 86.00 
83.00 46.00 1.00 11.00 10.30 1.00 4.00 -- -- 318.00 -- 
84.00 56.00 0.00 28.00 63.90 0.00 13.00 10.00 3.00 63.00 80.00 
85.00 73.00 0.00 18.00 44.40 1.00 6.00 7.00 2.00 176.00 198.00 
87.00 34.00 1.00 12.00 12.40 1.00 6.00 -- -- 110.00 -- 
88.00 81.00 0.00 17.00 23.60 1.00 9.00 9.00 5.00 108.00 104.00 
89.00 22.00 1.00 10.00 9.50 1.00 2.00 -- -- 31.00 -- 
90.00 53.00 0.00 32.00 60.90 1.00 10.00 7.00 4.00 159.00 38.00 
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Patient No. Age 
(yrs) 
Male/ 
Female 
(0/1) 
APACH
E II 
Predicted 
mortality 
(%) 
Medical/ 
Surgical 
(0/1) 
SOFA score 
admission 
SOFA score 
follow-up 
Follow-up 
sample 
(days) 
C-reactive 
protein 
admission 
(mg/l) 
C-reactive 
protein 
follow-up 
(mg/l) 
91.00 62.00 0.00 22.00 58.90 1.00 9.00 -- -- 268.00 -- 
96.00 63.00 1.00 18.00 4.80 0.00 3.00 2.00 3.00 76.00 27.00 
99.00 37.00 0.00 13.00 16.50 1.00 5.00 -- -- 287.00 -- 
100.00 50.00 1.00 26.00 38.20 0.00 4.00 4.00 3.00 253.00 171.00 
101.00 35.00 1.00 9.00 4.70 1.00 5.00 -- -- 231.00 -- 
102.00 26.00 0.00 23.00 45.70 1.00 4.00 2.00 2.00 28.00 198.00 
103.00 52.00 0.00 16.00 12.20 1.00 2.00 1.00 3.00 -- 69.00 
104.00 38.00 0.00 3.00 2.70 0.00 2.00 -- -- 1.00 -- 
105.00 39.00 0.00 34.00 87.50 0.00 11.00 8.00 2.00 25.00 23.00 
107.00 45.00 1.00 12.00 6.60 1.00 8.00 -- -- 261.00 -- 
108.00 44.00 1.00 6.00 0.90 0.00 3.00 -- -- 48.00 -- 
110.00 48.00 1.00 26.00 35.20 0.00 7.00 12.00 5.00 199.00 153.00 
111.00 23.00 0.00 9.00 4.30 1.00 7.00 2.00 5.00 6.00 245.00 
112.00 45.00 1.00 24.00 22.40 1.00 1.00 10.00 4.00 2.00 165.00 
113.00 70.00 0.00 27.00 47.70 0.00 4.00 5.00 3.00 14.00 205.00 
114.00 65.00 1.00 24.00 65.70 1.00 9.00 8.00 4.00 49.00 98.00 
115.00 47.00 0.00 10.00 1.50 0.00 2.00 -- -- 1.00 -- 
116.00 61.00 0.00 13.00 10.60 0.00 1.00 -- -- 3.00 -- 
117.00 48.00 0.00 13.00 8.50 1.00 3.00 3.00 4.00 9.00 88.00 
118.00 59.00 0.00 23.00 39.90 1.00 9.00 12.00 2.00 252.00 204.00 
119.00 67.00 1.00 18.00 14.40 0.00 2.00 -- -- 2.00 -- 
121.00 86.00 0.00 22.00 42.20 1.00 7.00 4.00 5.00 203.00 88.00 
123.00 60.00 0.00 16.00 14.60 0.00 7.00 6.00 3.00 2.00 207.00 
124.00 33.00 0.00 14.00 27.40 1.00 7.00 6.00 2.00 97.00 149.00 
126.00 68.00 0.00 27.00 46.00 0.00 5.00 -- -- 3.00 -- 
127.00 100.00 0.00 25.00 64.60 1.00 12.00 -- -- 316.00 -- 
128.00 80.00 1.00 30.00 56.90 1.00 7.00 -- -- 51.00 -- 
129.00 31.00 0.00 19.00 44.00 0.00 12.00 -- -- 63.00 -- 
131.00 65.00 0.00 21.00 55.30 1.00 8.00 -- -- 165.00 -- 
133.00 35.00 0.00 14.00 7.20 1.00 -- -- -- 35.00 -- 
135.00 41.00 1.00 16.00 14.30 1.00 2.00 -- -- 221.00 -- 
137.00 69.00 1.00 19.00 32.00 1.00 4.00 -- -- 218.00 -- 
139.00 54.00 1.00 23.00 55.80 1.00 8.00 -- -- 72.00 -- 
140.00 74.00 0.00 21.00 41.60 1.00 8.00 -- -- 51.00 -- 
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Patient No. Age 
(yrs) 
Male/ 
Female 
(0/1) 
APACH
E II 
Predicted 
mortality 
(%) 
Medical/ 
Surgical 
(0/1) 
SOFA score 
admission 
SOFA score 
follow-up 
Follow-up 
sample 
(days) 
C-reactive 
protein 
admission 
(mg/l) 
C-reactive 
protein 
follow-up 
(mg/l) 
141.00 67.00 0.00 32.00 78.00 1.00 10.00 2.00 11.00 143.00 80.00 
143.00 52.00 0.00 10.00 17.40 1.00 2.00 -- -- 39.00 -- 
146.00 38.00 0.00 18.00 24.20 1.00 6.00 5.00 6.00 73.00 22.00 
147.00 70.00 0.00 20.00 35.50 1.00 7.00 3.00 2.00 203.00 216.00 
148.00 71.00 0.00 25.00 53.30 0.00 5.00 -- -- 17.00 -- 
149.00 74.00 0.00 15.00 -- 1.00 5.00 -- -- 94.00 -- 
150.00 62.00 0.00 21.00 38.90 0.00 11.00 -- -- 295.00 -- 
151.00 36.00 0.00 8.00 8.60 1.00 0.00 -- -- 229.00 -- 
152.00 47.00 0.00 11.00 7.60 0.00 3.00 -- -- 26.00 -- 
153.00 77.00 1.00 27.00 46.00 0.00 4.00 -- -- 45.00 -- 
154.00 49.00 0.00 26.00 4.40 0.00 4.00 -- -- 39.00 -- 
155.00 43.00 0.00 25.00 3.80 0.00 8.00 -- -- 52.00 -- 
156.00 41.00 0.00 33.00 78.60 0.00 12.00 -- -- 316.00 -- 
157.00 61.00 0.00 31.00 81.40 1.00 14.00 -- -- 294.00 -- 
158.00 56.00 0.00 11.00 22.30 1.00 3.00 -- -- 163.00 -- 
159.00 60.00 1.00 19.00 11.30 1.00 4.00 -- -- 137.00 -- 
163.00 77.00 1.00 26.00 56.70 1.00 10.00 -- -- 269.00 -- 
164.00 62.00 1.00 14.00 9.70 0.00 10.00 -- -- 291.00 -- 
165.00 35.00 0.00 5.00 0.20 0.00 1.00 -- -- 0.60 -- 
166.00 63.00 0.00 13.00 13.40 1.00 8.00 -- -- 75.00 -- 
167.00 56.00 0.00 32.00 76.00 0.00 8.00 -- -- 74.00 -- 
168.00 52.00 1.00 26.00 56.90 0.00 10.00 -- -- 131.00 -- 
169.00 39.00 1.00 13.00 24.60 1.00 14.00 -- -- 273.00 -- 
171.00 67.00 0.00 27.00 60.50 0.00 14.00 -- -- 203.00 -- 
 
  
325 
 
Patient No. Albumin 
admission 
(g/l) 
Albumin 
follow-up 
(g/l) 
Total protein 
admission 
(g/l) 
Total protein 
follow-up 
(g/l) 
Triglycerides 
admission 
(mmol/l) 
Triglycerides 
follow-up 
(mmol/l) 
Cholesterol 
admission 
(mmol/l) 
Cholesterol 
follow-up 
(mmol/l) 
Plasma 
retinol 
admission 
(umol/l) 
Plasma 
retinol 
follow-up 
(umol/l) 
12.00 24.00 23.00 46.00 45.00 0.61 0.43 1.70 1.73 0.88 1.53 
13.00 27.00 22.00 55.00 47.00 2.80 1.95 4.27 2.08 1.30 0.31 
14.00 12.00 10.00 45.00 37.00 1.55 0.82 2.19 1.28 0.42 0.42 
15.00 23.00 16.00 63.00 54.00 1.52 -- 2.75 -- 0.18 1.50 
16.00 28.00 -- 72.00 -- 0.75 -- 3.76 -- 1.31 -- 
18.00 10.00 10.00 31.00 30.00 0.80 2.75 0.55 1.47 0.39 1.18 
19.00 12.00 14.00 68.00 38.00 0.72 1.77 3.06 2.09 1.11 1.69 
21.00 10.00 -- 25.00 -- 1.60 -- 2.60 -- 1.45 -- 
22.00 27.00 15.00 71.00 40.00 1.10 -- 3.00 -- 1.44 0.75 
23.00 10.00 13.00 39.00 48.00 0.50 0.80 1.10 1.60 0.24 0.51 
24.00 35.00 -- 74.00 -- 0.80 -- 4.90 -- 1.80 -- 
27.00 23.00 17.00 54.00 46.00 1.80 0.80 3.90 2.50 1.18 0.70 
29.00 9.00 10.00 25.00 39.00 0.80 1.10 0.90 1.80 0.22 1.48 
30.00 16.00 11.00 44.00 42.00 1.20 0.60 3.80 3.20 4.20 2.92 
31.00 22.00 -- 46.00 -- 0.60 -- 2.50 -- 1.22 -- 
32.00 17.00 -- 39.00 -- 1.10 -- 2.00 -- 0.09 -- 
33.00 17.00 10.00 41.00 35.00 0.80 1.00 2.10 1.70 0.35 0.46 
34.00 30.00 15.00 56.00 39.00 2.01 1.31 1.25 1.94 1.27 0.77 
35.00 9.00 13.00 27.00 36.00 0.70 1.28 1.27 1.74 0.21 0.35 
36.00 14.00 14.00 35.00 39.00 0.68 1.02 0.53 1.94 0.15 0.75 
37.00 12.00 12.00 45.00 39.00 0.38 0.65 0.84 1.35 0.85 1.49 
38.00 14.00 -- 56.00 -- 1.66 -- 2.40 -- 0.50 -- 
40.00 20.00 18.00 39.00 41.00 -- 2.10 -- 2.00 0.90 0.52 
41.00 19.00 -- 33.00 -- 0.64 -- 1.51 -- 1.62 -- 
42.00 17.00 18.00 32.00 37.00 0.50 0.80 2.10 2.40 0.84 0.57 
44.00 10.00 16.00 37.00 43.00 0.44 1.18 0.98 3.44 0.60 2.71 
45.00 14.00 14.00 41.00 45.00 0.69 1.18 2.41 2.07 1.04 2.12 
46.00 11.00 -- 32.00 -- 1.19 -- 1.88 -- 0.17 -- 
47.00 24.00 24.00 58.00 53.00 0.80 0.70 2.20 1.80 0.61 0.49 
48.00 10.00 9.00 57.00 47.00 0.70 0.80 0.90 0.90 0.02 0.03 
50.00 23.00 15.00 31.00 42.00 1.20 1.10 1.50 1.50 1.62 0.74 
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Patient No. Albumin 
admission 
(g/l) 
Albumin 
follow-up 
(g/l) 
Total protein 
admission 
(g/l) 
Total protein 
follow-up 
(g/l) 
Triglycerides 
admission 
(mmol/l) 
Triglycerides 
follow-up 
(mmol/l) 
Cholesterol 
admission 
(mmol/l) 
Cholesterol 
follow-up 
(mmol/l) 
Plasma 
retinol 
admission 
(umol/l) 
Plasma 
retinol 
follow-up 
(umol/l) 
51.00 14.00 19.00 43.00 47.00 0.50 0.60 1.20 1.60 0.02 0.28 
52.00 9.00 9.00 43.00 44.00 0.70 0.90 1.00 1.40 0.58 0.56 
53.00 9.00 9.00 34.00 33.00 2.50 2.60 1.70 1.90 0.26 0.48 
55.00 13.00 9.00 41.00 35.00 0.30 0.20 1.10 0.60 0.17 0.61 
56.00 16.00 -- 33.00 -- 1.07 -- 1.42 -- 0.91 -- 
57.00 10.00 -- 37.00 -- 0.55 -- 0.40 -- 0.22 -- 
58.00 19.00 12.00 39.00 39.00 0.95 0.39 2.12 1.13 1.14 0.83 
59.00 36.00 -- 66.00 -- 5.05 -- 4.23 -- 2.86 -- 
60.00 26.00 -- 75.00 -- 2.53 -- 4.56 -- 2.14 -- 
61.00 26.00 -- 65.00 -- 2.13 -- 4.60 -- 1.82 -- 
62.00 12.00 14.00 38.00 43.00 -- 0.93 -- 2.10 0.57 0.35 
63.00 14.00 -- 27.00 -- 1.34 -- 1.49 -- 0.87 -- 
64.00 18.00 -- 64.00 -- 1.47 -- 1.68 -- 1.47 -- 
67.00 20.00 16.00 35.00 36.00 0.87 1.40 1.21 2.47 0.22 1.10 
68.00 11.00 11.00 37.00 36.00 1.68 1.48 1.44 1.93 0.57 0.78 
69.00 14.00 16.00 36.00 41.00 0.53 1.63 0.71 0.96 0.26 0.35 
71.00 38.00 -- 75.00 -- 2.10 -- 3.20 -- 1.69 -- 
72.00 32.00 15.00 58.00 56.00 3.40 1.50 3.30 3.10 1.00 2.12 
73.00 31.00 -- 62.00 -- 1.80 -- 3.30 -- 1.22 -- 
74.00 15.00 13.00 48.00 42.00 0.90 1.00 1.30 3.80 0.66 1.16 
75.00 11.00 -- 37.00 -- 2.80 -- 2.00 -- 0.75 -- 
77.00 20.00 -- 47.00 -- 0.50 -- 2.10 -- 1.09 -- 
78.00 27.00 -- 61.00 -- 1.70 -- 4.20 -- 0.82 -- 
79.00 24.00 21.00 44.00 44.00 -- 1.00 -- 1.80 1.28 0.59 
80.00 14.00 -- 58.00 -- 0.90 -- 1.20 -- 0.48 -- 
81.00 10.00 21.00 23.00 44.00 0.60 1.90 1.10 2.20 0.70 0.67 
82.00 29.00 29.00 60.00 62.00 0.70 0.40 4.00 2.60 2.84 0.94 
83.00 21.00 -- 48.00 -- 0.80 -- 3.10 -- 0.31 -- 
84.00 9.00 9.00 29.00 32.00 0.90 2.20 0.90 1.10 0.39 0.84 
85.00 11.00 9.00 26.00 27.00 0.30 0.50 1.20 1.20 0.17 0.12 
87.00 18.00 -- 40.00 -- 0.70 -- 2.60 -- 0.67 -- 
88.00 12.00 11.00 51.00 51.00 0.80 0.60 1.70 1.70 0.61 1.35 
89.00 16.00 -- 33.00 -- 1.50 -- 2.70 -- 0.73 -- 
90.00 11.00 29.00 41.00 38.00 1.60 1.80 1.60 1.90 0.68 2.19 
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Patient No. Albumin 
admission 
(g/l) 
Albumin 
follow-up 
(g/l) 
Total protein 
admission 
(g/l) 
Total protein 
follow-up 
(g/l) 
Triglycerides 
admission 
(mmol/l) 
Triglycerides 
follow-up 
(mmol/l) 
Cholesterol 
admission 
(mmol/l) 
Cholesterol 
follow-up 
(mmol/l) 
Plasma 
retinol 
admission 
(umol/l) 
Plasma 
retinol 
follow-up 
(umol/l) 
91.00 14.00 -- 40.00 -- 1.30 -- 1.60 -- 0.36 -- 
96.00 29.00 28.00 64.00 56.00 1.60 1.10 4.40 4.40 1.60 2.00 
99.00 22.00 -- 52.00 -- 1.06 -- 2.50 -- 0.40 -- 
100.00 13.00 9.00 41.00 33.00 2.40 0.50 2.30 1.40 0.60 0.50 
101.00 25.00 -- 46.00 -- 0.70 -- 2.20 -- 0.30 -- 
102.00 19.00 19.00 38.00 39.00 0.60 2.40 1.70 1.80 0.90 0.50 
103.00 42.00 27.00 73.00 49.00 3.30 -- 4.10 -- 1.80 1.10 
104.00 34.00 -- 71.00 -- 4.70 -- 6.40 -- 2.10 -- 
105.00 30.00 29.00 66.00 57.00 1.00 0.60 2.00 1.90 0.40 0.20 
107.00 17.00 -- 39.00 -- -- -- -- -- 0.30 -- 
108.00 35.00 -- 70.00 -- -- -- -- -- 0.80 -- 
110.00 13.00 11.00 48.00 34.00 1.10 3.20 1.60 2.10 0.40 0.20 
111.00 28.00 13.00 53.00 37.00 2.00 2.10 4.00 1.60 1.80 0.20 
112.00 20.00 9.00 42.00 26.00 1.20 0.80 5.20 1.70 1.30 0.20 
113.00 31.00 19.00 60.00 43.00 1.30 0.40 2.70 1.40 2.00 0.60 
114.00 16.00 9.00 37.00 27.00 1.40 0.70 2.20 1.00 0.40 0.20 
115.00 39.00 -- 63.00 -- 0.90 -- 5.30 -- 1.90 -- 
116.00 24.00 -- 48.00 -- 1.00 -- 2.70 -- 1.30 -- 
117.00 32.00 23.00 55.00 45.00 4.50 2.80 4.20 3.00 1.90 0.70 
118.00 12.00 9.00 33.00 28.00 0.70 1.10 0.70 1.00 0.30 0.30 
119.00 25.00 -- 50.00 -- 0.50 -- 4.60 -- 1.20 -- 
121.00 15.00 15.00 37.00 39.00 0.30 1.00 1.00 1.40 0.20 0.80 
123.00 45.00 28.00 83.00 58.00 1.90 0.80 4.80 3.90 2.70 1.80 
124.00 15.00 14.00 40.00 44.00 0.40 0.80 1.10 1.30 0.20 0.30 
126.00 21.00 -- 46.00 -- 0.80 -- 5.00 -- 0.70 -- 
127.00 17.00 -- 59.00 -- 0.60 -- 1.20 -- 0.60 -- 
128.00 16.00 -- 46.00 -- 1.10 -- 2.40 -- 0.80 -- 
129.00 20.00 -- 53.00 -- -- -- -- -- 0.20 -- 
131.00 21.00 -- 47.00 -- 0.90 -- 1.00 -- 0.30 -- 
133.00 16.00 -- 36.00 -- 0.30 -- 0.90 -- 0.30 -- 
135.00 18.00 -- 58.00 -- 1.90 -- 2.80 -- 1.10 -- 
137.00 11.00 -- 34.00 -- 1.40 -- 2.20 -- 0.40 -- 
139.00 14.00 -- 33.00 -- -- -- 0.94 -- 0.80 -- 
140.00 9.00 -- 26.00 -- 0.40 -- 2.40 -- 0.40 -- 
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Patient No. Albumin 
admission 
(g/l) 
Albumin 
follow-up 
(g/l) 
Total protein 
admission 
(g/l) 
Total protein 
follow-up 
(g/l) 
Triglycerides 
admission 
(mmol/l) 
Triglycerides 
follow-up 
(mmol/l) 
Cholesterol 
admission 
(mmol/l) 
Cholesterol 
follow-up 
(mmol/l) 
Plasma 
retinol 
admission 
(umol/l) 
Plasma 
retinol 
follow-up 
(umol/l) 
141.00 9.00 9.00 40.00 42.00 -- 0.90 0.62 2.40 1.40 -- 
143.00 14.00 -- 60.00 -- 1.20 -- 2.20 -- 0.70 -- 
146.00 26.00 18.00 38.00 45.00 1.70 1.20 2.60 2.60 0.80 1.60 
147.00 32.00 24.00 56.00 51.00 0.30 0.30 3.10 2.70 0.50 0.20 
148.00 23.00 -- 54.00 -- 1.10 -- 3.90 -- 0.80 -- 
149.00 13.00 -- 40.00 -- 0.70 -- 1.00 -- 0.40 -- 
150.00 24.00 -- 55.00 -- 1.10 -- 1.60 -- 0.60 -- 
151.00 13.00 -- 47.00 -- 1.20 -- 4.70 -- 1.60 -- 
152.00 35.00 -- 65.00 -- 1.30 -- 4.80 -- 1.80 -- 
153.00 19.00 -- 50.00 -- 2.20 -- 2.30 -- 0.60 -- 
154.00 33.00 -- 62.00 -- 0.60 -- 4.60 -- 2.50 -- 
155.00 19.00 -- 68.00 -- 0.50 -- 2.80 -- 1.90 -- 
156.00 20.00 -- 73.00 -- 1.90 -- 2.60 -- 0.20 -- 
157.00 13.00 -- 44.00 -- 0.60 -- 0.90 -- 0.20 -- 
158.00 10.00 -- 34.00 -- 2.10 -- 1.60 -- 0.20 -- 
159.00 15.00 -- 39.00 -- 0.50 -- 1.40 -- 0.90 -- 
163.00 12.00 -- 38.00 -- 0.70 -- 1.50 -- 0.20 -- 
164.00 24.00 -- 58.00 -- 0.90 -- 1.90 -- 0.30 -- 
165.00 47.00 -- 75.00 -- 1.40 -- 5.50 -- 3.10 -- 
166.00 13.00 -- 37.00 -- 2.30 -- 4.10 -- 0.60 -- 
167.00 23.00 -- 43.00 -- 0.60 -- 2.50 -- 0.80 -- 
168.00 11.00 -- 38.00 -- 0.60 -- 0.60 -- 0.30 -- 
169.00 14.00 -- 50.00 -- 2.40 -- 2.60 -- 0.20 -- 
171.00 20.00 -- 52.00 -- 0.90 -- 1.80 -- 1.10 -- 
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Patient No. Plasma α-
tocopherol 
admission 
(umol/l) 
Plasma α-
tocopherol/ 
cholesterol 
admission 
(umol/mmol) 
Plasma α-
tocopherol 
follow-up 
(umol/l) 
Plasma α-
tocopherol/ 
cholesterol 
follow-up 
(umol/mmol) 
Plasma 
lutein 
admission 
(ug/l) 
Plasma 
lutein/ 
cholesterol 
admission 
(ug/mmol) 
Plasma 
lutein follow-
up (ug/l) 
Plasma 
lutein/ 
cholesterol 
follow-up 
(ug/mmol) 
Plasma 
lycopene 
admission 
(ug/l) 
Plasma 
lycopene/ 
cholesterol 
admission 
(ug/mmol) 
Plasma 
lycopene 
follow-up 
(ug/l) 
Plasma 
lycopene/ 
cholesterol 
follow-up 
(ug/mmol) 
12.00 14.36 8.45 12.70 7.34 30.10 17.71 37.40 21.62 28.90 17.00 27.30 15.78 
13.00 15.35 3.59 11.98 5.76 4.60 1.08 4.80 2.31 9.50 2.22 14.70 7.07 
14.00 16.26 7.42 10.49 8.20 9.10 4.16 5.10 3.98 15.60 7.12 6.90 5.39 
15.00 14.48 5.27 26.88 -- 7.40 2.69 8.30 -- 35.30 12.84 33.70 -- 
16.00 15.68 4.17 -- -- 21.40 5.69 -- -- 23.30 6.20 -- -- 
18.00 6.27 11.40 14.47 9.84 3.60 6.55 12.40 8.44 4.60 8.36 8.20 5.58 
19.00 17.70 5.78 15.40 7.37 33.50 10.95 23.50 11.24 102.50 33.50 49.60 23.73 
21.00 16.03 6.17 -- -- 4.60 1.77 -- -- 4.10 1.58 -- -- 
22.00 13.74 4.58 16.90 -- 22.20 7.40 11.80 -- 17.70 5.90 13.90 -- 
23.00 7.93 7.21 18.48 11.55 13.90 12.64 30.30 18.94 21.80 19.82 44.60 27.88 
24.00 26.95 5.50 -- -- 113.20 23.10 -- -- 43.10 8.80 -- -- 
27.00 24.42 6.26 21.91 8.76 38.30 9.82 21.90 8.76 22.00 5.64 16.00 6.40 
29.00 10.91 12.12 16.56 9.20 8.00 8.89 12.60 7.00 6.20 6.89 17.30 9.61 
30.00 33.79 8.89 23.73 7.42 41.70 10.97 24.50 7.66 84.40 22.21 57.10 17.84 
31.00 14.80 5.92 -- -- 53.40 21.36 -- -- 100.60 40.24 -- -- 
32.00 10.30 5.15 -- -- 18.00 9.00 -- -- 4.70 2.35 -- -- 
33.00 11.83 5.63 13.34 7.85 23.90 11.38 17.30 10.18 29.40 14.00 31.70 18.65 
34.00 19.65 15.72 23.17 11.94 32.00 25.60 33.10 17.06 47.00 37.60 176.10 90.77 
35.00 10.16 8.00 16.07 9.24 21.50 16.93 28.50 16.38 64.50 50.79 74.30 42.70 
36.00 6.44 12.15 14.56 7.51 8.50 16.04 18.30 9.43 13.40 25.28 21.70 11.19 
37.00 6.25 7.44 10.86 8.04 141.90 168.93 21.10 15.63 290.60 345.95 25.70 19.04 
38.00 20.99 8.75 -- -- 7.50 3.13 -- -- 12.10 5.04 -- -- 
40.00 17.38 -- 21.31 10.66 28.30 -- 21.90 10.95 70.60 -- 43.90 21.95 
41.00 10.05 6.66 -- -- 20.40 13.51 -- -- 37.40 24.77 -- -- 
42.00 12.37 5.89 14.77 6.15 53.50 25.48 51.90 21.63 65.90 31.38 47.90 19.96 
44.00 8.31 8.48 35.61 10.35 30.70 31.33 67.90 19.74 22.40 22.86 61.00 17.73 
45.00 15.25 6.33 19.08 9.22 9.90 4.11 6.60 3.19 16.30 6.76 12.50 6.04 
46.00 9.70 5.16 -- -- 9.80 5.21 -- -- 16.20 8.62 -- -- 
47.00 14.47 6.58 12.24 6.80 39.80 18.09 26.40 14.67 38.30 17.41 24.20 13.44 
48.00 8.06 8.96 7.13 7.92 14.00 15.56 10.70 11.89 11.40 12.67 7.10 7.89 
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Patient No. Plasma α-
tocopherol 
admission 
(umol/l) 
Plasma α-
tocopherol/ 
cholesterol 
admission 
(umol/mmol) 
Plasma α-
tocopherol 
follow-up 
(umol/l) 
Plasma α-
tocopherol/ 
cholesterol 
follow-up 
(umol/mmol) 
Plasma 
lutein 
admission 
(ug/l) 
Plasma 
lutein/ 
cholesterol 
admission 
(ug/mmol) 
Plasma 
lutein follow-
up (ug/l) 
Plasma 
lutein/ 
cholesterol 
follow-up 
(ug/mmol) 
Plasma 
lycopene 
admission 
(ug/l) 
Plasma 
lycopene/ 
cholesterol 
admission 
(ug/mmol) 
Plasma 
lycopene 
follow-up 
(ug/l) 
Plasma 
lycopene/ 
cholesterol 
follow-up 
(ug/mmol) 
50.00 9.98 6.65 15.88 10.59 9.40 6.27 11.20 7.47 6.90 4.60 10.10 6.73 
51.00 8.40 7.00 12.09 7.56 8.40 7.00 21.30 13.31 8.60 7.17 38.40 24.00 
52.00 7.83 7.83 8.64 6.17 4.20 4.20 5.90 4.21 6.90 6.90 8.00 5.71 
53.00 16.34 9.61 19.99 10.52 2.10 1.24 4.20 2.21 3.20 1.88 3.20 1.68 
55.00 8.12 7.38 7.12 11.87 16.00 14.55 7.30 12.17 26.80 24.36 17.10 28.50 
56.00 11.20 7.89 -- -- 34.90 24.58 -- -- 54.20 38.17 -- -- 
57.00 3.55 8.88 -- -- 4.40 11.00 -- -- 5.10 12.75 -- -- 
58.00 11.37 5.36 5.95 5.27 36.60 17.26 17.30 15.31 95.80 45.19 37.50 33.19 
59.00 33.30 7.87 -- -- 65.10 15.39 -- -- 116.60 27.57 -- -- 
60.00 30.79 6.75 -- -- 33.90 7.43 -- -- 164.80 36.14 -- -- 
61.00 31.14 6.77 -- -- 43.90 9.54 -- -- 58.80 12.78 -- -- 
62.00 14.40 -- 17.15 8.17 20.00 -- 18.10 8.62 40.70 -- 67.00 31.90 
63.00 9.63 6.46 -- -- 23.70 15.91 -- -- 45.50 30.54 -- -- 
64.00 19.42 11.56 -- -- 41.00 24.40 -- -- 35.40 21.07 -- -- 
67.00 12.43 10.27 25.83 10.46 21.60 17.85 42.60 17.25 13.00 10.74 36.80 14.90 
68.00 10.01 6.95 18.30 9.48 18.00 12.50 22.80 11.81 1.20 0.83 6.80 3.52 
69.00 5.31 7.48 11.39 11.86 4.70 6.62 11.50 11.98 3.70 5.21 16.60 17.29 
71.00 21.98 6.87 -- -- 69.60 21.75 -- -- 93.20 29.13 -- -- 
72.00 16.40 4.97 33.61 10.84 44.60 13.52 12.40 4.00 54.70 16.58 61.70 19.90 
73.00 19.99 6.06 -- -- 48.40 14.67 -- -- 15.80 4.79 -- -- 
74.00 11.23 8.64 12.79 3.37 2.10 1.62 -- -- 0.80 0.62 2.20 0.58 
75.00 20.40 10.20 -- -- 22.80 11.40 -- -- 15.40 7.70 -- -- 
77.00 13.23 6.30 -- -- 27.70 13.19 -- -- 59.80 28.48 -- -- 
78.00 24.55 5.85 -- -- 77.80 18.52 -- -- 147.30 35.07 -- -- 
79.00 17.25 -- 21.55 11.97 66.90 -- 57.00 31.67 170.70 -- 116.70 64.83 
80.00 11.19 9.33 -- -- 8.30 6.92 -- -- 20.40 17.00 -- -- 
81.00 6.08 5.53 16.42 7.46 18.10 16.45 30.00 13.64 24.50 22.27 37.20 16.91 
82.00 33.45 8.36 24.02 9.24 141.50 35.38 107.40 41.31 162.80 40.70 100.80 38.77 
83.00 17.97 5.80 -- -- 28.90 9.32 -- -- 43.50 14.03 -- -- 
84.00 5.33 5.92 8.20 7.45 2.50 2.78 3.70 3.36 1.90 2.11 1.50 1.36 
85.00 8.06 6.72 8.94 7.45 17.50 14.58 20.40 17.00 7.30 6.08 7.20 6.00 
87.00 16.63 6.40 -- -- 63.30 24.35 -- -- 78.30 30.12 -- -- 
88.00 12.70 7.47 17.83 10.49 9.40 5.53 8.10 4.76 20.80 12.24 18.40 10.82 
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Patient No. Plasma α-
tocopherol 
admission 
(umol/l) 
Plasma α-
tocopherol/ 
cholesterol 
admission 
(umol/mmol) 
Plasma α-
tocopherol 
follow-up 
(umol/l) 
Plasma α-
tocopherol/ 
cholesterol 
follow-up 
(umol/mmol) 
Plasma 
lutein 
admission 
(ug/l) 
Plasma 
lutein/ 
cholesterol 
admission 
(ug/mmol) 
Plasma 
lutein follow-
up (ug/l) 
Plasma 
lutein/ 
cholesterol 
follow-up 
(ug/mmol) 
Plasma 
lycopene 
admission 
(ug/l) 
Plasma 
lycopene/ 
cholesterol 
admission 
(ug/mmol) 
Plasma 
lycopene 
follow-up 
(ug/l) 
Plasma 
lycopene/ 
cholesterol 
follow-up 
(ug/mmol) 
89.00 19.22 7.12 -- -- 80.30 29.74 -- -- 133.20 49.33 -- -- 
90.00 15.93 9.96 17.29 9.10 18.80 11.75 19.30 10.16 63.40 39.63 83.50 43.95 
91.00 15.56 9.73 -- -- 44.10 27.56 -- -- 28.40 17.75 -- -- 
96.00 27.00 6.14 27.00 6.14 84.00 19.09 76.00 17.27 130.00 29.55 143.00 32.50 
99.00 15.00 6.00 -- -- 21.00 8.40 -- -- 71.00 28.40 -- -- 
100.00 19.00 8.26 12.00 8.57 9.00 3.91 9.00 6.43 9.00 3.91 9.00 6.43 
101.00 15.00 6.82 -- -- 31.00 14.09 -- -- 45.00 20.45 -- -- 
102.00 11.00 6.47 14.00 7.78 35.00 20.59 33.00 18.33 60.00 35.29 51.00 28.33 
103.00 41.00 10.00 29.00 -- 29.00 7.07 18.00 -- 142.00 34.63 120.00 -- 
104.00 36.00 5.63 -- -- 90.00 14.06 -- -- 193.00 30.16 -- -- 
105.00 13.00 6.50 10.00 5.26 50.00 25.00 32.00 16.84 44.00 22.00 21.00 11.05 
107.00 16.00 -- -- -- 12.00 -- -- -- 27.00 -- -- -- 
108.00 23.00 -- -- -- 68.00 -- -- -- 234.00 -- -- -- 
110.00 17.00 10.63 27.00 12.86 25.00 15.63 27.00 12.86 9.00 5.63 9.00 4.29 
111.00 26.00 6.50 18.00 11.25 106.00 26.50 29.00 18.13 273.00 68.25 65.00 40.63 
112.00 28.00 5.38 12.00 7.06 246.00 47.31 64.00 37.65 32.00 6.15 39.00 22.94 
113.00 17.00 6.30 9.00 6.43 38.00 14.07 14.00 10.00 57.00 21.11 20.00 14.29 
114.00 15.00 6.82 10.00 10.00 29.00 13.18 9.00 9.00 90.00 40.91 36.00 36.00 
115.00 24.00 4.53 -- -- 97.00 18.30 -- -- 188.00 35.47 -- -- 
116.00 12.00 4.44 -- -- 22.00 8.15 -- -- 96.00 35.56 -- -- 
117.00 36.00 8.57 29.00 9.67 54.00 12.86 26.00 8.67 139.00 33.10 109.00 36.33 
118.00 7.00 10.00 9.00 9.00 9.00 12.86 9.00 9.00 9.00 12.86 9.00 9.00 
119.00 32.00 6.96 -- -- 168.00 36.52 -- -- 176.00 38.26 -- -- 
121.00 8.00 8.00 15.00 10.71 9.00 9.00 17.00 12.14 9.00 9.00 9.00 6.43 
123.00 27.00 5.63 24.00 6.15 68.00 14.17 48.00 12.31 60.00 12.50 46.00 11.79 
124.00 7.00 6.36 11.00 8.46 9.00 8.18 9.00 6.92 16.00 14.55 22.00 16.92 
126.00 20.00 4.00 -- -- 36.00 7.20 -- -- 110.00 22.00 -- -- 
127.00 16.00 13.33 -- -- 88.00 73.33 -- -- 13.00 10.83 -- -- 
128.00 17.00 7.08 -- -- 11.00 4.58 -- -- 17.00 7.08 -- -- 
129.00 12.00 -- -- -- 9.00 -- -- -- 11.00 -- -- -- 
131.00 7.00 7.00 -- -- 9.00 9.00 -- -- 24.00 24.00 -- -- 
133.00 6.00 6.67 -- -- 11.00 12.22 -- -- 32.00 35.56 -- -- 
135.00 25.00 8.93 -- -- 9.00 3.21 -- -- 9.00 3.21 -- -- 
  
332 
Patient No. Plasma α-
tocopherol 
admission 
(umol/l) 
Plasma α-
tocopherol/ 
cholesterol 
admission 
(umol/mmol) 
Plasma α-
tocopherol 
follow-up 
(umol/l) 
Plasma α-
tocopherol/ 
cholesterol 
follow-up 
(umol/mmol) 
Plasma 
lutein 
admission 
(ug/l) 
Plasma 
lutein/ 
cholesterol 
admission 
(ug/mmol) 
Plasma 
lutein follow-
up (ug/l) 
Plasma 
lutein/ 
cholesterol 
follow-up 
(ug/mmol) 
Plasma 
lycopene 
admission 
(ug/l) 
Plasma 
lycopene/ 
cholesterol 
admission 
(ug/mmol) 
Plasma 
lycopene 
follow-up 
(ug/l) 
Plasma 
lycopene/ 
cholesterol 
follow-up 
(ug/mmol) 
137.00 20.00 9.09 -- -- 37.00 16.82 -- -- 103.00 46.82 -- -- 
139.00 6.00 6.38 -- -- 9.00 9.57 -- -- 16.00 17.02 -- -- 
140.00 5.00 2.08 -- -- 9.00 3.75 -- -- 9.00 3.75 -- -- 
141.00 6.00 9.68 22.00 9.17 9.00 14.52 11.00 4.58 12.00 19.35 24.00 10.00 
143.00 22.00 10.00 -- -- 9.00 4.09 -- -- 55.00 25.00 -- -- 
146.00 12.00 4.62 22.00 8.46 9.00 3.46 9.00 3.46 126.00 48.46 56.00 21.54 
147.00 12.00 3.87 11.00 4.07 47.00 15.16 36.00 13.33 56.00 18.06 48.00 17.78 
148.00 17.00 4.36 -- -- 16.00 4.10 -- -- 46.00 11.79 -- -- 
149.00 6.00 6.00 -- -- 9.00 9.00 -- -- 9.00 9.00 -- -- 
150.00 12.00 7.50 -- -- 12.00 7.50 -- -- 15.00 9.38 -- -- 
151.00 22.00 4.68 -- -- 67.00 14.26 -- -- 294.00 62.55 -- -- 
152.00 21.00 4.38 -- -- 69.00 14.38 -- -- 260.00 54.17 -- -- 
153.00 21.00 9.13 -- -- 15.00 6.52 -- -- 48.00 20.87 -- -- 
154.00 23.00 5.00 -- -- 70.00 15.22 -- -- 78.00 16.96 -- -- 
155.00 11.00 3.93 -- -- 15.00 5.36 -- -- 101.00 36.07 -- -- 
156.00 9.00 3.46 -- -- 9.00 3.46 -- -- 14.00 5.38 -- -- 
157.00 6.00 6.67 -- -- 9.00 10.00 -- -- 9.00 10.00 -- -- 
158.00 9.00 5.63 -- -- 9.00 5.63 -- -- 9.00 5.63 -- -- 
159.00 9.00 6.43 -- -- 30.00 21.43 -- -- 9.00 6.43 -- -- 
163.00 12.00 8.00 -- -- 19.00 12.67 -- -- 11.00 7.33 -- -- 
164.00 12.00 6.32 -- -- 32.00 16.84 -- -- 9.00 4.74 -- -- 
165.00 32.00 5.82 -- -- 92.00 16.73 -- -- 318.00 57.82 -- -- 
166.00 29.00 7.07 -- -- 8.00 1.95 -- -- 10.00 2.44 -- -- 
167.00 10.00 4.00 -- -- 19.00 7.60 -- -- 19.00 7.60 -- -- 
168.00 6.00 10.00 -- -- 12.00 20.00 -- -- 15.00 25.00 -- -- 
169.00 12.00 4.62 -- -- 9.00 3.46 -- -- 3.00 1.15 -- -- 
171.00 16.00 8.89 -- -- 24.00 13.33 -- -- 29.00 16.11 -- -- 
  
333 
 
Patient 
No. 
Plasma α-
carotene 
admission 
(ug/l) 
Plasma α-
carotene/ 
cholesterol 
admission 
(ug/mmol) 
Plasma α-
carotene 
follow-up 
(ug/l) 
Plasma α-
carotene/ 
cholesterol 
follow-up 
(ug/mmol) 
Plasma β-
carotene 
admission 
(ug/l) 
Plasma β-
carotene/ 
cholesterol 
admission 
(ug/mmol) 
Plasma β-
carotene 
follow-up 
(ug/l) 
Plasma β-
carotene/ 
cholesterol 
follow-up 
(ug/mmol) 
12.00 21.20 12.47 20.00 11.56 58.00 34.12 62.70 36.24 
13.00 9.00 2.11 1.40 0.67 0.50 0.12 10.90 5.24 
14.00 4.60 2.10 -- -- 8.90 4.06 0.60 0.47 
15.00 1.80 0.65 -- -- 3.90 1.42 0.40 -- 
16.00 4.20 1.12 -- -- 20.40 5.43 -- -- 
18.00 9.00 16.36 1.20 0.82 0.30 0.55 2.80 1.90 
19.00 16.60 5.42 8.90 4.26 117.90 38.53 60.30 28.85 
21.00 1.60 0.62 -- -- 10.20 3.92 -- -- 
22.00 11.30 3.77 6.90 -- 39.00 13.00 39.00 -- 
23.00 9.00 8.18 15.20 9.50 28.30 25.73 115.40 72.13 
24.00 12.00 2.45 -- -- 115.60 23.59 -- -- 
27.00 9.20 2.36 6.50 2.60 67.60 17.33 183.50 73.40 
29.00 0.90 1.00 1.60 0.89 4.40 4.89 38.90 21.61 
30.00 20.30 5.34 13.30 4.16 40.10 10.55 25.30 7.91 
31.00 13.10 5.24 -- -- 66.90 26.76 -- -- 
32.00 3.00 1.50 -- -- 9.30 4.65 -- -- 
33.00 12.60 6.00 12.90 7.59 39.00 18.57 57.80 34.00 
34.00 1.40 1.12 6.90 3.56 0.60 0.48 69.50 35.82 
35.00 8.30 6.54 11.20 6.44 34.30 27.01 54.40 31.26 
36.00 3.80 7.17 4.80 2.47 14.40 27.17 30.40 15.67 
37.00 29.10 34.64 6.70 4.96 200.70 238.93 83.20 61.63 
38.00 12.60 5.25 -- -- 110.90 46.21 -- -- 
40.00 8.00 -- 3.10 1.55 31.70 -- 11.10 5.55 
41.00 17.10 11.32 -- -- 45.20 29.93 -- -- 
42.00 11.80 5.62 14.60 6.08 57.10 27.19 76.40 31.83 
44.00 1.70 1.73 6.40 1.86 14.70 15.00 198.90 57.82 
45.00 2.40 1.00 1.70 0.82 15.60 6.47 50.20 24.25 
46.00 0.80 0.43 -- -- 2.60 1.38 -- -- 
47.00 11.50 5.23 8.30 4.61 31.20 14.18 22.50 12.50 
48.00 9.00 10.00 1.80 2.00 5.70 6.33 2.60 2.89 
50.00 1.60 1.07 1.70 1.13 25.90 17.27 23.30 15.53 
51.00 1.50 1.25 5.70 3.56 23.90 19.92 46.70 29.19 
  
334 
Patient 
No. 
Plasma α-
carotene 
admission 
(ug/l) 
Plasma α-
carotene/ 
cholesterol 
admission 
(ug/mmol) 
Plasma α-
carotene 
follow-up 
(ug/l) 
Plasma α-
carotene/ 
cholesterol 
follow-up 
(ug/mmol) 
Plasma β-
carotene 
admission 
(ug/l) 
Plasma β-
carotene/ 
cholesterol 
admission 
(ug/mmol) 
Plasma β-
carotene 
follow-up 
(ug/l) 
Plasma β-
carotene/ 
cholesterol 
follow-up 
(ug/mmol) 
52.00 0.70 0.70 0.70 0.50 0.60 0.60 0.40 0.29 
53.00 9.00 5.29 0.70 0.37 0.90 0.53 1.50 0.79 
55.00 11.70 10.64 6.20 10.33 18.30 16.64 9.30 15.50 
56.00 9.30 6.55 -- -- 29.70 20.92 -- -- 
57.00 0.90 2.25 -- -- 2.80 7.00 -- -- 
58.00 15.00 7.08 5.70 5.04 73.60 34.72 24.50 21.68 
59.00 6.60 1.56 -- -- 10.70 2.53 -- -- 
60.00 21.80 4.78 -- -- 85.00 18.64 -- -- 
61.00 5.60 1.22 -- -- 23.30 5.07 -- -- 
62.00 15.60 -- 22.40 10.67 53.10 -- 85.00 40.48 
63.00 6.20 4.16 -- -- 20.90 14.03 -- -- 
64.00 14.90 8.87 -- -- 65.60 39.05 -- -- 
67.00 4.70 3.88 11.00 4.45 22.00 18.18 126.00 51.01 
68.00 1.30 0.90 6.50 3.37 0.30 0.21 4.10 2.12 
69.00 0.60 0.85 0.80 0.83 2.00 2.82 10.60 11.04 
71.00 5.50 1.72 -- -- 16.00 5.00 -- -- 
72.00 2.90 0.88 7.70 2.48 0.50 0.15 187.20 60.39 
73.00 9.00 2.73 -- -- 51.50 15.61 -- -- 
74.00 0.50 0.38 9.00 2.37 0.30 0.23 0.50 0.13 
75.00 4.80 2.40 -- -- 18.20 9.10 -- -- 
77.00 6.80 3.24 -- -- 37.90 18.05 -- -- 
78.00 20.30 4.83 -- -- 109.60 26.10 -- -- 
79.00 8.90 -- 5.90 3.28 41.90 -- 22.10 12.28 
80.00 2.30 1.92 -- -- 10.60 8.83 -- -- 
81.00 4.30 3.91 8.00 3.64 14.60 13.27 21.60 9.82 
82.00 75.00 18.75 49.00 18.85 401.80 100.45 248.20 95.46 
83.00 15.90 5.13 -- -- 91.60 29.55 -- -- 
84.00 9.00 10.00 9.00 8.18 0.70 0.78 14.40 13.09 
85.00 6.10 5.08 7.00 5.83 9.00 7.50 13.40 11.17 
87.00 27.60 10.62 -- -- 141.30 54.35 -- -- 
88.00 5.80 3.41 6.10 3.59 5.30 3.12 43.00 25.29 
89.00 15.50 5.74 -- -- 62.60 23.19 -- -- 
90.00 2.70 1.69 3.50 1.84 10.10 6.31 64.70 34.05 
  
335 
Patient 
No. 
Plasma α-
carotene 
admission 
(ug/l) 
Plasma α-
carotene/ 
cholesterol 
admission 
(ug/mmol) 
Plasma α-
carotene 
follow-up 
(ug/l) 
Plasma α-
carotene/ 
cholesterol 
follow-up 
(ug/mmol) 
Plasma β-
carotene 
admission 
(ug/l) 
Plasma β-
carotene/ 
cholesterol 
admission 
(ug/mmol) 
Plasma β-
carotene 
follow-up 
(ug/l) 
Plasma β-
carotene/ 
cholesterol 
follow-up 
(ug/mmol) 
91.00 9.30 5.81 -- -- 12.50 7.81 -- -- 
96.00 12.00 2.73 13.00 2.95 31.00 7.05 33.00 7.50 
99.00 9.00 3.60 -- -- 9.00 3.60 -- -- 
100.00 9.00 3.91 9.00 6.43 9.00 3.91 9.00 6.43 
101.00 11.00 5.00 -- -- 46.00 20.91 -- -- 
102.00 9.00 5.29 9.00 5.00 44.00 25.88 56.00 31.11 
103.00 173.00 42.20 143.00 -- 167.00 40.73 218.00 -- 
104.00 9.00 1.41 -- -- 32.00 5.00 -- -- 
105.00 16.00 8.00 10.00 5.26 52.00 26.00 32.00 16.84 
107.00 9.00 -- -- -- 311.00 -- -- -- 
108.00 14.00 -- -- -- 48.00 -- -- -- 
110.00 9.00 5.63 9.00 4.29 11.00 6.88 16.00 7.62 
111.00 9.00 2.25 9.00 5.63 50.00 12.50 50.00 31.25 
112.00 36.00 6.92 15.00 8.82 522.00 100.38 164.00 96.47 
113.00 9.00 3.33 9.00 6.43 25.00 9.26 9.00 6.43 
114.00 10.00 4.55 9.00 9.00 53.00 24.09 18.00 18.00 
115.00 10.00 1.89 -- -- 51.00 9.62 -- -- 
116.00 9.00 3.33 -- -- 9.00 3.33 -- -- 
117.00 9.00 2.14 9.00 3.00 16.00 3.81 15.00 5.00 
118.00 9.00 12.86 9.00 9.00 9.00 12.86 9.00 9.00 
119.00 19.00 4.13 -- -- 140.00 30.43 -- -- 
121.00 9.00 9.00 9.00 6.43 9.00 9.00 27.00 19.29 
123.00 11.00 2.29 10.00 2.56 24.00 5.00 73.00 18.72 
124.00 9.00 8.18 9.00 6.92 9.00 8.18 22.00 16.92 
126.00 9.00 1.80 -- -- 14.00 2.80 -- -- 
127.00 9.00 7.50 -- -- 101.00 84.17 -- -- 
128.00 10.00 4.17 -- -- 39.00 16.25 -- -- 
129.00 9.00 -- -- -- 9.00 -- -- -- 
131.00 9.00 9.00 -- -- 16.00 16.00 -- -- 
133.00 9.00 10.00 -- -- 9.00 10.00 -- -- 
135.00 9.00 3.21 -- -- 176.00 62.86 -- -- 
137.00 16.00 7.27 -- -- 48.00 21.82 -- -- 
139.00 9.00 9.57 -- -- 9.00 9.57 -- -- 
  
336 
Patient 
No. 
Plasma α-
carotene 
admission 
(ug/l) 
Plasma α-
carotene/ 
cholesterol 
admission 
(ug/mmol) 
Plasma α-
carotene 
follow-up 
(ug/l) 
Plasma α-
carotene/ 
cholesterol 
follow-up 
(ug/mmol) 
Plasma β-
carotene 
admission 
(ug/l) 
Plasma β-
carotene/ 
cholesterol 
admission 
(ug/mmol) 
Plasma β-
carotene 
follow-up 
(ug/l) 
Plasma β-
carotene/ 
cholesterol 
follow-up 
(ug/mmol) 
140.00 9.00 3.75 -- -- 9.00 3.75 -- -- 
141.00 9.00 14.52 9.00 3.75 9.00 14.52 13.00 5.42 
143.00 44.00 20.00 -- -- 518.00 235.45 -- -- 
146.00 9.00 3.46 9.00 3.46 9.00 3.46 131.00 50.38 
147.00 9.00 2.90 9.00 3.33 23.00 7.42 24.00 8.89 
148.00 9.00 2.31 -- -- 11.00 2.82 -- -- 
149.00 9.00 9.00 -- -- 9.00 9.00 -- -- 
150.00 9.00 5.63 -- -- 9.00 5.63 -- -- 
151.00 38.00 8.09 -- -- 224.00 47.66 -- -- 
152.00 34.00 7.08 -- -- 185.00 38.54 -- -- 
153.00 -- -- -- -- 71.00 30.87 -- -- 
154.00 13.00 2.83 -- -- 10.00 2.17 -- -- 
155.00 5.00 1.79 -- -- 92.00 32.86 -- -- 
156.00 9.00 3.46 -- -- 9.00 3.46 -- -- 
157.00 9.00 10.00 -- -- 9.00 10.00 -- -- 
158.00 9.00 5.63 -- -- 9.00 5.63 -- -- 
159.00 9.00 6.43 -- -- 9.00 6.43 -- -- 
163.00 6.00 4.00 -- -- 31.00 20.67 -- -- 
164.00 4.00 2.11 -- -- 8.00 4.21 -- -- 
165.00 20.00 3.64 -- -- 115.00 20.91 -- -- 
166.00 0.70 0.17 -- -- 2.00 0.49 -- -- 
167.00 17.00 6.80 -- -- 20.00 8.00 -- -- 
168.00 3.00 5.00 -- -- 7.00 11.67 -- -- 
169.00 3.00 1.15 -- -- 6.00 2.31 -- -- 
171.00 3.00 1.67 -- -- 81.00 45.00 -- -- 
 
  
337 
 
Patient 
No. 
Total MDA 
admission 
(umol/l) 
Free MDA 
admission 
(umol/l) 
Free/ Total 
MDA 
admission 
Total MDA 
follow-up 
(umol/l) 
Free MDA 
follow-up 
(umol/l) 
Free/ 
Total 
MDA 
follow-up 
MDA/ 
Total 
Protein 
admission 
(umol/g) 
MDA/ 
Total 
Protein 
follow-up 
(umol/g) 
12.00 0.65 0.14 0.22 0.51 0.12 0.24 0.01 0.01 
13.00 0.91 0.16 0.18 0.54 0.17 0.31 0.02 0.01 
14.00 0.60 0.58 0.97 0.64 0.16 0.25 0.01 0.02 
15.00 0.96 0.17 0.18 0.76 0.14 0.18 0.02 0.01 
16.00 1.02 0.20 0.20 -- -- -- 0.01 -- 
18.00 0.80 0.19 0.24 0.49 0.17 0.35 0.03 0.02 
19.00 0.87 0.26 0.30 1.18 0.40 0.34 0.01 0.03 
21.00 2.34 0.62 0.26 -- -- -- 0.09 -- 
22.00 1.03 0.38 0.37 -- -- -- 0.01 -- 
23.00 0.22 0.19 0.86 0.40 0.11 0.28 0.01 0.01 
24.00 1.37 0.37 0.27 -- -- -- 0.02 -- 
27.00 1.12 0.22 0.20 0.75 0.25 0.33 0.02 0.02 
29.00 0.53 0.37 0.70 1.11 0.32 0.29 0.02 0.03 
30.00 0.93 0.97 1.04 0.76 0.56 0.74 0.02 0.02 
31.00 0.55 0.21 0.38 -- -- -- 0.01 -- 
32.00 0.77 0.23 0.30 -- -- -- 0.02 -- 
33.00 0.63 0.31 0.49 1.08 0.61 0.56 0.02 0.03 
34.00 0.82 0.14 0.17 0.45 0.13 0.29 0.01 0.01 
35.00 14.27 5.96 0.42 20.40 9.41 0.46 0.53 0.57 
36.00 0.78 0.20 0.26 1.70 0.33 0.19 0.02 0.04 
37.00 0.35 0.05 0.14 0.38 0.10 0.26 0.01 0.01 
38.00 0.52 0.04 0.08 -- -- -- 0.01 -- 
40.00 0.31 0.06 0.19 0.45 0.03 0.07 0.01 0.01 
41.00 0.48 0.05 0.10 -- -- -- 0.01 -- 
42.00 -- -- -- -- -- -- -- -- 
44.00 -- -- -- -- -- -- -- -- 
45.00 0.42 0.06 0.14 0.47 0.08 0.17 0.01 0.01 
46.00 0.32 0.03 0.09 -- -- -- 0.01 -- 
47.00 0.56 0.07 0.13 0.54 0.13 0.24 0.01 0.01 
48.00 0.34 0.04 0.12 0.51 0.14 0.27 0.01 0.01 
50.00 0.40 0.15 0.38 0.51 0.09 0.18 0.01 0.01 
51.00 0.27 0.10 0.37 0.54 0.13 0.24 0.01 0.01 
52.00 0.50 0.18 0.36 0.51 0.21 0.41 0.01 0.01 
  
338 
Patient 
No. 
Total MDA 
admission 
(umol/l) 
Free MDA 
admission 
(umol/l) 
Free/ Total 
MDA 
admission 
Total MDA 
follow-up 
(umol/l) 
Free MDA 
follow-up 
(umol/l) 
Free/ 
Total 
MDA 
follow-up 
MDA/ 
Total 
Protein 
admission 
(umol/g) 
MDA/ 
Total 
Protein 
follow-up 
(umol/g) 
53.00 0.39 0.10 0.26 0.42 0.09 0.21 0.01 0.01 
55.00 0.22 0.10 0.45 0.32 0.13 0.41 0.01 0.01 
56.00 0.25 -- -- -- -- -- 0.01 -- 
57.00 0.29 0.15 0.52 -- -- -- 0.01 -- 
58.00 0.67 0.09 0.13 0.44 0.10 0.23 0.02 0.01 
59.00 2.20 0.28 0.13 -- -- -- 0.03 -- 
60.00 0.75 0.07 0.09 -- -- -- 0.01 -- 
61.00 1.37 1.37 1.00 -- -- -- 0.02 -- 
62.00 0.69 0.05 0.07 0.71 0.71 1.00 0.02 0.02 
63.00 0.62 0.06 0.10 -- -- -- 0.02 -- 
64.00 0.60 0.02 0.03 -- -- -- 0.01 -- 
67.00 0.83 0.26 0.31 0.61 0.08 0.13 0.02 0.02 
68.00 0.37 0.16 0.43 0.76 0.14 0.18 0.01 0.02 
69.00 -- -- -- -- -- -- -- -- 
71.00 0.60 0.04 0.07 -- -- -- 0.01 -- 
72.00 -- -- -- -- -- -- -- -- 
73.00 1.34 0.05 0.04 -- -- -- 0.02 -- 
74.00 -- -- -- -- -- -- -- -- 
75.00 1.19 0.18 0.15 -- -- -- 0.03 -- 
77.00 1.03 0.08 0.08 -- -- -- 0.02 -- 
78.00 -- -- -- -- -- -- -- -- 
79.00 -- -- -- -- -- -- -- -- 
80.00 -- -- -- -- -- -- -- -- 
81.00 0.41 0.08 0.20 0.63 0.07 0.11 0.02 0.01 
82.00 -- -- -- -- -- -- -- -- 
83.00 0.89 0.04 0.04 -- -- -- 0.02 -- 
84.00 0.78 0.13 0.17 0.94 0.15 0.16 0.03 0.03 
85.00 -- -- -- -- -- -- -- -- 
87.00 0.24 0.02 0.08 -- -- -- 0.01 -- 
88.00 0.42 0.08 0.19 0.55 0.19 0.35 0.01 0.01 
89.00 -- -- -- -- -- -- -- -- 
90.00 -- -- -- -- -- -- -- -- 
91.00 -- -- -- -- -- -- -- -- 
96.00 -- -- -- -- -- -- -- -- 
  
339 
Patient 
No. 
Total MDA 
admission 
(umol/l) 
Free MDA 
admission 
(umol/l) 
Free/ Total 
MDA 
admission 
Total MDA 
follow-up 
(umol/l) 
Free MDA 
follow-up 
(umol/l) 
Free/ 
Total 
MDA 
follow-up 
MDA/ 
Total 
Protein 
admission 
(umol/g) 
MDA/ 
Total 
Protein 
follow-up 
(umol/g) 
99.00 0.73 0.05 0.07 -- -- -- 0.01 -- 
100.00 0.68 0.19 0.28 0.45 0.12 0.27 0.02 0.01 
101.00 0.32 0.07 0.22 -- -- -- 0.01 -- 
102.00 -- -- -- -- -- -- -- -- 
103.00 -- -- -- -- -- -- -- -- 
104.00 -- -- -- -- -- -- -- -- 
105.00 0.71 0.15 0.21 0.48 0.17 0.35 0.01 0.01 
107.00 0.77 0.08 0.10 -- -- -- 0.02 -- 
108.00 0.48 0.10 0.21 -- -- -- 0.01 -- 
110.00 0.48 0.09 0.19 0.84 0.12 0.14 0.01 0.02 
111.00 -- -- -- -- -- -- -- -- 
112.00 1.31 0.06 0.05 2.62 1.40 0.53 0.03 0.10 
113.00 1.56 0.35 0.22 0.47 0.05 0.11 0.03 0.01 
114.00 0.73 0.12 0.16 0.51 0.16 0.31 0.02 0.02 
115.00 1.06 0.05 0.05 -- -- -- 0.02 -- 
116.00 0.81 0.06 0.07 -- -- -- 0.02 -- 
117.00 1.61 0.06 0.04 0.46 0.06 0.13 0.03 0.01 
118.00 0.61 0.05 0.08 0.66 0.17 0.26 0.02 0.02 
119.00 1.40 0.06 0.04 -- -- -- 0.03 -- 
121.00 0.57 0.08 0.14 0.47 0.06 0.13 0.02 0.01 
123.00 0.87 0.04 0.05 0.81 0.10 0.12 0.01 0.01 
124.00 0.35 0.08 0.23 0.50 0.06 0.12 0.01 0.01 
126.00 0.55 0.06 0.11 -- -- -- 0.01 -- 
127.00 0.79 0.11 0.14 -- -- -- 0.01 -- 
128.00 0.94 0.10 0.11 -- -- -- 0.02 -- 
129.00 1.84 0.14 0.08 -- -- -- 0.03 -- 
131.00 0.44 0.09 0.20 -- -- -- 0.01 -- 
133.00 0.61 0.08 0.13 -- -- -- 0.02 -- 
135.00 0.56 0.06 0.11 -- -- -- 0.01 -- 
137.00 0.45 0.04 0.08 -- -- -- 0.01 -- 
139.00 0.63 0.04 0.06 -- -- -- 0.02 -- 
140.00 0.62 0.08 0.13 -- -- -- 0.02 -- 
141.00 0.66 0.12 0.18 0.40 0.11 0.28 0.02 0.01 
143.00 0.59 0.08 0.14 -- -- -- 0.01 -- 
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Patient 
No. 
Total MDA 
admission 
(umol/l) 
Free MDA 
admission 
(umol/l) 
Free/ Total 
MDA 
admission 
Total MDA 
follow-up 
(umol/l) 
Free MDA 
follow-up 
(umol/l) 
Free/ 
Total 
MDA 
follow-up 
MDA/ 
Total 
Protein 
admission 
(umol/g) 
MDA/ 
Total 
Protein 
follow-up 
(umol/g) 
146.00 0.70 0.07 0.10 0.47 0.11 0.23 0.02 0.01 
147.00 0.47 0.05 0.11 0.63 0.05 0.08 0.01 0.01 
148.00 -- -- -- -- -- -- -- -- 
149.00 0.52 0.07 0.13 -- -- -- 0.01 -- 
150.00 0.41 0.06 0.15 -- -- -- 0.01 -- 
151.00 0.48 0.06 0.13 -- -- -- 0.01 -- 
152.00 1.65 0.07 0.04 -- -- -- 0.03 -- 
153.00 0.68 0.10 0.15 -- -- -- 0.01 -- 
154.00 0.85 0.09 0.11 -- -- -- 0.01 -- 
155.00 1.08 0.19 0.18 -- -- -- 0.02 -- 
156.00 0.69 0.13 0.19 -- -- -- 0.01 -- 
157.00 0.38 0.22 0.58 -- -- -- 0.01 -- 
158.00 1.00 0.08 0.08 -- -- -- 0.03 -- 
159.00 0.62 0.08 0.13 -- -- -- 0.02 -- 
163.00 0.72 0.08 0.11 -- -- -- 0.02 -- 
164.00 0.56 0.05 0.09 -- -- -- 0.01 -- 
165.00 1.24 0.05 0.04 -- -- -- 0.02 -- 
166.00 0.92 0.09 0.10 -- -- -- 0.02 -- 
167.00 0.42 0.08 0.19 -- -- -- 0.01 -- 
168.00 -- -- -- -- -- -- -- -- 
169.00 -- -- -- -- -- -- -- -- 
171.00 -- -- -- -- -- -- -- -- 
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12.12 Appendix 12 Chapter 8 data 
Characteristics and biochemical measurements of patients (Chapter 8) 
Patient 
no. 
Age 
(yrs) 
Male/ 
Female 
(0/1) 
APACHE 
II 
Predicted 
Mortality 
(%) 
Medical/Surgical 
(0/1) 
Pro-ICU 
Pabrinex 
(doses) 
Pro + 
ICU 
Pabrinex 
(doses) 
ICU 
Death 
ICU 
stay 
(days) 
Hospital 
death 
Hospital 
stay 
(days) 
12.00 61.00 0.00 29.00 76.60 0.00 0.00 0.00 0.00 7.40 0.00 13.40 
13.00 43.00 1.00 12.00 11.70 1.00 0.00 2.00 0.00 48.10 1.00 50.10 
14.00 71.00 1.00 18.00 28.90 1.00 0.00 0.00 1.00 12.90 1.00 12.90 
15.00 53.00 1.00 19.00 32.20 0.00 0.00 1.00 0.00 4.80 0.00 10.80 
16.00 61.00 0.00 23.00 28.50 0.00 0.00 -- 0.00 1.00 0.00 10.00 
17.00 18.00 0.00 12.00 20.20 0.00 0.00 3.00 1.00 6.20 1.00 6.20 
18.00 67.00 0.00 18.00 44.40 1.00 0.00 0.00 1.00 59.50 1.00 59.50 
19.00 50.00 0.00 21.00 38.90 0.00 0.00 3.00 1.00 46.30 1.00 46.30 
21.00 61.00 0.00 34.00 76.80 1.00 0.00 -- 0.00 2.00 0.00 53.00 
22.00 52.00 0.00 13.00 9.90 0.00 95.00 101.00 0.00 3.70 0.00 77.00 
23.00 71.00 0.00 23.00 42.50 1.00 9.00 10.00 1.00 20.90 1.00 20.90 
24.00 77.00 1.00 21.00 35.00 0.00 0.00 -- 0.00 2.00 0.00 6.00 
27.00 76.00 1.00 23.00 46.00 0.00 1.00 3.00 0.00 21.70 0.00 21.70 
29.00 70.00 0.00 16.00 20.20 1.00 4.00 10.00 0.00 5.10 0.00 85.00 
30.00 73.00 1.00 25.00 53.30 1.00 0.00 2.00 1.00 15.50 1.00 15.50 
31.00 62.00 0.00 19.00 27.10 1.00 0.00 -- 0.00 0.50 0.00 25.00 
32.00 55.00 1.00 15.00 21.00 1.00 0.00 -- 0.00 2.20 0.00 22.20 
33.00 80.00 1.00 31.00 84.20 1.00 0.00 0.00 1.00 12.00 1.00 12.00 
34.00 53.00 0.00 26.00 68.60 1.00 6.00 7.00 0.00 29.40 0.00 85.00 
35.00 20.00 0.00 18.00 39.70 1.00 0.00 1.00 1.00 44.00 1.00 44.00 
36.00 43.00 1.00 38.00 92.60 0.00 5.00 10.00 0.00 25.50 0.00 27.50 
37.00 60.00 0.00 27.00 63.10 0.00 0.00 0.00 0.00 21.80 0.00 29.00 
38.00 74.00 0.00 20.00 23.00 1.00 0.00 -- 0.00 1.00 0.00 150.00 
40.00 47.00 0.00 22.00 28.50 1.00 0.00 2.00 0.00 1.90 0.00 19.90 
41.00 76.00 1.00 29.00 79.90 1.00 0.00 -- 0.00 1.40 0.00 21.40 
42.00 79.00 0.00 21.00 30.90 1.00 0.00 3.00 0.00 3.20 0.00 27.00 
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Patient 
no. 
Age 
(yrs) 
Male/ 
Female 
(0/1) 
APACHE 
II 
Predicted 
Mortality 
(%) 
Medical/Surgical 
(0/1) 
Pro-ICU 
Pabrinex 
(doses) 
Pro + 
ICU 
Pabrinex 
(doses) 
ICU 
Death 
ICU 
stay 
(days) 
Hospital 
death 
Hospital 
stay 
(days) 
44.00 81.00 0.00 34.00 86.30 0.00 0.00 0.00 1.00 16.10 1.00 16.10 
45.00 74.00 0.00 33.00 75.20 0.00 0.00 0.00 1.00 16.00 1.00 16.00 
46.00 41.00 1.00 8.00 15.60 1.00 0.00 -- 0.00 0.80 0.00 18.80 
47.00 76.00 0.00 29.00 77.20 1.00 0.00 0.00 1.00 34.60 1.00 36.80 
48.00 67.00 0.00 31.00 68.10 1.00 1,000.00 1,007.00 1.00 18.40 1.00 18.40 
50.00 60.00 0.00 19.00 48.00 1.00 0.00 0.00 0.00 6.20 0.00 124.20 
51.00 46.00 1.00 24.00 49.70 0.00 1,000.00 1,006.00 1.00 4.60 1.00 4.60 
52.00 61.00 0.00 33.00 78.60 0.00 7.00 10.00 1.00 7.70 1.00 7.70 
53.00 67.00 1.00 18.00 21.20 0.00 0.00 0.00 1.00 11.10 1.00 11.10 
55.00 80.00 1.00 31.00 73.30 0.00 0.00 3.00 1.00 8.20 1.00 8.20 
56.00 40.00 1.00 6.00 10.20 1.00 0.00 -- 0.00 0.40 0.00 0.40 
57.00 60.00 0.00 27.00 60.20 1.00 0.00 -- 1.00 1.80 1.00 1.80 
58.00 41.00 0.00 21.00 17.80 1.00 0.00 0.00 0.00 19.70 0.00 36.70 
59.00 68.00 0.00 20.00 32.30 0.00 0.00 -- 0.00 0.80 0.00 12.00 
60.00 57.00 0.00 24.00 67.00 0.00 0.00 -- 0.00 6.50 0.00 59.50 
61.00 76.00 1.00 18.00 14.40 0.00 0.00 -- 0.00 0.70 0.00 22.70 
62.00 74.00 0.00 20.00 19.90 1.00 0.00 0.00 0.00 0.90 0.00 253.00 
63.00 62.00 0.00 18.00 44.40 1.00 1,000.00 -- 0.00 1.00 0.00 508.00 
64.00 66.00 0.00 34.00 81.00 0.00 0.00 -- 0.00 22.40 0.00 46.00 
65.00 38.00 1.00 17.00 26.20 0.00 0.00 -- 0.00 18.90 0.00 37.00 
67.00 68.00 1.00 31.00 80.30 0.00 1,000.00 0.00 0.00 5.00 1.00 8.00 
68.00 74.00 0.00 24.00 49.70 0.00 0.00 7.00 0.00 10.70 0.00 27.70 
69.00 61.00 0.00 22.00 54.90 1.00 1,000.00 1,004.00 0.00 76.40 1.00 122.40 
71.00 25.00 0.00 17.00 1.20 0.00 0.00 -- 0.00 2.00 0.00 3.50 
72.00 51.00 0.00 21.00 12.40 0.00 1.00 1.00 0.00 15.50 0.00 40.00 
73.00 69.00 0.00 12.00 20.20 0.00 0.00 -- 0.00 5.80 0.00 23.00 
74.00 65.00 0.00 33.00 80.40 0.00 0.00 7.00 0.00 19.60 0.00 40.00 
75.00 28.00 1.00 14.00 18.50 1.00 0.00 -- 0.00 0.60 0.00 58.00 
77.00 54.00 1.00 17.00 1.20 0.00 0.00 -- 0.00 0.80 0.00 12.00 
78.00 45.00 0.00 12.00 5.50 1.00 0.00 -- 0.00 0.90 0.00 12.00 
79.00 41.00 0.00 7.00 7.60 1.00 0.00 0.00 0.00 9.30 0.00 19.00 
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Patient 
no. 
Age 
(yrs) 
Male/ 
Female 
(0/1) 
APACHE 
II 
Predicted 
Mortality 
(%) 
Medical/Surgical 
(0/1) 
Pro-ICU 
Pabrinex 
(doses) 
Pro + 
ICU 
Pabrinex 
(doses) 
ICU 
Death 
ICU 
stay 
(days) 
Hospital 
death 
Hospital 
stay 
(days) 
80.00 38.00 0.00 16.00 23.30 1.00 1,000.00 -- 0.00 0.80 0.00 41.00 
81.00 71.00 0.00 25.00 35.90 1.00 0.00 1.00 0.00 8.30 0.00 20.00 
82.00 80.00 1.00 17.00 12.70 0.00 0.00 1.00 0.00 10.30 0.00 29.00 
83.00 46.00 1.00 11.00 10.30 1.00 0.00 -- 0.00 2.90 0.00 10.00 
84.00 56.00 0.00 28.00 63.90 0.00 1,000.00 1,006.00 0.00 15.40 0.00 35.00 
85.00 73.00 0.00 18.00 44.40 1.00 0.00 0.00 0.00 1.40 0.00 160.00 
87.00 34.00 1.00 12.00 12.40 1.00 0.00 -- 0.00 2.30 0.00 12.00 
88.00 81.00 0.00 17.00 23.60 1.00 1,000.00 1,004.00 1.00 9.30 1.00 10.00 
89.00 22.00 1.00 10.00 9.50 1.00 0.00 -- 0.00 0.20 0.00 1.00 
90.00 53.00 0.00 32.00 60.90 1.00 0.00 2.00 0.00 3.00 0.00 36.00 
91.00 62.00 0.00 22.00 58.90 1.00 0.00 -- 0.00 1.70 0.00 14.00 
94.00 32.00 1.00 25.00 53.30 0.00 0.00 -- 0.00 17.30 0.00 24.00 
96.00 63.00 1.00 18.00 4.80 0.00 0.00 0.00 0.00 1.90 0.00 15.00 
99.00 37.00 0.00 13.00 16.50 1.00 0.00 -- 0.00 2.10 0.00 11.00 
100.00 50.00 1.00 26.00 38.20 0.00 0.00 12.00 0.00 2.60 0.00 119.00 
101.00 35.00 1.00 9.00 4.70 1.00 0.00 -- 0.00 0.80 0.00 6.00 
102.00 26.00 0.00 23.00 45.70 1.00 0.00 0.00 0.00 2.30 0.00 77.00 
103.00 52.00 0.00 16.00 12.20 1.00 0.00 0.00 0.00 2.00 0.00 48.00 
104.00 38.00 0.00 3.00 2.70 0.00 0.00 -- 0.00 0.30 0.00 5.00 
105.00 39.00 0.00 34.00 87.50 0.00 1,000.00 1,001.00 0.00 3.00 0.00 58.00 
107.00 45.00 1.00 12.00 6.60 1.00 0.00 -- 0.00 3.10 0.00 48.00 
108.00 44.00 1.00 6.00 0.90 0.00 0.00 -- 0.00 0.80 0.00 5.00 
110.00 48.00 1.00 26.00 35.20 0.00 0.00 8.00 1.00 4.90 1.00 6.00 
111.00 23.00 0.00 9.00 4.30 1.00 0.00 7.00 0.00 9.20 0.00 48.00 
112.00 45.00 1.00 24.00 22.40 1.00 0.00 0.00 1.00 10.70 1.00 12.00 
113.00 70.00 0.00 27.00 47.70 0.00 0.00 2.00 1.00 6.50 1.00 7.00 
114.00 65.00 1.00 24.00 65.70 1.00 0.00 3.00 0.00 32.80 1.00 61.00 
115.00 47.00 0.00 10.00 1.50 0.00 0.00 -- 0.00 0.60 0.00 14.00 
116.00 61.00 0.00 13.00 10.60 0.00 0.00 -- 0.00 2.40 0.00 37.00 
117.00 48.00 0.00 13.00 8.50 1.00 0.00 2.00 0.00 4.20 0.00 18.00 
118.00 59.00 0.00 23.00 39.90 1.00 0.00 1.00 0.00 12.10 0.00 24.00 
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Patient 
no. 
Age 
(yrs) 
Male/ 
Female 
(0/1) 
APACHE 
II 
Predicted 
Mortality 
(%) 
Medical/Surgical 
(0/1) 
Pro-ICU 
Pabrinex 
(doses) 
Pro + 
ICU 
Pabrinex 
(doses) 
ICU 
Death 
ICU 
stay 
(days) 
Hospital 
death 
Hospital 
stay 
(days) 
119.00 67.00 1.00 18.00 14.40 0.00 0.00 -- 0.00 1.30 0.00 9.00 
121.00 86.00 0.00 22.00 42.20 1.00 0.00 3.00 0.00 6.60 0.00 20.00 
123.00 60.00 0.00 16.00 14.60 0.00 1,000.00 1,004.00 0.00 3.10 0.00 23.00 
124.00 33.00 0.00 14.00 27.40 1.00 1.00 4.00 0.00 4.70 0.00 10.00 
126.00 68.00 0.00 27.00 46.00 0.00 1,000.00 -- 0.00 1.60 0.00 240.00 
127.00 100.00 0.00 25.00 64.60 1.00 0.00 -- 0.00 3.50 0.00 60.00 
128.00 80.00 1.00 30.00 56.90 1.00 0.00 -- 0.00 2.90 0.00 144.00 
129.00 31.00 0.00 19.00 44.00 0.00 0.00 -- 0.00 2.90 0.00 54.00 
131.00 65.00 0.00 21.00 55.30 1.00 0.00 -- 0.00 6.70 1.00 24.00 
133.00 35.00 0.00 14.00 7.20 1.00 0.00 -- 0.00 0.90 0.00 9.00 
135.00 41.00 1.00 16.00 14.30 1.00 0.00 -- 0.00 0.60 0.00 17.00 
137.00 69.00 1.00 19.00 32.00 1.00 0.00 -- 0.00 0.80 0.00 7.00 
139.00 54.00 1.00 23.00 55.80 1.00 0.00 -- 0.00 2.60 0.00 69.00 
140.00 74.00 0.00 21.00 41.60 1.00 0.00 -- 0.00 2.10 1.00 11.00 
141.00 67.00 0.00 32.00 78.00 1.00 0.00 -- 0.00 19.60 0.00 50.00 
143.00 52.00 0.00 10.00 17.40 1.00 0.00 -- 1.00 9.80 1.00 11.00 
146.00 38.00 0.00 18.00 24.20 1.00 6.00 21.00 0.00 10.30 0.00 20.00 
147.00 70.00 0.00 20.00 35.50 1.00 0.00 0.00 0.00 1.50 0.00 29.00 
148.00 71.00 0.00 25.00 53.30 0.00 0.00 -- 0.00 0.80 1.00 5.00 
149.00 74.00 0.00 15.00 -- 1.00 0.00 -- 1.00 13.80 1.00 15.00 
150.00 62.00 0.00 21.00 38.90 0.00 0.00 -- 0.00 35.20 0.00 66.00 
151.00 36.00 0.00 8.00 8.60 1.00 0.00 -- 0.00 1.20 0.00 62.00 
152.00 47.00 0.00 11.00 7.60 0.00 0.00 -- 0.00 2.00 0.00 10.00 
153.00 77.00 1.00 27.00 46.00 0.00 8.00 -- 0.00 3.10 0.00 14.00 
154.00 49.00 0.00 26.00 4.40 0.00 0.00 -- 0.00 0.90 0.00 8.00 
155.00 43.00 0.00 25.00 3.80 0.00 0.00 -- 0.00 0.80 0.00 7.00 
156.00 41.00 0.00 33.00 78.60 0.00 0.00 -- 1.00 1.80 1.00 3.00 
157.00 61.00 0.00 31.00 81.40 1.00 0.00 -- 0.00 11.40 0.00 53.00 
158.00 56.00 0.00 11.00 22.30 1.00 1.00 -- 0.00 9.00 0.00 74.00 
159.00 60.00 1.00 19.00 11.30 1.00 0.00 -- 0.00 1.50 0.00 22.00 
163.00 77.00 1.00 26.00 56.70 1.00 0.00 -- 0.00 1.40 0.00 48.00 
  
345 
Patient 
no. 
Age 
(yrs) 
Male/ 
Female 
(0/1) 
APACHE 
II 
Predicted 
Mortality  
(%) 
Medical/Surgical 
(0/1) 
Pro-ICU 
Pabrinex 
(doses) 
Pro + 
ICU 
Pabrinex 
(doses) 
ICU 
Death 
ICU 
stay 
(days) 
Hospital 
death 
Hospital 
stay 
(days) 
164.00 62.00 1.00 14.00 9.70 0.00 0.00 -- 0.00 7.00 0.00 16.00 
165.00 35.00 0.00 5.00 0.20 0.00 0.00 -- 0.00 1.00 0.00 6.00 
166.00 63.00 0.00 13.00 13.40 1.00 0.00 -- 0.00 0.60 0.00 13.00 
167.00 56.00 0.00 32.00 76.00 0.00 1.00 -- 0.00 2.10 1.00 4.00 
168.00 52.00 1.00 26.00 56.90 0.00 3.00 -- 0.00 34.10 0.00 57.00 
169.00 39.00 1.00 13.00 24.60 1.00 66.00 -- 0.00 24.60 0.00 55.00 
171.00 67.00 0.00 27.00 60.50 0.00 0.00 -- 0.00 2.30 0.00 10.00 
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Patient no. 
Ventilation 
(days) 
SOFA 
score 
admission 
SOFA 
score 
follow up 
Follow up 
sample 
(days) 
C-reactive 
protein 
admission 
(mg/l) 
C-reactive 
protein 
follow up 
(mg/l) 
Albumin 
admission 
(g/l) 
Albumin 
follow up 
(g/l) 
Whole blood 
TDP 
admission 
(ng/g Hb) 
Whole 
blood TDP 
follow up 
(ng/g Hb) 
Plasma 
FAD 
admission 
(nmol/l) 
12.00 6.00 7.00 7.00 2.00 126.00 156.00 24.00 23.00 928.00 886.00 77.20 
13.00 49.00 5.00 9.00 3.00 22.00 261.00 27.00 22.00 789.00 1,450.00 111.70 
14.00 14.00 8.00 9.00 2.00 220.00 124.00 12.00 10.00 1,173.00 1,050.00 81.20 
15.00 5.00 8.00 2.00 5.00 257.00 73.00 23.00 16.00 1,435.00 796.00 375.90 
16.00 1.00 6.00 -- -- 122.00 -- 28.00 -- 994.00 -- 75.00 
17.00 6.00 2.00 0.00 4.00 3.00 55.00 33.00 26.00 693.00 593.00 289.60 
18.00 60.00 10.00 10.00 4.00 152.00 64.00 10.00 10.00 402.00 374.00 29.80 
19.00 47.00 10.00 9.00 4.00 143.00 101.00 12.00 14.00 1,094.00 2,445.00 133.40 
21.00 2.00 8.00 -- -- 23.00 -- 10.00 -- 617.00 -- 195.90 
22.00 4.00 2.00 3.00 4.00 20.00 67.00 27.00 15.00 2,341.00 2,112.00 58.70 
23.00 22.00 8.00 4.00 7.00 125.00 216.00 10.00 13.00 978.00 1,036.00 87.00 
24.00 3.00 4.00 -- -- 81.00 -- 35.00 -- 1,317.00 -- 70.30 
27.00 21.60 5.00 4.00 3.00 103.00 133.00 23.00 17.00 705.00 1,530.00 170.10 
29.00 4.00 4.00 4.00 4.00 59.00 20.00 9.00 10.00 1,652.00 1,906.00 22.80 
30.00 13.00 11.00 7.00 3.00 26.00 179.00 16.00 11.00 891.00 5,491.00 826.50 
31.00 1.00 11.00 -- -- 50.00 -- 22.00 -- 744.00 -- 42.40 
32.00 0.00 6.00 -- -- 434.00 -- 17.00 -- 778.00 -- 58.80 
33.00 13.00 7.00 8.00 5.00 259.00 173.00 17.00 10.00 510.00 583.00 41.30 
34.00 1.00 6.00 7.00 4.00 404.00 336.00 30.00 15.00 3,650.00 3,498.00 658.40 
35.00 44.00 10.00 7.00 3.00 119.00 303.00 9.00 13.00 483.00 752.00 36.70 
36.00 24.00 13.00 10.00 4.00 132.00 70.00 14.00 14.00 2,672.00 3,000.00 1,915.70 
37.00 16.00 10.00 9.00 4.00 81.00 35.00 12.00 12.00 1,270.00 915.00 321.50 
38.00 2.00 4.00 -- -- 127.00 -- 14.00 -- 626.00 -- 41.90 
40.00 3.00 9.00 4.00 3.00 15.00 234.00 20.00 18.00 330.00 1,043.00 67.40 
41.00 2.00 8.00 -- -- 184.00 -- 19.00 -- 768.00 -- 37.60 
42.00 3.00 4.00 6.00 4.00 8.00 149.00 17.00 18.00 574.00 1,241.00 29.90 
44.00 16.10 7.00 3.00 8.00 151.00 55.00 10.00 16.00 506.00 892.00 546.20 
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Patient no. 
Ventilation 
(days) 
SOFA 
score 
admission 
SOFA 
score 
follow up 
Follow up 
sample 
(days) 
C-reactive 
protein 
admission 
(mg/l) 
C-reactive 
protein 
follow up 
(mg/l) 
Albumin 
admission 
(g/l) 
Albumin 
follow up 
(g/l) 
Whole blood 
TDP 
admission 
(ng/g Hb) 
Whole 
blood TDP 
follow up 
(ng/g Hb) 
Plasma 
FAD 
admission 
(nmol/l) 
45.00 16.00 11.00 5.00 5.00 258.00 164.00 14.00 14.00 1,379.00 860.00 37.00 
46.00 1.00 1.00 -- -- 250.00 -- 11.00 -- 804.00 -- 31.10 
47.00 33.00 7.00 7.00 2.00 64.00 72.00 24.00 24.00 1,002.00 1,131.00 1,179.40 
48.00 15.00 6.00 11.00 4.00 119.00 123.00 10.00 9.00 2,127.00 3,085.00 529.60 
50.00 5.00 7.00 4.00 6.00 180.00 141.00 23.00 15.00 828.00 860.00 52.40 
51.00 5.00 14.00 16.00 3.00 56.00 58.00 14.00 19.00 1,406.00 1,664.00 53.70 
52.00 8.00 11.00 11.00 3.00 565.00 257.00 9.00 9.00 3,524.00 4,591.00 67.20 
53.00 12.00 11.00 10.00 3.00 148.00 131.00 9.00 9.00 196.00 207.00 61.80 
55.00 9.00 8.00 8.00 4.00 107.00 71.00 13.00 9.00 676.00 3,011.00 30.40 
56.00 1.00 6.00 -- -- 37.00 -- 16.00 -- 518.00 -- 28.60 
57.00 3.00 10.00 -- -- 181.00 -- 10.00 -- 560.00 -- 10.40 
58.00 19.00 4.00 12.00 2.00 6.00 36.00 19.00 12.00 506.00 502.00 35.60 
59.00 2.00 5.00 -- -- 32.00 -- 36.00 -- 1,130.00 -- 69.30 
60.00 5.00 3.00 -- -- 166.00 -- 26.00 -- 923.00 -- 52.70 
61.00 0.00 5.00 -- -- 380.00 -- 26.00 -- 1,037.00 -- 58.70 
62.00 2.00 1.00 2.00 3.00 88.00 180.00 12.00 14.00 800.00 598.00 28.70 
63.00 2.00 2.00 -- -- 117.00 -- 14.00 -- 2,092.00 -- 18.80 
64.00 21.00 13.00 -- -- 311.00 -- 18.00 -- 556.00 -- 31.00 
65.00 18.00 9.00 -- -- 163.00 -- 23.00 -- 1,226.00 -- 41.20 
67.00 5.00 4.00 4.00 5.00 438.00 52.00 20.00 16.00 763.00 1,456.00 24.10 
68.00 11.00 14.00 12.00 5.00 67.00 139.00 11.00 11.00 459.00 1,515.00 19.60 
69.00 75.00 10.00 13.00 4.00 179.00 356.00 14.00 16.00 544.00 2,446.00 10.30 
71.00 1.00 3.00 -- -- 2.00 -- 38.00 -- 792.00 -- 42.20 
72.00 15.00 11.00 7.00 12.00 40.00 89.00 32.00 15.00 1,677.00 2,300.00 78.20 
73.00 7.00 3.00 -- -- 2.00 -- 31.00 -- -- -- 38.20 
74.00 18.00 6.00 11.00 4.00 77.00 28.00 15.00 13.00 631.00 2,192.00 -- 
75.00 1.00 10.00 -- -- 184.00 -- 11.00 -- 727.00 -- 28.70 
77.00 2.00 7.00 -- -- 2.00 -- 20.00 -- 667.00 -- 33.20 
78.00 2.00 4.00 -- -- 177.00 -- 27.00 -- 598.00 -- 53.00 
79.00 8.00 4.00 3.00 3.00 2.00 251.00 24.00 21.00 500.00 689.00 77.60 
80.00 2.00 9.00 -- -- 126.00 -- 14.00 -- 2,300.00 -- 54.50 
  
348 
Patient no. 
Ventilation 
(days) 
SOFA 
score 
admission 
SOFA 
score 
follow up 
Follow up 
sample 
(days) 
C-reactive 
protein 
admission 
(mg/l) 
C-reactive 
protein 
follow up 
(mg/l) 
Albumin 
admission 
(g/l) 
Albumin 
follow up 
(g/l) 
Whole blood 
TDP 
admission 
(ng/g Hb) 
Whole 
blood TDP 
follow up 
(ng/g Hb) 
Plasma 
FAD 
admission 
(nmol/l) 
81.00 9.00 5.00 6.00 3.00 8.00 284.00 10.00 21.00 617.00 1,973.00 43.60 
82.00 8.00 1.00 1.00 2.00 4.00 86.00 29.00 29.00 739.00 1,961.00 19.20 
83.00 0.00 4.00 -- -- 318.00 -- 21.00 -- 511.00 -- 42.20 
84.00 14.00 13.00 10.00 3.00 63.00 80.00 9.00 9.00 1,652.00 2,661.00 27.40 
85.00 2.00 6.00 7.00 2.00 176.00 198.00 11.00 9.00 350.00 359.00 25.30 
87.00 2.00 6.00 -- -- 110.00 -- 18.00 -- 700.00 -- 39.30 
88.00 10.00 9.00 9.00 5.00 108.00 104.00 12.00 11.00 1,176.00 2,306.00 29.50 
89.00 1.00 2.00 -- -- 31.00 -- 16.00 -- 579.00 -- 41.90 
90.00 3.00 10.00 7.00 4.00 159.00 38.00 11.00 29.00 724.00 2,220.00 20.90 
91.00 1.00 9.00 -- -- 268.00 -- 14.00 -- 687.00 -- -- 
94.00 17.00 18.00 -- -- 147.00 -- 14.00 -- 810.00 -- 61.40 
96.00 2.00 3.00 2.00 3.00 76.00 27.00 29.00 28.00 894.00 691.00 46.40 
99.00 2.00 5.00 -- -- 287.00 -- 22.00 -- 1,983.00 -- 33.40 
100.00 0.00 4.00 4.00 3.00 253.00 171.00 13.00 9.00 2,287.00 2,459.00 20.30 
101.00 0.00 5.00 -- -- 231.00 -- 25.00 -- 385.00 -- 24.30 
102.00 2.00 4.00 2.00 2.00 28.00 198.00 19.00 19.00 415.00 508.00 26.20 
103.00 2.00 2.00 1.00 3.00 -- 69.00 42.00 27.00 910.00 1,538.00 53.10 
104.00 1.00 2.00 -- -- 1.00 -- 34.00 -- 545.00 -- 73.40 
105.00 3.00 11.00 8.00 2.00 25.00 23.00 30.00 29.00 1,271.00 2,232.00 25.50 
107.00 0.00 8.00 -- -- 261.00 -- 17.00 -- 827.00 -- 45.30 
108.00 0.00 3.00 -- -- 48.00 -- 35.00 -- 653.00 -- 44.90 
110.00 6.00 7.00 12.00 5.00 199.00 153.00 13.00 11.00 918.00 3,164.00 18.20 
111.00 7.00 7.00 2.00 5.00 6.00 245.00 28.00 13.00 664.00 1,220.00 42.70 
112.00 12.00 1.00 10.00 4.00 2.00 165.00 20.00 9.00 923.00 459.00 64.70 
113.00 7.00 4.00 5.00 3.00 14.00 205.00 31.00 19.00 576.00 1,123.00 51.40 
114.00 34.00 9.00 8.00 4.00 49.00 98.00 16.00 9.00 288.00 2,218.00 30.40 
115.00 0.00 2.00 -- -- 1.00 -- 39.00 -- 610.00 -- 67.80 
116.00 3.00 1.00 -- -- 3.00 -- 24.00 -- 391.00 -- 34.90 
117.00 4.00 3.00 3.00 4.00 9.00 88.00 32.00 23.00 713.00 804.00 64.40 
118.00 12.00 9.00 12.00 2.00 252.00 204.00 12.00 9.00 1,367.00 333.00 16.60 
119.00 1.00 2.00 -- -- 2.00 -- 25.00 -- 635.00 -- 68.20 
  
349 
Patient no. 
Ventilation 
(days) 
SOFA 
score 
admission 
SOFA 
score 
follow up 
Follow up 
sample 
(days) 
C-reactive 
protein 
admission 
(mg/l) 
C-reactive 
protein 
follow up 
(mg/l) 
Albumin 
admission 
(g/l) 
Albumin 
follow up 
(g/l) 
Whole blood 
TDP 
admission 
(ng/g Hb) 
Whole 
blood TDP 
follow up 
(ng/g Hb) 
Plasma 
FAD 
admission 
(nmol/l) 
121.00 6.00 7.00 4.00 5.00 203.00 88.00 15.00 15.00 482.00 1,776.00 13.70 
123.00 2.00 7.00 6.00 3.00 2.00 207.00 45.00 28.00 1,729.00 1,627.00 85.80 
124.00 4.00 7.00 6.00 2.00 97.00 149.00 15.00 14.00 1,884.00 2,241.00 18.00 
126.00 1.00 5.00 -- -- 3.00 -- 21.00 -- 1,248.00 -- 158.60 
127.00 0.00 12.00 -- -- 316.00 -- 17.00 -- 494.00 -- 17.40 
128.00 2.00 7.00 -- -- 51.00 -- 16.00 -- 685.00 -- 34.60 
129.00 3.00 12.00 -- -- 63.00 -- 20.00 -- 1,779.00 -- 37.80 
131.00 6.00 8.00 -- -- 165.00 -- 21.00 -- 531.00 -- 19.90 
133.00 2.00 0.00 -- -- 35.00 -- 16.00 -- 1,627.00 -- 47.70 
135.00 2.00 2.00 -- -- 221.00 -- 18.00 -- 1,302.00 -- 40.50 
137.00 1.00 4.00 -- -- 218.00 -- 11.00 -- 610.00 -- 43.70 
139.00 2.00 8.00 -- -- 72.00 -- 14.00 -- 773.00 -- 48.30 
140.00 0.00 8.00 -- -- 51.00 -- 9.00 -- 502.00 -- 99.80 
141.00 20.00 10.00 2.00 11.00 143.00 80.00 9.00 9.00 610.00 979.00 40.10 
143.00 45.00 2.00 -- -- 39.00 -- 14.00 -- 1,140.00 -- 61.50 
146.00 10.00 6.00 5.00 6.00 73.00 22.00 26.00 18.00 2,413.00 2,604.00 58.00 
147.00 0.00 7.00 3.00 2.00 203.00 216.00 32.00 24.00 545.00 598.00 57.60 
148.00 2.00 5.00 -- -- 17.00 -- 23.00 -- 423.00 -- 78.40 
149.00 11.00 5.00 -- -- 94.00 -- 13.00 -- 364.00 -- 26.10 
150.00 26.00 11.00 -- -- 295.00 -- 24.00 -- 653.00 -- 41.80 
151.00 2.00 0.00 -- -- 229.00 -- 13.00 -- 257.00 -- 41.80 
152.00 2.00 3.00 -- -- 26.00 -- 35.00 -- 595.00 -- 100.40 
153.00 0.00 4.00 -- -- 45.00 -- 19.00 -- 608.00 -- 52.80 
154.00 2.00 4.00 -- -- 39.00 -- 33.00 -- 2,552.00 -- 84.50 
155.00 2.00 8.00 -- -- 52.00 -- 19.00 -- 1,788.00 -- 45.30 
156.00 3.00 12.00 -- -- 316.00 -- 20.00 -- 300.00 -- 48.00 
157.00 9.00 14.00 -- -- 294.00 -- 13.00 -- 1,005.00 -- 21.40 
158.00 2.00 3.00 -- -- 163.00 -- 10.00 -- 1,656.00 -- 45.80 
159.00 2.00 4.00 -- -- 137.00 -- 15.00 -- 992.00 -- 43.00 
163.00 1.00 10.00 -- -- 269.00 -- 12.00 -- 520.00 -- 34.60 
164.00 5.00 10.00 -- -- 291.00 -- 24.00 -- 854.00 -- 45.80 
  
350 
Patient no. 
Ventilation 
(days) 
SOFA 
score 
admission 
SOFA 
score 
follow up 
Follow up 
sample 
(days) 
C-reactive 
protein 
admission 
(mg/l) 
C-reactive 
protein 
follow up 
(mg/l) 
Albumin 
admission 
(g/l) 
Albumin 
follow up 
(g/l) 
Whole blood 
TDP 
admission 
(ng/g Hb) 
Whole 
blood TDP 
follow up 
(ng/g Hb) 
Plasma 
FAD 
admission 
(nmol/l) 
165.00 2.00 1.00 -- -- 0.60 -- 47.00 -- 853.00 -- 87.60 
166.00 2.00 8.00 -- -- 75.00 -- 13.00 -- 598.00 -- 66.90 
167.00 3.00 8.00 -- -- 74.00 -- 23.00 -- 1,926.00 -- 58.90 
168.00 35.00 10.00 -- -- 131.00 -- 11.00 -- 2,061.00 -- 39.40 
169.00 25.00 14.00 -- -- 273.00 -- 14.00 -- 2,574.00 -- 75.80 
171.00 0.00 14.00 -- -- 203.00 -- 20.00 -- 808.00 -- 49.50 
 
  
351 
 
Patient no. 
Plasma 
FAD 
follow up 
(nmol/l) 
Plasma 
FMN 
admission 
(nmol/l) 
Plasma 
FMN 
follow up 
(nmol/l) 
Plasma 
riboflavin 
admission 
(nmol/l) 
Plasma 
riboflavin 
follow up 
(nmol/l) 
Red cell 
FAD 
admission 
(nmol/g 
Hb) 
Red cell 
FAD 
follow up 
(nmol/g 
Hb) 
Red cell 
FMN 
admission 
(nmol/g Hb) 
Red cell 
FMN follow 
up (nmol/g 
Hb) 
Red cell 
riboflavin 
admission 
(nmol/ g 
Hb) 
Red cell 
riboflavin 
follow up 
(nmol/ g 
Hb) 
12.00 79.90 -- -- 32.70 39.50 1.76 1.70 0.14 0.14 0.05 0.05 
13.00 63.50 -- -- 42.70 103.90 1.53 1.54 0.16 0.14 0.06 0.05 
14.00 56.80 -- -- 170.30 300.00 1.82 1.91 0.14 0.12 0.09 0.08 
15.00 145.60 -- -- -- -- 1.46 1.42 -- -- 0.03 -- 
16.00 -- -- -- 77.20 -- 1.05 -- 0.08 -- 0.03 -- 
17.00 73.70 -- -- -- -- 1.33 1.24 0.08 0.08 0.04 0.02 
18.00 62.20 -- -- 7.80 3.00 1.13 1.08 0.07 0.06 0.01 0.01 
19.00 1,510.30 -- -- -- -- 1.69 1.90 -- -- 0.04 0.12 
21.00 -- -- -- 53.00 -- 1.42 -- 0.09 -- 0.03 -- 
22.00 55.00 18.50 4.70 279.00 172.10 2.09 2.00 0.22 0.21 0.22 0.14 
23.00 157.00 -- -- -- -- 1.63 1.67 0.09 0.09 0.02 0.03 
24.00 -- -- -- 62.70 -- 2.29 -- -- -- 0.05 -- 
27.00 307.10 -- -- -- -- 1.63 1.88 -- -- 0.10 0.10 
29.00 33.20 -- -- 198.70 66.20 1.57 1.86 0.11 0.13 0.07 0.06 
30.00 1,697.50 -- -- -- -- 1.97 2.02 -- -- 0.14 0.27 
31.00 -- -- -- 13.50 -- 1.30 -- 0.08 -- 0.03 -- 
32.00 -- -- -- 18.20 -- 1.38 -- 0.09 -- 0.03 -- 
33.00 25.30 -- -- -- -- 1.20 1.26 0.08 0.08 0.01 0.01 
34.00 908.30 -- -- -- -- 1.86 2.04 0.13 0.18 0.19 0.10 
35.00 42.50 -- -- -- -- 1.35 1.68 0.09 0.10 0.01 0.01 
36.00 911.30 -- -- -- -- 2.17 2.03 0.14 0.13 0.17 0.06 
37.00 414.40 -- -- -- -- 1.58 1.74 0.10 0.11 0.07 0.08 
38.00 -- -- -- 45.60 -- 1.70 -- 0.11 -- 0.06 -- 
40.00 51.70 -- -- -- -- 1.41 1.33 0.09 0.09 0.01 0.01 
41.00 -- -- -- -- -- 1.20 -- 0.06 -- 0.04 -- 
42.00 28.90 -- -- 43.00 40.10 1.29 -- 0.08 -- 0.02 -- 
44.00 346.50 -- -- -- -- 2.04 2.15 0.17 0.17 0.07 0.06 
  
352 
Patient no. 
Plasma 
FAD 
follow up 
(nmol/l) 
Plasma 
FMN 
admission 
(nmol/l) 
Plasma 
FMN 
follow up 
(nmol/l) 
Plasma 
riboflavin 
admission 
(nmol/l) 
Plasma 
riboflavin 
follow up 
(nmol/l) 
Red cell 
FAD 
admission 
(nmol/g 
Hb) 
Red cell 
FAD 
follow up 
(nmol/g 
Hb) 
Red cell 
FMN 
admission 
(nmol/g Hb) 
Red cell 
FMN follow 
up (nmol/g 
Hb) 
Red cell 
riboflavin 
admission 
(nmol/ g 
Hb) 
Red cell 
riboflavin 
follow up 
(nmol/ g 
Hb) 
45.00 881.50 -- -- -- -- 2.21 2.19 0.14 0.15 0.02 0.06 
46.00 -- -- -- 31.90 -- 1.21 -- 0.08 -- 0.01 -- 
47.00 1,224.70 -- -- -- -- 1.85 2.15 0.15 0.16 0.09 0.17 
48.00 5,478.50 -- -- -- -- 2.14 2.55 0.16 0.18 0.11 0.62 
50.00 58.20 34.20 6.90 44.30 29.10 1.49 1.46 0.10 0.10 0.04 0.02 
51.00 89.60 11.50 7.10 106.50 330.60 1.80 1.89 0.16 0.15 0.11 0.17 
52.00 100.40 -- -- 748.10 910.80 2.30 2.30 0.11 0.10 0.17 0.24 
53.00 56.30 -- -- -- -- 1.04 0.96 0.05 0.05 0.01 0.00 
55.00 43.80 -- 3.60 4.10 237.70 1.22 2.00 0.08 0.14 -- 0.12 
56.00 -- 4.90 -- 16.60 -- 1.45 -- 0.07 -- 0.14 -- 
57.00 -- -- -- 52.50 -- 1.33 -- 0.13 -- 0.04 -- 
58.00 22.70 7.70 5.20 15.40 12.40 1.16 1.14 0.07 0.07 0.02 0.02 
59.00 -- -- -- 53.70 -- 1.22 -- 0.07 -- 0.01 -- 
60.00 -- -- -- 11.80 -- 1.17 -- 0.05 -- 0.00 -- 
61.00 -- -- -- 38.00 -- 1.21 -- 0.06 -- 0.01 -- 
62.00 32.80 5.40 4.30 6.60 9.60 1.20 1.09 0.06 0.05 0.01 0.01 
63.00 -- -- -- 48.00 -- 1.80 -- 0.26 -- 0.09 -- 
64.00 -- -- -- 10.00 -- 1.06 -- 0.06 -- 0.01 -- 
65.00 -- -- -- 57.30 -- 1.91 -- 0.36 -- 0.03 -- 
67.00 26.70 -- -- 34.00 39.80 1.72 1.68 0.19 0.19 0.08 0.07 
68.00 38.90 -- 8.20 5.90 577.10 1.54 2.30 0.11 0.17 0.02 0.20 
69.00 36.00 -- 10.70 571.90 616.80 1.34 2.26 0.12 0.22 0.03 0.25 
71.00 -- -- -- 8.60 -- 0.97 -- 0.05 -- 0.01 -- 
72.00 86.30 6.10 12.10 55.70 559.90 1.78 2.40 0.09 0.13 0.03 0.21 
73.00 -- -- -- 40.70 -- 1.38 -- 0.14 -- 0.05 -- 
74.00 115.40 -- 6.80 -- 1,166.10 1.44 1.96 0.13 0.17 0.04 0.28 
75.00 -- -- -- 53.90 -- 2.10 -- 0.48 -- 0.09 -- 
77.00 -- -- -- 24.80 -- 1.81 -- 0.13 -- 0.03 -- 
78.00 -- -- -- 139.00 -- 1.93 -- 0.17 -- 0.06 -- 
79.00 51.10 12.40 6.90 18.40 17.40 1.24 1.21 0.07 0.07 0.01 0.01 
  
353 
Patient no. 
Plasma 
FAD 
follow up 
(nmol/l) 
Plasma 
FMN 
admission 
(nmol/l) 
Plasma 
FMN 
follow up 
(nmol/l) 
Plasma 
riboflavin 
admission 
(nmol/l) 
Plasma 
riboflavin 
follow up 
(nmol/l) 
Red cell 
FAD 
admission 
(nmol/g 
Hb) 
Red cell 
FAD 
follow up 
(nmol/g 
Hb) 
Red cell 
FMN 
admission 
(nmol/g Hb) 
Red cell 
FMN follow 
up (nmol/g 
Hb) 
Red cell 
riboflavin 
admission 
(nmol/ g 
Hb) 
Red cell 
riboflavin 
follow up 
(nmol/ g 
Hb) 
80.00 -- -- -- 140.80 -- 2.23 -- 0.28 -- 0.14 -- 
81.00 68.70 -- -- 7.10 33.00 1.56 1.66 0.09 0.09 0.01 0.03 
82.00 57.30 2.80 4.60 3.00 14.50 1.31 1.68 0.08 0.11 0.01 0.02 
83.00 -- -- -- 7.80 -- 1.49 -- 0.08 -- 0.01 -- 
84.00 26.70 21.90 19.30 62.00 356.00 1.75 2.51 0.14 0.20 0.04 0.17 
85.00 34.80 3.60 4.10 6.70 8.00 1.30 1.33 0.09 0.10 0.05 0.03 
87.00 -- 24.40 -- 65.60 -- 1.62 -- 0.12 -- 0.03 -- 
88.00 43.90 -- -- 43.30 401.00 1.35 2.21 0.07 0.14 0.03 0.15 
89.00 -- -- -- 6.80 -- 1.17 -- 0.08 -- 0.01 -- 
90.00 39.70 -- -- 11.70 74.30 2.06 1.88 0.11 0.11 0.03 0.06 
91.00 -- -- -- -- -- 1.25 -- 0.08 -- 0.04 -- 
94.00 -- -- -- 14.30 -- 1.87 -- 0.14 -- 0.02 -- 
96.00 55.00 -- -- 20.20 11.20 2.12 2.00 0.15 0.14 0.06 0.06 
99.00 -- -- -- 43.40 -- 1.48 -- 0.09 -- 0.01 -- 
100.00 12.80 -- -- 337.50 172.10 2.56 2.50 0.33 0.25 0.21 0.12 
101.00 -- -- -- 11.90 -- -- -- -- -- -- -- 
102.00 26.20 28.10 23.10 27.00 36.80 1.31 1.27 0.08 0.07 0.02 0.02 
103.00 35.00 -- -- 43.10 26.30 1.59 1.59 0.16 0.16 0.07 0.07 
104.00 -- 28.40 -- 33.80 -- 1.31 -- 0.06 -- 0.02 -- 
105.00 19.10 29.30 -- 133.80 114.20 1.80 1.70 0.19 0.19 0.19 0.13 
107.00 -- -- -- 29.60 -- 1.67 -- 0.17 -- 0.06 -- 
108.00 -- 28.70 -- 11.80 -- 1.23 -- 0.05 -- 0.01 -- 
110.00 71.80 -- 16.70 -- 516.30 1.13 2.63 0.06 0.17 0.01 0.16 
111.00 25.50 -- -- 24.30 20.90 1.37 1.80 0.06 0.11 0.01 0.02 
112.00 18.70 19.40 -- 28.60 54.00 1.15 1.33 0.12 0.14 0.03 0.05 
113.00 24.10 30.70 -- 68.60 62.20 1.31 1.37 0.06 0.06 0.01 0.01 
114.00 12.40 -- 34.10 -- 66.20 1.14 1.40 0.06 0.08 0.01 0.02 
115.00 -- 17.30 -- 7.30 -- 1.02 -- 0.05 -- 0.01 -- 
116.00 -- 6.80 -- 13.60 -- 1.29 -- -- -- 0.01 -- 
117.00 36.00 19.60 -- 39.90 44.00 1.53 1.58 -- -- 0.02 0.03 
  
354 
Patient no. 
Plasma 
FAD 
follow up 
(nmol/l) 
Plasma 
FMN 
admission 
(nmol/l) 
Plasma 
FMN 
follow up 
(nmol/l) 
Plasma 
riboflavin 
admission 
(nmol/l) 
Plasma 
riboflavin 
follow up 
(nmol/l) 
Red cell 
FAD 
admission 
(nmol/g 
Hb) 
Red cell 
FAD 
follow up 
(nmol/g 
Hb) 
Red cell 
FMN 
admission 
(nmol/g Hb) 
Red cell 
FMN follow 
up (nmol/g 
Hb) 
Red cell 
riboflavin 
admission 
(nmol/ g 
Hb) 
Red cell 
riboflavin 
follow up 
(nmol/ g 
Hb) 
118.00 22.10 -- -- 193.10 29.00 1.85 1.48 -- -- 0.04 0.02 
119.00 -- 16.60 -- 24.00 -- 1.33 -- 0.08 -- 0.02 -- 
121.00 30.50 -- -- 14.00 26.20 1.54 1.79 0.14 0.16 0.03 0.05 
123.00 50.50 7.70 -- 115.00 69.40 1.77 1.88 -- -- 0.05 0.06 
124.00 39.40 11.60 -- 55.80 97.90 1.56 1.78 -- -- 0.02 0.01 
126.00 -- 75.60 -- 458.00 -- 1.23 -- -- -- 0.04 -- 
127.00 -- -- -- 374.20 -- 2.58 -- -- -- 0.23 -- 
128.00 -- -- -- 14.30 -- 1.75 -- 0.09 -- 0.03 -- 
129.00 -- -- -- 188.00 -- 1.88 -- -- -- 0.04 -- 
131.00 -- -- -- 69.70 -- 1.68 -- -- -- 0.04 -- 
133.00 -- 7.20 -- 40.20 -- 1.55 -- -- -- 0.02 -- 
135.00 -- -- -- 81.50 -- 1.91 -- -- -- 0.03 -- 
137.00 -- -- -- 4.50 -- 1.84 -- 0.10 -- 0.12 -- 
139.00 -- -- -- 48.60 -- 2.02 -- 0.11 -- 0.03 -- 
140.00 -- -- -- 21.90 -- 2.13 -- 0.13 -- 0.09 -- 
141.00 56.20 -- -- 9.20 199.10 1.53 2.11 0.08 0.14 0.02 0.08 
143.00 -- -- -- 34.60 -- 1.84 -- 0.12 -- 0.08 -- 
146.00 85.50 -- -- 196.30 288.50 2.13 2.22 0.13 0.13 0.07 0.07 
147.00 59.90 -- -- 6.50 7.50 1.23 1.17 0.06 0.06 0.01 0.02 
148.00 -- -- -- 26.20 -- 1.54 -- 0.09 -- 0.01 -- 
149.00 -- -- -- 27.60 -- 1.36 -- 0.08 -- 0.04 -- 
150.00 -- -- -- 5.50 -- 1.42 -- 0.07 -- 0.01 -- 
151.00 -- -- -- 5.50 -- 1.24 -- 0.06 -- 0.01 -- 
152.00 -- -- -- 18.60 -- 1.29 -- 0.07 -- 0.03 -- 
153.00 -- -- -- 23.00 -- 1.37 -- 0.07 -- 0.00 -- 
154.00 -- -- -- 90.50 -- 1.82 -- 0.15 -- 0.11 -- 
155.00 -- -- -- 26.50 -- 1.44 -- 0.09 -- 0.03 -- 
156.00 -- -- -- 7.80 -- 1.22 -- 0.06 -- 0.01 -- 
157.00 -- -- -- 228.60 -- 1.37 -- 0.08 -- 0.02 -- 
158.00 -- -- -- 62.20 -- 1.58 -- 0.12 -- 0.09 -- 
  
355 
Patient no. 
Plasma 
FAD 
follow up 
(nmol/l) 
Plasma 
FMN 
admission 
(nmol/l) 
Plasma 
FMN 
follow up 
(nmol/l) 
Plasma 
riboflavin 
admission 
(nmol/l) 
Plasma 
riboflavin 
follow up 
(nmol/l) 
Red cell 
FAD 
admission 
(nmol/g 
Hb) 
Red cell 
FAD 
follow up 
(nmol/g 
Hb) 
Red cell 
FMN 
admission 
(nmol/g Hb) 
Red cell 
FMN follow 
up (nmol/g 
Hb) 
Red cell 
riboflavin 
admission 
(nmol/ g 
Hb) 
Red cell 
riboflavin 
follow up 
(nmol/ g 
Hb) 
159.00 -- -- -- 21.10 -- 1.43 -- 0.07 -- 0.01 -- 
163.00 -- -- -- 9.40 -- 1.15 -- 0.05 -- 0.00 -- 
164.00 -- -- -- 10.60 -- 1.47 -- 0.08 -- 0.01 -- 
165.00 -- -- -- 19.80 -- 1.27 -- 0.06 -- 0.01 -- 
166.00 -- -- -- 29.20 -- 1.47 -- 0.09 -- 0.05 -- 
167.00 -- -- -- 7.30 -- 1.39 -- 0.09 -- 0.02 -- 
168.00 -- -- -- 307.40 -- 1.82 -- 0.11 -- 0.05 -- 
169.00 -- -- -- 85.60 -- 1.77 -- 0.14 -- 0.07 -- 
171.00 -- -- -- 20.30 -- 1.77 -- 0.13 -- 0.06 -- 
 
  
356 
 
Patient no. 
White cell 
FAD 
admission 
(pmol/ 10 (6) 
cells) 
White cell 
FAD follow 
up (pmol/ 10 
(6) cells) 
White cell 
FMN 
admission 
(pmol/ 10 
(6) cells) 
White cell 
FMN follow up 
(pmol/ 10 (6) 
cells) 
White cell 
riboflavin 
admission 
(pmol/ 10 (6) 
cells) 
White cell 
riboflavin 
follow up 
(pmol/ 10 (6) 
cells) 
Plasma 
PLP 
admission 
(nmol/l) 
Plasma 
PLP 
follow up 
(nmol/l) 
12.00 11.77 10.93 0.55 0.52 0.41 0.43 16.90 12.10 
13.00 11.59 13.64 0.53 0.67 0.33 0.55 49.20 17.60 
14.00 11.54 11.18 0.43 0.41 0.62 0.64 5.10 3.10 
15.00 13.99 11.58 -- -- 0.68 0.52 48.20 37.40 
16.00 11.53 -- 0.53 -- 0.35 -- 67.80 -- 
17.00 12.30 12.78 0.81 0.94 0.34 0.46 98.00 30.00 
18.00 12.77 10.47 0.49 0.38 0.59 0.39 8.50 6.60 
19.00 13.00 14.92 -- -- 0.54 0.89 13.10 59.10 
21.00 13.48 -- 0.94 -- 0.54 -- 332.60 -- 
22.00 12.59 -- 0.64 -- 0.69 -- 197.50 71.50 
23.00 13.28 12.20 0.91 0.69 0.69 0.59 15.80 9.30 
24.00 13.59 -- -- -- 0.64 -- 39.40 -- 
27.00 15.98 13.36 -- -- 0.97 0.86 21.70 30.30 
29.00 13.25 12.27 0.99 0.78 0.66 0.52 26.70 19.80 
30.00 12.81 13.76 -- -- 0.84 1.00 12.60 15.10 
31.00 13.50 -- 0.93 -- 0.59 -- 17.20 -- 
32.00 9.92 -- 0.71 -- 0.47 -- 3.80 -- 
33.00 15.23 16.25 0.62 0.60 0.55 0.53 6.80 2.30 
34.00 15.76 15.82 0.59 0.56 0.83 0.86 69.10 19.70 
35.00 16.89 17.11 0.55 0.79 0.59 0.79 6.90 11.60 
36.00 17.29 13.87 0.82 0.64 1.28 0.84 33.10 7.60 
37.00 12.97 12.86 0.82 0.76 0.54 0.58 141.40 27.00 
38.00 -- -- -- -- -- -- 6.00 -- 
40.00 12.88 14.80 0.84 0.83 0.42 0.68 13.90 30.30 
41.00 14.46 -- 0.80 -- 0.51 -- 9.00 -- 
42.00 12.23 -- 0.39 -- 0.42 -- 21.40 45.90 
44.00 11.22 15.13 0.52 0.56 0.82 0.81 37.10 26.20 
  
357 
Patient no. 
White cell 
FAD 
admission 
(pmol/ 10 (6) 
cells) 
White cell 
FAD follow 
up (pmol/ 10 
(6) cells) 
White cell 
FMN 
admission 
(pmol/ 10 
(6) cells) 
White cell 
FMN follow up 
(pmol/ 10 (6) 
cells) 
White cell 
riboflavin 
admission 
(pmol/ 10 (6) 
cells) 
White cell 
riboflavin 
follow up 
(pmol/ 10 (6) 
cells) 
Plasma 
PLP 
admission 
(nmol/l) 
Plasma 
PLP 
follow up 
(nmol/l) 
45.00 12.41 12.33 0.68 0.59 0.52 0.68 154.40 7.20 
46.00 9.52 -- 0.56 -- 0.60 -- 4.80 -- 
47.00 13.08 13.17 0.52 0.58 0.81 0.78 295.70 357.20 
48.00 -- 12.45 -- 0.69 -- 0.90 9.40 16.90 
50.00 13.82 13.30 0.63 0.70 0.83 0.66 7.90 5.00 
51.00 16.31 15.85 0.74 0.90 0.93 1.22 28.80 45.50 
52.00 14.41 13.55 0.71 0.67 1.32 1.13 38.10 70.10 
53.00 13.19 13.42 0.74 0.79 0.48 0.54 1.70 1.50 
55.00 -- 12.09 -- 0.53 -- 0.59 1.20 22.00 
56.00 12.73 -- 0.40 -- 0.61 -- 4.00 -- 
57.00 9.24 -- 0.46 -- 0.47 -- 10.30 -- 
58.00 -- -- -- -- -- -- 37.40 28.10 
59.00 8.32 -- 0.53 -- 0.33 -- 151.80 -- 
60.00 13.01 -- 0.76 -- 0.42 -- 13.20 -- 
61.00 -- -- -- -- -- -- 10.90 -- 
62.00 15.78 11.46 0.78 0.55 0.47 0.38 6.40 6.00 
63.00 12.94 -- 0.84 -- 0.78 -- 15.90 -- 
64.00 11.29 -- 0.86 -- 0.75 -- 34.40 -- 
65.00 12.65 -- 0.65 -- 0.89 -- 63.10 -- 
67.00 14.52 -- 0.77 -- 1.01 -- 2.60 9.30 
68.00 11.43 -- 0.52 -- 3.27 -- 9.20 13.10 
69.00 18.25 -- 1.51 -- 0.67 -- 17.60 121.70 
71.00 13.37 -- 0.76 -- 0.48 -- 89.80 -- 
72.00 14.37 14.22 0.53 0.71 0.61 0.91 169.60 20.60 
73.00 -- -- -- -- -- -- 27.30 -- 
74.00 12.38 13.51 0.65 0.67 0.56 0.93 45.60 42.50 
75.00 14.16 -- 0.93 -- 1.04 -- 20.70 -- 
77.00 11.23 -- 1.02 -- 0.31 -- 43.80 -- 
78.00 12.69 -- 0.92 -- 0.66 -- 30.60 -- 
79.00 15.04 15.05 0.81 0.76 0.62 0.67 65.20 26.70 
80.00 15.30 -- 1.03 -- 1.10 -- 21.10 -- 
  
358 
Patient no. 
White cell 
FAD 
admission 
(pmol/ 10 (6) 
cells) 
White cell 
FAD follow 
up (pmol/ 10 
(6) cells) 
White cell 
FMN 
admission 
(pmol/ 10 
(6) cells) 
White cell 
FMN follow up 
(pmol/ 10 (6) 
cells) 
White cell 
riboflavin 
admission 
(pmol/ 10 (6) 
cells) 
White cell 
riboflavin 
follow up 
(pmol/ 10 (6) 
cells) 
Plasma 
PLP 
admission 
(nmol/l) 
Plasma 
PLP 
follow up 
(nmol/l) 
81.00 12.45 14.36 0.37 0.44 0.33 0.74 43.30 174.80 
82.00 15.78 16.22 0.75 0.88 0.53 0.61 40.80 84.40 
83.00 13.31 -- 0.98 -- 0.49 -- 8.60 -- 
84.00 13.59 11.15 0.37 0.28 0.77 0.89 22.00 27.00 
85.00 15.81 13.64 0.72 0.90 0.71 0.69 10.40 10.20 
87.00 13.10 -- 1.10 -- 0.73 -- 9.60 -- 
88.00 8.21 11.95 0.37 0.30 0.28 0.69 17.90 24.30 
89.00 20.45 -- 1.73 -- 1.02 -- 6.80 -- 
90.00 -- -- -- -- -- -- 2.20 45.20 
91.00 -- -- -- -- -- -- 14.10 -- 
94.00 -- -- -- -- -- -- 23.00 -- 
96.00 -- -- -- -- -- -- 9.00 9.00 
99.00 -- -- -- -- -- -- 111.00 -- 
100.00 16.74 29.25 0.43 0.55 1.36 2.07 49.00 44.00 
101.00 -- -- -- -- -- -- 9.00 -- 
102.00 -- -- -- -- -- -- 33.00 54.00 
103.00 14.01 11.20 0.60 0.37 0.33 0.45 34.00 84.00 
104.00 -- -- -- -- -- -- 28.00 -- 
105.00 12.74 13.24 0.50 0.61 0.61 0.56 50.00 101.00 
107.00 14.19 -- 0.46 -- 0.77 -- 9.00 -- 
108.00 12.17 -- 0.40 -- 0.42 -- 9.00 -- 
110.00 11.30 11.57 0.48 0.51 0.36 0.67 9.00 63.00 
111.00 12.89 13.63 0.38 0.51 0.45 0.60 126.00 93.00 
112.00 12.53 -- 0.41 -- 0.62 -- 16.00 9.00 
113.00 -- -- -- -- -- -- 25.00 24.00 
114.00 7.89 10.52 0.27 0.34 0.23 0.55 19.00 9.00 
115.00 11.85 -- 0.39 -- 0.37 -- 9.00 -- 
116.00 90.15 -- -- -- -- -- 31.00 -- 
117.00 11.62 8.34 -- -- -- -- 60.00 155.00 
118.00 8.75 5.85 -- -- -- -- 20.00 10.00 
119.00 -- -- -- -- -- -- 18.00 -- 
  
359 
Patient no. 
White cell 
FAD 
admission 
(pmol/ 10 (6) 
cells) 
White cell 
FAD follow 
up (pmol/ 10 
(6) cells) 
White cell 
FMN 
admission 
(pmol/ 10 
(6) cells) 
White cell 
FMN follow up 
(pmol/ 10 (6) 
cells) 
White cell 
riboflavin 
admission 
(pmol/ 10 (6) 
cells) 
White cell 
riboflavin 
follow up 
(pmol/ 10 (6) 
cells) 
Plasma 
PLP 
admission 
(nmol/l) 
Plasma 
PLP 
follow up 
(nmol/l) 
121.00 -- -- -- -- -- -- 12.00 28.00 
123.00 6.58 8.47 -- -- -- -- 306.00 74.00 
124.00 8.40 8.25 -- -- -- -- 38.00 37.00 
126.00 -- -- -- -- -- -- 127.00 -- 
127.00 -- -- -- -- -- -- 9.00 -- 
128.00 11.66 -- 0.40 -- 0.53 -- 9.00 -- 
129.00 -- -- -- -- -- -- 22.00 -- 
131.00 -- -- -- -- -- -- 15.00 -- 
133.00 -- -- -- -- -- -- 155.00 -- 
135.00 8.46 -- -- -- -- -- 9.00 -- 
137.00 -- -- -- -- -- -- 15.00 -- 
139.00 -- -- -- -- -- -- 21.00 -- 
140.00 -- -- -- -- -- -- 27.00 -- 
141.00 -- -- -- -- -- -- 11.00 9.00 
143.00 -- -- -- -- -- -- 9.00 -- 
146.00 -- -- -- -- -- -- 131.00 33.00 
147.00 -- -- -- -- -- -- 29.00 32.00 
148.00 -- -- -- -- -- -- 30.00 -- 
149.00 -- -- -- -- -- -- 13.00 -- 
150.00 -- -- -- -- -- -- 13.00 -- 
151.00 -- -- -- -- -- -- 10.00 -- 
152.00 -- -- -- -- -- -- 15.00 -- 
153.00 -- -- -- -- -- -- 16.00 -- 
154.00 -- -- -- -- -- -- 251.00 -- 
155.00 -- -- -- -- -- -- 29.00 -- 
156.00 -- -- -- -- -- -- 21.00 -- 
157.00 -- -- -- -- -- -- 132.00 -- 
158.00 -- -- -- -- -- -- 25.00 -- 
159.00 -- -- -- -- -- -- 35.00 -- 
163.00 -- -- -- -- -- -- 22.00 -- 
164.00 -- -- -- -- -- -- 7.00 -- 
  
360 
Patient no. 
White cell 
FAD 
admission 
(pmol/ 10 (6) 
cells) 
White cell 
FAD follow 
up (pmol/ 10 
(6) cells) 
White cell 
FMN 
admission 
(pmol/ 10 
(6) cells) 
White cell 
FMN follow up 
(pmol/ 10 (6) 
cells) 
White cell 
riboflavin 
admission 
(pmol/ 10 (6) 
cells) 
White cell 
riboflavin 
follow up 
(pmol/ 10 (6) 
cells) 
Plasma 
PLP 
admission 
(nmol/l) 
Plasma 
PLP 
follow up 
(nmol/l) 
165.00 -- -- -- -- -- -- 62.00 -- 
166.00 -- -- -- -- -- -- 12.00 -- 
167.00 -- -- -- -- -- -- 45.00 -- 
168.00 -- -- -- -- -- -- 32.00 -- 
169.00 -- -- -- -- -- -- 39.00 -- 
171.00 -- -- -- -- -- -- 22.00 -- 
 
  
361 
 
Patient no. 
Plasma PL 
admission 
(nmol/l) 
Plasma PL 
follow up 
(nmol/l) 
Red cell 
PLP 
admission 
(pmol/g Hb) 
Red cell 
PLP follow 
up (pmol/g 
Hb) 
Red cell PL 
admission 
(pmol/g Hb) 
Red cell PL 
follow up 
(pmol/g Hb) 
12.00 3.00 4.70 348.39 23.50 59.14 79.31 
13.00 10.00 6.60 345.35 41.10 70.93 209.78 
14.00 9.80 12.00 624.69 34.30 129.63 126.74 
15.00 359.20 14.30 2,282.98 11.20 12,431.91 102.35 
16.00 1,111.60 -- 7,870.37 -- 23,635.80 -- 
17.00 9.00 -- 331.03 14.00 101.15 84.34 
18.00 12.00 -- 216.30 14.50 54.35 65.59 
19.00 3.80 41.10 334.18 138.70 45.57 894.38 
21.00 27.60 -- 563.10 -- 279.76 -- 
22.00 246.30 87.60 25,583.33 334.40 53,479.76 2,716.46 
23.00 4.70 3.40 396.30 15.50 101.23 54.43 
24.00 6.90 -- 241.98 -- 103.70 -- 
27.00 2.30 12.20 116.28 47.70 39.53 442.53 
29.00 75.10 18.40 2,274.16 139.80 4,038.20 918.52 
30.00 14.80 42.60 173.91 107.20 90.22 823.60 
31.00 3.10 -- 158.89 -- 36.67 -- 
32.00 4.10 -- 317.24 -- 40.23 -- 
33.00 0.90 3.10 176.25 16.80 18.75 53.66 
34.00 89.80 42.10 3,922.58 167.40 3,627.96 1,798.72 
35.00 1.60 7.50 131.03 13.30 35.63 83.33 
36.00 155.10 20.10 2,983.13 70.80 7,756.63 403.61 
37.00 2.90 5.70 205.26 21.60 50.00 71.43 
38.00 0.60 -- 310.26 -- 32.05 -- 
40.00 2.70 10.90 155.42 29.80 18.07 116.28 
41.00 9.50 -- 198.77 -- 30.86 -- 
42.00 4.70 16.30 240.45 -- 41.57 -- 
  
362 
Patient no. 
Plasma PL 
admission 
(nmol/l) 
Plasma PL 
follow up 
(nmol/l) 
Red cell 
PLP 
admission 
(pmol/g Hb) 
Red cell 
PLP follow 
up (pmol/g 
Hb) 
Red cell PL 
admission 
(pmol/g Hb) 
Red cell PL 
follow up 
(pmol/g Hb) 
44.00 5.50 10.40 720.99 38.00 97.53 94.12 
45.00 2.50 6.00 325.93 17.00 105.56 -- 
46.00 2.40 -- 211.63 -- 26.74 -- 
47.00 18.30 30.30 316.88 36.50 64.94 54.93 
48.00 19.20 752.70 1,013.92 1,496.10 241.77 28,867.65 
50.00 0.50 2.10 313.92 21.30 -- -- 
51.00 285.50 634.50 11,113.89 2,636.20 13,498.61 25,896.15 
52.00 109.70 259.20 7,519.74 216.40 3,788.16 1,432.43 
53.00 1.30 2.00 168.67 12.00 28.92 23.81 
55.00 0.90 109.90 191.80 411.70 -- 5,027.14 
56.00 1.00 -- 260.98 -- 23.17 -- 
57.00 8.90 -- 208.33 -- 15.48 -- 
58.00 6.50 3.90 241.05 19.80 58.95 49.06 
59.00 1,106.40 -- 8,840.00 -- 22,254.44 -- 
60.00 5.30 -- 138.71 -- 21.51 -- 
61.00 6.10 -- 181.25 -- 27.50 -- 
62.00 8.10 6.10 176.74 6.80 -- -- 
63.00 7.10 -- 321.35 -- 51.69 -- 
64.00 2.20 -- 139.74 -- 24.36 -- 
65.00 12.60 -- 642.50 -- 166.25 -- 
67.00 1.30 6.60 111.39 4.70 17.72 15.22 
68.00 0.90 250.60 213.98 497.30 26.88 8,679.57 
69.00 2.40 134.50 265.88 181.60 24.71 1,624.39 
71.00 3.60 -- 103.57 103.57 14.29 -- 
72.00 864.70 1.20 13,716.88 27.00 12,640.26 76.19 
73.00 9.00 7.00 150.00 -- 57.14 -- 
74.00 9.00 114.60 254.55 262.90 -- -- 
75.00 0.70 -- 153.85 -- 6.41 -- 
77.00 5.00 -- 263.46 -- 44.23 -- 
78.00 1.70 -- 279.07 -- 44.19 -- 
79.00 1.80 4.10 157.14 10.70 25.51 12.24 
  
363 
Patient no. 
Plasma PL 
admission 
(nmol/l) 
Plasma PL 
follow up 
(nmol/l) 
Red cell 
PLP 
admission 
(pmol/g Hb) 
Red cell 
PLP follow 
up (pmol/g 
Hb) 
Red cell PL 
admission 
(pmol/g Hb) 
Red cell PL 
follow up 
(pmol/g Hb) 
80.00 9.50 -- 798.80 -- 90.36 -- 
81.00 -- -- 307.69 66.00 39.74 317.86 
82.00 -- 19.90 171.26 76.00 27.59 713.16 
83.00 2.90 -- 104.55 -- 31.82 -- 
84.00 -- -- 1,598.80 314.70 585.54 4,074.68 
85.00 6.10 4.70 201.20 21.50 -- 30.34 
87.00 2.00 -- 177.89 -- 26.32 -- 
88.00 117.20 28.60 2,785.37 188.90 2,850.00 1,067.53 
89.00 2.60 -- 204.85 -- 41.75 -- 
90.00 9.00 46.00 241.46 150.40 39.02 2,013.79 
91.00 3.00 -- 209.00 -- 28.00 -- 
94.00 9.00 -- 243.68 -- -- -- 
96.00 9.00 9.00 245.83 9.10 16.67 29.87 
99.00 258.00 -- 2,581.63 -- 4,807.14 -- 
100.00 912.00 55.00 10,787.95 330.00 38,222.89 3,465.91 
101.00 9.00 -- -- -- -- -- 
102.00 9.00 -- 177.89 11.90 35.79 30.21 
103.00 15.00 -- 149.44 42.60 38.20 301.18 
104.00 10.00 -- 219.15 -- 60.64 -- 
105.00 45.00 160.00 808.79 154.40 263.74 2,152.81 
107.00 9.00 -- 232.98 -- -- -- 
108.00 9.00 -- 147.47 -- 75.76 -- 
110.00 9.00 1,057.00 186.21 145.40 -- 2,950.00 
111.00 9.00 15.00 300.00 98.40 38.82 331.25 
112.00 9.00 9.00 160.67 19.10 21.35 37.65 
113.00 9.00 22.00 265.22 75.40 40.22 333.01 
114.00 8.00 122.00 196.77 166.40 -- 1,959.79 
115.00 9.00 -- 127.00 -- 23.00 -- 
116.00 12.00 -- 383.87 -- 107.53 -- 
117.00 9.00 25.00 222.68 66.50 -- 258.82 
118.00 30.00 9.00 594.38 18.30 312.36 -- 
  
364 
Patient no. 
Plasma PL 
admission 
(nmol/l) 
Plasma PL 
follow up 
(nmol/l) 
Red cell 
PLP 
admission 
(pmol/g Hb) 
Red cell 
PLP follow 
up (pmol/g 
Hb) 
Red cell PL 
admission 
(pmol/g Hb) 
Red cell PL 
follow up 
(pmol/g Hb) 
119.00 9.00 -- 127.55 -- 21.43 -- 
121.00 9.00 -- 209.30 83.40 29.07 440.23 
123.00 519.00 -- 11,912.94 409.70 6,764.71 1,747.92 
124.00 11.00 19.00 846.15 94.80 -- -- 
126.00 1,346.00 -- 21,893.41 -- 35,813.19 -- 
127.00 9.00 -- 342.68 -- -- -- 
128.00 9.00 -- 285.23 -- 23.86 -- 
129.00 744.00 -- 23,853.33 -- 48,515.56 -- 
131.00 9.00 -- 348.31 -- -- -- 
133.00 84.00 -- 1,989.00 -- 2,460.00 -- 
135.00 9.00 -- 454.88 -- -- -- 
137.00 4.00 -- 244.59 -- 66.22 -- 
139.00 -- -- 305.41 -- 39.19 -- 
140.00 23.00 -- 195.71 -- 17.14 -- 
141.00 19.00 19.00 31.71 16.20 20.73 74.29 
143.00 2.00 -- 380.28 -- 46.48 -- 
146.00 78.00 21.00 5,550.67 186.90 3,320.00 452.94 
147.00 4.00 3.00 310.81 20.40 50.00 46.84 
148.00 3.00 -- 502.67 -- 77.33 -- 
149.00 1.00 -- 179.73 -- 55.41 -- 
150.00 9.00 -- 167.53 -- 36.36 -- 
151.00 9.00 -- 234.21 -- 51.32 -- 
152.00 4.00 -- 166.25 -- 47.50 -- 
153.00 2.00 -- 193.06 -- 51.39 -- 
154.00 332.00 -- 27,441.10 -- 9,686.30 -- 
155.00 4.00 -- 405.13 -- 58.97 -- 
156.00 9.00 -- 289.33 -- 12.00 -- 
157.00 308.00 -- 21,889.74 -- 9,160.26 -- 
158.00 151.00 -- 4,984.62 -- 6,673.08 -- 
159.00 4.00 -- 266.23 -- 44.16 -- 
163.00 18.00 -- 158.02 -- 48.15 -- 
  
365 
Patient no. 
Plasma PL 
admission 
(nmol/l) 
Plasma PL 
follow up 
(nmol/l) 
Red cell 
PLP 
admission 
(pmol/g Hb) 
Red cell 
PLP follow 
up (pmol/g 
Hb) 
Red cell PL 
admission 
(pmol/g Hb) 
Red cell PL 
follow up 
(pmol/g Hb) 
164.00 14.00 -- 180.25 -- 43.21 -- 
165.00 21.00 -- 310.98 -- 89.02 -- 
166.00 14.00 -- 387.80 -- 50.00 -- 
167.00 256.00 -- 3,000.00 -- 2,523.81 -- 
168.00 301.00 -- 4,359.26 -- 7,925.93 -- 
169.00 301.00 -- 1,150.60 -- 787.95 -- 
171.00 177.00 -- 347.56 -- 59.76 -- 
 
  
366 
 
Patient no. 
White cell 
PLP 
admission 
(pmol/ 10 (6) 
cells) 
White cell 
PLP follow up 
(pmol/ 10 (6) 
cells) 
White cell PL 
admission 
(pmol/ 10 (6) 
cells) 
White cell PL 
follow up 
(pmol/ 10 (6) 
cells) 
Plasma 
ascorbic acid 
admission 
(umol/l) 
White cell 
ascorbic acid 
admission 
(umol/ 10 (9) 
cells) 
Plasma 
ascorbic 
acid 
follow up 
(umol/l) 
White cell 
ascorbic acid 
follow up 
(umol/ 10 (9) 
cells) 
12.00 1.98 1.97 0.75 0.77 -- -- 21.00 -- 
13.00 2.67 2.55 0.79 1.31 24.00 1.90 2.00 2.64 
14.00 2.30 2.09 1.15 1.45 0.90 2.45 3.00 3.12 
15.00 4.06 2.69 6.88 0.68 16.00 2.93 0.90 2.10 
16.00 8.24 -- 5.35 -- 1.00 1.39 -- -- 
17.00 3.29 2.48 0.48 0.43 1.00 -- 0.90 -- 
18.00 2.34 2.08 0.70 0.73 4.00 1.91 3.00 1.45 
19.00 2.22 5.18 0.43 4.34 37.00 1.76 15.00 2.17 
21.00 3.01 -- 1.30 -- 2.00 0.69 -- -- 
22.00 6.16 -- 10.29 -- 136.00 2.57 25.00 -- 
23.00 3.13 2.15 0.66 0.42 20.00 3.02 10.00 1.11 
24.00 2.52 -- 1.03 -- 21.00 1.81 -- -- 
27.00 2.19 2.35 0.73 1.71 13.00 3.39 28.00 1.41 
29.00 4.38 3.57 6.08 3.58 -- -- 17.00 3.76 
30.00 2.42 4.09 1.22 7.17 11.00 1.56 -- -- 
31.00 2.31 -- 0.32 -- 3.00 1.91 -- -- 
32.00 1.30 -- 0.24 -- 3.00 1.32 -- -- 
33.00 1.39 1.95 0.34 0.98 8.00 1.70 5.00 2.10 
34.00 5.18 5.88 5.29 3.52 59.00 2.91 25.00 2.69 
35.00 1.93 2.79 0.38 0.69 0.90 2.63 4.00 2.50 
36.00 2.46 2.12 9.79 3.07 59.00 3.81 16.00 3.53 
37.00 1.74 1.90 0.56 0.73 -- -- 6.00 2.04 
38.00 -- -- -- -- -- -- -- -- 
40.00 3.47 1.94 0.35 0.56 20.00 1.93 11.00 2.20 
41.00 2.18 -- 0.34 -- 19.00 3.30 -- -- 
42.00 2.64 -- 0.38 -- 0.90 1.82 4.00 -- 
  
367 
Patient no. 
White cell 
PLP 
admission 
(pmol/ 10 (6) 
cells) 
White cell 
PLP follow up 
(pmol/ 10 (6) 
cells) 
White cell PL 
admission 
(pmol/ 10 (6) 
cells) 
White cell PL 
follow up 
(pmol/ 10 (6) 
cells) 
Plasma 
ascorbic acid 
admission 
(umol/l) 
White cell 
ascorbic acid 
admission 
(umol/ 10 (9) 
cells) 
Plasma 
ascorbic 
acid 
follow up 
(umol/l) 
White cell 
ascorbic acid 
follow up 
(umol/ 10 (9) 
cells) 
44.00 1.85 2.07 0.60 1.04 -- -- 9.00 1.29 
45.00 2.05 1.88 0.72 0.48 1.00 0.75 2.00 0.84 
46.00 1.75 -- 0.34 -- -- -- -- -- 
47.00 2.12 2.14 0.54 0.55 0.90 0.60 0.90 0.67 
48.00 -- 3.81 -- 9.22 -- -- 74.00 -- 
50.00 1.50 1.62 0.52 0.60 50.00 2.35 3.00 2.43 
51.00 6.15 4.85 4.66 7.28 11.00 3.06 7.00 4.86 
52.00 1.97 1.54 6.15 5.95 102.00 -- 60.00 -- 
53.00 1.44 1.48 0.26 0.37 0.90 -- 1.00 -- 
55.00 -- 4.67 -- 6.65 -- -- -- -- 
56.00 1.64 -- 0.17 -- 4.00 -- -- -- 
57.00 0.37 -- 0.07 -- -- -- -- -- 
58.00 -- -- -- -- -- -- -- -- 
59.00 7.21 -- 4.39 -- -- -- -- -- 
60.00 1.68 -- 0.18 -- 12.00 -- -- -- 
61.00 -- -- -- -- -- -- -- -- 
62.00 1.94 1.38 0.27 0.17 0.90 -- -- -- 
63.00 2.79 -- 0.56 -- 0.90 -- -- -- 
64.00 1.35 -- 0.31 -- 4.00 -- -- -- 
65.00 1.46 -- 1.04 -- 14.00 -- -- -- 
67.00 1.58 -- 0.44 -- 11.00 -- 9.00 -- 
68.00 1.32 -- -- -- -- -- -- -- 
69.00 1.76 -- -- -- -- -- -- -- 
71.00 2.49 -- 0.30 -- 6.00 -- -- -- 
72.00 3.98 1.81 8.06 1.48 79.00 -- -- -- 
73.00 -- -- -- -- 0.90 -- -- -- 
74.00 2.26 7.24 0.28 6.46 2.00 -- 69.00 -- 
75.00 2.07 -- 0.37 -- 0.90 -- -- -- 
77.00 2.57 -- 0.24 -- -- -- -- -- 
78.00 2.05 -- 0.38 -- -- -- -- -- 
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Patient no. 
White cell 
PLP 
admission 
(pmol/ 10 (6) 
cells) 
White cell 
PLP follow up 
(pmol/ 10 (6) 
cells) 
White cell PL 
admission 
(pmol/ 10 (6) 
cells) 
White cell PL 
follow up 
(pmol/ 10 (6) 
cells) 
Plasma 
ascorbic acid 
admission 
(umol/l) 
White cell 
ascorbic acid 
admission 
(umol/ 10 (9) 
cells) 
Plasma 
ascorbic 
acid 
follow up 
(umol/l) 
White cell 
ascorbic acid 
follow up 
(umol/ 10 (9) 
cells) 
79.00 3.56 1.86 0.53 0.54 0.90 -- 2.00 -- 
80.00 2.68 -- 1.09 -- 2.00 1.47 -- -- 
81.00 2.83 2.77 0.37 1.70 10.00 1.54 6.00 1.46 
82.00 2.58 5.13 0.43 4.73 0.90 -- 22.00 -- 
83.00 1.65 -- 0.17 -- 1.00 1.60 -- -- 
84.00 3.35 3.26 3.00 5.22 1.00 1.57 16.00 1.42 
85.00 1.64 1.84 0.34 0.40 1.00 -- 0.90 -- 
87.00 1.36 -- 0.20 -- 3.00 -- -- -- 
88.00 3.83 2.68 4.02 3.93 -- -- 20.00 -- 
89.00 2.05 -- 0.43 -- 12.00 1.94 -- -- 
90.00 -- -- -- -- -- -- 6.00 -- 
91.00 -- -- -- -- -- -- -- -- 
94.00 1.02 -- -- -- -- -- -- -- 
96.00 -- -- -- -- -- -- 13.00 -- 
99.00 6.10 -- 7.13 -- 29.00 1.79 -- -- 
100.00 3.63 5.70 7.78 10.32 2.00 1.95 24.00 5.80 
101.00 -- -- -- -- 17.00 2.12 -- -- 
102.00 -- -- -- -- 9.00 -- 5.00 -- 
103.00 2.64 2.14 0.46 1.37 35.00 -- 18.00 -- 
104.00 -- -- -- -- 0.90 -- -- -- 
105.00 2.14 4.80 0.97 4.41 5.00 8.77 0.90 1.90 
107.00 1.89 -- 0.53 -- 16.00 -- -- -- 
108.00 2.32 -- 0.50 -- 3.00 1.42 -- -- 
110.00 0.89 3.48 0.18 5.35 5.00 1.50 17.00 2.54 
111.00 3.20 3.43 0.49 1.18 2.00 1.99 3.00 4.08 
112.00 2.47 -- 0.53 -- -- 2.27 1.00 -- 
113.00 -- -- -- -- 2.00 -- 2.00 -- 
114.00 1.43 3.34 0.33 6.95 0.90 0.46 2.00 1.02 
115.00 2.18 -- 0.35 -- 17.00 0.99 -- -- 
116.00 -- -- -- -- 0.90 0.74 -- -- 
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Patient no. 
White cell 
PLP 
admission 
(pmol/ 10 (6) 
cells) 
White cell 
PLP follow up 
(pmol/ 10 (6) 
cells) 
White cell PL 
admission 
(pmol/ 10 (6) 
cells) 
White cell PL 
follow up 
(pmol/ 10 (6) 
cells) 
Plasma 
ascorbic acid 
admission 
(umol/l) 
White cell 
ascorbic acid 
admission 
(umol/ 10 (9) 
cells) 
Plasma 
ascorbic 
acid 
follow up 
(umol/l) 
White cell 
ascorbic acid 
follow up 
(umol/ 10 (9) 
cells) 
117.00 -- -- -- -- 2.00 -- 2.00 -- 
118.00 -- -- -- -- 0.90 -- 0.90 -- 
119.00 -- -- -- -- 11.00 -- -- -- 
121.00 -- -- -- -- 2.00 -- 7.00 -- 
123.00 -- -- -- -- 2.00 -- 20.00 -- 
124.00 -- -- -- -- -- -- 7.00 -- 
126.00 -- -- -- -- 10.00 -- -- -- 
127.00 -- -- -- -- -- -- -- -- 
128.00 1.63 -- 0.35 -- 2.00 -- -- -- 
129.00 -- -- -- -- -- -- -- -- 
131.00 -- -- -- -- -- -- -- -- 
133.00 -- -- -- -- 17.00 -- -- -- 
135.00 -- -- -- -- 5.00 2.04 -- -- 
137.00 -- -- -- -- 4.00 -- -- -- 
139.00 -- -- -- -- 11.00 -- -- -- 
140.00 -- -- -- -- 1.00 -- -- -- 
141.00 -- -- -- -- 0.90 -- 0.90 -- 
143.00 -- -- -- -- 3.00 -- -- -- 
146.00 -- -- -- -- -- -- 8.00 -- 
147.00 -- -- -- -- 12.00 -- 10.00 -- 
148.00 -- -- -- -- -- -- -- -- 
149.00 -- -- -- -- -- -- -- -- 
150.00 -- -- -- -- 5.00 -- -- -- 
151.00 -- -- -- -- -- -- -- -- 
152.00 -- -- -- -- -- -- -- -- 
153.00 -- -- -- -- -- -- -- -- 
154.00 -- -- -- -- 58.00 -- -- -- 
155.00 -- -- -- -- 28.00 -- -- -- 
156.00 -- -- -- -- -- -- -- -- 
157.00 -- -- -- -- 29.00 -- -- -- 
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Patient no. 
White cell 
PLP 
admission 
(pmol/ 10 (6) 
cells) 
White cell 
PLP follow up 
(pmol/ 10 (6) 
cells) 
White cell PL 
admission 
(pmol/ 10 (6) 
cells) 
White cell PL 
follow up 
(pmol/ 10 (6) 
cells) 
Plasma 
ascorbic acid 
admission 
(umol/l) 
White cell 
ascorbic acid 
admission 
(umol/ 10 (9) 
cells) 
Plasma 
ascorbic 
acid 
follow up 
(umol/l) 
White cell 
ascorbic acid 
follow up 
(umol/ 10 (9) 
cells) 
158.00 -- -- -- -- -- -- -- -- 
159.00 -- -- -- -- -- -- -- -- 
163.00 -- -- -- -- -- -- -- -- 
164.00 -- -- -- -- 0.90 -- -- -- 
165.00 -- -- -- -- -- -- -- -- 
166.00 -- -- -- -- -- -- -- -- 
167.00 -- -- -- -- -- -- -- -- 
168.00 -- -- -- -- -- -- -- -- 
169.00 -- -- -- -- -- -- -- -- 
171.00 -- -- -- -- -- -- -- -- 
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12.13 Appendix 13 Chapter 9 data 
Appendix 13. Characteristics and biochemical measurements of patients (Chapter 9) 
Patient 
no. 
Age 
(yrs) 
Male/ 
Female 
(0/1) 
APACHE 
II 
Predicted 
mortality 
(%) 
Medical/ 
Surgical 
(0/1) 
ICU stay 
(days) 
Hospital 
death  
Hospital 
stay 
(days) 
Ventilation 
(days) 
SOFA score 
admission 
12.00 61.00 0.00 29.00 76.60 0.00 7.40 0.00 13.40 6.00 7.00 
13.00 43.00 1.00 12.00 11.70 1.00 48.10 1.00 50.10 49.00 5.00 
14.00 71.00 1.00 18.00 28.90 1.00 12.90 1.00 12.90 14.00 8.00 
15.00 53.00 1.00 19.00 32.20 0.00 4.80 0.00 10.80 5.00 8.00 
16.00 61.00 0.00 23.00 28.50 0.00 1.00 0.00 10.00 1.00 6.00 
17.00 18.00 0.00 12.00 20.20 0.00 6.20 1.00 6.20 6.00 2.00 
18.00 67.00 0.00 18.00 44.40 1.00 59.50 1.00 59.50 60.00 10.00 
19.00 50.00 0.00 21.00 38.90 0.00 46.30 1.00 46.30 47.00 10.00 
21.00 61.00 0.00 34.00 76.80 1.00 2.00 0.00 53.00 2.00 8.00 
22.00 52.00 0.00 13.00 9.90 0.00 3.70 0.00 77.00 4.00 2.00 
23.00 71.00 0.00 23.00 42.50 1.00 20.90 1.00 20.90 22.00 8.00 
24.00 77.00 1.00 21.00 35.00 0.00 2.00 0.00 6.00 3.00 4.00 
27.00 76.00 1.00 23.00 46.00 0.00 21.70 0.00 21.70 21.60 5.00 
29.00 70.00 0.00 16.00 20.20 1.00 5.10 0.00 85.00 4.00 4.00 
30.00 73.00 1.00 25.00 53.30 1.00 15.50 1.00 15.50 13.00 11.00 
31.00 62.00 0.00 19.00 27.10 1.00 0.50 0.00 25.00 1.00 11.00 
32.00 55.00 1.00 15.00 21.00 1.00 2.20 0.00 22.20 0.00 6.00 
33.00 80.00 1.00 31.00 84.20 1.00 12.00 1.00 12.00 13.00 7.00 
34.00 53.00 0.00 26.00 68.60 1.00 29.40 0.00 85.00 1.00 6.00 
35.00 20.00 0.00 18.00 39.70 1.00 44.00 1.00 44.00 44.00 10.00 
36.00 43.00 1.00 38.00 92.60 0.00 25.50 0.00 27.50 24.00 13.00 
37.00 60.00 0.00 27.00 63.10 0.00 21.80 0.00 29.00 16.00 10.00 
38.00 74.00 0.00 20.00 23.00 1.00 1.00 0.00 150.00 2.00 4.00 
40.00 47.00 0.00 22.00 28.50 1.00 1.90 0.00 19.90 3.00 9.00 
41.00 76.00 1.00 29.00 79.90 1.00 1.40 0.00 21.40 2.00 8.00 
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Patient 
no. 
Age 
(yrs) 
Male/ 
Female 
(0/1) 
APACHE 
II 
Predicted 
mortality 
(%) 
Medical/ 
Surgical 
(0/1) 
ICU stay 
(days) 
Hospital 
death  
Hospital 
stay 
(days) 
Ventilation 
(days) 
SOFA score 
admission 
42.00 79.00 0.00 21.00 30.90 1.00 3.20 0.00 27.00 3.00 4.00 
44.00 81.00 0.00 34.00 86.30 0.00 16.10 1.00 16.10 16.10 7.00 
45.00 74.00 0.00 33.00 75.20 0.00 16.00 1.00 16.00 16.00 11.00 
46.00 41.00 1.00 8.00 15.60 1.00 0.80 0.00 18.80 1.00 1.00 
47.00 76.00 0.00 29.00 77.20 1.00 34.60 1.00 36.80 33.00 7.00 
48.00 67.00 0.00 31.00 68.10 1.00 18.40 1.00 18.40 15.00 6.00 
50.00 60.00 0.00 19.00 48.00 1.00 6.20 0.00 124.20 5.00 7.00 
51.00 46.00 1.00 24.00 49.70 0.00 4.60 1.00 4.60 5.00 14.00 
52.00 61.00 0.00 33.00 78.60 0.00 7.70 1.00 7.70 8.00 11.00 
53.00 67.00 1.00 18.00 21.20 0.00 11.10 1.00 11.10 12.00 11.00 
55.00 80.00 1.00 31.00 73.30 0.00 8.20 1.00 8.20 9.00 8.00 
56.00 40.00 1.00 6.00 10.20 1.00 0.40 0.00 0.40 1.00 6.00 
57.00 60.00 0.00 27.00 60.20 1.00 1.80 1.00 1.80 3.00 10.00 
58.00 41.00 0.00 21.00 17.80 1.00 19.70 0.00 36.70 19.00 4.00 
59.00 68.00 0.00 20.00 32.30 0.00 0.80 0.00 12.00 2.00 5.00 
60.00 57.00 0.00 24.00 67.00 0.00 6.50 0.00 59.50 5.00 3.00 
61.00 76.00 1.00 18.00 14.40 0.00 0.70 0.00 22.70 0.00 5.00 
62.00 74.00 0.00 20.00 19.90 1.00 0.90 0.00 253.00 2.00 1.00 
63.00 62.00 0.00 18.00 44.40 1.00 1.00 0.00 508.00 2.00 2.00 
64.00 66.00 0.00 34.00 81.00 0.00 22.40 0.00 46.00 21.00 13.00 
65.00 38.00 1.00 17.00 26.20 0.00 18.90 0.00 37.00 18.00 9.00 
67.00 68.00 1.00 31.00 80.30 0.00 5.00 1.00 8.00 5.00 4.00 
68.00 74.00 0.00 24.00 49.70 0.00 10.70 0.00 27.70 11.00 14.00 
69.00 61.00 0.00 22.00 54.90 1.00 76.40 1.00 122.40 75.00 10.00 
71.00 25.00 0.00 17.00 1.20 0.00 2.00 0.00 3.50 1.00 3.00 
72.00 51.00 0.00 21.00 12.40 0.00 15.50 0.00 40.00 15.00 11.00 
73.00 69.00 0.00 12.00 20.20 0.00 5.80 0.00 23.00 7.00 3.00 
74.00 65.00 0.00 33.00 80.40 0.00 19.60 0.00 40.00 18.00 6.00 
75.00 28.00 1.00 14.00 18.50 1.00 0.60 0.00 58.00 1.00 10.00 
77.00 54.00 1.00 17.00 1.20 0.00 0.80 0.00 12.00 2.00 7.00 
78.00 45.00 0.00 12.00 5.50 1.00 0.90 0.00 12.00 2.00 4.00 
79.00 41.00 0.00 7.00 7.60 1.00 9.30 0.00 19.00 8.00 4.00 
80.00 38.00 0.00 16.00 23.30 1.00 0.80 0.00 41.00 2.00 9.00 
81.00 71.00 0.00 25.00 35.90 1.00 8.30 0.00 20.00 9.00 5.00 
82.00 80.00 1.00 17.00 12.70 0.00 10.30 0.00 29.00 8.00 1.00 
83.00 46.00 1.00 11.00 10.30 1.00 2.90 0.00 10.00 0.00 4.00 
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Patient 
no. 
Age 
(yrs) 
Male/ 
Female 
(0/1) 
APACHE 
II 
Predicted 
mortality 
(%) 
Medical/ 
Surgical 
(0/1) 
ICU stay 
(days) 
Hospital 
death  
Hospital 
stay 
(days) 
Ventilation 
(days) 
SOFA score 
admission 
84.00 56.00 0.00 28.00 63.90 0.00 15.40 0.00 35.00 14.00 13.00 
85.00 73.00 0.00 18.00 44.40 1.00 1.40 0.00 160.00 2.00 6.00 
87.00 34.00 1.00 12.00 12.40 1.00 2.30 0.00 12.00 2.00 6.00 
88.00 81.00 0.00 17.00 23.60 1.00 9.30 1.00 10.00 10.00 9.00 
89.00 22.00 1.00 10.00 9.50 1.00 0.20 0.00 1.00 1.00 2.00 
90.00 53.00 0.00 32.00 60.90 1.00 3.00 0.00 36.00 3.00 10.00 
91.00 62.00 0.00 22.00 58.90 1.00 1.70 0.00 14.00 1.00 9.00 
94.00 32.00 1.00 25.00 53.30 0.00 17.30 0.00 24.00 17.00 18.00 
96.00 63.00 1.00 18.00 4.80 0.00 1.90 0.00 15.00 2.00 3.00 
99.00 37.00 0.00 13.00 16.50 1.00 2.10 0.00 11.00 2.00 5.00 
100.00 50.00 1.00 26.00 38.20 0.00 2.60 0.00 119.00 0.00 4.00 
101.00 35.00 1.00 9.00 4.70 1.00 0.80 0.00 6.00 0.00 5.00 
102.00 26.00 0.00 23.00 45.70 1.00 2.30 0.00 77.00 2.00 4.00 
103.00 52.00 0.00 16.00 12.20 1.00 2.00 0.00 48.00 2.00 2.00 
104.00 38.00 0.00 3.00 2.70 0.00 0.30 0.00 5.00 1.00 2.00 
105.00 39.00 0.00 34.00 87.50 0.00 3.00 0.00 58.00 3.00 11.00 
107.00 45.00 1.00 12.00 6.60 1.00 3.10 0.00 48.00 0.00 8.00 
108.00 44.00 1.00 6.00 0.90 0.00 0.80 0.00 5.00 0.00 3.00 
110.00 48.00 1.00 26.00 35.20 0.00 4.90 1.00 6.00 6.00 7.00 
111.00 23.00 0.00 9.00 4.30 1.00 9.20 0.00 48.00 7.00 7.00 
112.00 45.00 1.00 24.00 22.40 1.00 10.70 1.00 12.00 12.00 1.00 
113.00 70.00 0.00 27.00 47.70 0.00 6.50 1.00 7.00 7.00 4.00 
114.00 65.00 1.00 24.00 65.70 1.00 32.80 1.00 61.00 34.00 9.00 
115.00 47.00 0.00 10.00 1.50 0.00 0.60 0.00 14.00 0.00 2.00 
116.00 61.00 0.00 13.00 10.60 0.00 2.40 0.00 37.00 3.00 1.00 
117.00 48.00 0.00 13.00 8.50 1.00 4.20 0.00 18.00 4.00 3.00 
118.00 59.00 0.00 23.00 39.90 1.00 12.10 0.00 24.00 12.00 9.00 
119.00 67.00 1.00 18.00 14.40 0.00 1.30 0.00 9.00 1.00 2.00 
121.00 86.00 0.00 22.00 42.20 1.00 6.60 0.00 20.00 6.00 7.00 
123.00 60.00 0.00 16.00 14.60 0.00 3.10 0.00 23.00 2.00 7.00 
124.00 33.00 0.00 14.00 27.40 1.00 4.70 0.00 10.00 4.00 7.00 
126.00 68.00 0.00 27.00 46.00 0.00 1.60 0.00 240.00 1.00 5.00 
127.00 100.00 0.00 25.00 64.60 1.00 3.50 0.00 60.00 0.00 12.00 
128.00 80.00 1.00 30.00 56.90 1.00 2.90 0.00 144.00 2.00 7.00 
129.00 31.00 0.00 19.00 44.00 0.00 2.90 0.00 54.00 3.00 12.00 
131.00 65.00 0.00 21.00 55.30 1.00 6.70 1.00 24.00 6.00 8.00 
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Patient 
no. 
Age 
(yrs) 
Male/ 
Female 
(0/1) 
APACHE 
II 
Predicted 
mortality 
(%) 
Medical/ 
Surgical 
(0/1) 
ICU stay 
(days) 
Hospital 
death  
Hospital 
stay 
(days) 
Ventilation 
(days) 
SOFA score 
admission 
133.00 35.00 0.00 14.00 7.20 1.00 0.90 0.00 9.00 2.00 0.00 
135.00 41.00 1.00 16.00 14.30 1.00 0.60 0.00 17.00 2.00 2.00 
137.00 69.00 1.00 19.00 32.00 1.00 0.80 0.00 7.00 1.00 4.00 
139.00 54.00 1.00 23.00 55.80 1.00 2.60 0.00 69.00 2.00 8.00 
140.00 74.00 0.00 21.00 41.60 1.00 2.10 1.00 11.00 0.00 8.00 
141.00 67.00 0.00 32.00 78.00 1.00 19.60 0.00 50.00 20.00 10.00 
143.00 52.00 0.00 10.00 17.40 1.00 9.80 1.00 11.00 45.00 2.00 
146.00 38.00 0.00 18.00 24.20 1.00 10.30 0.00 20.00 10.00 6.00 
147.00 70.00 0.00 20.00 35.50 1.00 1.50 0.00 29.00 0.00 7.00 
148.00 71.00 0.00 25.00 53.30 0.00 0.80 1.00 5.00 2.00 5.00 
149.00 74.00 0.00 15.00 -- 1.00 13.80 1.00 15.00 11.00 5.00 
150.00 62.00 0.00 21.00 38.90 0.00 35.20 0.00 66.00 26.00 11.00 
151.00 36.00 0.00 8.00 8.60 1.00 1.20 0.00 62.00 2.00 0.00 
152.00 47.00 0.00 11.00 7.60 0.00 2.00 0.00 10.00 2.00 3.00 
153.00 77.00 1.00 27.00 46.00 0.00 3.10 0.00 14.00 0.00 4.00 
154.00 49.00 0.00 26.00 4.40 0.00 0.90 0.00 8.00 2.00 4.00 
155.00 43.00 0.00 25.00 3.80 0.00 0.80 0.00 7.00 2.00 8.00 
156.00 41.00 0.00 33.00 78.60 0.00 1.80 1.00 3.00 3.00 12.00 
157.00 61.00 0.00 31.00 81.40 1.00 11.40 0.00 53.00 9.00 14.00 
158.00 56.00 0.00 11.00 22.30 1.00 9.00 0.00 74.00 2.00 3.00 
159.00 60.00 1.00 19.00 11.30 1.00 1.50 0.00 22.00 2.00 4.00 
163.00 77.00 1.00 26.00 56.70 1.00 1.40 0.00 48.00 1.00 10.00 
164.00 62.00 1.00 14.00 9.70 0.00 7.00 0.00 16.00 5.00 10.00 
165.00 35.00 0.00 5.00 0.20 0.00 1.00 0.00 6.00 2.00 1.00 
166.00 63.00 0.00 13.00 13.40 1.00 0.60 0.00 13.00 2.00 8.00 
167.00 56.00 0.00 32.00 76.00 0.00 2.10 1.00 4.00 3.00 8.00 
168.00 52.00 1.00 26.00 56.90 0.00 34.10 0.00 57.00 35.00 10.00 
169.00 39.00 1.00 13.00 24.60 1.00 24.60 0.00 55.00 25.00 14.00 
171.00 67.00 0.00 27.00 60.50 0.00 2.30 0.00 10.00 0.00 14.00 
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Patient 
no. 
C-reactive 
protein 
admission 
(mg/l) 
Albumin 
admission 
(g/l) 
Total 
protein 
admission 
(g/l) 
Whole 
blood TDP 
admission 
(ng/gHb) 
Red cell 
FAD 
admission 
(nmol/gHb) 
Red cell PLP 
admission 
(pmol/gHb) 
Triglycerides 
admission 
(mmol/l) 
Cholesterol 
admission 
(mmol/l) 
Plasma 
retinol 
admission 
(umol/l) 
Plasma α-
tocopherol 
admission 
(umol/l) 
12.00 126.00 24.00 46.00 928.00 1.76 348.39 0.61 1.70 0.88 14.36 
13.00 22.00 27.00 55.00 789.00 1.53 345.35 2.80 4.27 1.30 15.35 
14.00 220.00 12.00 45.00 1,173.00 1.82 624.69 1.55 2.19 0.42 16.26 
15.00 257.00 23.00 63.00 1,435.00 1.46 2,282.98 1.52 2.75 0.18 14.48 
16.00 122.00 28.00 72.00 994.00 1.05 7,870.37 0.75 3.76 1.31 15.68 
17.00 3.00 33.00 73.00 693.00 1.33 331.03 0.71 2.83 1.90 17.00 
18.00 152.00 10.00 31.00 402.00 1.13 216.30 0.80 0.55 0.39 6.27 
19.00 143.00 12.00 68.00 1,094.00 1.69 334.18 0.72 3.06 1.11 17.70 
21.00 23.00 10.00 25.00 617.00 1.42 563.10 1.60 2.60 1.45 16.03 
22.00 20.00 27.00 71.00 2,341.00 2.09 25,583.33 1.10 3.00 1.44 13.74 
23.00 125.00 10.00 39.00 978.00 1.63 396.30 0.50 1.10 0.24 7.93 
24.00 81.00 35.00 74.00 1,317.00 2.29 241.98 0.80 4.90 1.80 26.95 
27.00 103.00 23.00 54.00 705.00 1.63 116.28 1.80 3.90 1.18 24.42 
29.00 59.00 9.00 25.00 1,652.00 1.57 2,274.16 0.80 0.90 0.22 10.91 
30.00 26.00 16.00 44.00 891.00 1.97 173.91 1.20 3.80 4.20 33.79 
31.00 50.00 22.00 46.00 744.00 1.30 158.89 0.60 2.50 1.22 14.80 
32.00 434.00 17.00 39.00 778.00 1.38 317.24 1.10 2.00 0.09 10.30 
33.00 259.00 17.00 41.00 510.00 1.20 176.25 0.80 2.10 0.35 11.83 
34.00 404.00 30.00 56.00 3,650.00 1.86 3,922.58 2.01 1.25 1.27 19.65 
35.00 119.00 9.00 27.00 483.00 1.35 131.03 0.70 1.27 0.21 10.16 
36.00 132.00 14.00 35.00 2,672.00 2.17 2,983.13 0.68 0.53 0.15 6.44 
37.00 81.00 12.00 45.00 1,270.00 1.58 205.26 0.38 0.84 0.85 6.25 
38.00 127.00 14.00 56.00 626.00 1.70 310.26 1.66 2.40 0.50 20.99 
40.00 15.00 20.00 39.00 330.00 1.41 155.42 -- -- 0.90 17.38 
41.00 184.00 19.00 33.00 768.00 1.20 198.77 0.64 1.51 1.62 10.05 
42.00 8.00 17.00 32.00 574.00 1.29 240.45 0.50 2.10 0.84 12.37 
44.00 151.00 10.00 37.00 506.00 2.04 720.99 0.44 0.98 0.60 8.31 
45.00 258.00 14.00 41.00 1,379.00 2.21 325.93 0.69 2.41 1.04 15.25 
46.00 250.00 11.00 32.00 804.00 1.21 211.63 1.19 1.88 0.17 9.70 
47.00 64.00 24.00 58.00 1,002.00 1.85 316.88 0.80 2.20 0.61 14.47 
48.00 119.00 10.00 57.00 2,127.00 2.14 1,013.92 0.70 0.90 0.02 8.06 
  
376 
Patient 
no. 
C-reactive 
protein 
admission 
(mg/l) 
Albumin 
admission 
(g/l) 
Total 
protein 
admission 
(g/l) 
Whole 
blood TDP 
admission 
(ng/gHb) 
Red cell 
FAD 
admission 
(nmol/gHb) 
Red cell PLP 
admission 
(pmol/gHb) 
Triglycerides 
admission 
(mmol/l) 
Cholesterol 
admission 
(mmol/l) 
Plasma 
retinol 
admission 
(umol/l) 
Plasma α-
tocopherol 
admission 
(umol/l) 
50.00 180.00 23.00 31.00 828.00 1.49 313.92 1.20 1.50 1.62 9.98 
51.00 56.00 14.00 43.00 1,406.00 1.80 11,113.89 0.50 1.20 0.02 8.40 
52.00 565.00 9.00 43.00 3,524.00 2.30 7,519.74 0.70 1.00 0.58 7.83 
53.00 148.00 9.00 34.00 196.00 1.04 168.67 2.50 1.70 0.26 16.34 
55.00 107.00 13.00 41.00 676.00 1.22 191.80 0.30 1.10 0.17 8.12 
56.00 37.00 16.00 33.00 518.00 1.45 260.98 1.07 1.42 0.91 11.20 
57.00 181.00 10.00 37.00 560.00 1.33 208.33 0.55 0.40 0.22 3.55 
58.00 6.00 19.00 39.00 506.00 1.16 241.05 0.95 2.12 1.14 11.37 
59.00 32.00 36.00 66.00 1,130.00 1.22 8,840.00 5.05 4.23 2.86 33.30 
60.00 166.00 26.00 75.00 923.00 1.17 138.71 2.53 4.56 2.14 30.79 
61.00 380.00 26.00 65.00 1,037.00 1.21 181.25 2.13 4.60 1.82 31.14 
62.00 88.00 12.00 38.00 800.00 1.20 176.74 -- -- 0.57 14.40 
63.00 117.00 14.00 27.00 2,092.00 1.80 321.35 1.34 1.49 0.87 9.63 
64.00 311.00 18.00 64.00 556.00 1.06 139.74 1.47 1.68 1.47 19.42 
65.00 163.00 23.00 54.00 1,226.00 1.91 642.50 1.12 1.36 0.23 10.05 
67.00 438.00 20.00 35.00 763.00 1.72 111.39 0.87 1.21 0.22 12.43 
68.00 67.00 11.00 37.00 459.00 1.54 213.98 1.68 1.44 0.57 10.01 
69.00 179.00 14.00 36.00 544.00 1.34 265.88 0.53 0.71 0.26 5.31 
71.00 2.00 38.00 75.00 792.00 0.97 103.57 2.10 3.20 1.69 21.98 
72.00 40.00 32.00 58.00 1,677.00 1.78 13,716.88 3.40 3.30 1.00 16.40 
73.00 2.00 31.00 62.00 -- 1.38 150.00 1.80 3.30 1.22 19.99 
74.00 77.00 15.00 48.00 631.00 1.44 254.55 0.90 1.30 0.66 11.23 
75.00 184.00 11.00 37.00 727.00 2.10 153.85 2.80 2.00 0.75 20.40 
77.00 2.00 20.00 47.00 667.00 1.81 263.46 0.50 2.10 1.09 13.23 
78.00 177.00 27.00 61.00 598.00 1.93 279.07 1.70 4.20 0.82 24.55 
79.00 2.00 24.00 44.00 500.00 1.24 157.14 -- -- 1.28 17.25 
80.00 126.00 14.00 58.00 2,300.00 2.23 798.80 0.90 1.20 0.48 11.19 
81.00 8.00 10.00 23.00 617.00 1.56 307.69 0.60 1.10 0.70 6.08 
82.00 4.00 29.00 60.00 739.00 1.31 171.26 0.70 4.00 2.84 33.45 
83.00 318.00 21.00 48.00 511.00 1.49 104.55 0.80 3.10 0.31 17.97 
84.00 63.00 9.00 29.00 1,652.00 1.75 1,598.80 0.90 0.90 0.39 5.33 
85.00 176.00 11.00 26.00 350.00 1.30 201.20 0.30 1.20 0.17 8.06 
87.00 110.00 18.00 40.00 700.00 1.62 177.89 0.70 2.60 0.67 16.63 
88.00 108.00 12.00 51.00 1,176.00 1.35 2,785.37 0.80 1.70 0.61 12.70 
  
377 
Patient 
no. 
C-reactive 
protein 
admission 
(mg/l) 
Albumin 
admission 
(g/l) 
Total 
protein 
admission 
(g/l) 
Whole 
blood TDP 
admission 
(ng/gHb) 
Red cell 
FAD 
admission 
(nmol/gHb) 
Red cell PLP 
admission 
(pmol/gHb) 
Triglycerides 
admission 
(mmol/l) 
Cholesterol 
admission 
(mmol/l) 
Plasma 
retinol 
admission 
(umol/l) 
Plasma α-
tocopherol 
admission 
(umol/l) 
89.00 31.00 16.00 33.00 579.00 1.17 204.85 1.50 2.70 0.73 19.22 
90.00 159.00 11.00 41.00 724.00 2.06 241.46 1.60 1.60 0.68 15.93 
91.00 268.00 14.00 40.00 687.00 1.25 209.00 1.30 1.60 0.36 15.56 
94.00 147.00 14.00 47.00 810.00 1.87 243.68 2.60 1.90 0.20 14.00 
96.00 76.00 29.00 64.00 894.00 2.12 245.83 1.60 4.40 1.60 27.00 
99.00 287.00 22.00 52.00 1,983.00 1.48 2,581.63 1.06 2.50 0.40 15.00 
100.00 253.00 13.00 41.00 2,287.00 2.56 10,787.95 2.40 2.30 0.60 19.00 
101.00 231.00 25.00 46.00 385.00 -- -- 0.70 2.20 0.30 15.00 
102.00 28.00 19.00 38.00 415.00 1.31 177.89 0.60 1.70 0.90 11.00 
103.00 -- 42.00 73.00 910.00 1.59 149.44 3.30 4.10 1.80 41.00 
104.00 1.00 34.00 71.00 545.00 1.31 219.15 4.70 6.40 2.10 36.00 
105.00 25.00 30.00 66.00 1,271.00 1.80 808.79 1.00 2.00 0.40 13.00 
107.00 261.00 17.00 39.00 827.00 1.67 232.98 -- -- 0.30 16.00 
108.00 48.00 35.00 70.00 653.00 1.23 147.47 -- -- 0.80 23.00 
110.00 199.00 13.00 48.00 918.00 1.13 186.21 1.10 1.60 0.40 17.00 
111.00 6.00 28.00 53.00 664.00 1.37 300.00 2.00 4.00 1.80 26.00 
112.00 2.00 20.00 42.00 923.00 1.15 160.67 1.20 5.20 1.30 28.00 
113.00 14.00 31.00 60.00 576.00 1.31 265.22 1.30 2.70 2.00 17.00 
114.00 49.00 16.00 37.00 288.00 1.14 196.77 1.40 2.20 0.40 15.00 
115.00 1.00 39.00 63.00 610.00 1.02 127.00 0.90 5.30 1.90 24.00 
116.00 3.00 24.00 48.00 391.00 1.29 383.87 1.00 2.70 1.30 12.00 
117.00 9.00 32.00 55.00 713.00 1.53 222.68 4.50 4.20 1.90 36.00 
118.00 252.00 12.00 33.00 1,367.00 1.85 594.38 0.70 0.70 0.30 7.00 
119.00 2.00 25.00 50.00 635.00 1.33 127.55 0.50 4.60 1.20 32.00 
121.00 203.00 15.00 37.00 482.00 1.54 209.30 0.30 1.00 0.20 8.00 
123.00 2.00 45.00 83.00 1,729.00 1.77 11,912.94 1.90 4.80 2.70 27.00 
124.00 97.00 15.00 40.00 1,884.00 1.56 846.15 0.40 1.10 0.20 7.00 
126.00 3.00 21.00 46.00 1,248.00 1.23 21,893.41 0.80 5.00 0.70 20.00 
127.00 316.00 17.00 59.00 494.00 2.58 342.68 0.60 1.20 0.60 16.00 
128.00 51.00 16.00 46.00 685.00 1.75 285.23 1.10 2.40 0.80 17.00 
129.00 63.00 20.00 53.00 1,779.00 1.88 23,853.33 -- -- 0.20 12.00 
131.00 165.00 21.00 47.00 531.00 1.68 348.31 0.90 1.00 0.30 7.00 
133.00 35.00 16.00 36.00 1,627.00 1.55 1,989.00 0.30 0.90 0.30 6.00 
135.00 221.00 18.00 58.00 1,302.00 1.91 454.88 1.90 2.80 1.10 25.00 
  
378 
Patient 
no. 
C-reactive 
protein 
admission 
(mg/l) 
Albumin 
admission 
(g/l) 
Total 
protein 
admission 
(g/l) 
Whole 
blood TDP 
admission 
(ng/gHb) 
Red cell 
FAD 
admission 
(nmol/gHb) 
Red cell PLP 
admission 
(pmol/gHb) 
Triglycerides 
admission 
(mmol/l) 
Cholesterol 
admission 
(mmol/l) 
Plasma 
retinol 
admission 
(umol/l) 
Plasma α-
tocopherol 
admission 
(umol/l) 
137.00 218.00 11.00 34.00 610.00 1.84 244.59 1.40 2.20 0.40 20.00 
139.00 72.00 14.00 33.00 773.00 2.02 305.41 -- 0.94 0.80 6.00 
140.00 51.00 9.00 26.00 502.00 2.13 195.71 0.40 2.40 0.40 5.00 
141.00 143.00 9.00 40.00 610.00 1.53 31.71 -- 0.62 1.40 6.00 
143.00 39.00 14.00 60.00 1,140.00 1.84 380.28 1.20 2.20 0.70 22.00 
146.00 73.00 26.00 38.00 2,413.00 2.13 5,550.67 1.70 2.60 0.80 12.00 
147.00 203.00 32.00 56.00 545.00 1.23 310.81 0.30 3.10 0.50 12.00 
148.00 17.00 23.00 54.00 423.00 1.54 502.67 1.10 3.90 0.80 17.00 
149.00 94.00 13.00 40.00 364.00 1.36 179.73 0.70 1.00 0.40 6.00 
150.00 295.00 24.00 55.00 653.00 1.42 167.53 1.10 1.60 0.60 12.00 
151.00 229.00 13.00 47.00 257.00 1.24 234.21 1.20 4.70 1.60 22.00 
152.00 26.00 35.00 65.00 595.00 1.29 166.25 1.30 4.80 1.80 21.00 
153.00 45.00 19.00 50.00 608.00 1.37 193.06 2.20 2.30 0.60 21.00 
154.00 39.00 33.00 62.00 2,552.00 1.82 27,441.10 0.60 4.60 2.50 23.00 
155.00 52.00 19.00 68.00 1,788.00 1.44 405.13 0.50 2.80 1.90 11.00 
156.00 316.00 20.00 73.00 300.00 1.22 289.33 1.90 2.60 0.20 9.00 
157.00 294.00 13.00 44.00 1,005.00 1.37 21,889.74 0.60 0.90 0.20 6.00 
158.00 163.00 10.00 34.00 1,656.00 1.58 4,984.62 2.10 1.60 0.20 9.00 
159.00 137.00 15.00 39.00 992.00 1.43 266.23 0.50 1.40 0.90 9.00 
163.00 269.00 12.00 38.00 520.00 1.15 158.02 0.70 1.50 0.20 12.00 
164.00 291.00 24.00 58.00 854.00 1.47 180.25 0.90 1.90 0.30 12.00 
165.00 0.60 47.00 75.00 853.00 1.27 310.98 1.40 5.50 3.10 32.00 
166.00 75.00 13.00 37.00 598.00 1.47 387.80 2.30 4.10 0.60 29.00 
167.00 74.00 23.00 43.00 1,926.00 1.39 3,000.00 0.60 2.50 0.80 10.00 
168.00 131.00 11.00 38.00 2,061.00 1.82 4,359.26 0.60 0.60 0.30 6.00 
169.00 273.00 14.00 50.00 2,574.00 1.77 1,150.60 2.40 2.60 0.20 12.00 
171.00 203.00 20.00 52.00 808.00 1.77 347.56 0.90 1.80 1.10 16.00 
 
  
379 
 
Patient 
no. 
Red cell α-
tocopherol 
admission 
(pmol/gHb) 
Plasma 
lutein 
admission 
(ug/l) 
Plasma 
lycopene 
admission 
(ug/l) 
Plasma α-
carotene 
admission 
(ug/l) 
Plasma β-
carotene 
admission 
(ug/l) 
Total 
MDA 
admission 
(umol/l) 
Free 
MDA 
admission 
(umol/l) 
Free/ 
Total 
MDA 
admission 
MDA/ Total 
protein 
admission 
(umol/g) 
Plasma 
ascorbic 
acid 
admission 
(umol/l) 
White cell 
ascorbic acid 
admission 
(umol/10(9) 
cells) 
12.00 17.58 30.10 28.90 21.20 58.00 0.65 0.14 0.22 0.01 -- -- 
13.00 11.30 4.60 9.50 9.00 0.50 0.91 0.16 0.18 0.02 24.00 1.90 
14.00 22.20 9.10 15.60 4.60 8.90 0.60 0.58 0.97 0.01 0.90 2.45 
15.00 3.40 7.40 35.30 1.80 3.90 0.96 0.17 0.18 0.02 16.00 2.93 
16.00 16.48 21.40 23.30 4.20 20.40 1.02 0.20 0.20 0.01 1.00 1.39 
17.00 19.66 -- -- -- -- 1.11 0.23 0.21 0.02 1.00 -- 
18.00 16.01 3.60 4.60 9.00 0.30 0.80 0.19 0.24 0.03 4.00 1.91 
19.00 18.62 33.50 102.50 16.60 117.90 0.87 0.26 0.30 0.01 37.00 1.76 
21.00 16.00 4.60 4.10 1.60 10.20 2.34 0.62 0.26 0.09 2.00 0.69 
22.00 18.73 22.20 17.70 11.30 39.00 1.03 0.38 0.37 0.01 136.00 2.57 
23.00 13.47 13.90 21.80 9.00 28.30 0.22 0.19 0.86 0.01 20.00 3.02 
24.00 22.18 113.20 43.10 12.00 115.60 1.37 0.37 0.27 0.02 21.00 1.81 
27.00 19.14 38.30 22.00 9.20 67.60 1.12 0.22 0.20 0.02 13.00 3.39 
29.00 19.67 8.00 6.20 0.90 4.40 0.53 0.37 0.70 0.02 -- -- 
30.00 39.28 41.70 84.40 20.30 40.10 0.93 0.97 1.04 0.02 11.00 1.56 
31.00 17.83 53.40 100.60 13.10 66.90 0.55 0.21 0.38 0.01 3.00 1.91 
32.00 11.39 18.00 4.70 3.00 9.30 0.77 0.23 0.30 0.02 3.00 1.32 
33.00 16.94 23.90 29.40 12.60 39.00 0.63 0.31 0.49 0.02 8.00 1.70 
34.00 15.33 32.00 47.00 1.40 0.60 0.82 0.14 0.17 0.01 59.00 2.91 
35.00 26.99 21.50 64.50 8.30 34.30 14.27 5.96 0.42 0.53 0.90 2.63 
36.00 12.38 8.50 13.40 3.80 14.40 0.78 0.20 0.26 0.02 59.00 3.81 
37.00 16.08 141.90 290.60 29.10 200.70 0.35 0.05 0.14 0.01 -- -- 
38.00 18.59 7.50 12.10 12.60 110.90 0.52 0.04 0.08 0.01 -- -- 
40.00 21.05 28.30 70.60 8.00 31.70 0.31 0.06 0.19 0.01 20.00 1.93 
41.00 25.22 20.40 37.40 17.10 45.20 0.48 0.05 0.10 0.01 19.00 3.30 
42.00 15.59 53.50 65.90 11.80 57.10 -- -- -- -- 0.90 1.82 
44.00 18.50 30.70 22.40 1.70 14.70 -- -- -- -- -- -- 
45.00 16.23 9.90 16.30 2.40 15.60 0.42 0.06 0.14 0.01 1.00 0.75 
46.00 -- 9.80 16.20 0.80 2.60 0.32 0.03 0.09 0.01 -- -- 
47.00 18.55 39.80 38.30 11.50 31.20 0.56 0.07 0.13 0.01 0.90 0.60 
  
380 
Patient 
no. 
Red cell α-
tocopherol 
admission 
(pmol/gHb) 
Plasma 
lutein 
admission 
(ug/l) 
Plasma 
lycopene 
admission 
(ug/l) 
Plasma α-
carotene 
admission 
(ug/l) 
Plasma β-
carotene 
admission 
(ug/l) 
Total 
MDA 
admission 
(umol/l) 
Free 
MDA 
admission 
(umol/l) 
Free/ 
Total 
MDA 
admission 
MDA/ Total 
protein 
admission 
(umol/g) 
Plasma 
ascorbic 
acid 
admission 
(umol/l) 
White cell 
ascorbic acid 
admission 
(umol/10(9) 
cells) 
48.00 24.40 14.00 11.40 9.00 5.70 0.34 0.04 0.12 0.01 -- -- 
50.00 18.10 9.40 6.90 1.60 25.90 0.40 0.15 0.38 0.01 50.00 2.35 
51.00 -- 8.40 8.60 1.50 23.90 0.27 0.10 0.37 0.01 11.00 3.06 
52.00 16.99 4.20 6.90 0.70 0.60 0.50 0.18 0.36 0.01 102.00 -- 
53.00 20.19 2.10 3.20 9.00 0.90 0.39 0.10 0.26 0.01 0.90 -- 
55.00 26.96 16.00 26.80 11.70 18.30 0.22 0.10 0.45 0.01 -- -- 
56.00 17.05 34.90 54.20 9.30 29.70 0.25 -- -- 0.01 4.00 -- 
57.00 21.03 4.40 5.10 0.90 2.80 0.29 0.15 0.52 0.01 -- -- 
58.00 17.17 36.60 95.80 15.00 73.60 0.67 0.09 0.13 0.02 -- -- 
59.00 21.69 65.10 116.60 6.60 10.70 2.20 0.28 0.13 0.03 -- -- 
60.00 21.47 33.90 164.80 21.80 85.00 0.75 0.07 0.09 0.01 12.00 -- 
61.00 27.94 43.90 58.80 5.60 23.30 1.37 1.37 1.00 0.02 -- -- 
62.00 18.07 20.00 40.70 15.60 53.10 0.69 0.05 0.07 0.02 0.90 -- 
63.00 13.00 23.70 45.50 6.20 20.90 0.62 0.06 0.10 0.02 0.90 -- 
64.00 20.23 41.00 35.40 14.90 65.60 0.60 0.02 0.03 0.01 4.00 -- 
65.00 20.07 -- -- -- -- 0.63 0.08 0.13 0.01 14.00 -- 
67.00 29.75 21.60 13.00 4.70 22.00 0.83 0.26 0.31 0.02 11.00 -- 
68.00 19.01 18.00 1.20 1.30 0.30 0.37 0.16 0.43 0.01 -- -- 
69.00 16.86 4.70 3.70 0.60 2.00 -- -- -- -- -- -- 
71.00 17.68 69.60 93.20 5.50 16.00 0.60 0.04 0.07 0.01 6.00 -- 
72.00 9.77 44.60 54.70 2.90 0.50 -- -- -- -- 79.00 -- 
73.00 16.66 48.40 15.80 9.00 51.50 1.34 0.05 0.04 0.02 0.90 -- 
74.00 13.46 2.10 0.80 0.50 0.30 -- -- -- -- 2.00 -- 
75.00 17.85 22.80 15.40 4.80 18.20 1.19 0.18 0.15 0.03 0.90 -- 
77.00 26.49 27.70 59.80 6.80 37.90 1.03 0.08 0.08 0.02 -- -- 
78.00 -- 77.80 147.30 20.30 109.60 -- -- -- -- -- -- 
79.00 25.28 66.90 170.70 8.90 41.90 -- -- -- -- 0.90 -- 
80.00 -- 8.30 20.40 2.30 10.60 -- -- -- -- 2.00 1.47 
81.00 21.71 18.10 24.50 4.30 14.60 0.41 0.08 0.20 0.02 10.00 1.54 
82.00 21.44 141.50 162.80 75.00 401.80 -- -- -- -- 0.90 -- 
83.00 12.79 28.90 43.50 15.90 91.60 0.89 0.04 0.04 0.02 1.00 1.60 
84.00 16.02 2.50 1.90 9.00 0.70 0.78 0.13 0.17 0.03 1.00 1.57 
85.00 22.33 17.50 7.30 6.10 9.00 -- -- -- -- 1.00 -- 
  
381 
Patient 
no. 
Red cell α-
tocopherol 
admission 
(pmol/gHb) 
Plasma 
lutein 
admission 
(ug/l) 
Plasma 
lycopene 
admission 
(ug/l) 
Plasma α-
carotene 
admission 
(ug/l) 
Plasma β-
carotene 
admission 
(ug/l) 
Total 
MDA 
admission 
(umol/l) 
Free 
MDA 
admission 
(umol/l) 
Free/ 
Total 
MDA 
admission 
MDA/ Total 
protein 
admission 
(umol/g) 
Plasma 
ascorbic 
acid 
admission 
(umol/l) 
White cell 
ascorbic acid 
admission 
(umol/10(9) 
cells) 
87.00 18.91 63.30 78.30 27.60 141.30 0.24 0.02 0.08 0.01 3.00 -- 
88.00 23.14 9.40 20.80 5.80 5.30 0.42 0.08 0.19 0.01 -- -- 
89.00 19.83 80.30 133.20 15.50 62.60 -- -- -- -- 12.00 1.94 
90.00 22.65 18.80 63.40 2.70 10.10 -- -- -- -- -- -- 
91.00 18.69 44.10 28.40 9.30 12.50 -- -- -- -- -- -- 
94.00 13.45 -- -- -- -- 0.85 0.21 0.25 0.02 -- -- 
96.00 29.52 84.00 130.00 12.00 31.00 -- -- -- -- -- -- 
99.00 11.60 21.00 71.00 9.00 9.00 0.73 0.05 0.07 0.01 29.00 1.79 
100.00 22.67 9.00 9.00 9.00 9.00 0.68 0.19 0.28 0.02 2.00 1.95 
101.00 16.68 31.00 45.00 11.00 46.00 0.32 0.07 0.22 0.01 17.00 2.12 
102.00 23.38 35.00 60.00 9.00 44.00 -- -- -- -- 9.00 -- 
103.00 31.49 29.00 142.00 173.00 167.00 -- -- -- -- 35.00 -- 
104.00 13.43 90.00 193.00 9.00 32.00 -- -- -- -- 0.90 -- 
105.00 21.66 50.00 44.00 16.00 52.00 0.71 0.15 0.21 0.01 5.00 8.77 
107.00 12.87 12.00 27.00 9.00 311.00 0.77 0.08 0.10 0.02 16.00 -- 
108.00 -- 68.00 234.00 14.00 48.00 0.48 0.10 0.21 0.01 3.00 1.42 
110.00 23.88 25.00 9.00 9.00 11.00 0.48 0.09 0.19 0.01 5.00 1.50 
111.00 22.55 106.00 273.00 9.00 50.00 -- -- -- -- 2.00 1.99 
112.00 24.97 246.00 32.00 36.00 522.00 1.31 0.06 0.05 0.03 -- 2.27 
113.00 13.13 38.00 57.00 9.00 25.00 1.56 0.35 0.22 0.03 2.00 -- 
114.00 16.57 29.00 90.00 10.00 53.00 0.73 0.12 0.16 0.02 0.90 0.46 
115.00 -- 97.00 188.00 10.00 51.00 1.06 0.05 0.05 0.02 17.00 0.99 
116.00 -- 22.00 96.00 9.00 9.00 0.81 0.06 0.07 0.02 0.90 0.74 
117.00 -- 54.00 139.00 9.00 16.00 1.61 0.06 0.04 0.03 2.00 -- 
118.00 16.69 9.00 9.00 9.00 9.00 0.61 0.05 0.08 0.02 0.90 -- 
119.00 -- 168.00 176.00 19.00 140.00 1.40 0.06 0.04 0.03 11.00 -- 
121.00 -- 9.00 9.00 9.00 9.00 0.57 0.08 0.14 0.02 2.00 -- 
123.00 19.07 68.00 60.00 11.00 24.00 0.87 0.04 0.05 0.01 2.00 -- 
124.00 -- 9.00 16.00 9.00 9.00 0.35 0.08 0.23 0.01 -- -- 
126.00 -- 36.00 110.00 9.00 14.00 0.55 0.06 0.11 0.01 10.00 -- 
127.00 -- 88.00 13.00 9.00 101.00 0.79 0.11 0.14 0.01 -- -- 
128.00 -- 11.00 17.00 10.00 39.00 0.94 0.10 0.11 0.02 2.00 -- 
129.00 5.15 9.00 11.00 9.00 9.00 1.84 0.14 0.08 0.03 -- -- 
  
382 
Patient 
no. 
Red cell α-
tocopherol 
admission 
(pmol/gHb) 
Plasma 
lutein 
admission 
(ug/l) 
Plasma 
lycopene 
admission 
(ug/l) 
Plasma α-
carotene 
admission 
(ug/l) 
Plasma β-
carotene 
admission 
(ug/l) 
Total 
MDA 
admission 
(umol/l) 
Free 
MDA 
admission 
(umol/l) 
Free/ 
Total 
MDA 
admission 
MDA/ Total 
protein 
admission 
(umol/g) 
Plasma 
ascorbic 
acid 
admission 
(umol/l) 
White cell 
ascorbic acid 
admission 
(umol/10(9) 
cells) 
131.00 -- 9.00 24.00 9.00 16.00 0.44 0.09 0.20 0.01 -- -- 
133.00 -- 11.00 32.00 9.00 9.00 0.61 0.08 0.13 0.02 17.00 -- 
135.00 -- 9.00 9.00 9.00 176.00 0.56 0.06 0.11 0.01 5.00 2.04 
137.00 -- 37.00 103.00 16.00 48.00 0.45 0.04 0.08 0.01 4.00 -- 
139.00 -- 9.00 16.00 9.00 9.00 0.63 0.04 0.06 0.02 11.00 -- 
140.00 -- 9.00 9.00 9.00 9.00 0.62 0.08 0.13 0.02 1.00 -- 
141.00 -- 9.00 12.00 9.00 9.00 0.66 0.12 0.18 0.02 0.90 -- 
143.00 -- 9.00 55.00 44.00 518.00 0.59 0.08 0.14 0.01 3.00 -- 
146.00 -- 9.00 126.00 9.00 9.00 0.70 0.07 0.10 0.02 -- -- 
147.00 -- 47.00 56.00 9.00 23.00 0.47 0.05 0.11 0.01 12.00 -- 
148.00 -- 16.00 46.00 9.00 11.00 -- -- -- -- -- -- 
149.00 -- 9.00 9.00 9.00 9.00 0.52 0.07 0.13 0.01 -- -- 
150.00 -- 12.00 15.00 9.00 9.00 0.41 0.06 0.15 0.01 5.00 -- 
151.00 -- 67.00 294.00 38.00 224.00 0.48 0.06 0.13 0.01 -- -- 
152.00 -- 69.00 260.00 34.00 185.00 1.65 0.07 0.04 0.03 -- -- 
153.00 -- 15.00 48.00 -- 71.00 0.68 0.10 0.15 0.01 -- -- 
154.00 -- 70.00 78.00 13.00 10.00 0.85 0.09 0.11 0.01 58.00 -- 
155.00 -- 15.00 101.00 5.00 92.00 1.08 0.19 0.18 0.02 28.00 -- 
156.00 -- 9.00 14.00 9.00 9.00 0.69 0.13 0.19 0.01 -- -- 
157.00 -- 9.00 9.00 9.00 9.00 0.38 0.22 0.58 0.01 29.00 -- 
158.00 -- 9.00 9.00 9.00 9.00 1.00 0.08 0.08 0.03 -- -- 
159.00 -- 30.00 9.00 9.00 9.00 0.62 0.08 0.13 0.02 -- -- 
163.00 -- 19.00 11.00 6.00 31.00 0.72 0.08 0.11 0.02 -- -- 
164.00 -- 32.00 9.00 4.00 8.00 0.56 0.05 0.09 0.01 0.90 -- 
165.00 -- 92.00 318.00 20.00 115.00 1.24 0.05 0.04 0.02 -- -- 
166.00 -- 8.00 10.00 0.70 2.00 0.92 0.09 0.10 0.02 -- -- 
167.00 -- 19.00 19.00 17.00 20.00 0.42 0.08 0.19 0.01 -- -- 
168.00 -- 12.00 15.00 3.00 7.00 -- -- -- -- -- -- 
169.00 -- 9.00 3.00 3.00 6.00 -- -- -- -- -- -- 
171.00 -- 24.00 29.00 3.00 81.00 -- -- -- -- -- -- 
 
 
